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Structured Abstract  
Objectives: The RTI International−University of North Carolina at Chapel Hill Evidence-based 
Practice Center (RTI-UNC EPC) systematically reviewed the evidence on (a) the effectiveness of 
community- and population-based interventions to prevent tobacco use and to increase consumer 
demand for and implementation of effective cessation interventions; (b) the impacts of smokeless 
tobacco marketing on smoking, use of those products, and population harm; and (c) the 
directions for future research.  
 
Data Sources: We searched MEDLINE®, Cumulative Index to Nursing and Applied Health 
(CINAHL), Cochrane libraries, Cochrane Clinical Trials Register, Psychological Abstracts, and 
Sociological Abstracts from January 1980 through June 10, 2005. We included English-language 
randomized controlled trials, other trials, and observational studies, with sample size and follow-
up restrictions. We used 15 Cochrane Collaboration systematic reviews, 5 prior systematic 
reviews, and 2 meta-analyses as the foundation for this report.  
 
Review Methods: Trained reviewers abstracted detailed data from included articles into 
evidence tables and completed quality assessments; other senior reviewers confirmed accuracy 
and resolved disagreements.  
 
Results: We identified 1,288 unique abstracts; 642 did not meet inclusion criteria, 156 
overlapped with prior reviews, and 2 were not published articles. Of 488 full-text articles 
retrieved and reviewed, we excluded 298 for several reasons, marked 88 as background, and 
retained 102. Evidence (consistent with previous reviews) showed that (a) school-based 
prevention interventions have short-term (but not long-term) effects on adolescents; (b) 
multicomponent approaches, including telephone counseling, increase the number of users who 
attempt to quit; (c) self-help strategies alone are ineffective, but counseling and pharmacotherapy 
used either alone or in combination can improve success rates of quit attempts; and (d) provide 
training and academic detailing improve provider delivery of cessation treatments, but evidence 
is insufficient to show that these approaches yield higher quit rates.  
Recent evidence on the following topics was insufficient to change prior review findings:  
(a) effectiveness of population-based prevention interventions; (b) effectiveness of provider-
based interventions to reduce tobacco initiation; (c) effectiveness of community- and provider-
based interventions to increase use of proven cessation strategies; (d) effectiveness of marketing 
campaigns to switch tobacco users from smoking to smokeless tobacco products; and (e) 
effectiveness of interventions in populations with comorbidities and risk behaviors (e.g., 
depression, substance and alcohol abuse). No evidence was available on the way in which 
smokeless tobacco product marketing affects population harm. 
 
Conclusions: The evidence base has notable gaps and numerous study deficiencies. We found 
little information to address some of the issues that previous authoritative reviews had not 
covered, some information to substantiate earlier conclusions and recommendations from those 
reviews, and no evidence that would overturn any previous recommendations.  
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Executive Summary 
Introduction 
The RTI International−University of North Carolina at Chapel Hill Evidence-based Practice 
Center (RTI−UNC EPC) conducted a systematic review of the literature on issues of tobacco 
use, prevention, cessation, and control on behalf of the National Institutes of Health (NIH), 
Office of Medical Applications of Research (OMAR), through the Agency for Healthcare 
Research and Quality (AHRQ). OMAR commissioned this review to summarize the available 
literature, frame the discussions regarding benefits and harms, and highlight the limitations of the 
entire evidence base for a State-of-the-Science (SOS) conference in June 2006.  
We synthesized existing literature on five main research issues needed to make progress 
toward public health gains worldwide. Specific substantive key questions (KQs) were:  
 
1. What are the effective population- and community-based interventions to prevent tobacco 
use in diverse populations of adolescents and young adults? 
2. What are effective strategies for increasing consumer demand among diverse populations 
for and use of proven individually oriented cessation treatments? 
3. What are effective strategies for increasing implementation of proven population-level 
tobacco use cessation strategies, particularly by health care systems and communities? 
4. What effect does smokeless tobacco product marketing and use have on population harm 
from tobacco use? 
5. What is the effectiveness of prevention and of cessation interventions in populations with 
co-occurring morbidities and risk behaviors? 
Methods 
Literature Searches 
We searched MEDLINE®, the Cumulative Index to Nursing and Applied Health (CINAHL), 
The Cochrane Library, Psychological Abstracts, and Sociological Abstracts using Medical 
Subject Headings as search terms or key words when appropriate; we also manually searched 
reference lists. With our Technical Expert Panel (TEP), we generated a list of inclusion and 
exclusion for each question. We limited our review to human studies conducted in developed 
countries and published in English. We considered studies with participants ages 13 and older, of 
both sexes, and of diverse racial and ethnic populations. We limited studies to those with study 
duration of more than 6 months and minimum sample sizes of 30 for randomized controlled 
trials (RCTs) and 100 for other experimental or observational studies. We excluded articles that 
did not report outcomes related to our KQs or provide sufficient information to be abstracted. We 
also excluded all editorials, letters, and commentaries.  
Finally, for work on KQs 1, 2, 3, and 5, we relied on prior systematic reviews (publication 
dates in parentheses): 
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• The Guide to Community Preventive Services (2005),  
• Treating Tobacco Use and Dependence (2000),  
• Reducing Tobacco Use: A Report of the Surgeon General (2000), 
• Several Cochrane Collaboration Reviews (1998-2005),  
• Treating nicotine use and dependence of pregnant and parenting smokers: an update 
(2004), 
• Smoking cessation approaches for persons with mental illness or addictive disorders 
(2002),  
• A meta-analysis of smoking cessation interventions with individuals in substance abuse 
treatment or recovery (2004), and 
• Growing up tobacco free: preventing nicotine addiction in children and youths (1994).  
We included original research studies (1) published beyond the date range included in the 
systematic reviews, (2) concerning topics related to the questions not covered by the reviews, 
and (3) providing sufficient detail regarding their methods and outcomes.  
We made decisions about including studies only after dual review. We assessed the quality of 
trials or other types of study using criteria from the U.S. Preventive Services Task Force and the 
National Health Service Centre for Reviews and Dissemination. We rated strength of evidence 
using categories (strong, sufficient, insufficient) based on criteria from the Task Force on 
Community Preventive Services.  
Results 
KQ 1. Effective Population- and Community-Based Interventions to 
Prevent Tobacco Use in Adolescents and Young Adults 
Population-based interventions. Prior systematic reviews investigating tobacco prevention 
among adolescents and young adults reported strong evidence of effectiveness for increasing the 
unit price of tobacco products and mass media campaigns run concurrently with other 
interventions. Evidence of effectiveness was sufficient for restricting tobacco product 
distribution, regulating the mechanisms of sale, enforcing access-to-minors laws, and merchant 
education and training when conducted in conjunction with community mobilization.  
Two population-based studies had some success in reducing tobacco initiation among 
adolescents and young adults. Alone, they provided little conclusive evidence about such 
programs. One study on regulating and enforcing youth access laws augments sufficient 
evidence from prior reviews. We found no other research to add to existing evidence for 
population-based interventions.  
Community-based interventions. Prior reviews reported limited and mixed evidence of 
effectiveness of community-based efforts aimed at tobacco prevention. Sufficient evidence was 
found for short-term effects (less than 2 years) of school-based prevention programs.  
Interventions implemented in a single school year or conducted over multiple school years 
produced mixed results in 10 school-based studies. Consistent with prior reviews, we found 
sufficient evidence to demonstrate that prevention measures conducted in schools have positive 
short-term effects but insufficient evidence for long-term effects. We found no community-based 
studies. 
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Provider-based interventions. We did not identify any systematic reviews evaluating 
provider-based tobacco prevention. Our only provider-based study had no intervention effects, 
giving us insufficient evidence to determine the effectiveness of such efforts.  
KQ 2. Effective Strategies for Increasing Consumer Demand for and 
Use of Proven Individually Oriented Cessation Treatments 
Multicomponent strategies to increase the number of users who attempt to quit. Prior 
reviews found strong evidence of effectiveness for telephone cessation support to increase 
tobacco use cessation for adults, especially when combined with other counseling formats. We 
identified three studies of telephone counseling with related print materials. Consistent with prior 
reviews, two trials reported significant increases in cessation in the short term. One trial reported 
no difference.  
Two studies showed telephone counseling targeting youth and young adults achieves quit 
rates comparable to those for adults. Though promising, the small number of studies is 
insufficient to confirm the effect of telephone counseling for these groups. 
Strategies to improve the success of quit attempts. Prior systematic reviews reported 
consistent evidence that counseling by a trained therapist in one or more face-to-face sessions is 
effective for assisting smokers in their quit attempts. Evidence was insufficient to evaluate 
whether groups are more effective than intensive individual counseling or to support the use of 
particular psychological components beyond typically included support and skills training. 
Limited evidence suggests that adding group therapy to other forms of treatment produces extra 
benefit.  
Prior systematic reviews reported insufficient evidence of the effectiveness of self-help in 
assisting smokers in their quit attempts. Meta-analyses reported strong, consistent evidence that 
pharmacologic treatments for smoking cessation can help people quit smoking and some 
evidence that the combination of the nicotine patch with a self-administered form of nicotine 
replacement therapy is more effective than a single form of nicotine replacement.  
We identified studies evaluating the efficacy of self-help strategies, counseling, single 
pharmaceuticals, combination pharmacotherapy, and pharmacotherapy combined with 
psychological counseling. Studies in our review of strategies to improve success of quit attempts 
were consistent with previous reviews in finding that self-help strategies alone are not 
efficacious and that the use of counseling, pharmacotherapies either alone or in combination, or 
pharmacotherapies combined with psychological counseling increases the likelihood of 
successful quitting.  
Strategies to improve the success of quit attempts for special populations. In a meta-
analysis comparing augmented smoking cessation treatment with usual care for hospitalized 
patients, smoking cessation treatments were effective for hospitalized patients. Another review 
showed no strong evidence that clinical diagnosis affects the likelihood of quitting among 
hospitalized patients. The same review found that intensive intervention (inpatient contact plus 
followup for at least 1 month) with hospitalized patients was associated with a significantly 
higher quit rate compared to control. Prior reviews of interventions with pregnant smokers 
included studies with substantial variation in the intensity of the intervention and the extent of 
reminders and reinforcement through pregnancy and found that participants in intervention 
conditions experience significant reduction in continued smoking in late pregnancy. An earlier 
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review showed that smoking cessation treatments are effective across different racial and ethnic 
minorities and should be offered to members of those groups.  
We found results both consistent and inconsistent with prior reviews for interventions with 
special populations. When evaluating interventions with hospitalized patients by diagnosis, 
studies in our review were in agreement with findings of a prior review showing no strong 
evidence that clinical diagnosis affects the likelihood of quitting. Results of our review were 
inconsistent with two prior reviews indicating that hospitalized patients were more likely to quit 
smoking as the intensity of intervention increased. Although some studies in our review found 
significant gains in abstinence in the short term, all studies showed an absence of effect at 12-
month assessment. The findings of our review remain consistent with those of prior reviews that 
counseling does increase the likelihood of abstinence among pregnant smokers. Investigators 
found quit rates for indigenous Maori in New Zealand similar to those observed in other trials of 
bupropion. These findings are consistent with an earlier review showing that smoking cessation 
treatments are effective for racial and ethnic minorities. 
KQ 3. Effective Strategies for Increasing the Implementation of Proven 
Population-Level Tobacco Use Cessation Strategies, Particularly by 
Health Care Systems and Communities 
Community-based strategies. Past systematic reviews reported little convincing evidence 
that community interventions reduce adult smoking. Three new studies focusing on different 
strategies and populations produced inconsistent results. Positive results emerged only in a trial 
using community-based pharmacists to discuss smoking cessation when smokers sought a 
variety of other services. These results are consistent with prior reviews.  
Provider and health care system-based strategies. Prior reviews reported strong evidence 
of effectiveness for provider reminder systems with provider education, with or without client 
education, and for multicomponent interventions that include client telephone support. However, 
they reported insufficient evidence of effectiveness to recommend provider education alone and 
provider feedback and assessment. Sufficient evidence in our review indicated that implementing 
provider-based interventions such as training improves provider delivery of cessation treatment, 
but evidence was insufficient to conclude that implementing these approaches leads to higher 
abstinence. 
In examining interventions in health care systems, we found sufficient evidence that 
academic detailing improves provider delivery of effective smoking cessation treatments. Family 
physicians and providers in office-based private practices, public clinics, hospitals, and 
orthodontist offices improved their knowledge and use of effective strategies from personal 
educational visits in their own practice setting, including education, audit, and feedback.  
The evidence was insufficient to suggest that resultant improvement in treatment practices 
leads to significant, long-term increases in cessation among those being treated. Too few studies 
reported quit rates for the population served; those that did showed no long-term, consistent 
effects on cessation. One study tested the relationship between provider attitudes and smoking 
behavior on uptake and use of effective interventions, but found no effect. 
Evidence was promising but insufficient to suggest that interventions proven effective in 
earlier trials could be sustained as part of routine care. Only one study examined this important 
aspect of improving the odds of maintaining an effective program. Investigators found that 
successfully implementing a proven strategy after completion of the original trial is possible, that 
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the sustained program produced quit rates comparable with those observed in the trial, and that 
success was more likely among cancer, cardiovascular, and pulmonary patients.  
KQ 4. Effect of Smokeless Tobacco Product Marketing and Use on 
Population Harm from Tobacco Use  
Prior systematic reviews did not address these issues directly. Two new studies focused on 
smokeless tobacco use. One reported smokers were more likely to quit smoking than become 
users of smokeless tobacco, and users of smokeless tobacco were significantly more likely than 
nonusers of tobacco to become smokers. Another study found advertising exposure increased 
adolescent susceptibility to smokeless tobacco, resulting in a sevenfold increase in current use. 
We found no evidence on how smokeless tobacco marketing affects population harm. Based on 
these studies, we found insufficient evidence to draw firm conclusions about the impact of 
marketing these products on increased use or substitution of smokeless tobacco for smoking.  
KQ 5. Effectiveness of Prevention and of Cessation Interventions in 
Populations with Co-occurring Morbidities and Risk Behaviors 
Tobacco cessation for persons with comorbidities. Past reviews agree that, absent relevant 
studies on smoking cessation in psychiatric populations, clinicians should use smoking cessation 
treatments recommended for the general population. Three studies evaluated smoking cessation 
for people with psychiatric conditions. In one, pharmacotherapy was effective (consistent with 
prior reviews). In a second study, counseling and cognitive behavioral therapy were not effective 
for adults with a history of major depressive disorder (MDD), except in a secondary analysis 
categorizing adults into single-episode MDD and recurring MDD. In the third study, 
motivational interviewing or brief advice was not effective for adolescents hospitalized for 
psychiatric and substance use problems. Prior reviews did not report effective adolescent 
interventions. Evidence is insufficient and inconsistent to draw conclusions about the 
effectiveness of interventions in these populations or to overturn the current recommendation. 
Tobacco cessation for persons with substance abuse addictions. Prior meta-analyses 
reported that people with chemical and nicotine dependency should receive counseling and 
pharmacotherapy to assist with smoking cessation. These types of interventions had positive 
short-term effects for stopping smoking but not for long-term abstinence. Two studies of 
smoking cessation interventions among alcohol and substance abusers reported significant 
effects for smoking cessation when compared to a control group. Both studies treated nicotine 
dependency concurrently with other addiction treatment. One study reported no effects on 
abstinence for other addictive substances; the other reported lower alcohol abstinence with 
concurrent treatments. The findings support past recommendations that counseling and 
pharmacotherapy have positive short-term effects for such interventions, but the body of 
evidence is insufficient, given the number of studies, to merit recommendations.  
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Discussion 
General Conclusions 
In most instances, evidence from new research covered in our review was consistent with 
previous systematic reviews. Even in combination with previous reviews, our findings are 
insufficient to draw new or different conclusions from those offered by earlier reviews. Overall, 
the evidence base to address the numerous issues raised for the SOS conference has critical gaps 
and deficiencies, particularly for questions unaddressed by prior reviews.  
Future Research  
Lacunae in the literature can be addressed by both future research and improvement in 
methods. We recommend efforts to examine the following key-question-specific issues, focusing 
on whether, how, and how well certain programs work to influence tobacco initiation, use, or 
cessation. 
KQ 1: Tobacco prevention 
• Effect of tobacco industry and product restrictions (specifically, laws that regulate the 
content, labeling, promotion, and advertising of tobacco products) on adolescents and 
young adults; 
• Community mobilization with increased enforcement of tobacco youth access laws and 
regulations; 
• Concurrent implementation of effective population-based tobacco interventions (e.g., 
pricing, restricting access, regulations, and media campaigns) in different combinations; 
• Community-based tobacco prevention strategies implemented simultaneously; 
• Combinations of school-based interventions with community mobilization, media 
campaigns, and enforcement of tobacco youth access laws and regulations; and 
• Tobacco prevention efforts in provider-based settings for adolescents and young adults. 
KQ 2: Attempts to quit tobacco use 
• Role of mass media in driving individuals to quit lines and other cessation services; 
• Audience research on effectiveness of messages to motivate target audiences of 
adolescents, young adults, and persons with low income and educational status; 
• Comparisons of specific components of telephone counseling and their relative impact on 
enrollment and continuation, individual motivation to quit, and smoking status; 
• Appropriateness of cessation services such as number and timing of calls, role of feedback 
to the caller’s primary provider, and participants’ satisfaction; 
• Relative population impact of proven cessation interventions, such as proactive telephone 
counseling support compared with in-person intervention;  
• Differential rates of success and enrollment and whether they offset or enhance each 
other;  
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• Effectiveness of multiple intervention formats, of combination pharmacotherapy, and of 
adjuncts other than pharmacotherapy in comparison with individual counseling; 
• Ways to reduce withdrawal symptoms and cravings among those attempting to quit using 
tobacco products; 
• Ways to minimize side effects associated with use of individual pharmacotherapies and 
combined pharmaceutical regimes; and  
• Techniques to increase persistence of effect on smoking abstinence over time. 
KQ 3: Cessation efforts in different settings  
• Ways to reach out to smokers in the general population and to special populations with 
messages that motivate individuals to become aware of, promote, and use existing 
cessation services; 
• Interventions to change provider practice patterns and related smoking outcomes for 
patients; 
• Academic detailing strategies and their impact across and within practice types;  
• Relationship of provider attitudes and smoking behavior to provider use of effective 
interventions; and  
• Institutional barriers hampering adoption of effective strategies in health systems and 
among providers. 
KQ 4: Smokeless tobacco marketing and use 
• Impact of tobacco industry marketing on use of smokeless tobacco and whether 
populations are differentially affected;  
• Possible links between point-of-purchase tobacco promotion and advertising and 
increased use of smokeless tobacco among adolescents and young adults; and  
• Treatments to complement efforts aimed at smokeless tobacco cessation. 
KQ 5: Populations with psychiatric comorbidities and risk behaviors 
• Tailored treatments and therapies for populations with psychiatric comorbidities and risk 
behaviors; 
• Effects of combined pharmacotherapies for population with psychiatric comorbidities and 
risk behaviors; 
• Effects of pharmacotherapy for people with a history of depression and people currently 
diagnosed with clinical depression; 
• Timing (e.g., simultaneous, before, or after) of tobacco use treatment and treatment for 
psychiatric and substance abuse problems; and 
• Barriers to tobacco treatment in patients with other health problems such as 
contraindications of pharmacotherapy and validity of clinicians’ concerns about hindering 
sobriety. 
8 
Improved Methods  
Investigators need to use markedly better and more rigorous methods for all new research 
into tobacco prevention, control, and cessation. Critical improvements include more rigorous and 
longer studies, standardized definitions of interventions, appropriate measurement tools 
(including biomarkers for verification), better statistical and analytic approaches (e.g., use of 
intent-to-treat methods), improved tactics for reducing attrition, and better documentation of 
methods and results. 
 
 Evidence Report 
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Chapter 1. Introduction  
Scope of the Problem 
Tobacco use is the leading cause of preventable illness and death in the United States: it 
causes numerous cancers, heart disease, stroke, complications of pregnancy, and chronic 
obstructive pulmonary disease.1,2 Each year, 440,000 deaths and $157 billion in health-related 
economic costs result from tobacco use.3 Approximately 44.5 million people, or 20.9 percent of 
the adult population, reported smoking in 2004.4 Almost one-third of all tobacco users will die 
prematurely because of their dependence on tobacco.5 
Tobacco Use and Its Impact 
The morbidity and mortality caused by tobacco use, documented by the reports of the 
Surgeons General since 1964, are clear and pervasive.1,2,6 Tobacco use begins primarily in 
adolescence and frequently leads to nicotine addiction.7 High rates of tobacco initiation among 
adolescents,8 variable smoking cessation rates in general and at-risk populations,9 and 
inconsistent implementation of smoking cessation interventions underscore the need for 
evidence-based research outlining recommended tobacco prevention and cessation strategies. 
With aggressive marketing of tobacco products, particularly smokeless tobacco, continuing to 
expand and build market share through product development,10 smoking cessation interventions 
must maximize their exposure to tobacco users during critical periods of transition or “teachable 
moments” to reduce the significant morbidity and mortality rates associated with tobacco use. 
Many factors affect an individual’s tobacco use and associated tobacco-related mortality and 
morbidity. Disparities in both are reported by race and ethnicity, gender, level of education, 
socioeconomic status, and geographic region.2,11 Individuals most likely to smoke and to suffer 
and die from smoking-related disease are less educated, more likely to live in poverty, and more 
likely to be American Indians and Alaska Natives.8 
Most adult smokers (98 percent) began smoking as adolescents or young adults; 82 percent 
started before age 18, and 16 percent started between the ages of 18 and 24.12 Each day more 
than 3,000 additional children and adolescents become regular tobacco users; one-third of them 
will die from tobacco-related causes.13,14 
Predictors for smoking initiation vary by race and ethnicity; for example, black males are 
more responsive to peer pressure than other groups. Overall, children most likely to begin 
smoking are those engaged in other unhealthy or risky activities such as drinking, truancy, and 
delinquency.12 Preventing youth tobacco initiation and the transition from experimentation to 
addiction are both difficult. Adolescents are more susceptible than people in other age groups to 
influences from their families, friends, peers, society, and the tobacco industry that encourage 
tobacco use.15  
Half of American youth have tried cigarettes by the time they are seniors in high school, and 
nearly one-quarter (23 percent) of seniors are current smokers. The prevalence of current 
smoking among high school seniors peaked in 1997 before beginning a decline that continued 
through 2004. However, this important decline in smoking has decelerated sharply. Among 8th 
graders the decline has halted and, because of strong cohort effects for smoking, the decline is 
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predicted to stop in the upper grades as well. The slowdown in price increases for tobacco 
products together with reductions in funding at both the national and state levels for antismoking 
campaigns have contributed to these developments.16  
The smoking rate among young adults ages 18 to 24 is 23.8 percent, slightly higher than that 
among high school seniors. The national health objective for 2010 is to reduce the prevalence of 
cigarette smoking among adults to 12 percent or lower.8 Because data suggest that smoking 
initiation is a problem among both adolescents and young adults, a strong focus on preventing 
tobacco use initiation among these age groups is needed.  
Smokeless tobacco can also lead to nicotine addiction and dependence.17 Two types of 
smokeless tobacco are sold in the United States: chewing tobacco (i.e., loose-leaf tobacco, plug, 
or twist) and snuff (i.e., finely ground tobacco that can be dry, moist, or in sachets).18,19 These 
products, which contain 28 carcinogens, are known to increase the risk of developing oral 
cancers.19 An estimated 7 percent of high school students are current users of smokeless 
tobacco.20 
Once users are dependent on tobacco, whether cigarettes or smokeless products, quitting is 
very difficult, although an estimated 70 percent of smokers would like to quit.8,21 The drug 
dependence resulting from tobacco use hampers efforts to sustain abstinence from tobacco for 
either a prolonged period or a lifetime.5 As a result, many users make multiple attempts to quit.  
In 2004, an estimated 14.6 million (40.5 percent) US adult smokers reported trying to quit by 
stopping smoking for at least 1 day during the preceding 12 months.8 In 2000, an estimated 70 
percent of smokers said they wanted to quit, but few succeeded without help.22 Tobacco use 
treatment doubles quitting success rates.5 
The rate of smoking is higher among people with psychiatric conditions and substance abuse 
problems.9,23 Populations with co-occurring morbidities have shown a lack of responsiveness to 
smoking cessation treatments; fewer than 15 percent of psychiatric patients quit.23 For people 
suffering from alcoholism, quitting tobacco before achieving sustained abstinence is particularly 
difficult.24 People with comorbidities often have overlapping conditions such as multiple 
addictions and/or psychiatric, cognitive, or medical conditions that may require more sensitive or 
specialized strategies and services for smoking cessation.9 
Barriers to the use of these services exist for both tobacco users and health care providers. 
Some smokers are reluctant to disclose their smoking status to their clinicians, do not believe that 
their clinicians can help them to quit smoking, or assume that they will get “attitude” from their 
clinicians instead of help with quitting tobacco use.25 More than one-third of current smokers 
report that they were never asked about their smoking status or urged to quit by their 
clinician.26,27 Fewer than 15 percent of smokers who saw a physician in the past year reported 
being offered assistance in quitting.28 Among current smokers and former smokers who were 
trying to quit and had seen a health care provider in the past year, only 61.8 percent received 
advice to quit from those providers.29  
Individuals who continue to use tobacco products put themselves and their families at 
considerable risk of harm associated with tobacco use. By continuing to use tobacco, they are 
increasing their risk of smoking-attributable mortality and morbidity. They also expose members 
of their families and households to secondhand smoke and its health and safety consequences. 
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Need and Purpose of This Systematic Review 
The National Institutes of Health (NIH) Office of Medical Applications of Research 
(OMAR) reviews and evaluates clinically relevant NIH research program information and 
promotes the effective transfer of this information to the health care community. OMAR 
accomplishes this objective through its Consensus Development Program. This includes major 
Consensus Development conferences and State-of-the-Science (SOS) conferences when only 
less definitive evidence is available. 
As background for an upcoming SOS meeting, OMAR commissioned this systematic review 
on “Tobacco Use: Prevention, Cessation, and Control” through the Agency for Healthcare 
Research and Quality (AHRQ). The aim is to summarize the available literature, frame the 
discussions regarding benefits and harms, and highlight the limitations of the entire evidence 
base. Through this report, OMAR seeks to increase the scientific rigor of the June 2006 SOS 
conference.  
The findings of our review clarify what is known about effective interventions and strategies 
for tobacco prevention and treatment as a means of providing authoritative background 
information for participants at the SOS conference. More broadly, we expect that our findings 
will be useful to major stakeholders in this arena, including policymakers, advocacy groups and 
community organizations, directors of smoking prevention and cessation programs, health care 
providers, smokers, and adolescents and young adults. We also identify future research priorities 
useful to government agencies and private sector funding organizations.  
Uses of This Report 
Quite apart from its use at the OMAR SOS conference in June 2006, we anticipate that this 
report will be of value to members of the various professional organizations whose missions 
include the prevention and cessation of tobacco use in all populations. These organizations 
include the American Legacy Foundation, the American Cancer Society, the American Heart 
Association, the Campaign For Tobacco-Free Kids, the March of Dimes, the National Heart, 
Lung and Blood Institute, the National Cancer Institute, and the Indian Health Service in the 
Department of Health and Human Services. More generally, the report will assist these and other 
organizations in their mission to inform and educate practitioners, policymakers, insurers, media 
representatives, high-risk populations, youth, and the general public.  
From this review, NIH and relevant institutes can guide funding policies by identifying 
serious gaps in the research on tobacco prevention and cessation strategies in diverse 
populations, strategies for implementing proven tobacco cessation treatments, and the effects of 
smokeless tobacco product marketing on population use. This review can also inform 
practitioners on the current evidence about outcomes associated with tobacco initiation and 
cessation, as well as tobacco implementation practices and smokeless tobacco marketing and use. 
Researchers will benefit from the concise analysis of the current status of the field, which will 
enable them to design future studies to address deficiencies in the field. Health educators can use 
this report to improve health communication. Finally, policymakers can use this report to 
allocate resources toward future research and initiatives that are likely to be successful. 
 14 
Production of This Evidence Report 
Technical Expert Panel 
We identified experts in the field of tobacco use, prevention, cessation, and control to 
provide assistance throughout the project. The Technical Expert Panel (TEP) (see Appendix E)* 
contributes to AHRQ’s broader goals of (1) creating and maintaining science partnerships and 
public-private partnerships and of (2) meeting the needs of an array of potential customers and 
users of this product. The TEP served as both a resource and a sounding board during the project. 
Our TEP comprised seven individuals: one clinical educator, three representatives from 
professional and advocacy groups concerned with smoking and health, and three experts in social 
marketing, media campaigns, and prevention. 
To ensure accountability and scientifically relevant work, we asked the TEP for advice at all 
stages of the project. TEP members participated in conference calls and e-mail exchanges to 
 
• Refine the analytic framework and key questions at the beginning of the project, 
• Refine the scope of the project, and 
• Discuss inclusion and exclusion criteria. 
 
Because of their extensive knowledge of the literature on these topics and their active 
involvement in professional organizations and in the clinical field, we also asked TEP members 
to participate in external peer review of the draft report. 
A Note on Terminology 
Adolescents are defined as individuals ages 13 to 18, and young adults are defined as college 
age, approximately 18 to 24 years of age. Adults are defined as individuals ages 18 and older and 
overlap the young adult category. Comorbidity and co-occurring morbidities refer to a dual 
diagnosis of concurrent disorders such as depression and nicotine addiction. 
Organization of this Report 
Chapter 2 describes our methods, including the development of key questions and their 
analytic framework, our search strategies, and inclusion/exclusion criteria. In Chapter 3, we 
present the results of our literature search and synthesis on five of the six key questions that 
OMAR posed for this review. We also report on the numbers of publications reviewed, present 
findings on prior reviews and current literature, and grade the quality of all articles. Chapter 4 
discusses these findings further, rates the overall strength of the bodies of literature, and 
highlights methodological shortcomings of the extant research; the chapter also offers 
recommendations for future research (of particular interest to NIH and AHRQ) and restates the 
major conclusions. Appendices (available electronically at http://www.ahrq.gov/clinic/tp/ 
tobusetp.htm) begin with a detailed description of our search strings (Appendix A),  followed by 
our quality rating forms (Appendix B), detailed evidence tables (Appendix C), a list of excluded 
                                                 
 
* Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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studies (Appendix D), and acknowledgments, including the TEP and peer reviewers (Appendix 
E). 
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Chapter 2. Methods  
In this chapter, we document the procedures the RTI International−University of North 
Carolina Evidence-based Practice Center (RTI−UNC EPC) used to develop this comprehensive 
evidence report on tobacco use prevention, cessation, and population harm. To provide a 
framework for the review, we first present the key questions and their underlying analytic 
framework. We then discuss the previous publications and analyses on which we built our 
systematic review. Following that section, we describe our strategy for identifying articles 
relevant to our key questions, our inclusion/exclusion criteria, and the process we used to 
abstract relevant information from eligible articles and generate our evidence tables. We also 
discuss our criteria for grading the quality of individual articles and rating the strength of the 
evidence as a whole. Finally, we explain the peer review process. 
Key Questions and Analytic Framework 
This report spans key questions regarding 
prevention of tobacco use among youth, 
tobacco cessation for diverse populations of 
adults in a variety of settings, and population 
harm resulting from smokeless tobacco 
marketing. Table 1 lists the key questions 
(KQs) as they were related from the Agency 
for Healthcare Research and Quality 
(AHRQ). 
Key Questions 
KQ 1 seeks to understand how to use 
community- and population-based 
interventions to prevent initiation of tobacco 
use among adolescents and young adults 
across diverse populations. For those 
individuals who do become dependent on 
tobacco products, eventual disease, disability, 
and death can be avoided if they quit using 
tobacco products. KQ 2 seeks to identify 
strategies that increase the likelihood that tobacco users will want and use effective individual 
treatments. Because creating demand for tobacco use cessation is insufficient as a strategy if 
tobacco users do not respond by using these services or if effective treatments and strategies are 
not available in communities and health care systems, KQ 3 asks for a summary of proven 
strategies to increase the implementation of proven population-level tobacco use cessation 
strategies in health care systems and communities.  
Although consensus exists around some tobacco use cessation strategies, controversy 
surrounds other suggested strategies for harm reduction, such as the use of smokeless tobacco 
products. Arguing that the harm associated with smoking cigarettes is much greater for both the 
individual and for those around the smoker than the harm associated with products that are not 
Table 1. Final Key Questions 
KQ 1. What are the effective population- and 
community-based interventions to prevent 
tobacco use among adolescents and young 
adults, including among diverse populations? 
KQ 2. What are effective strategies for increasing 
consumer demand for and use of proven 
individually oriented cessation treatments, 
including among diverse populations? 
KQ 3. What are effective strategies for increasing 
the implementation of proven population-level 
tobacco use cessation strategies, particularly 
by health care systems and communities? 
KQ 4. What is the effect of smokeless tobacco 
product marketing and use on population 
harm from tobacco use? 
KQ 5. What is the effectiveness of prevention and 
cessation interventions in populations with 
co-occurring morbidities and risk behaviors? 
KQ 6. What research is needed to make the most 
progress and greatest public health gains 
nationally and internationally (based on work 
for questions 1–5)? 
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directly smoked, marketers are promoting smokeless tobacco use as a safer and much less costly 
alternative to smoking. KQ 4 asks about the effect of smokeless tobacco product marketing and 
use on population harm. This complex question requires us to assess, with regard to tobacco-
related morbidity and mortality, (1) the impact of smokeless tobacco marketing on smokeless 
tobacco initiation, (2) the prevalence of smokeless tobacco use alone and/or the substitution of 
smokeless tobacco for cigarette smoking, and (3) the association of smokeless tobacco use with 
overall harm and changes in harm (either positive or negative). 
Although most cessation strategies are appropriate for most special populations, recent 
reviews have highlighted issues of effectiveness with some populations, such as those with co-
occurring morbidities and risk factors;30 this population is the focus of KQ 5. Finally, KQ 6 
focuses on directions for future research prompted by answers to the above topics. 
Recent systematic reviews have identified effective strategies at the individual, community, 
and population levels for preventing initiation, helping tobacco users to quit, and implementing 
strategies within the health care system and communities that help tobacco users to quit. These 
reviews dealt with issues affecting diverse populations, including populations with co-occurring 
morbidities and risk behaviors. The issues driving these recent reviews are similar to those issues 
addressed in KQs 1, 2, 3, and 5 of this review. Therefore, we updated or expanded searches 
completed for these recent reviews or undertook entirely new searches for issues not addressed in 
recent reviews. We explain our search and synthesis strategy in more detail below. 
Analytic Frameworks 
Our overall analytic framework (Figure 1), describes the progression from tobacco initiation 
to tobacco dependence to tobacco-related morbidity and mortality, along with populations of 
interest, intervention strategies, and possible associations and outcomes for all KQs except KQ 6 
(on research).  
Figure 2 depicts in more detail the relationship of our overall model to issues relating to each 
of the KQs. The framework indicates the population of interest, the level of intervention 
(individual or population), activities evaluation (e.g., prevention, cessation, marketing), and the 
expected outcomes of the intervention. To understand what is known about how to interrupt this 
progression from initiation to dependence to disease, disability, and death, we focused this 
systematic review on individual, community, and population strategies for tobacco use 
prevention, cessation, and control. 
Previous Reviews 
A good deal of research has been published on these issues, and some has been compiled in 
previous overviews and syntheses. Where possible, we elected to include systematic reviews as 
updates. We selected previous reviews that specifically covered all or parts of the key questions 
above as the basis for this report (see Chapter 3, Table 5). As a result, if studies already 
evaluated in existing reviews that met our inclusion criteria addressed the same outcomes of 
interest for the KQs, we did not reabstract data from them. By contrast, we did examine and 
extract data from studies published after these existing reviews for this report. To make this 
approach clear, we briefly describe existing appraisals of the evidence on each KQ (as depicted 
in Figures 1 and 2) before presenting our specific methods of literature searches and analysis. 
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Figure 1. Overall analytic framework for tobacco use, initiation, and cessation 
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Figure 2. Analytic framework for smoking cessation 
 
Adapted from Hopkins et al., 200131 
KQ 1. Effective Population- and Community-Based Interventions to 
Prevent Tobacco Use 
For KQ 1, we focused our review on five main strategies: 
 
1. Unit price increases on tobacco products,  
2. Mass media education campaigns combined with other interventions to reduce tobacco 
use initiation,  
3. Interventions to reduce youth access to tobacco products (i.e., laws that regulate and 
enforce bans on sales of tobacco products to, or their purchase or consumption by, 
children and adolescents),  
4. School-based education interventions to prevent tobacco use, and  
5. Tobacco industry and product restrictions (i.e., laws that regulate the content, labeling, 
promotion, and advertising of tobacco products).31 
 
Recently, the Guide to Community Preventive Services (hereafter, Community Guide) 
reviewed strategies 1, 2, and 3 and studies that combined two or more interventions in a 
coordinated effort to restrict minors’ access to tobacco products.7 The Institute of Medicine’s 
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report, Growing Up Tobacco Free,32 and the 2000 report of the Surgeon General, Reducing 
Tobacco Use,2 reviewed all five strategies. The Cochrane Collaboration reviewed strategies 233 
and 4.34  
We undertook new searches for strategies not yet reviewed by the Community Guide (i.e., 
numbers 4 and 5), updated the searches for strategies 1 through 3, and searched for strategies 
other than those identified above. We explored the literature for the differential effect of 
prevention strategies among diverse populations, including those among adolescents and young 
adults who are most likely to initiate tobacco use and become regular users.  
KQ 2. Effective Strategies for Increasing Consumer Demand for and 
Use of Individually Oriented Cessation Treatments 
Interventions to increase the number of tobacco users who seek assistance in quitting and 
who successfully quit include efforts to increase the number of users who attempt to quit, to 
improve the success rate for quit attempts, and to support both of these goals.7 This question 
focuses on both sets of interventions.  
Proven individual strategies for helping smokers to quit include counseling and behavioral 
therapy and, except when contraindicated, the use of firstline and secondline medications.5 More 
often than not, individuals are trying to quit without the type of assistance that can double or 
even triple the chances of success.5 Other strategies intended to motivate tobacco users to 
attempt to quit or to reduce relapse among recent quitters include telephone support and mass 
media interventions.  
Telephone support provides an option for individuals reluctant to discuss tobacco use with 
their health care providers. In some cases, telephone support also allows on-demand assistance, 
provides a no-cost service, or includes provision of pharmacotherapies. These features remove or 
at least mitigate some of the barriers that tobacco users may perceive or experience in their 
attempts to receive assistance from their health care providers.  
Mass media interventions are designed and implemented to provide cessation information 
and motivation for tobacco users who are trying to quit.7 The three main subtypes of mass media 
interventions are campaigns, cessation series, and cessation contests. Mass media campaigns 
provide brief, recurring messages; cessation series consist of broadcasted instructional segments; 
and cessation contests are community-wide events of short duration that recruit and motivate 
users of tobacco products to participate in a program to quit by a certain date.7 Mass media 
intervention strategies can also drive tobacco users to call telephone quit lines, thereby increasing 
the number of smokers who seek help.7 
Reviews of community interventions to increase tobacco use cessation have focused on four 
main approaches: (1) multicomponent efforts to increase patient tobacco use cessation, which 
include telephone information or counseling support; (2) mass media campaigns combined with 
other interventions; (3) mass media cessation series; and (4) mass media cessation contests. The 
Community Guide focused on all four issues,7 the 2000 Surgeon General’s Report focused on 
only the second and third,2 the Clinical Practice Guideline focused on the first,5and the Centers 
for Disease Control and Prevention (CDC) Best Practices publication focused on the second.35  
Using the searches in the sources identified above as a base, we updated the searches for all 
strategies. We expanded searches for interventions lacking sufficient evidence at the time of the 
most recent review, for new interventions or strategies introduced in the literature since the most 
recent review, and, to the extent possible, for the differential impact of all strategies on diverse 
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populations. Our cessation searches specifically looked for studies related to the following 
factors: race or ethnicity, socioeconomic status, education level, gender, age (i.e., adolescents 
and adults), hospitalization, and pregnancy. 
KQ 3. Effective Strategies for Increasing Implementation of 
Population-Level Tobacco Use Cessation Strategies 
The Cochrane Collaboration published a systematic review focused on community 
interventions.36 Reviews of health care system interventions to implement effective treatments 
appear in the Community Guide,7 the 2000 Surgeon General’s report,2 the Clinical Practice 
Guideline,5 and Melvin and Gaffney.37  
The Cochrane Collaboration review assesses the effectiveness of community interventions in 
reducing the prevalence of smoking among adults (18 years of age and older).36 It addressed two 
main questions: (1) Do community-based interventions reduce smoking (measured by 
prevalence, cigarette consumption, quit rates, or initiation rates) compared with no intervention 
in comparison communities? (2) Which characteristics of these studies are related to their 
efficacy? Selected studies evaluated the effectiveness of community interventions in which 
smoking behavior change was a part of the intervention program using either a controlled trial 
that randomized communities or geographical regions or a nonrandomized controlled trial that 
allocated communities or geographical regions. 
Even when tobacco users feel comfortable approaching their providers, they may not receive 
effective treatments. Some providers indicate that they do not know how to intervene effectively 
with smokers,38 that they experience disappointment and discouragement given the cyclical 
nature of relapse and remission they observe among smokers,5 and that they are not trained to 
deal with co-occurring morbidities and risk behaviors. Finally, for both providers and tobacco 
users, the costs associated with providing or receiving effective treatment are barriers. For 
example, many providers are not reimbursed for cessation counseling, and tobacco users may 
have no health insurance or only limited health insurance coverage for cessation treatments. 
Recent reviews of interventions that help providers and health care systems implement 
strategies to increase cessation of tobacco use by clients highlight numerous, sometimes 
multifaceted programs. Among programs studied are provider reminder systems with or without 
client education,2,5,36,37 health care provider education alone or with feedback and 
assessment,5,7,36,37 reduction of client out-of-pocket costs for effective cessation therapies,2,5,7 and 
multicomponent interventions that include client telephone support.5,7,36,37 Melvin and Gaffney 
reviewed the literature for interventions that increase the likelihood that health care providers 
will provide effective strategies to pregnant and postpartum women either proactively or in 
response to client demand.37  
We updated and expanded, as necessary, the recently completed reviews on both community 
and health care interventions. The existing reviews on these topics were comprehensive and 
needed little expansion. We expanded searches for interventions lacking sufficient evidence at 
the time of the most recent review and for new interventions or strategies introduced in the 
literature since the most recent review.  
KQ 4. Effect of Smokeless Tobacco Product Marketing and Use  
KQ 4 asks us to examine whether substituting smokeless tobacco for smoking results in less 
smoking-related harm on a population basis and whether smokeless tobacco marketing leads to 
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greater use and/or substitution of smokeless tobacco for smoking. Evidence in reports of the 
Surgeons General and other sources link smokeless tobacco causally with oral leukoplakia and 
oral cancers.2,39 Smokeless tobacco may also increase the risk of cancers in other sites.17 We 
examined the harms associated with smokeless tobacco use and determined whether others have 
used data on these harms to model the potential health effects of substituting smokeless tobacco 
for smoking. Some studies’ approaches to promoting smokeless tobacco use are related to 
current use of these products.40-45  
We are unaware of any studies that have followed the entire analytic framework we 
suggest—assessing (1) the impact of marketing smokeless tobacco on its use or its substitution 
for smoking cigarettes, (2) the impact of smokeless tobacco use on overall harm, and (3) the 
possibility of reduced harm associated with smokeless tobacco use in terms of overall tobacco-
related morbidity and mortality. We reviewed the relevant literature to determine whether any 
studies describe any or all of these relationships. We believe that assessing the public health 
significance of harm reduction associated with smokeless tobacco use will be difficult given that 
only 3.4 percent of Americans ages 12 and older used these products in the past month.2 Also, 
this statistic includes women’s smokeless tobacco use and deflates the importance of this health 
issue because most of these users are young men. The current rate of smokeless tobacco use is 6 
percent among men and only 0.3 percent among women.20  
We also note that recently some tobacco companies have begun to market their smokeless 
tobacco products directly as less harmful alternatives to tobacco, likening them to nicotine 
replacement products and emphasizing that smokeless tobacco does not carry the same risks to 
others as smoking does with secondhand or environmental tobacco smoke.46 We searched for 
studies examining this harm reduction relationship. The review for KQ 4 focuses on adolescents, 
young adults, and adults, especially in relation to harm reduction for tobacco-related morbidity 
and mortality. We focused on studies of marketing approaches for adolescents and young adults 
given their routine and repeated targeting by the tobacco industry and their greater likelihood of 
using smokeless tobacco products. However, we believe that it is too early to determine if these 
harm reduction approaches to smokeless tobacco marketing are effective in increasing its use. 
KQ 5. Effectiveness of Interventions in Populations with Co-Occurring 
Morbidities and Risk Behaviors 
The term “psychiatric comorbidity,” as used in the Treating Tobacco Use and Dependence 
clinical practice guideline, refers to the co-occurrence of smoking with another psychiatric 
disorder.5 We use this narrow definition because individuals with psychiatric illnesses are 
approximately twice as likely as the general population to smoke tobacco. These individuals also 
tend to smoke more heavily than other smokers.47-50 
Co-occurring risk behaviors include those behaviors that trigger tobacco use, such as alcohol 
or other substance use or abuse. As many as 20 percent of patients seeking smoking cessation 
services may have a history of alcohol abuse or dependence.48-50 Among abusers of alcohol and 
drugs, smoking occurs at rates well above population averages (e.g., greater than 70 percent).51-53  
Treatment of individuals with these co-occurring morbidities or other risk behaviors remains 
a controversial topic, because some believe that smoking cessation and nicotine withdrawal 
exacerbate a patient’s comorbid condition and, thereby, present unique case management 
challenges.  
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The clinical practice guideline examined the efficacy of tobacco treatment among patients 
with psychiatric comorbidity.5 Another recent review of smoking cessation approaches for 
individuals with mental illness or addictive disorders examined empirical studies conducted 
between 1991 and 2000.30 The majority of interventions combined medication and 
psychoeducation. We updated and expanded these reviews to examine the effectiveness of 
cessation interventions in populations with co-occurring morbidities and risk behaviors. 
No previous review addressed the effectiveness of prevention interventions in this 
population. We examined studies identified through searches focused on populations with co-
occurring morbidities and risk behaviors to determine if any analyses reported smoking 
prevention and cessation outcomes. We found few studies on smoking cessation and no studies 
on prevention (because the population is already smoking).  
KQ 6. Needed Research 
Current systematic reviews include recommendations for further research and areas of 
insufficient evidence. Through this newer review, we identified findings that are both consistent 
and inconsistent with previously identified needs for research, and we pinpointed important gaps 
in research.  
Literature Review Methods 
Inclusion and Exclusion Criteria 
After discussions with our Technical Expert Panel (TEP), we generated a list of article 
inclusion and exclusion criteria (Table 2) for these KQs. We limited our review to human studies 
conducted in developed countries and published in English. We considered studies with 
participants ages 13 and older of both genders from diverse racial and ethnic populations.  
We excluded editorials, letters, commentaries, articles that did not report outcomes related to 
our key questions, and studies that did not provide sufficient information to be abstracted. To 
avoid reporting short-term fluctuations among the populations and to ensure sufficient sample 
sizes to observe changes over time, we limited our review to randomized controlled trials (RCTs) 
with 30 or more individuals or observational studies and nonrandomized controlled trials with 
100 or more individuals, followed for a minimum of 6 months, with or without comparison 
groups. Our TEP concurred with this plan.  
Literature Search and Retrieval Process 
Databases and search terms. To identify the relevant literature for our review, we 
conducted systematic searches based on search terms and hand-searched reference lists. We 
searched standard electronic databases: MEDLINE®, the Cumulative Index to Nursing and 
Applied Health (CINAHL), Cochrane Collaboration libraries, Cochrane Clinical Trials Register, 
Psychological Abstracts, and Sociological Abstracts.  
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Table 2. Tobacco use: inclusion/exclusion criteria 
Category Criteria 
Study population 
 
Humans, all races, ethnicities, and cultural groups 
KQ 1: Adolescents (13-18 years of age), young adults (18-24 years of age), and diverse 
populations 
KQ 2: Adolescents, young adults, adults (18 years of age and older), and diverse 
populations 
KQ 3: Adults and diverse populations 
KQ 4: Adolescents, young adults, and adults 
KQ 5: Adolescents, young adults, and adults with comorbidities and risk behaviors 
Study outcomes KQ 1: Reduced initiation of tobacco use 
KQ 2: Increased quit rates; greater numbers of smoking cessation participants (i.e., 
increased participation) 
KQ 3: Increased quit rates; change in provider behaviors concerning smoking cessation  
KQ 4: Increased use; increased substitution of smokeless tobacco for smoking; harm 
reduction 
KQ 5: Reduced initiation of tobacco use; increased quit rates 
Study geography  Developed countries: United States, Canada, United Kingdom, Western Europe, Australia, 
and New Zealand  
Time period KQ 1: Studies that addressed prevention of adolescent and youth tobacco use: January 1, 
2000, to June 10, 2005 
Studies that addressed product restrictions in the tobacco industry aimed at countering 
youth tobacco use: January 1, 1980, to June 10, 2005 
KQ 2 and KQ 3: January 1, 1999, to June 10, 2005 
KQ 4 and KQ 5: January 1, 1980, to June 10, 2005 
Publication languages English only 
Admissible evidence (study 
design and other criteria) 
Original research studies that provide sufficient detail regarding methods and results to 
enable use and adjustment of the data and results; relevant outcomes must be able to be 
abstracted from data presented in the papers.  
 
Eligible study designs include 
• Randomized controlled trials (RCTs);  
• Nonrandomized controlled trials; and  
• Observational studies: prospective and retrospective cohort studies, case-control 
studies, and cross-sectional studies.  
 
Single case reports or small case series are excluded.  
 
Sample sizes must be appropriate for the study question addressed in the paper.  
RCTs: 30 or more participants  
Observational studies and nonrandomized controlled trials: 100 or more participants  
KQ, key question 
Based on the inclusion/exclusion criteria specified above, we generated a list of Medical 
Subject Heading (MeSH) search terms, supplemented by key word searches to search 
MEDLINE® (Table 3). Comparable terms were used to search other databases. Finally, we 
asked our TEP and external peer reviewers to suggest articles that we might have missed. 
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Article selection process. 
Once we had identified articles 
through the electronic database 
search, review articles, and 
bibliographies, we examined 
abstracts and the full text of the 
articles to determine whether 
the studies met our inclusion 
criteria. Two reviewers initially 
evaluated abstracts for 
inclusion or exclusion; only one 
reviewer was needed to include 
an article, but two reviewers 
were required to exclude an 
article. Dr. Ranney, the Study 
Director, reconciled all 
conflicts. As articles appeared 
that met inclusion criteria at the 
abstract review stage, we 
obtained the article’s full text. 
For the full text review, two 
reviewers read each article and 
determined whether it met our 
eligibility criteria. Again, Dr. 
Ranney adjudicated any 
disagreements. Dr. Ranney and 
Dr. Cathy Melvin, our Scientific Director, reviewed articles excluded by the first two reviewers 
and assigned reasons for exclusion or, when appropriate, included them in the pool for 
abstraction.  
Literature Synthesis 
Development of Evidence Tables and Data Abstraction Process 
Senior staff for this systematic review jointly developed evidence tables using two designs: 
one design for primary data collection studies and one for systematic reviews. The designs are 
intended to provide sufficient information so that readers can understand the study and determine 
its quality; we emphasized presenting information essential to answering the main questions. The 
formats of the two sets of evidence tables were based on successful designs used for prior 
systematic reviews. 
The primary data collection evidence tables contain information on  
 
• Study characteristics (author, year, study setting, funding source, time period covered); 
• Research objective, population, and study design (inclusion, exclusion criteria); 
• Sample design (technique and size); 
Table 3. Medical subject headings and text words 
Medical Subject Headings 
Tobacco use cessation Marketing 
Smoking cessation Social marketing 
Smoking/prevention and control Choice behavior 
Smoking (and as text term) Advertising 
Primary prevention  
  
Community networks Tobacco, smokeless 
Community health services Spit tobacco (text term) 
Community health planning Chewing tobacco (text term) 
Community health aides Dip tobacco (text term) 
Community health nursing Oral tobacco (text term) 
Community health centers  
Community mental health services Comorbidity 
Community medicine Risk-taking 
Community mental health centers Risk factors 
 Depressive disorder 
Randomized controlled trials Depression 
Single-blind method Bipolar disorder 
Double-blind method Attention deficit disorder with 
hyperactivity 
Random allocation Stress disorders, post-traumatic 
 Diabetes mellitus 
Consumer satisfaction Hypertension 
Consumer participation Heart diseases 
Health services needs and demand  Asthma 
 Obesity 
Health plan implementation  
Diffusion of Innovation  
Patient education  
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• Definitions of smoking; 
• Intervention methods, description, and assessment; 
• Baseline data; 
• Statistical analysis, data verification, and dependent variables; 
• Results (outcome measures); and  
• Quality rating and comments. 
 
The evidence tables for systematic reviews report on  
 
• Study demographics (author, year, geographic area, funding source, time period covered); 
• Study characteristics (inclusion criteria, population, characteristics of studies, method of 
review, study design, what studies are included in the meta-analysis); 
• Aim of review; 
• Main results; and 
• Quality rating (adverse events). 
 
For this work, the RTI-UNC EPC team decided to abstract data from included articles 
directly into a proprietary systematic review database program, TRIALSTAT. We trained data 
abstractors intensively, thoroughly familiarizing them with the abstraction form design 
(Appendix B†), required information and formats, and examples of abstracted articles. As the 
work progressed, we shared various reporting requirements with abstractors to ensure that 
information appeared in a consistent and easily understandable manner.  
For the primary data literature, the first reviewer (a research assistant from the University of 
North Carolina at Chapel Hill) entered data from the article into the database. The second, senior 
reviewer (either Dr. Ranney or Dr. Melvin) read the article and edited the initial table entry for 
accuracy, completeness, and consistency. For the systematic review literature, Dr. Ranney 
entered data from the review into the database, and Dr. Melvin read the article and edited the 
initial table entry for accuracy, completeness, and consistency. In both cases, the two abstractors 
reconciled all disagreements by consensus discussion. 
The final evidence tables are presented in their entirety in Appendix C. Below are the table 
titles for each question. Within each evidence table, entries are listed alphabetically by the last 
name of the first author. Abbreviations and acronyms used in the tables appear in a glossary at 
the beginning of the appendix.  
 
• KQ 1 
o Evidence Table 1. Effective population-based interventions 
o Evidence Table 2. Effective school-based interventions 
o Evidence Table 3. Effective provider-based interventions  
• KQ 2 
o Evidence Table 4. Multicomponent interventions to increase the number of users who 
quit smoking 
o Evidence Table 5. Strategies to improve success rates for quit attempts for general 
and special populations 
                                                 
 
† Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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• KQ 3 
o Evidence Table 6. Population-based strategies to increase the implementation of 
proven population-level tobacco use cessation strategies 
o Evidence Table 7. Provider and health care systems strategies to increase 
implementation of population-level tobacco use cessation  
• KQ 4 
o Evidence Table 8. Effect of smokeless tobacco product marketing and use on 
population harm from tobacco use 
• KQ 5 
o Evidence Table 9. Tobacco cessation interventions for persons with co-occurring 
morbidities and risk behaviors 
• Systematic Review and Meta-analysis 
o Evidence Table 10. Systematic and meta-analysis reviews 
Quality and Strength of Evidence Evaluation 
Quality of studies. We assessed the internal validity (i.e., quality) of trials based on 
predefined criteria developed by the US Preventive Services Task Force (ratings are good, fair, 
or poor)54 and the National Health Service Centre for Reviews and Dissemination.55 We assessed 
and reported external validity (i.e., generalizability) but did not use these judgments in our 
quality ratings.  
We developed three quality rating forms, two for the primary data literature (one for 
randomized controlled trials and one for observational studies and non-randomized controlled 
trials) and the other for the systematic review literature. We tested several drafts of these forms, 
revising them as needed to ensure that they efficiently captured the desired information. The 
final grading forms can be found in Appendix B. Elements of internal validity assessment for 
primary data literature included, among others, randomization and allocation concealment, 
similarity of compared groups at baseline, use of intention-to-treat analysis, and overall and 
differential attrition. The assessment of the systematic review literature focused on issues of 
validity, such as whether the search strategy was systematic and comprehensive, and issues of 
reliability, including whether the authors used a standard method of critical appraisal.  
Two independent reviewers assigned quality ratings; they resolved any disagreements by 
discussion and consensus or by consulting a third, independent party. Primary data articles that 
had one or two minor study design issues were considered “good”; an example of such an article 
is one in which an intention-to-treat analysis was not conducted, but the author addressed the 
issue of loss to followup by surveying those who did not complete the study. We had a wide and 
diverse range of “fair” articles, which were articles that had several minor study design issues, 
such as lack of reporting on baseline group differences or a weak sampling technique. Articles 
that had multiple major study design issues, such as postrandomization of exclusions, high 
refusal rates, high attrition rates, no comparison of groups at baseline, and lack of information 
about control or comparison groups, received a quality grade of “poor.” 
All but one of the systematic literature reviews and meta-analyses were of good quality; the 
exception was “fair.” The systematic reviews assessed were primarily from the Cochrane 
Collaboration, which is known for conducting comprehensive literature searches and employing 
stringent appraisal criteria. The two meta-analyses were of high quality; one is recognized in the 
field of tobacco control as the “gold standard,” and the other was rated “good.”  
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Strength of the available evidence. We rated the strength of the evidence for the 
interventions based on the criteria developed for the Task Force on Community Preventive 
Services,56 which we deemed most applicable to the study designs in this review (Table 4). Our 
evaluation employed three domains to determine the strength of the evidence for each 
intervention: quality of the research, including design suitability and study execution; quantity of 
studies, including the number of studies and the adequacy of the sample size; and consistency of 
findings among the studies. The available evidence for an intervention was determined to be 
strong, “sufficient,” or “insufficient.”  
Bodies of evidence rated as strong included an adequate number of studies that were of good 
or fair quality, had study designs that were appropriate for the intervention being evaluated or 
issue being addressed, and were consistent in the direction of their findings. Sufficient bodies of 
evidence also contained studies of good or fair quality, but the suitability of the studies’ designs 
was not as consistently appropriate and, therefore, more relevant studies were required to rate the 
evidence in the category. As per the Task Force model, the reasons for determining that a body 
of evidence was “insufficient” included unsuitable study designs, too few studies to determine 
the effectiveness of an intervention, too small an effect size, and inconsistent findings among 
studies of an intervention.56 We graded the strength of evidence applicable to each of the key 
questions separately.  
Table 4. Modified body of evidence assessment table from Guide to Community Preventive Services 
Evidence of Effectiveness Execution of Study Design Design Suitability Number of Studies 
Strong Good 
Good 
Good or fair 
Greatest 
Greatest or moderate 
Greatest 
At least 2 studies 
At least 5 studies 
At least 5 studies 
Sufficient Good 
Good or fair 
Good or fair 
Greatest 
Greatest or moderate 
Greatest, moderate, or least  
At least 1 study 
At least 3 studies 
At least 5 studies 
Insufficient Insufficient execution Insufficient design Too few studies 
Task Force on Community Preventive Services, 200556 
Peer Review Process 
Among the more important activities involved in producing a credible evidence report is 
conducting an unbiased and broadly based review of the draft report. External reviewers for this 
report included clinicians and representatives of professional societies and advocacy groups, 
including TEP members (see Appendix D).‡ We charged peer reviewers with commenting on the 
content, structure, and format of the evidence report and asked them to complete a peer review 
checklist. We revised the report, as appropriate, based on their comments. 
 
                                                 
 
‡ Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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Chapter 3. Results 
This chapter presents results of our literature search and our findings for five key questions 
(KQs) regarding tobacco prevention, cessation, and control. These form the background for a 
State-of-the-Science (SOS) conference scheduled for June 12−14, 2006, under the auspices of 
the Office of Medical Applications Research (OMAR) of the National Institutes of Health (NIH). 
We report here on the following issues:  
 
• KQ 1, initiation of tobacco use among young people;  
• KQ 2, demand for and use of cessation treatments;  
• KQ 3, increasing use and implementation of health care and community cessation 
programs;  
• KQ 4, impact of smokeless tobacco product marketing on use, and  
• KQ 5, cessation treatments for individuals with comorbidities and risk behaviors. 
KQ 6 is covered in Chapter 4 and deals with the limitations of these bodies of literature and our 
recommendations for future research.  
We discussed specific approaches for the first three KQs with our Technical Expert Panel 
(TEP) because, as noted in Chapter 2, we had a considerable pool of existing publications on 
which to draw. In each section below, we report first on previous reviews that covered the KQ, 
then on specific details about the yields of the literature searches and characteristics of the 
studies, and finally on literature pertaining to each question. Where appropriate, we provide 
summary tables presenting selected information on each included study that had a quality rating 
of good or fair.  
Appendix C* contains all the full evidence tables for each question. Evidence tables are 
organized by major analytic topic; studies are then listed alphabetically by author. A glossary at 
the beginning of the appendix defines all acronyms and abbreviations appearing in the tables. If 
several articles report on a single study, they are grouped in a single entry (row); if a study or 
article has information concerning more than one KQ, it appears in every relevant evidence table.  
Results of Literature Searches 
Our literature searches yielded 1288 possible articles (see Figure 3). (Appendix A presents 
the search terms and yield for each database searched in June 2005.) Beginning with the 1,288 
titles and abstracts, we excluded 642 entries at the abstract level because it was apparent that 
they did not meet our inclusion criteria.  
                                                 
 
* Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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Figure 3. Tobacco use: prevention, cessation, and control article disposition 
Title and abstracts identified through searches
N = 1,288
Citations excluded
N = 642
Published in abstract form only
N = 2
Full text articles excluded:
N = 298
    1 Foreign language
106 Wrong outcome/off topic
  12 Sample size too small
    3 Outside specified geographic area
  93 Wrong publication type
  22 Wrong study design
    8 Followup too short
  53 Wrong date
Full text articles retrieved
N = 488
Full text articles included in review
N = 102
Marked as background
N = 88
Full text not obtained – overlapped with 
included meta-analysis
N = 156
 
To focus our review on the most rigorous research and avoid duplicating previous reviews, 
we did a cross-walk (i.e., checked for duplicate articles) between the 644 citations and the 
citations from related systematic reviews and meta-analyses (Table 5). Articles that overlapped 
with systematic reviews and meta-analyses are listed in Appendix D. This process further 
narrowed the pool to 488 articles, which we then pulled and fully reviewed. Of the reviewed 
articles, 102 studies were included in this report. Table 5 lists the systematic reviews, meta-
analyses, and dates of included literature used as a basis for topics equivalent to KQs 1, 2, 3, and 
5.  
Specifically, the following publications have extensively covered tobacco prevention and 
cessation intervention strategies in diverse populations:  
 
• The Guide to Community Preventive Services (2005),  
• Treating Tobacco Use and Dependence (2000),  
• Reducing Tobacco Use, A Report of the Surgeon General, (2000),  
• The Cochrane Collaboration reviews (1998–2005),  
• Treating nicotine use and dependence of pregnant and parenting smokers, (2003),  
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• A meta-analysis of smoking cessation interventions with individuals in substance abuse 
treatment or recovery (2004),  
• Smoking cessation approaches for persons with mental illness or addictive disorders 
(2002), and  
• Growing up tobacco free: preventing nicotine addiction in children and youths (1994). 
 
The cross-walk identified 156 common citations. Because these reviews served as the 
starting point for the evidence-based report, we did not abstract the 156 shared citations.  
Table 5. Systematic reviews and meta-analysis used for this report 
Review Type Authors Topic 
Included 
Research 
Cochrane Ebbert JO, Rowland LC, Montori V, Vickers 
KS, Erwin PC, Dale LC, Stead, LF57 
Interventions for smokeless tobacco use 
cessation 
1992 to Mar. 
2004 
Cochrane Lancaster T, Stead LF58 Physician Advice for Smoking 
Cessation 
1974 to 2003 
Cochrane Lancaster T, Stead L59 Self-help interventions for smoking 
cessation 
1981 to Apr. 
2005 
Cochrane Lancaster T, Stead LF60 Individual behavioural counseling for 
smoking cessation 
1984 to Feb. 
2005 
Cochrane Lumley J, Oliver SS, Chamberlain C, and 
Oakley L61 
Interventions for promoting smoking 
cessation during pregnancy 
1976 to Mar. 
2004 
Cochrane Moher M, Hey K, Lancaster T62 Workplace interventions for smoking 
cessation 
1981 to Feb. 
2005 
Cochrane Rigotti NA, Munafo MR,Murphy MFG, 
Stead LF63 
Interventions for smoking cessation in 
hospitalised patients 
1974 to 2002 
Cochrane Secker-Walker RH, Gnich W, Platt S, 
Lancaster T36 
Community interventions for reducing 
smoking among adults 
1970 to Jan. 
2002 
Cochrane Sowden A, Arblaster L33 Mass media interventions for preventing 
smoking in young people 
1983 to Aug. 
1998 
Cochrane Sowden A, Stead L64 Community interventions for preventing 
smoking in young people 
1983 to Sept. 
2002 
Cochrane Stead LF, Lancaster T65 Group behaviour therapy programmes 
for smoking cessation 
1981 to Feb. 
2005 
Cochrane Stead LF, Lancaster T, Perera R66 Telephone counseling for smoking 
cessation 
1991 to Oct. 
2002 
Cochrane Thomas R34 School-based programmes for 
preventing smoking 
1980 to Jan. 
2002 
Systematic 
review 
el-Guebaly N, Cathcart J, Currie S, Brown 
D, Gloster S30 
Smoking cessation approaches for 
persons with mental illness or addictive 
disorders 
1990 to 2000 
Meta-analysis Fiore MC, Bailey WC, Cohen SF, et al.5 Clinical practice guideline update: 
Treating Tobacco Use and Dependence 
1995 to 1999 
Meta-analysis Prochaska JJ, Delucchi K, Hall SM9 A meta-analysis of smoking cessation 
interventions with individuals in 
substance abuse treatment or recovery 
1991 to 2003 
Systematic 
review 
Lynch BS, Bonnie RJ32 Growing up tobacco free: preventing 
nicotine addiction in children and youths 
1990 to 1993 
Systematic 
review 
Melvin, CL, Gaffney, C37 Treating nicotine use and dependence 
of pregnant and parenting smokers:  An 
update 
1994 to 2003 
Systematic 
review 
US Department of Health and Human 
Services 
Reducing tobacco use: a report of the 
Surgeon General 
Not reported 
Systematic 
review 
Zaza S, Briss PA, Harris KW7 The Community Preventive Services 
Guide: Tobacco (Chapter 1) 
1976 to May 
2000 
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We included original research studies that (1) were published beyond the date range included 
in the systematic reviews, (2) concerned topics related to the questions not covered by the 
reviews, and (3) provided sufficient detail regarding their methods and outcomes. The 
approaches for each specific question are as follows. For KQ 1, we included studies published 
between January 1, 2000, and June 10, 2005, that addressed topics 1 through 4 in Chapter 2. We 
also relied on the synthesis of previous reviews and meta-analyses for research and 
recommendations published before 2000. We included all primary data collection studies that 
addressed product restrictions in the tobacco industry (i.e., laws that regulate the content, 
labeling, promotion, and advertising of tobacco products), which represents subjects that the 
other systematic reviews did not cover. For KQ 2 and KQ 3, we included studies published 
between January 1, 1999, and June 10, 2005. We relied on the synthesis of past reviews and 
meta-analyses for research and recommendations published before 1999. For KQs 4 and 5, we 
included research found between January 1, 1980, and June 10, 2005, pertaining to the specific 
question.  
KQ 1. Effective Population- and Community-Based 
Interventions to Prevent Tobacco Use 
The primary goals of population- and community-based interventions are to prevent or delay 
experimentation with tobacco and to prevent the transition from experimentation to regular use. 
Additionally, these interventions motivate and encourage people to quit. For the purpose of this 
report, population-based interventions employed traditional population sampling techniques such 
as random-digit dialing, and nationwide surveys to recruit participants and collect data. These 
interventions are easily generalizable to large groups of people. Community-based interventions 
are directed at a distinct segment of society that shares similarities or fellowship, and 
generalizability is limited by the uniqueness of the community studied.  
As shown in our analytic frameworks for KQ 1 (in Chapter 2), we examined the effectiveness 
of population- and community-based strategies to prevent tobacco use by reducing tobacco 
initiation among adolescents and young adults. Prevention of tobacco use is measured by 
differences or changes in (1) self-reported tobacco use among adolescents and young adults,  
(2) self-reported purchases of tobacco products, (3) tobacco obtained from commercial sources 
(e.g., vending machines), and (4) retailer sales of tobacco products to minors.7  
Population-Based Interventions to Limit Access and Reduce Initiation 
Nicotine addiction begins at an early age; 89 percent of adult daily smokers have tried 
cigarettes before age 18.32 In 2004, current use of tobacco was reported by 28 percent of high 
school students and 11.7 percent of middle school students.8 Cigarettes are the most commonly 
used tobacco product for both middle and high school students.  
Population-based intervention efforts to reduce tobacco use initiation among adolescents and 
young adults include at least four mechanisms: (1) increases in the unit price of tobacco 
products; (2) laws that regulate and enforce bans on sales, purchases, and consumption of 
tobacco products by underage youth; (3) laws that regulate the content, labeling, promotion, and 
advertising of tobacco products; and (4) mass media education campaigns.  
Synthesis of prior systematic reviews. Past reviews have evaluated interventions to limit 
access to tobacco products and reduce tobacco use initiation among adolescent and young adults. 
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They include (1) increasing the unit price of tobacco products, (2) enforcing tobacco laws and 
regulations, (3) implementing tobacco industry and product restrictions, and (4) disseminating 
mass media campaigns.2,7,32,33 
Increasing the unit price of tobacco products. An increase in the excise tax on tobacco, 
which requires passage of legislation or a statewide referendum, results in an overall increase in 
the cost of tobacco products. For adolescents and young adults with limited incomes, higher 
prices make cigarettes less attractive.7 Several earlier reports agree on the positive effects of 
economic approaches to reducing tobacco initiation.2,7,32 Recommendations from the Institute of 
Medicine state that a tax increase of $2.00 for each pack would make tobacco less accessible and 
raise money for tobacco control, health care, and other uses. Unit price has a direct influence on 
the demand for cigarettes.2 Eight studies that evaluated intervention strategies that increased the 
price of tobacco products provided price elasticity of demand estimates by combining 
information on local tobacco product prices and price changes or differences in survey responses 
over time on tobacco use and consumption.7 A 10 percent price increase in tobacco prices results 
in an approximately 4 percent decrease in consumption of tobacco products by adolescents (13 to 
18 years of age). A similar strong effect is found for young adults (18 to 24 years of age).7  
Enforcing tobacco laws and regulations. Minors obtain tobacco from retailers (merchants), 
commercial sources (vending machines), and social sources (other adults); all contribute to 
initiation and regular use of tobacco.7 Restricting distribution, regulating the mechanisms of sale, 
enforcing minimum age laws, and providing merchant education and training have some success 
in reducing minors’ access to tobacco.2 Multicomponent interventions designed to reduce 
minors’ access to tobacco include numerous strategies: stronger restrictions on retailer sales of 
tobacco products; restrictions directed at youth purchases, possession, and use; active 
reinforcement of tobacco sales laws; and retailer education interventions with or without 
reinforcement.7,32 Thirteen multicomponent studies, with 10 different combinations of 
interventions, investigated how restricting minors’ access to tobacco affects tobacco initiation. 
Only five of these studies used differences or changes in tobacco use among youth as the 
outcome variable. Four of the studies coordinated community mobilization efforts with retailer 
education with enforcement, stronger local ordinance for retailers, enforcement of retailer sales 
laws, school-based education, or local ordinances directed at youth tobacco purchase, possession, 
or use.7 Interventions to reduce youth access to tobacco products that combined two or more 
interventions in a coordinated effort decreased students’ self-reported tobacco use by 5.8 
percentage points over a period of 2 to 4 years.7 
Tobacco industry and product restrictions. In 1998, the Master Settlement Agreement 
prohibited tobacco advertising that targets people under 18 years of age. Despite this agreement, 
tobacco companies consistently allocate a higher proportion of their expenditures for advertising 
of youth brands to youth-oriented magazines.67 Reviews on tobacco industry and product 
restriction are still in progress.31 Strategies for regulating tobacco packaging, labeling, and 
contents are long-term steps, recommended by the Institute of Medicine Committee on 
Preventing Nicotine Addiction in Children and Youths,32 to sustain progress toward reducing 
health consequences of tobacco use. Warnings on cigarette packages in the United States are 
weaker and less conspicuous then those in other countries. In addition, purchasers of tobacco do 
not receive information about toxic constituents in tobacco smoke. To protect adolescents and 
young adults from inducement that might influence their decision to start smoking, implementing 
stricter regulations on packaging, advertising, and promotion is imperative and will likely reduce 
both prevalence and uptake of tobacco use.2  
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Mass media education campaigns. Mass media education campaigns disseminate brief 
recurring messages with the intent of providing information that will motivate children and 
adolescents to remain tobacco free.7 Campaign methods include broadcast messages on 
television and radio, billboards, print, and movies. Media campaigns increase awareness of the 
strategies that the tobacco industry uses to promote tobacco and they attempt to facilitate changes 
in both tobacco use behaviors and public tobacco policies. They also use educational messages 
relating to demand reduction to provide information and support to adolescents to help them 
decide to remain tobacco free.7 Reviews of mass media campaigns and community interventions 
that include a media component report some evidence that these are effective, particularly when 
combined with other intervention activities such as school- and community-based education 
programs and increases in excise taxes on tobacco.33,64  
A review of 12 studies evaluated the effectiveness of mass media campaigns in reducing 
tobacco use among adolescents.7 The studies conducted the media campaign in conjunction with 
other intervention strategies such as school- and community-based educational programs, 
contests, and increased excise taxes. Mass media campaigns conducted concurrently with other 
interventions generally showed reductions of tobacco use among youth in the intervention 
communities. Five of these studies reported absolute differences in self-reported tobacco use. 
The media campaigns decreased the number of adolescents using tobacco by approximately 2.4 
percentage points.7 Campaigns that last 2 years increase the effectiveness of the campaign.  
Synthesis of current literature. Fifteen original studies examined interventions designed to 
reduce tobacco initiation among adolescents and young adults (KQ 1).68-82 In reviewing these 
studies, we used a three-level component rating scale to assess the quality of each study. We 
rated them good, fair, or poor based on the rigor of the study design and how well the study was 
conducted. Quality review ratings for KQ 1 consisted of 1 good rating, 12 fair ratings, and 2 poor 
ratings (poor ratings had one or more fatal flaws in design or conduct of the study). Therefore, 
we discuss 13 studies for KQ 1. Information on the two studies we rated as poor are in the 
evidence tables (Appendix C).† We organized the KQ 1 studies by population-based (Evidence 
Table 1), school-based (Evidence Table 2), and provider-based interventions (Evidence Table 3).  
Population-based interventions to reduce tobacco initiation. Two of the 13 studies were 
population-based.73,79 As shown in Table 6, the studies were conducted in the United States and 
received quality ratings of fair. Sample sizes ranged from 1,316 to 3,831 adolescents ages 12 to 
17. One study addressed youth access, specifically youth access ordinances and regulations,79 
and the other was an intervention designed to prevent adolescent tobacco and alcohol use by 
targeting family risk factors.73  
We did not find studies implementing other prevention strategies related to unit price of 
tobacco products, tobacco industry and product restrictions, or media campaigns alone or in 
combination with other tobacco prevention interventions. With the exception of tobacco industry 
and product restrictions, these interventions have been covered extensively in past systematic 
reviews. New studies investigating these topics either did not meet our inclusion criteria, in 
particular did not report on the outcome variable for KQ 1 (i.e., reduced initiation of tobacco use 
among adolescents and young adults), or are not in publication. 
                                                 
 
† Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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Table 6. Effective population-based interventions 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Ennett et al., 
200173 
 
United States 
 
48 contiguous 
states 
RCT 
 
4 mailings 
over 14 
months 
 
3 and 12 
months 
 
G1: Booklets mailed 
to parents followed by 
telephone discussion 
with health educator 
and parents 
C1: Did not receive 
“Family Matters” 
program 
1,316 
adolescent- 
parent pairs 
(adolescents 
ages 12–14 
years) 
Effects present for non- Hispanic 
whites only (n=791) 
 
Adolescents in the control group 
were more than 1.5 times as 
likely to smoke at the 3-month 
followup than adolescents in the 
intervention (OR, 1.59; P = 
0.008, lower bound CI, 1.19 for 
a one-way test of significance)  
 
Program parents were more 
likely to discuss peer and media 
influences and set rules about 
smoking 
Fair 
Thomson et 
al., 200479 
 
United States 
 
Boston, MA 
Cross-
sectional  
 
NA 
 
NA 
G1: parent 
involvement in 
community-level 
tobacco ordinances 
3,831 youth 
(12–17 years) 
Youth living in towns that ban 
free-standing displays were less 
likely to perceive tobacco as 
easy to purchase (AOR, 0.6; 
95% CI, 0.5-0.9; P = 0.007)  
 
Increased perceived access was 
associated with being older (P < 
0.0001) and male (P ≤ 0.002) 
Fair 
AOR, adjusted odds ratio; C1, control group; CI, confidence interval; G1, intervention group 1; NA, not applicable; NR, not 
reported; OR, odds ratio; RCT, randomized controlled trial. 
Restricting adolescents’ access to tobacco products is a population-based intervention aimed 
at reducing tobacco initiation. A study using Massachusetts statewide youth tobacco access 
ordinances and regulations examined the effects of these provisions on youth perceived access to 
tobacco products, youth purchase attempts, and youth tobacco use.79 In this cross-sectional study, 
the investigators surveyed youth from across Massachusetts using a random sample of 
households. Interviewers collected demographic data from the adult resident, screened for 
eligibility, and requested permission to interview all youth in the household between the ages of 
12 and 17. After excluding inconsistent reports of resident’s town, zip code, or telephone 
exchange and towns having no identified youth respondents, interviewers collected data from 
3,831 participants in 314 towns. The Massachusetts Tobacco Control Program produces a 
biannual report on six provisions of youth access ordinances from each town: 
 
1. Licensing (requires retailers to have a license to sell tobacco products), 
2. Fines for merchants who sell tobacco products to minors; 
3. Vending machine restrictions (a complete ban or restricted to adult-only establishment) 
4. Ban on free-standing displays of tobacco products  
5. Ban on sale of single cigarettes and  
6. Ban on distribution of free samples. 
The six provisions were used as predictor variables in the analysis. Additionally, a measure of 
antismoking sentiment provided a baseline measure in each town before expansion of the local 
youth access ordinance. The antismoking measure was highly correlated with the town-level 
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socioeconomic measure. The outcome variables were dichotomous; smoking status was defined 
as “ever smoker” (has smoked or puffed a cigarette in one’s lifetime) or “current smoker” (has 
smoked at least one cigarette in the past 30 days).79  
In the fully adjusted model, only two provisions were statistically significant and only one in 
the expected direction. Youth living in towns that ban free-standing displays were less likely to 
perceive tobacco as easy to purchase (adjusted odds ratio [AOR], 0.6; 95% confidence interval 
[CI], 0.5-0.9; P = 0.007). Counterintuitively, youth reported easy access in towns that required 
tobacco vendors to have a license (odds ratio [OR], 1.3; 95% CI, 1.1-1.5; P = 0.009). Overall, 37 
percent believed that it was easy to buy cigarettes in their town. No associations were found 
between youth access ordinances and attempts to purchase or between ordinances and tobacco 
use. Individual factors associated with increased attempts to purchase were associated with being 
older (P < 0.01) and male (P = 0.004). Individual factors associated with tobacco use were being 
older, living with a smoker, and having a close friend who smokes (P < 0.0001).79  
The second population-based study enrolled 1,316 adolescent-parent pairs throughout the 
contiguous United States through random-digit dialing into a family-directed program called 
Family Matters.73 Pairs completed baseline interviews by telephone, were matched with another 
pair by date and time of completion, and were randomly assigned to either receive the Family 
Matters program or serve as controls. This program used both global attributes of families, such 
as supervision and attachment, and substance-specific family characteristics, such as parental 
drug use, to reduce tobacco initiation. The program assumes that changing global family 
characteristics (supervision, supportiveness, involvement, and communication) and substance-
specific characteristics (parent expectations and attitudes toward child’s drug use; parental 
monitoring, rules, and encouragement about drug use; availability of and outside influences 
regarding drugs; parental drug use) will change a third domain—adolescent cognitions regarding 
drug use and, in turn, will ultimately influence adolescent use.73 
The investigators completed successive mailings of four booklets to parents and their 12- to 
14-year-old children between July 1996 and September 1997 (1 year and 2 months). Following 
each mailing, telephone discussions occurred between parents (or guardians) and health 
educators. Families who completed the program spent an average of 4.5 hours doing the 
program; parents spent an additional hour talking with the health educator by telephone. The 
program measured exposure to the Family Matters program, adolescent tobacco and alcohol use, 
three sets of mediator variables, and sociodemographic characteristics at 3- and 12-month 
followups. Self-reported smoking status, without biochemical verification, categorized never-
smoked adolescents as nonusers and adolescents who smoked even a puff of a cigarette as 
users.73  
Baseline data showed fewer non-Hispanic whites students in the Family Matters intervention 
than in controls. The effects of the intervention were present only among non-Hispanic white 
adolescents—a subset of the population (n = 791). Adolescents in the control group were more 
than 1.5 times as likely to smoke at the 3-month followup assessment than adolescents in the 
Family Matters intervention (OR, 1.59; P = 0.008, lower bound CI = 1.19 for a one-way test of 
significance). No significant effects were evident at the 12-month followup. The conceptual 
model underlying the Family Matters program was validated for non-Hispanic whites only.73  
Community-Based Interventions to Prevent Tobacco Initiation 
Community-based interventions are coordinated, widespread programs in a particular 
geographic area, such as a school district, or in a grouping of people who share common interests 
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or needs.64 The Surgeon General’s report on Reducing Tobacco Use2 and two Cochrane reports 
on school-based programs and community interventions review smoking prevention strategies 
for young people.34,64 
Synthesis of prior systematic reviews. Previous reviews have found limited support for 
school- and community-based interventions to reduce tobacco use initiation among adolescents 
and young adults.34,64 No prior systematic reviews were identified for provider-based 
interventions. School-based interventions reviewed include various educational strategies. 
Examples include classroom programs or curricula that provided information, used social 
influence approaches, and taught social competence. These programs often moved beyond the 
school population to involve parents and the community.34 Community-based interventions for 
preventing smoking among young people integrate an array of strategies such as community 
empowerment, dissemination of health education materials, media advocacy, youth antitobacco 
activities, contests, letters to schools and parents, school programs, and use of peer leaders to 
raise awareness and discourage tobacco use.64  
School-based smoking prevention programs. Schools in the United States have existing 
tobacco use prevention policies and programs, but current interventions are not optimal. 
Effective educational strategies conducted in conjunction with other interventions such as mass 
media and community activities, can postpone or prevent smoking onset in 20 percent to 40 
percent of adolescents.2 Such multifaceted programs reach adolescents on multiple levels by 
enlisting the positive influences of parents, community organizations, the mass media, and 
school programs.  
An extensive review of all randomized controlled trials (RCTs) of behavioral interventions in 
schools to prevent tobacco use (ages 5 to 12 and 13 to 18) identified 16 studies of acceptable 
quality.34 The various strategies included information-giving methods, social influence 
approaches, generic skills training, and community interventions. Short-term positive effects 
were found in eight studies; however, no long-term effects were significant. Long-term is 
defined as 2 years after the end of the program; anything less than 2 years was considered a 
short-term effect.34  
Community-based smoking prevention interventions. Some support exists for the premise that 
community interventions are effective at reducing the uptake of tobacco in young people. Of 13 
studies comparing community interventions to no interventions, only 2 showed lower smoking 
prevalence. A comparison of a multicomponent community intervention with a community 
receiving a mass media campaign alone also showed a lower rate of smoking prevalence. Three 
studies compared community interventions to school-based interventions, but only one found 
differences in reported smoking prevalence.83  
Synthesis of current literature. Of the 13 studies addressing KQ 1, 10 involved school-
based efforts68-72,74-76,81,82 and 1 tested a provider-based intervention.80 Sample sizes ranged from 
26 to 99 schools and 103 to 8,352 participants. These studies were conducted in the United States 
(5), the Netherlands (2), Australia (1), Canada (1), Norway (1), and the United Kingdom (1). We 
rated one study as good and the rest as fair.  
Community interventions have been covered comprehensively in past systematic reviews.2,64 
We did not identify any community-based tobacco prevention studies; those that we learned 
about either did not meet our inclusion criteria or are not yet in publication. 
School-based interventions to reduce tobacco initiation. An effective method for reaching 
adolescents and young adults is to use school systems. Implementing tobacco prevention 
interventions in schools is convenient and allows for both optimum exposure of the intervention 
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strategies and regular assessment of effectiveness. The school-based tobacco prevention studies 
in this report are heterogeneous in terms of prevention strategies, definitions of tobacco use, and 
length of follow-up assessments. Biochemical verification of self-reported smoking status, unless 
otherwise stated, was not used in these studies. Virtually all the studies defined smoking status 
differently.  
Table 7 lists the various definitions of abstinence and tobacco use in the 10 school-based 
tobacco prevention studies reviewed. Interventions that sustain significant outcomes 2 years after 
the end of the intervention are considered to have long-term effects. School-based tobacco 
prevention programs were divided by length of exposure. Programs were implemented either 
within a single school year or over multiple school years. Single-year interventions are discussed 
first, followed by multiple-year interventions.  
Table 7. School-based tobacco prevention program smoking status definitions 
Author/Year Smoking Status Definition of Smoking Status 
Single-School-Year Smoking Prevention Programs 
Never smoker Never smoked a cigarette or even took a puff of a cigarette 
Noncurrent smoker Smoked in the past but not in the past month 
Ausems et al., 
200468 
Current smoker Smoked during the past month 
Nonweekly smoker Smoked less than one cigarette per week Aveyard et al., 
200169 Regular weekly smoker Smoked at least one cigarette per week 
Nonsmoker Never smokers, experimenters that no longer smoke, and quitters Crone et al., 200371 
Smoker Smokes at least once a week or less than once a week and 
experimenters that continue to smoke 
Nonsmoker Not specified Perry et al., 200375 
Current smoker Measured by amount of current tobacco use (response categories not 
specified) 
Nonsmoker Never smokers Unger et al., 200481 
Smoker Tried smoking between 6th and 7th grade 
Multiple-School-Year Smoking Prevention Programs 
Never smoker No history of smoking 
Tried once Tried once 
Experimental smoker Smoked less than once a week 
Quit Smoked and quit 
Brown et al., 200270 
Regular Smoked weekly 
Ever smoker Lifetime use 
Past-month smoker Frequency of use within past month 
Ellickson et al., 
200372 
Weekly Smoker Frequency of use within past year 
Nonsmoker Nonsmokers and smoked less than weekly Josendal et al., 
200574 Smoker Smoked daily or weekly 
Nonsmoker Did not smoke within the past 7 days Schofield et al., 
200376 Smoker Smoked within the past 7 days 
Nonsmoker Never smoked or former tobacco smokers 
Experimental smoker Smoked less than one pack per week 
Winkelby et al., 
200482 
Regular smoker Smoked more than one pack per week 
 
Five school-based interventions were conducted within a single school year.68,69,71,75,81 As 
shown in Table 8, these interventions used classroom instruction, computer-based programs, 
competition, parent involvement, community advocacy, and personalized letters. Students were 
in grades six through eight in middle, lower secondary, and vocational schools. 
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Table 8. Effective school-based interventions 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Single School Year Interventions 
Ausems et al., 
200468 
 
The 
Netherlands 
 
Middle and high 
(school level); 
vocational 
schools 
RCT 
 
5 months 
 
6, 12, and 18 
months 
G1: In school: 3 
lessons 
 
G2: Out of school: 3 
tailored letters 
G3: Both 
 
C1: Control, not 
described 
 
 
36 schools 
Number of 
students not 
reported 
At 12 months, the in-school 
intervention prevented more 
students from continuing to 
compared with controls 
(OR = 0.49, 95% CI, 0.29 – 
0.84)  
 
At 18 months, the tailored 
letters intervention prevented 
more smoking initiation 
compared with the controls 
(OR = 0.42, 95% CI, 0.18 – 
0.96) 
Fair 
Aveyard et al., 
200169 
 
United Kingdom 
 
Adolescents 
(ages 13 to 24) 
living in West 
Midlands 
RCT 
 
Up to 6 
sessions over 
an academic 
year 
 
1 and 2 years 
G1: 3 computer-
based program 
lessons with videos 
and 3 classroom 
lessons related to 
Transtheoretic Model 
 
C1: Standard lessons 
52 schools  
8,352 
students 
 
At 1- or 2-year followup, no 
evidence of change in stage 
or regular smoking  
Fair 
Crone et al., 
200371 
 
The 
Netherlands 
 
Lower 
secondary 
schools 
RCT 
 
8 months 
 
8 and 20 
months 
G1: 3 classroom 
lessons on 
knowledge, attitudes, 
and social influence 
 
C1: Usual drug 
prevention program  
 
26 schools 
2,562 
students 
At 20 months, nonsmokers 
who became smokers 
increased less in intervention 
groups than control group, the 
program successfully 
decreased smoking for regular 
smokers and maintained 
nonsmoking for nonsmokers 
versus control  
 
Those with perceived social 
pressure were more likely to 
be smokers 
Fair 
Perry et al., 
200375 
 
United States 
 
Middle and 
junior high 
schools in 
Minneapolis/St. 
Paul, 
Minnesota 
RCT 
 
8 months 
 
8 and 20 
months  
G1: D.A.R.E. 
curriculum taught by 
police officers (10 
sessions) 
 
G2: G1 plus D.A.R.E. 
Plus—peer led, 
parental involvement 
in extracurricular 
activities 
 
Control: Delayed 
program—D.A.R.E. 
offered in next school 
year 
24 schools 
6,237 
students 
D.A.R.E. Plus significantly 
less likely than D.A.R.E. to 
show an increase in current 
smoking or intentions to use 
tobacco for boys  
 
No significant differences for 
girls 
Fair 
C1, Control Group; D.A.R.E., Drug Abuse Resistance Education; G1, intervention group; RCT, randomized controlled trial 
42 
Table 8. Effective school-based interventions (continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Unger et al., 
200481 
 
United States 
 
6th and 7th 
graders in 
Southern 
California 
RCT 
 
8 weeks over 
an academic 
year 
 
12 months 
G1: 8 weekly 
classroom sessions 
by health educators 
relating smoking 
issues to several 
cultures 
 
C1: Without the 
cultural references 
16 schools 
1,970 
students 
Overall, intervention effect 
was not significant  
 
Hispanic boys in the 
intervention group were less 
likely to report ever smoking 
at 1 year followup than the 
control group  
Fair 
Multiple School Year Interventions 
Brown et al., 
200270 
 
Canada  
 
High schools 
(9th and 10th 
grades) 
RCT 
 
Students 
receiving 
tobacco 
prevention in 
elementary 
schools 
recruited for 
intervention in 
9th and 10th 
grade 
 
At the end of 
each academic 
year 
G1: Extracurricular 
activities, teacher-
facilitated 
 
C1: Usual care 
30 schools, 
2,776 
students 
Male never smokers at 
baseline in the intervention 
group were significantly less 
likely to become “regular” 
smokers in 10th grade than 
controls  
 
No significant effect for 
females 
Fair 
Ellickson et al., 
200372 
 
United States 
 
Urban, rural, 
and middle 
schools in 
South Dakota 
RCT 
 
NR (11 lessons 
in 7th grade 
and 3 lessons 
in 8th grade) 
 
18 months 
G1: 11 interactive 
teaching lessons in 
7th grade, and 3 
lessons in 8th grade, 
booster lessons in 9th 
and 10th  
 
G2: Same as G1 but 
no booster sessions 
 
C1: Regular 
prevention 
curriculums 
55 schools 
4,276 
students 
Treatment results for G1, G2 
combined through 8th grade; 
other results NR 
 
At 18 months, cigarette 
initiation rates in G1+G2: were 
significantly lower than in the 
controls 
 
Project ALERT significantly 
reduced proportion of new 
smokers  
Fair 
Josendal et al., 
200574 
 
Norway 
 
7th to 9th grade 
schools 
RCT 
 
Minimum class 
and lessons 5 
times per year: 
8 hours in 7th 
grade; 5 hours 
in 8th grade; 6 
hours in 9th 
grade  
 
End of each 
academic 
year—7th, 8th, 
9th grade 
G1: Classroom (5 
times per year), 
teacher in-service, 
parental involvement 
 
G2: Same as GI, but 
no teacher in-service 
course 
 
G3: Same as GI, but 
no parental 
involvement 
 
C1: Education on 
smoking and health, 
but about half of the 
number of hours as in 
G1 or G2 
99 schools 
4,223 
students 
Full program (G1) had 
significantly fewer smokers 
than controls across all 3 
years  
 
Intervention without the 
parental involvement or the 
teacher in-service (G2 or G3) 
had significantly fewer 
smokers than the controls 
 
Odds of becoming a smoker 
(daily, weekly, any) during the 
intervention period were 
significantly lower in the full 
program group (G1) than in 
the controls 
Good 
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Table 8. Effective school-based interventions (continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Schofield et al., 
200376 
 
Australia 
 
7th to 10th 
grades in New 
South Wales 
school district 
RCT 
 
2 school years 
 
24 months 
G1: Self-help, group 
counseling, social 
support 
 
C1: Offered and 
received none of the 
experimental activities
22 schools 
1,852 
students 
Proportion of students who 
smoked in past 7 days did not 
differ significantly by treatment 
condition, intervention not 
effective 
 
Significantly greater 
improvement in smoking 
knowledge for the intervention 
group compared with the 
control 
 
Positive attitudes toward 
smoking significantly 
decreased among smokers 
Fair 
Winkelby et al., 
200482 
 
United States 
 
High Schools 
(11th or 12th 
grades) in San 
Francisco and 
San Jose, 
California 
 
RCT 
 
Weekly lessons 
and activities 
over an 
academic 
semester 
 
At the end of 
each semester 
and 6 months 
after the end of 
the semester 
G1: Three-phase 
advocacy and 
empowerment 
 
C1: Existing 
substance abuse 
curriculum, not 
specific to tobacco 
10 
continuation 
high 
schools 
813 
students 
Regular smokers had greatest 
statistically significant net 
decrease in tobacco use 
 
No differences in nonsmokers 
at baseline between 
intervention and control 
groups in uptake of smoking 
at followup 
 
 
Fair 
 
One study implemented the intervention in a primarily Hispanic population,81 another in 
primarily non-Hispanic, white populations,75 and the other studies did not specify ethnicity of the 
population studied.68,69,71 The sample size for the five studies implementing within-school-year 
interventions ranged from 16 to 52 schools and 1,970 to 8,352 students. 
The length of exposure students received was as short as 8 weeks81 and as long as 8 
months.75 Followup assessments ranged from 6 months to 24 months. All prevention strategies 
included classroom lessons that included educational instruction typically combined with one or 
several other activities such as group discussion, role-play, videos, skills training, or computer-
based lessons.68,69,71,75,81 Drug Abuse Resistance Education (D.A.R.E.), a well-known, school-
based tobacco prevention program in the United States, also included parent involvement and a 
community youth action team in the multicomponent intervention.75 
Three single-year smoking prevention programs compared their effects with those in control 
groups that received either standard smoking information, the original drug prevention program 
already in place, or the same classroom lessons without cultural sensitivity.69,71,81 An 8-month 
prevention program used educational strategies and competition to reduce tobacco initiation in 
26 lower secondary education (mean age 13) schools in The Netherlands.71 Three lessons on 
knowledge, attitudes, and social influences were followed by a class agreement either not to start 
smoking or to stop smoking for the next 5 months. To increase students’ motivation, the National 
Institute Against Smoking rewarded classes in which less than 10 percent of the students were 
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smokers at the end of the 5 months; it also conducted a photography contest to find the best 
photograph that expressed a nonsmoking class.71 
Smoking status measured by self-report was assessed at baseline, at the end of the 
intervention, and at 1-year followup. At the end of the intervention, the proportion of 
nonsmokers who became smokers had increased less in the intervention group (9.6 percent) than 
in the control group (14 percent) (OR, 0.61; 95% CI, 0.41-0.90). The proportion of smokers had 
also increased significantly less in the intervention group (2.6 percent) than in the control group 
(7.9 percent) (OR, 0.62; 95% CI, 0.43-0.90). The groups did not differ significantly at 1-year 
followup.  
Aveyard et al. implemented a computer-based tobacco prevention intervention in 52 schools 
in West Midlands, United Kingdom.69 During school year 9, students ranging in age from 13 to 
14 years received three class lessons and three interactive computer sessions (including video 
clips of young people discussing their smoking). The intervention continued throughout the 
ninth-grade year; the investigators administered a self-report questionnaire at baseline and at 
years 1 and 2.69 At followup in years 1 and 2, the intervention and control groups did not differ 
significantly in effect (year 1: AOR, 1.14; 95% CI, 0.93-1.39; year 2: AOR 1.06; 95% CI, 0.86-
1.31).69  
Project FLAVOR (Fun Learning about Vitality, Origins, and Respect), a school-based 
program that incorporates a curriculum sensitive to multiple cultures, focused on psychosocial 
risk factors to prevent tobacco initiation in eight of 16 middle schools in Southern California.81 
The students were predominantly Hispanic (57 percent) and Asian American (27 percent) sixth 
and seventh graders. The culturally sensitive intervention programs provided eight weekly 
classroom sessions conducted by health educators that addressed smoking-related psychosocial 
concepts through activities such as role-playing, trivia games, and art projects.81  
Students were surveyed at baseline and at 1-year followup. Overall, 8 percent of the 
intervention group and 11 percent of the control group initiated smoking (OR, 0.75; 95% CI, 
0.48-1.18), but this difference was not significant. For one subgroup—Hispanic male never 
smokers—the intervention prevented smoking initiation between the two grades (OR, 0.49; 95% 
CI, 0.27-0.88).81  
Two single-school-year smoking prevention programs compared classroom instruction to an 
alternative, more innovative tobacco prevention program.68,75 Vocational students (mean age 13) 
in 36 schools in The Netherlands participated in an in-school and out-of-school intervention to 
reduce tobacco initiation.68 The in-school and out-of-school interventions and a combined in- 
and out-of-school intervention were compared with a control group (not described). The in-
school intervention had three classroom lessons consisting of educational instruction by the 
teacher reading from the workbook, a classroom discussion, a workbook task, and an additional 
task that summarized the main points of the lesson. The out-of-school intervention comprised 
three tailored letters with smoking prevention messages; the letters were illustrated with a picture 
puzzle and several cartoons. It also included a competition in which students could win CD 
vouchers. The letters were mailed to students’ homes at 3-week intervals.68  
Students’ self-reported their smoking status at pretest and 6, 12, and 18 months following the 
intervention. Immediate treatment effects were not apparent at 6 months; at 12 months the in-
school intervention was more effective at discontinuing smoking than the control condition (OR, 
0.49; 95% CI, 0.29-0.84). At 18 months, the tailored out-of-school intervention was effective in 
preventing smoking initiation compared with the control condition (OR, 0.42; 95% CI, 0.18-
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0.96). The combined approach was not as successful as the in-school and the out-of-school 
efforts.68  
D.A.R.E., based on the decisionmaking model, has been widely implemented in elementary 
schools and extensively evaluated. D.A.R.E. Plus, a new multicomponent curriculum used in 
middle and high schools, has received less attention than the original program.75 An independent 
evaluation of D.A.R.E. and D.A.R.E. Plus in 24 Minnesota middle and junior high schools was 
conducted with seventh- and eighth-grade students (51.6 percent male, 67.3 percent white, 7.5 
percent African American, 12.7 percent Asian American, 3.6 percent Hispanic, 4.0 percent 
American Indian, and 4.9 percent of mixed or other ethnicity). The research team matched 
students on socioeconomic status, drug use, and size of school and randomly assigned schools to 
one of three conditions: D.A.R.E. only, D.A.R.E. Plus, or control group. The D.A.R.E. program, 
taught by trained D.A.R.E. police officers, consisted of 10 sessions providing skills in resisting 
influences to use drugs, building character, and building citizenship skills. The D.A.R.E. Plus 
program has three components: (1) “On the VERGE,” a classroom-based, peer-led, parental 
involvement program; (2) Youth Action Teams to implement in-school extracurricular activities; 
and (3) Youth Action Teams to address neighborhood and school-wide issues. The control group 
was eligible to receive D.A.R.E. Plus in 2001.75  
Students received D.A.R.E. and D.A.R.E. Plus for about 8 months from September 1999 
through April 2000.75 The researchers collected baseline measures from seventh graders in fall 
1999; the first followup was in spring 2000 (i.e., at the end of the intervention); and the final data 
collection occurred among eighth-grade students in spring 2001 (i.e., 12 months following the 
intervention). Self-reported smoking status was reported through surveys.75  
The investigators used a three-level, linear, random-coefficient model to test for significant 
differences over time; they reported group slopes. No outcomes comparing D.A.R.E. with the 
control schools were significant. Boys in the D.A.R.E. Plus condition were significantly less 
likely than those in the control schools to show increases in tobacco use and intentions to use 
tobacco (P = 0.04). Boys in the D.A.R.E. Plus condition were significantly less likely than those 
in the D.A.R.E. condition to show increases in tobacco use and intentions to use tobacco  
(P = 0.04). No effects for tobacco use among girls were significant.75 
Interventions implemented within a school year were able to reduce tobacco initiation among 
adolescents shortly after the completion of the intervention.68,71 Two studies reviewed in this 
report found effects for boys but not girls; one of these studies, the culturally sensitive 
intervention, reduced tobacco initiation exclusively among Hispanic boys.75,81 
Several school-based interventions (in the United States, Australia, Canada, and Norway) 
occurred over multiple school years.70,72,74,76,82 The interventions included classroom instruction, 
teacher training, parent involvement, extracurricular school activities, community assessment, 
advocacy, and projects.70,72,74,76,82 Students ranged from seventh graders through 12th graders. 
Study populations varied. One study implemented the intervention in a primarily Latino 
population;82 another involved both rural and urban communities with a high percentage of 
Native Americans (12.5 percent nonwhite);72 and the other studies did not specify ethnicity of 
the population.70,74,76 The sample size for the five multiple-year studies ranged from 22 to 99 
schools and 813 to 4,276 students.  
Students were exposed to smoking prevention interventions from 2 to 3 years. Investigators 
collected follow-up measures at the end of the interventions70,72,74,76,82 and up to 6 months 
following conclusion of the interventions.82 Two studies used control groups that were later 
eligible for the intervention;72,76 other control groups received some type of prevention 
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activities.70,74,82 Only two multiple-year studies relied significantly on classroom instruction;72,74 
the other tobacco prevention studies used multicomponent interventions that included school, 
family, and community activities.70,76,82  
Project ALERT, a well-known adolescent drug prevention program, aims to change students’ 
perceptions of drug norms and the social, emotional, and physical consequences of drug use. A 
revised version of Project ALERT emphasizes curbing alcohol misuse (rather than abstinence), 
increases attention to current smokers, and brings parents into the prevention process.72 
In urban and rural communities in South Dakota, Project ALERT was evaluated in 55 middle 
schools with seventh- and eighth-grade students (13 percent nonwhite; 51 percent male).72 The 
curriculum included 11 lessons in seventh grade and three lessons in 8th grade that used 
interactive teaching methods focusing on motivation and resistance skill-building. Another 
important element of this program was home learning, which sought to involve parents in 
substance use prevention. The control schools receive a delayed experimental program at the 
conclusion of the study. 
Students completed surveys at baseline in the fall of seventh grade and 18 months later in the 
spring of 8th grade. Self-reported smoking status was validated by collecting salivary cotinine 
levels for a random subsample of 654 students. At 18 months, cigarette initiation rates in Project 
ALERT (25.5 percent) were significantly lower than in the control group (31.6 percent,  
P < 0.01). From the baseline assessment to the 18-month followup, Project ALERT reduced the 
proportion of new smokers by 19 percent (P < 0.01).72  
BE smokeFREE comprises an intensive intervention conducted over 3 school years. The 
program delivered classroom sessions at least five times per year from sixth through 8th grade.74 
A nationally representative sample of 99 secondary schools in Norway implemented this 
program.74 Three treatment groups—the model intervention (i.e., classroom instruction, teacher 
in-service training, and parent involvement), the model intervention without the teacher in-
service, and the model intervention without parent involvement—were each compared with a 
control group. The classroom instruction contained nontraditional school activities such as 
videos, games, and group work. The intervention used 8 hours in seventh grade, 5 hours in eighth 
grade, and 6 hours in ninth grade. During eighth grade, however, students and teachers requested 
adjustments to the intervention. Therefore, in ninth grade, students developed, carried out, and 
evaluated their own campaign to promote a smokefree lifestyle among the seventh graders. 
Parent involvement (not described) was included in the intervention. The control group received 
education on smoking and health but only for about half the number of hours as the intervention 
groups.74 
Students self-reported smoking behaviors on surveys administered by teachers at the end of 
each of the 3 academic years. The proportions of smokers were significantly higher in the control 
group than in the model intervention for all 3 follow-up years (1995, F = 5.66; P < 0.01; 1996,  
F = 7.19; P < 0.001; 1997, F = 4.05; P < 0.05). In both the interventions without teacher in-
service training and without parent involvement, the proportions of smokers on all follow-up 
occasions were higher than in the model intervention but lower than in the control group (1995, 
F = 2.84; P < 0.01; 1996, F = 3.98; P < 0.001; 1997, F = 2.46; P < 0.05). The odds of becoming 
a smoker during the intervention period were significantly lower in the model intervention than 
in the control group for daily smoking (Wald’s 9.81, P = 0.02), for weekly smoking (Wald’s 
15.65, P = 0.0001), and for any smoking (Wald’s 16.54, P = 0.0001).74  
Several school-based tobacco prevention programs not only involve students but also include 
parents and surrounding communities. In one particular intervention, students were recruited 
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from elementary schools with tobacco prevention programs.70 Thirty Canadian high schools 
selected for the study enrolled at least 30 students who had participated in an elementary school 
smoking prevention study; receiving such students was an eligibility requirement for schools.70 
In the 15 intervention schools, the investigators recruited teachers, staff, students, and 
community members to participate in antismoking activities. Teachers helped students, staff, and 
community members to plan and implement prevention and cessation activities tailored to each 
intervention school to build commitment and strengthen school social norms toward not 
smoking. The research staff provided consultation, conducted semiannual workshops for teachers 
and student leaders, developed resources for dissemination to all intervention schools, produced 
newsletters, and provided a $1,000 per school annual budget. 
Students in the ninth and tenth grades were exposed to the intervention for 1 year; data on 
smoking status were collected by survey at the end of the year. Investigators collected a “bogus” 
biochemical verification using carbon monoxide (CO) breath samples to enhance validity of the 
self-reported data. The control schools had “usual” programs but these were not described.70  
Extracurricular activities produced by the intervention schools consisted of quit-and-win 
contests, poster contests, displays, health fairs, and smoking surveys (not associated with the 
study survey). On average, 3.8 intervention activities occurred in the 9th grade and 3.5 activities 
in 10th grade. At baseline, intervention schools had a marginally higher proportion of students 
who had previously been in the elementary intervention condition (P = 0.10). After adjusting for 
the baseline difference, male nonsmokers at baseline were significantly less likely to be “regular” 
smokers in 10th grade in the intervention schools than males in the control schools (9.8 percent 
vs. 16.4 percent, P = 0.02). Among females, intervention and control groups did not differ.70 
High schools from San Francisco and San Jose, California, were randomly allocated in a 
school-based intervention study conducted in 10 continuation high schools.82 Advocacy activities 
related to advertising, availability, and use of tobacco were implemented in the intervention 
school to reduce tobacco initiation among students. Twenty-five 11th and 12th grade students 
volunteered to participate from each school (43 percent Latino, 21 percent white, 15 percent of 
mixed ethnicity, 13 percent Asian or Pacific Islander, 4 percent African American, and 4 percent 
other).82  
The three-phase intervention lasted 2 years. It included advocacy and empowerment classes 
that dispelled misconceptions about cigarette smoking and raised students’ awareness of 
environmental influences (e.g., tobacco company advertising). It also helped students to develop 
advocacy skills (e.g., by practicing persuasive communication) and to conduct a community 
assessment and advocacy project. The control groups received an existing substance abuse 
curriculum not specific to tobacco that was developed for continuation high school students.82  
Students completed surveys at baseline, at the end of the semester, and 6 months after the end 
of the intervention. The two groups differed slightly at baseline for smoking and 
sociodemographic characteristics, but the investigators did not report percentages. The results, 
reported as net percentage changes from baseline smoking to after intervention, showed no 
significant changes after the intervention or at 6-month followup for nonsmokers (0.2 percent net 
change, P = 0.93).82 
Using community organization theory, one group studied 7th through 10th grade students in 
22 schools in New South Wales, Australia; the researchers encouraged intervention schools to 
adopt their own Health Promoting Schools (HPS) program.76 A key individual identified for each 
school took responsibility for planning, implementing, and monitoring HPS strategies such as 
developing a minimum set of health promotion actions for the school.  
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The schools received this community-based tobacco prevention intervention for 2 years. In 
November 1995, the investigators collected baseline data; in November 1997, they administered 
a posttest survey to the same cohort. They used a self-reported retrospective diary; students 
reporting having smoked any amount of cigarettes within the past 7 days were considered 
smokers.  
In the final analysis, the research team matched pre-post data, which considerably reduced 
the sample size (N = 1,852). The odds of males smoking at posttest were almost half the odds of 
females (AOR, 0.55; 95% CI, 0.35-0.87). The proportion of students who had smoked in the last 
week did not differ significantly by treatment condition, indicating that the intervention was not 
effective.76  
Provider-based interventions to reduce tobacco initiation. Only one study (Table 9) used 
providers to reduce tobacco initiation.80 The study participants were survivors of pediatric cancer 
from St. Jude Children’s Research Hospital in Memphis, Tennessee, who were currently disease-
free and at least 1 year from completion of antineoplastic therapy. On enrollment, the 
investigators randomly assigned 103 patients, stratified by age (ages 10 to 13 years and ages 14 
to 18 years), gender, and race, to the tobacco-risk counseling intervention or a standard care 
group. The intervention occurred in a single session with periodic reinforcement of tobacco goals 
by telephone. A physician feedback letter reinforced the antitobacco messages, and tobacco 
literature was mailed to the patient. To reinforce previously established goals and address 
barriers, the investigators did follow-up telephone counseling at 1 and 3 months. Patients in the 
control group were asked about their tobacco use and briefly advised about the health risks 
associated with tobacco use. All tobacco users were advised to stop; nonsmokers were 
encouraged to continue to resist tobacco.80  
Table 9. Effective provider-based interventions 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Tyc et al., 
200380 
 
United States 
 
St Jude’s 
Children’s 
Research 
Hospital, 
Memphis, 
Tennessee 
RCT 
 
Education and 
counseling 
over 3 months 
 
6 and 12 
months 
G1: Self-help, 
individual counseling, 
health professional 
telephone counseling, 
video 
 
C1: Brief advice to stop 
smoking or continue 
not smoking 
103 cancer 
survivors (10 to 
18 years of age)
Intervention group had 
higher mean knowledge 
and perceived vulnerability 
scores and lower intention-
to-use tobacco scores 
Fair 
C, Control Group; G, Intervention Group; RCT, randomized controlled trial. 
Patients in the intervention and control groups were assessed by questionnaire at baseline and 
at 6 months and 12 months following the intervention.80 Baseline measures were similar across 
the two groups; 95.1 percent of the participants were classified as nonsmokers. At 12 months, 
multivariate comparison of difference scores for patient smoking status (12-month scores minus 
baseline scores) found no differences (all were P > 0.10), indicating the intervention had no 
effect on smoking initiation.  
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KQ 2. Effective Strategies for Increasing Consumer Demand 
For and Use of Proven Individually Oriented Cessation 
Treatments 
We discuss KQ 2 in two main parts: evidence concerning interventions aimed at increasing 
the number of smokers who attempt to quit, and evidence about strategies for improving the 
impact of those interventions. As with KQ 1, in both cases we first review the existing 
information from recent systematic reviews, and then we turn to the new literature uncovered by 
our searches. Appendix C‡ presents the two evidence tables (Evidence Tables 4 and 5) with the 
details of studies from the current literature. 
Increasing the Number of Users Who Attempt to Quit 
Spontaneous and unassisted rates of tobacco use cessation among tobacco users are low (3 
percent to 10 percent).5 Interventions to increase the number of tobacco users who seek 
assistance in quitting and who successfully quit include efforts to increase the number of users 
who attempt to quit, improve the success rate for quit attempts, and achieve both of these goals.7 
Proven individual strategies for helping smokers to quit include counseling, behavioral 
therapy, and, except when contraindicated, the use of first-line and second-line medications.5 
More often than not, individuals are trying to quit without assistance that can double or, in some 
cases, triple their chances of success.5 
Synthesis of prior systematic reviews. Reviews of population-wide interventions to 
increase tobacco use cessation have focused on five elements: (1) multicomponent efforts to 
increase patient tobacco use cessation, which include telephone information or counseling 
support; (2) mass media campaigns combined with other interventions; (3) mass media cessation 
series; (4) mass media cessation contests; and (5) increases in the unit price of tobacco products. 
The Task Force on Community Preventive Services (hereafter, Task Force) focused on all five 
issues.7 The 2000 update of the 1996 Agency for Health care Policy and Research (AHCPR) 
guideline (Treating Tobacco Use and Dependence)5 and a 2003 Cochrane Review concentrated 
on the first topic (multicomponent efforts).66 
Multicomponent efforts. Based on a systematic review of 32 studies evaluating the 
effectiveness of telephone cessation support, the Task Force found strong evidence of 
effectiveness for telephone cessation support to increase tobacco use cessation when 
implemented with other interventions such as educational approaches or clinical therapies in 
clinical and community settings.7 Telephone support was coordinated with additional 
interventions, including client education, provider-delivered counseling, nicotine replacement, a 
smoking cessation clinic, and a televised cessation series. Effective telephone counseling 
interventions combined either proactive telephone support (i.e., the provider initiated contact) or 
reactive telephone support (i.e., the caller initiated contact, with provider followup) and client 
cessation materials. In the 30 studies comparing differences in cessation of tobacco use based on 
use of or exposure to telephone support, tobacco use cessation increased 2.6 percentage points 
(range, -3.4 to +23) in follow-up periods of 5 weeks to 34 months (median, 12 months).7 
                                                 
 
‡ Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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On the basis of a meta-analysis of various formats of psychosocial treatments (e.g., self-help, 
proactive telephone counseling, group counseling, and individual counseling), Fiore et al. found 
proactive telephone counseling to be effective at increasing abstinence rates relative to no 
intervention (OR, 1.2; 95% CI, 1.1-1.4).5 The estimated abstinence rate based on this meta-
analysis was 13.1 percent (95% CI, 11.4-14.8). The guideline update also found, as did the Task 
Force, that interventions delivered in multiple formats increased abstinence rates compared with 
no format. Odds ratios for one format were 1.5 (95% CI, 1.2-1.8); for two, 1.9 (95% CI, 1.6-2.2) 
and for three or four, 2.5 (95% CI, 2.1-3.0). Estimated abstinence rates were 15.1 (95% CI, 12.8-
17.4), 18.5 (95% CI, 15.8-21.1), and 23.2 (95% CI, 19.9-26.6), respectively, compared with a 
no-counseling format.  
In another meta-analysis using all less-intensive intervention arms as the control (as opposed 
to those providing tailored self-help materials), telephone counseling increased quit rates (OR, 
1.56; 95% CI, 1.38-1.77).66 Investigators found no differences in quit rates in four trials that 
added telephone counseling support to a face-to-face intervention, in four trials that added 
telephone counseling support for users of nicotine replacement therapy, or in trials comparing 
different types of telephone counseling. 
Mass media campaigns combined with other interventions. Mass media educational 
campaigns employ brief, recurring messages over time to provide information or motivation to 
tobacco users and others (e.g., family members, households, peers) with the goal of increasing or 
improving efforts to stop using tobacco products. Campaigns can focus on cessation, include 
cessation themes within a broader range of tobacco messages, or be combined with other 
interventions such as an excise tax increase or other related, community-wide education efforts.  
Mass media campaigns, when combined with other activities, were effective in increasing 
tobacco use cessation by approximately 2 percentage points, in reducing overall tobacco 
consumption measured on a population basis by almost 13 percent, and in lowering the 
prevalence of tobacco use by approximately 3 percentage points.7 Mass media campaigns can 
also increase the number of people who seek telephone support for quitting smoking. The Task 
Force found “strong” evidence of the effectiveness of such campaigns when combined with 
activities to increase tobacco use cessation and reduce tobacco consumption; activities include 
excise tax increases or other community-wide educational efforts.7  
Mass media cessation series. Mass media cessation series consist of broadcasted instructional 
segments designed to recruit, inform, and motivate users of tobacco products to try quitting and 
to succeed.7 Cessation series can be coordinated with broadcasts or print promotions that precede 
the series itself, community education, or organization of cessation groups in the community. 
Such series can last a period of several weeks to several months. 
 After reviewing nine studies evaluating cessation series, the Task Force found insufficient 
evidence to determine the effectiveness of such interventions in increasing the number of people 
who successfully stop using tobacco products.7 Studies included cessation series combined with 
other interventions such as community education, organized cessation groups or programs, or 
telephone support.  
Mass media cessation contests. Cessation contests are community-wide events of short 
duration that use mass media to recruit and motivate users of tobacco products to participate in a 
program to quit by a certain date or during a specified time period. Mass media and small media 
(e.g., posters and flyers) promote available services and recruit tobacco product users.  
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The Task Force found insufficient evidence to determine the effectiveness of such contests in 
increasing the number of people who quit using tobacco products.7 This conclusion was based on 
only one study that showed some improvement in self-reported cessation at 6-month followup.  
Summary. Proactive telephone counseling is effective in increasing tobacco use cessation. 
Mass media education campaigns combined with other interventions are also effective in 
increasing tobacco use cessation. However, other types of mass media education, such as media 
cessation series and cessation contests, were not found to be effective.  
Synthesis of current literature. Seven randomized trials describing multicomponent 
interventions to increase tobacco use cessation met inclusion criteria (Table 10). Four involved 
counseling support; of these, three investigated proactive telephone counseling and support for 
cessation,84-86 and one trial of genetic susceptibility counseling incorporated smoking cessation 
counseling.87 Two other studies were long-term follow-up studies of intervention effect; one 
study included participants in a randomized trial of a computer-tailored smoking intervention88 
and the other included participants in a randomized trial of the Lung Health Study (LHS) 
smoking intervention.89 The final study focused on adolescents to examine the effectiveness of a 
family-directed program addressing tobacco and alcohol use among teens.90 We did not find any 
new articles meeting our criteria that addressed the effects of mass media and tobacco price on 
increasing the number of tobacco users who attempt to quit or who are successful in quitting. 
Adults were the target group in four studies,86-89 and adolescents and young adults were the 
target group in the other three.84,85,90 Trials enrolling only adults examined interventions 
designed to increase tobacco use cessation by providing proactive telephone counseling support86 
and incorporating genetic susceptibility to lung cancer into smoking cessation counseling.87 Of 
the studies enrolling only adolescents and young adults, one tested the efficacy of self-help 
materials with or without proactive telephone counseling to increase cessation among teen 
smokers;84 the other examined the effects of telephone counseling on smoking cessation among 
smokers 18 to 25 years of age and smokers over 25 years of age.85  
For the trials, recruitment strategies included radio and newspaper advertisements,86 contact 
with youth in shopping malls and an amusement park,84 telephone calls to a random sample of 
families with children 12 to 14 years of age,90 chart review and clinician referral,87 and a survey 
of callers to a national quit line.85 In the studies of persistent intervention effect, investigators 
recruited the original subjects in one study by mailed announcements to a random sample of 
residents in a defined area88 and, in the other, by random sample of an unspecified population for 
a multicenter trial.89  
Smokers were defined in various ways at intake: daily smokers;86 daily smokers for 1 year 
and with an expired CO level of greater than 8 parts per million (ppm);89 having smoked a 
cigarette within the last week;84 more than an occasional smoker;88 current, daily smokers willing 
to make a quit attempt within the next 2 weeks;85 smokers with some level of lung impairment;87 
and use of tobacco on 1 or more days during the past 30 days.90  
Interventions were very different across trials, although all involved distribution of self-help 
print materials. Some interventions were tailored to stages of change; others were not. The 
intervention in one trial had five conditions involving combinations of counseling with variable 
numbers of follow-up calls (two or six) and different print materials (booklet or pamphlet).86 In 
another intervention group, participants received an eight-page personal counseling letter written 
by a computer according to answers that participants gave on a 62-item enrollment questionnaire 
and two 16-page self-help booklets corresponding to their current stage of change and the next 
stage of change.88 At 2, 4, and 12 months after entering the study, intervention participants  
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Table 10. Multicomponent interventions to increase the number of users who quit smoking  
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Bauman et al., 
200090 
 
United States 
 
Population-
based 
RCT 
 
2 months 
 
3 and 12 months 
postcompletion 
or dropout 
G1: Mailing of booklets 
and telephone 
counseling 
 
C1: NR 
 
 
85 parent-
adolescent 
pairs 
No statistically significant 
difference in tobacco use 
between control and 
treatment for baseline 
cigarette users  
Fair 
Etter et al., 
200488 
 
Switzerland, 
Western 
Europe 
 
Population-
based 
RCT 
 
12 months 
 
7 and 24 months 
post-baseline 
G1: Tailored counseling 
letters and booklets 
 
C1: A single letter 
identifying person as 
part of the control group
2,934 adults At 7 months, significantly 
more people in the 
intervention than in the 
control group were 
abstinent for at least 1 
month (G1: 5.8%; C1: 
2.2%; P ≤ 0.001) 
 
No difference between 
groups at 24 months.  
Fair 
Lipkus et al., 
200484 
 
United States 
 
Community-
based 
RCT 
 
2 months 
 
4 and 8 months 
post-baseline 
G1: 2 self-help booklets 
in mail; 6-minute video; 
3 telephone counseling 
 
C1: 2 self-help booklets 
in mail; 6-minute video; 
no telephone 
counseling 
402 
adolescents 
No differences in 
abstinence at 4- or 8-month 
followup or for sustained 
abstinence 
 
Participants completing 
more counseling calls were 
more likely to report 
cessation at 4 and 8 
months (8-month OR = 
1.54, 95% CI, 1.15-2.07,  
P < 0.007) 
Fair 
McBride et al., 
200287 
 
United States 
 
Practice/ 
provider 
settings 
RCT 
 
10 weeks 
 
6 and 12 months 
G1: Provider advice to 
quit smoking; referral to 
smoking specialist; self-
help guide; if eligible, 
nicotine patches  
 
G2: Self-help guide; if 
eligible, nicotine 
patches and refills; 
biomarker feedback 
and tailored booklet 
557  
adults; low 
SES; African 
American 
Significantly more 
participants of G2 than G1 
were not smoking at 6 
months (G1: 10%, G2: 
19%; P = 0.03) and had 
sustained abstinence  
(G1: 5%, G2: 11%;  
P = 0.08) 
 
Fair 
Murray et al., 
200289 
 
United States,  
Canada 
 
Practice/ 
provider 
settings 
RCT 
 
3 months 
 
11 years 
 
G1: Ipratropium 
bromide inhaler, 
placebo inhaler 
 
C1: Usual care 
4,517 adults More participants in G1 
than in C1 had sustained 
abstinence (G1: 21.9%, 
C1: 6.0%; P ≤ 0.001) 
Fair 
ACS, American Cancer Society; C, control group; G, intervention group(s); NR, not reported; OR, odds ratio; RCT, randomized 
controlled trial; SES, socioeconomic status. 
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Table 10. Multicomponent interventions to increase the number of users who quit smoking (continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Rabius et al., 
200485 
 
United States 
 
Population-
based 
RCT 
 
Varies by quit 
date, up to 5 
followup calls, up 
to 2 weeks 
postquit date 
 
3 and 6 months 
G1: ACS booklets and 
standard advice plus 
up to 5 sessions of 
proactive telephone 
counseling 
 
C1: ACS booklets and 
standard advice  
3,522  
young adults, 
adults 
G1 group had higher rates 
of 48-hour abstinence than 
C1 group at 3 months (18–
25 years: G1: 19.6%,  
C1: 9.3%; P < 0.005; over 
25 years: G1: 15.1%, C1: 
9.6%; P < 0.001)  
 
Participants abstinent at 3 
months were called at 6-
month followups: (18–25 
years: G1: 9.8%, 
C1: 3.2%; P < 0.01;over-25 
years: G1: 8.8%,  
C1: 5.3%; P < 0.005) 
Fair 
Smith et al., 
200486 
 
Canada 
 
Population-
based 
RCT 
 
 
 
3, 6, and 12 
months 
G1: Telephone 
counseling, 2 follow-up 
calls, booklet  
 
G2: Telephone 
counseling, 2 follow-up 
calls, pamphlet 
 
G3: Telephone 
counseling, 6 follow-up 
calls, booklet  
 
G4: Telephone 
counseling, 6 follow-up 
calls, pamphlet 
 
C1: Print materials only
632 
adults 
Intervention groups 
combined (G1, G2, G3) 
had significantly higher 
continuous abstinence 
rates than control group:  
(G1, 2, 3: 5%, 
C1: 1%; P ≤ 0.05) 
Fair 
 
could answer tailoring questions again to receive a new letter. In another trial, content of calls 
was customized and based on each participant’s stage of readiness to quit.84 Calls were designed 
to encourage use of self-help booklets, move the participant toward quitting, and assist those 
ready to quit.84 In another study, the intervention used three booklets with standard advice plus 
up to five sessions of proactive telephone counseling.85 One study incorporated genetic 
susceptibility for lung cancer counseling and related print material (an eight-page test result 
booklet) into usual smoking cessation counseling.87 Only one trial included nicotine replacement 
therapy as part of the study, but the therapy was made available to both the intervention and 
control groups.87 
Followup to assess smoking status occurred at various times in the current trials: 3 and 6 
months;85 3 and 12 months;90 3, 6, and 12 months;86 4 and 8 months;84 and 6 and 12 months.87 In 
the persistence of effect studies, followup occurred at 7 and 24 months88 and at 11 years.89 
Followup occurred at the specified time after baseline in three studies,84,87,88 after the quit date in 
one,85 and after completion of the intervention in another.90  
Outcome measures included various definitions of abstinence: 1-month abstinence (not 
smoking even a puff of a tobacco cigarette, cigar, or pipe in the last 4 weeks);88 1-week 
abstinence (not smoking even a puff of a tobacco cigarette, cigar, or pipe in the past 7  
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days);84,86-88 no smoking in the past 48 hours;85 and self-reported cessation with no time frame 
specified.89 Continuous abstinence, which five studies used as a primary outcome, was defined as 
abstinence at all reporting periods.84-87,89  
Smoking status results. Of the four trials of counseling support, three focused on telephone 
counseling and associated print materials.84-87 One study reported statistically significant 
increases in continuous abstinence among those receiving telephone counseling compared with 
control participants receiving only print materials (5 percent vs. 1 percent, P < 0.05).86 Another 
study reported statistically significant higher rates of prevalence of reported abstinence during 
the past 48 hours for participants in the treatment group compared with those in the control group 
in two age categories (younger than 18 years of age and 18 to 25 years of age). At 3-month 
followup, differences by age were 19.6 percent vs. 9.3 percent (P < 0.005) for younger smokers 
and 15.1 percent vs. 9.6 percent for older smokers.85 The trial of counseling support showed that 
smoking cessation was greater for the group receiving genetic feedback and counseling than for 
controls at 6 months but not at 12 months.87 Finally, one trial failed to show any significant 
group differences in either abstinence at each follow-up assessment or in continuous 
abstinence.84  
Other outcomes. Beyond smoking status, four studies also assessed other primary and 
secondary outcomes associated with multicomponent interventions: quit attempts, days of 
smoking abstinence, and use of nicotine replacement. One study of persistent effect found that 
more participants in the intervention group than in the control group reported making a 1-month 
quit attempt and having more days of smoking abstinence.88 More participants in the intervention 
group than in the control group had used nicotine replacement products in two studies.85,88 Two 
studies showed no difference in nicotine replacement therapy use across groups.86,87  
Adolescents and young adults. Two studies in this review showed that telephone counseling 
that targets youths achieved success comparable to that shown for adult smokers.84,85 This 
finding suggests that younger smokers can benefit from telephone counseling. Three-month quit 
rates were 19.6 percent for persons 18 to 25 years of age who received telephone counseling and 
9.3 percent for those who received self-help booklets only (P < 0.005). The proportions reporting 
abstinence during the preceding 48 hours at both the 3- and 6-month follow-up interviews were 
also significantly different in the treatment group for this age cohort (9.8 percent vs. 3.2 percent, 
P < 0.01)85  
Persistence of effect. Two studies reported long-term follow-up results of previous RCTs. 
The trial of a computer-tailored smoking cessation program showed, at the 7-month assessment, 
a significant increase in 4-week abstinence rates and 7-day quit rates compared with rates for 
controls. At 24 months after intervention, these differences had disappeared.88 The second 
follow-up study found that smokers exposed to an aggressive smoking intervention program who 
sustained abstinence for a 5-year period were very likely to still be abstinent after 11 years.87,89 
Improving the Success Rate of Quit Attempts 
Synthesis of prior systematic reviews. Self-help approaches. In a meta-analysis including 
self-help as one format for assisting smokers in their quit attempts, Fiore et al. showed that self-
help was of marginal efficacy.5 Further meta-analysis of studies in which self-help constituted 
the sole difference in treatment arms also indicated that self-help is of marginal efficacy. Little 
evidence supported the view that providing multiple types of self-help, when offered without any 
person-to-person intervention, significantly enhanced treatment outcomes. 
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Lancaster and Stead reported that providing smokers with materials to support quit attempts 
is of limited benefit unless the materials take into account each smoker’s individual 
characteristics.59 Advice and behavioral counseling can help smokers to quit.59 Giving the same 
type of support via written materials or other media has not been found to be very helpful, 
although people given no other support may experience a small benefit.  
These same authors examined 33 trials that compared self-help materials to no intervention 
or tested materials used in addition to advice.59 In 11 trials in which self-help was compared with 
no intervention, a pooled effect just reached statistical significance (N = 13,733; OR, 1.24, 95% 
CI, 1.07-1.45). Four other trials in which the control group received alternative written materials 
did not show an effect for the smoking self-help materials. The review failed to find evidence of 
benefit from adding self-help materials to either face-to-face advice or to nicotine replacement 
therapy.  
Seventeen trials used materials tailored for the characteristics of individual smokers; meta-
analysis by Lancaster and Stead supported a small benefit for tailored materials (N = 20,414; 
OR, 1.42; 95% CI, 1.26-1.61).59 The evidence was strongest for tailored materials compared with 
no intervention, but it also showed that tailored materials were more helpful than standard 
materials. A small number of other trials failed to detect benefits from using additional materials 
or targeted materials or to find differences between different self-help programs.  
Counseling. In another review, Lancaster and Stead looked at trials of counseling by a trained 
therapist in one or more face-to-face sessions (separate from medical care).60 All trials involved 
sessions lasting more than 10 minutes, with most including further telephone contact for support. 
A review of 21 trials with more than 7,000 participants showed that individual counseling for 
smoking cessation was more effective than the control (OR, 1.56; 95% CI, 1.32-1.84). In a 
subgroup of three trials in which counseling had been tested as an adjunct to nicotine 
replacement therapy, the point estimate of effect was smaller and did not reach significance (OR, 
1.34; 95% CI, 0.98-1.83). Meta-analysis did not detect a greater effect of intensive counseling 
than brief counseling, although the confidence intervals are wide and do not exclude the 
possibility of a clinically useful dose-response effect (OR, 0.98; 95% CI, 0.61-1.56).  
In another review by Stead and Lancaster of 16 studies that compared a group program with 
controls receiving no intervention, cessation increased with the use of a group program (N = 
4,395; OR, 2.04; 95% CI, 1.60-2.60).65 In seven trials, group programs were more effective than 
no intervention controls (N = 815; OR, 2.17; 95% CI, 1.37-3.45). No evidence emerged that 
group therapy was more effective than a similar intensity of individual counseling. Also, limited 
evidence suggested that programs with components for increasing cognitive and behavioral skills 
and avoiding relapse were more effective than programs of the same length or shorter without 
these components.  
Group therapy was shown to more than double the chances of quitting as compared with self-
help and other less intensive interventions.65 Evidence is insufficient to evaluate whether groups 
are more effective than intensive individual counseling and to support the use of particular 
psychological components in a program beyond the support and skills training normally 
included. Only limited evidence suggests that adding group therapy to other forms of treatment 
(adjunctive group therapy), such as advice from a health professional or nicotine replacement, 
produced extra benefit.65 Not all smokers making a quit attempt want to attend group meetings, 
but those who do are likely to find the meetings helpful if such activities offer assistance 
equivalent to intensive individual counseling.65  
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In updating the 1996 AHCPR clinical practice guideline, Fiore et al. found that minimal 
interventions lasting less than 3 minutes increased overall tobacco abstinence rates.5 They also 
reported a strong dose-response relation between length of person-to-person contact during a 
counseling session and successful treatment outcomes. In general, intensive interventions were 
more effective than less intensive interventions.  
The Fiore et al. review also indicated that intensive interventions for smoking cessation 
should include an assessment to ensure that tobacco users are willing to make a quit attempt 
using an intensive treatment program.5 Other assessments can provide information useful in 
counseling (e.g., stress level, presence of comorbidity), but little consistent evidence exists to 
show that a smoker’s status on a specialized assessment is useful in treatment matching. 
Regardless of their standing on specialized assessments, all smokers have the potential to benefit 
from cessation interventions. Tailored interventions based on specialized assessments (e.g., 
stages of change) do not consistently produce higher long-term quit rates than nontailored 
interventions of equal intensity. Because of the evidence of a strong dose-response relation, the 
intensity of a smoking cessation program should be defined as a session lasting longer than 10 
minutes, with four or more sessions, for a total contact time longer than 30 minutes.  
In terms of format, Fiore et al. used meta-analysis to compare self-help, proactive telephone 
counseling, group counseling, and individual counseling with no format.5 All four formats 
increased the likelihood of success in quitting; group counseling (OR, 1.3; 95% CI, 1.1-1.6) and 
individual counseling (OR, 1.7; 95% CI, 1.4-2.0) had the two highest odds ratios.  
The use of adjuvant self-help material is optional, but follow-up assessment intervention 
procedures should be used.5 Smoking cessation interventions that used more than two formats 
were more effective than interventions that used a single format.  
Particular types of counseling and behavioral therapies are especially effective.5 Practical 
counseling (e.g., problem-solving and skills-training approaches) and the provision of 
intratreatment social support and extratreatment social support (e.g., help in securing social 
support outside of treatment) are associated with significant increases in abstinence rates, as are 
aversive smoking techniques (e.g., rapid smoking). Tobacco dependence treatments are effective 
across diverse populations (e.g., populations varying in gender, age, and ethnicity).  
The review in the 2000 Surgeon General’s report found that pharmacologic treatment of 
nicotine addiction, combined with behavioral support, enabled 20 percent to 25 percent of users 
to remain abstinent at 1 year after treatment.2 Even less intense measures, such as physicians’ 
advising their patients to quit smoking, produced cessation rates of 5 percent to 10 percent. 
Evidence was mixed on the efficacy of self-help manuals as an aid to smoking cessation. 
Programs using advice and counseling—whether minimal or more intensive—have helped a 
substantial proportion of people quit smoking. The success of counseling and advice rises with 
the intensity of the program and may be improved by increasing the frequency and duration of 
contact.  
Pharmaceuticals. Fiore et al. found that pharmacotherapies such as bupropion sustained 
release (SR) or nicotine replacement therapies (e.g., nicotine gum, nicotine inhaler, nicotine 
patch, nicotine nasal spray) consistently increased abstinence rates.5 They conducted two sets of 
meta-analyses. One meta-analysis examined first-line pharmacotherapies (i.e., those agents 
found to be safe and effective for smoking cessation and approved by the US Food and Drug 
Administration [FDA] for such use). The other was for second-line pharmacotherapies (i.e., 
agents where evidence of their efficacy for treating tobacco dependence exists, but they have a 
more limited role than first-line pharmacotherapies both because the FDA has not approved them 
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for a tobacco dependence treatment indication and because they raise more concerns about 
potential side effects than first-line medications). 
First-line pharmacotherapies, which include bupropion and the nicotine replacement 
therapies, consistently increased abstinence rates.5 Second-line pharmacotherapies, including 
clonidine and nortriptyline, also demonstrated efficacy. The combination of the nicotine patch 
with a self-administered form of nicotine replacement therapy (either gum or nasal spray) was 
more effective than a single form of nicotine replacement. Evidence was inconsistent on 
effectiveness of other pharmaceutical treatments (e.g., antidepressants other than bupropion SR 
and nortriptyline, anxiolytics, benzodiazepines, beta-blockers, silver acetate, and 
mecamylamine).  
The Surgeon General’s report indicated strong, consistent evidence that pharmacologic 
treatments for smoking cessation (nicotine replacement therapies and bupropion, in particular) 
can help people quit smoking.2 Clonidine and nortriptyline may have some utility for smoking 
cessation, but, as noted, the FDA has not approved them for this indication. 
Synthesis of current literature. We identified 31 studies not covered by earlier publications 
that involved self-help, counseling, and pharmaceutical therapies. (Table 11).91-121 Of these, we 
rated 10 articles as poor quality and do not discuss them further in this section.92-96,108,110,111,117,118 
Detailed data on all studies can be found in Evidence Table 5.  
Self-help approaches. Two studies examined a self-help approach to improving cessation 
rates. One study involved patients recently discharged from intensive care units (ICUs).115 This 
intervention included (1) verbal encouragement to remain nonsmoking at ICU discharge and at 
8-week and 6-month clinic follow-up visits, (2) instructions for patient’s immediate family not to 
smoke in the same room as the patient, and (3) a 6-week self-help ICU rehabilitation manual for 
the patient and his or her relatives. The manual emphasized the importance of remaining 
nonsmoking and provided practical tips for smoking cessation along with other general tips. 
Patients receiving an ICU rehabilitation package were much less likely to return to smoking 
after discharge from the ICU than control patients, even though control patients received verbal 
encouragement to quit smoking during the recovery period.115 The investigators could not 
determine whether the smoking cessation advice in the ICU rehabilitation package or the whole 
package in general was responsible for the high quit rate. Including an exercise program in the 
package may have enhanced the likelihood of quitting smoking.  
The other trial included patients undergoing lung cancer screening.109 Participants in one 
intervention group received a handout with a list of 10 Internet sites related to stopping smoking 
and a brief description of each site; those in another group received two self-help booklets for 
smoking cessation, one of which provided up-to-date information on available 
pharmacotherapies for nicotine dependence. 
In this trial, the groups did not differ significantly in 7-day point prevalence quit rates or in 
advancement in motivational readiness.109 At 1-year followup, more of the subjects receiving 
Internet-based resources reported making a stop attempt (68 percent vs. 48 percent; P = 0.011).  
Counseling. Five studies evaluated the effects of counseling—two studies in the hospital 
setting,112,120 one in a combination of primary care clinics and hospitals,119 and two in private 
practices.105,121 All female adult smokers were eligible for enrollment in one hospital-based 
studies120 and all adult smokers in the other.112 All diabetic adult and young adult smokers were 
eligible for enrollment in the combined-setting study.119 All interventions included nurse  
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Table 11. Strategies to improve success rates for quit attempts for general and special populations 
Author  
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Aveyard et al., 
2003105 
 
United Kingdom 
 
Practice/ 
Provider Settings 
RCT 
 
9 months 
 
12 months 
post baseline 
G1: Pro-Change self-help 
system with workbook and 3 
questionnaires to generate 
tailored feedback 
 
G2: G1 plus three telephone 
calls 
 
G3: G1 plus three nurse visits 
 
C1: 2 standard self-help quit 
guides and 2 tip cards 
2471 
adults 
No statistically 
significant difference in 
quit rates between 
intervention and control 
groups (G1=11%, 
G2=12%, G3=10%, 
C1=10%) in 
biochemically-confirmed 
abstinence for  6-
months sustained 
abstinence and 12-
months point 
prevalence 
Fair 
Bohadana et al., 
200091 
 
France, 
Western Europe 
 
Practice/provider 
settings 
RCT 
 
26 weeks 
 
6 weeks; 3, 6, 
and 12 months  
G1: Nicotine inhaler and nicotine 
patch 
 
C1: Nicotine inhaler and placebo 
patch 
 
 
400  
adults  
Abstinence was greater 
at 3 months for 
intervention group than 
control group (P = 0.02) 
 
No significant difference 
between groups at 6- 
and 12-month followups 
Fair 
Canga et al., 
2000119 * 
 
Spain, 
Western Europe 
 
Practice/provider 
settings 
 
Hospital 
RCT with 
systematic 
randomization 
 
6 months 
 
6 months 
G1: Interview with nurse; self-
help materials; 3 months of 
transdermal NRT if eligible; 5 
follow-up contacts 
 
C1: Usual care for diabetic 
smokers established in the 
Navarre diabetes care program 
280 
young 
adults, 
adults 
Those in the 
intervention were 
significantly more likely 
than those in the control 
to quit at 6-month 
followup (validated):  
(P ≤ 0.001) 
Fair 
Carpenter et al., 
200498 
 
United States 
 
Population-based 
RCT 
 
24 weeks 
 
3, 6, 12 and 24 
weeks 
G1: Telephone-based reduction 
counseling and NRT and brief 
advice to quit 
 
G2: Motivational advice (5Rs) 
and brief advice 
 
C1: No treatment 
616 
adults 
At 6 months, those 
receiving either 
intervention had greater  
percentages of “24 hour 
quit attempts” (G1: 43% 
and G2: 51%) than 
those who received no 
treatment (C1: 16%)  
(P < 0.01) 
Fair 
Clark et al., 
2004109 
 
United States 
 
Hospital 
 
Practice/provider 
settings 
RCT 
 
Given 
materials at 
time of chest 
CT scan 
 
1 and 12 
months 
G1: Internet cessation resources 
handout with Web site 
addresses 
 
C1: Standard self-help 
material—NCI handout, ACS 
booklet  
171 
adults, 
> 50 
years of 
age 
No statistically 
significant differences in 
smoking status found at 
1-month or 1-year 
followup  
 
Fair 
ACS, American Cancer Society; C, Control Group; CBT, cognitive behavioral therapy; CT, computed tomography; ICU, 
intensive care unit; G, Intervention Group(s); NCI, National Cancer Institute; ng/ml, nanogram per milliliter; NRT, nicotine 
replacement therapy, RCT, randomized controlled trials.  
*: General and special populations 
†: Special populations only 
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Table 11. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Author  
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Dalsgareth et al., 
2004106 
 
Denmark 
 
Hospital 
RCT 
 
7 weeks 
 
26 weeks post-
baseline 
G1: 2 motivating phone 
calls,  5 clinic visits, and 
sustained-release 
bupropion hydrochloride 
 
C1: 2 motivating phone 
calls, 5 clinic visits, and 
placebo 
336 adult 
hospital 
employees 
Continuous abstinence 
at 26 weeks: 
G1 = 18% 
C1 = 7% 
P = 0.008 
Fair 
Garvey et al., 
2000107 
 
United States 
 
Population-
based 
RCT 
 
2 months 
 
1, 7, 14, 30 days 
and 2, 3, 6, 9, 
and 12 months 
post-cessation 
All subjects received Self 
help booklet and brief 
behavioral counseling,  
(5-10 minutes per visit, for 
1 year) 
 
G1: Low dependence 2 mg 
gum 
 
G2: Low dependence 4 mg 
gum 
 
G3: High dependence 2 
mg gum 
 
G4: High dependence 4 
mg gum 
608 adults At 1 year follow-up quit 
rates for low 
dependence were 
Placebo 11.2% 
2 mg gum 19.5% 
4 mg gum 18.4% (NS) 
 
High dependence 
smokers quit rates at 1 
year 
2 mg gum compared to 
placebo (15.7% vs. 
6.1%, P = 0.02) 
4 mg gum compared to 
placebo (20.7% vs. 
6.1% P = 0.002) 
Fair 
Hall et al., 200497 
 
United States 
 
Population-
based 
RCT 
 
Brief: 12 weeks 
Extended: 52 
weeks 
 
12, 24, 36, 52 
weeks 
G1: Brief nortriptyline: 
nortriptyline for 12 weeks; 
5 counseling sessions and 
NRT patch at week 5 
 
C1: Brief placebo: placebo 
for 12 weeks; 5 counseling 
sessions and NRT at week 
5 
 
G2: Extended nortriptyline: 
G1 + extended 
pharmacotherapy and 
counseling (1/month) for 
52 weeks 
 
C2: Extended placebo: G2 
but used placebo instead 
of nortriptyline 
160 adults At 12 weeks 
nortriptyline was more 
effective than placebo 
(OR = 0.69, 95% CI; 
0.49-0.92, P = 0.02) 
and placebo at 52 
weeks (OR = 0.47; 95% 
CI; 0.30-0.75, P = 
0.001); however 52 
weeks of nortriptyline 
did not differ 
significantly from 
placebo at that same 
time frame 
Fair 
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Table 11. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Author  
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Hennrikus et al., 
2005112 * 
 
United States 
 
Hospital 
RCT 
 
6 months 
 
7 to 18 days,  
12 months 
postdischarge  
 
G1: 2 smoking cessation 
manuals; community 
resources directory; 
medical record label to cue 
to providers; postdischarge 
letter  
 
G2: G1 plus extended 
bedside counseling 
session and 3 to 6 
telephone calls for 6 
months postdischarge 
 
C1: 2 cessation manuals 
and community resources 
directory 
2,095  
adults 
Cotinine corrected 
intention-to-treat 
analysis found 
percentage of 
abstinence at 12-month 
followup (P > 0.05) NS 
Fair 
Hitsman et al., 
1999113 
 
United States 
 
Population-
based 
RCT 
 
10 weeks  
 
1 week, 1, 3, 
and 6 months 
postquit date 
G1: Individual cognitive 
behavioral therapy, 
fluoxetine 30mg for 10 
weeks, fluoxetine 
compliance level set at  
< 150ng/ml  
 
G2: Same as G1, except 
fluoxetine dose of 60mg 
and fluoxetine compliance 
level set at 300ng/ml  
 
C1: Individual cognitive 
behavioral therapy plus 
placebo 
253  
adults 
No significant results 
found at 1, 3, and 6 
month followup. 
 
Individual differences 
that predict cessation 
when fluoxetine is 
combined with CBT 
include higher levels of 
weight concern, degree 
of depression, and 
levels of nicotine 
dependence 
Fair 
Holt et al., 
2005114 * 
 
New Zealand 
 
Community-
based 
 
Population-
based 
RCT 
 
2 months 
 
3 and 7 weeks, 
3, 6, 9, and 12 
months 
posttarget quit 
date 
G1: Bupropion; counseling
 
C1: Placebo and 
counseling 
 
134  
adolescents; 
young adults; 
adults 
People in the 
intervention group were 
significantly more likely 
than those in the control 
to be continuously 
abstinent at 3 months  
Fair 
Jones et al., 
2001115 * 
 
United Kingdom 
 
Hospital 
RCT 
 
6 months 
 
8 weeks, 6 
months postICU 
discharge 
G1: Verbal 
encouragement to 
patients to remain 
nonsmokers and for 
immediate family not to 
smoke in the same room 
as the patient, plus self- 
help manual 
 
C1: G1 without the 
manual 
61 
adults 
Of the smokers pre-ICU 
admission, more 
returned to smoking in 
the control group at 6-
mos followup 
Fair 
 
61 
Table 11. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Author  
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Jorenby et al., 
1999116 
 
United States 
 
Community-
based 
 
RCT 
 
9 weeks 
 
10 weeks, 3, 6, 
and 12 months 
post start of 
study 
G1: bupropion and  
nicotine patch  
 
G2: bupropion and 
placebo patch 
 
G3: placebo tablets and 
nicotine patch 
 
C1: placebo tablets and 
placebo patch  
893  
adults 
Those receiving 
buproprion and patch 
were most likely  
(P ≤ 0.001) to be 
abstinent at 6 and 12 
months  
Fair 
Killen et al., 
200099 
 
United States 
 
Population-
based 
RCT 
 
17 weeks 
 
4, 10 and 26 
weeks 
G1: NRT transdermal 
system patch for 8 weeks 
plus 20 mg paroxetine for 
9 weeks 
 
G2: NRT transdermal 
system patch for 8 weeks 
plus 40 mg paroxetine for 
9 weeks 
 
C1: NRT transdermal 
system patch for 8 weeks 
plus placebo for 9 weeks 
224 adults No significant 
differences in 
abstinence groups 
found between groups 
at any follow up time 
period  
Good 
Lancaster et al., 
1999121 
 
United Kingdom 
 
Practice/provider 
settings 
RCT with 
systematic 
randomization 
 
6 weeks 
 
3 and 12 months 
postquit date 
G1: Brief advice to quit 
from general practitioner, 
plus: extended counseling 
a nurse; leaflet on 
cessation; fact sheet on 
NRT; invitation to contact 
the research nurse for 
more intensive, tailored 
counseling; NRT if 
necessary 
 
C1: Brief advice to quit 
from the patients’ general 
practitioners 
497 
adults 
No significant 
differences found 
between groups at 3 
and 12 month followups 
Fair 
Lerman et al., 
2004100 
 
United States 
 
Population-
based 
 
RCT 
 
8 weeks 
 
8 weeks and 6 
months 
G1: 8 weeks of nicotine 
nasal spray and 7 
sessions of behavioral 
group counseling  
 
G2: 8 weeks of 
transdermal nicotine 
therapy (i.e., patch) and 7 
sessions of behavioral 
group counseling 
299 adults No statistically 
significant difference 
found between 
treatment groups at 6 
months (G1: 12.2%, 
G2: 15%, NS) 
 
Smokers who were 
highly dependent, 
obese, or members of 
minority groups 
achieved higher rates of 
abstinence with nasal 
spray 
Fair 
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Table 11. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Author  
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
MacLeod et al., 
2003104 
 
Australia 
 
Population-
based 
RCT 
 
10 weeks 
 
1, 2, 3 and 6 
months 
G1: Nicotine Patch and 5 
telephone counseling calls 
 
C1: Nicotine Patch only 
854 adults Telephone counseling 
improves cessation 
rates when used in 
conjunction with the 
patch 
 
28-day continuous 
abstinence rates at 6-
months: G1 30.6%, C1 
22.4%, P = 0.01 
 
90-day continuous 
abstinence rates G1 
26.7%, C1 18.6%,  
P = 0.004 
Good 
McBride et al., 
2004122 † 
 
United States 
 
Military Medical 
Center 
RCT 
 
First trimester 
to delivery and 
12 months 
postpartum   
 
28 weeks 
pregnant 
 
Postpartum 
 
2, 6, and 12 
months 
G1: Usual care plus late 
pregnancy relapse kit, and 6 
counseling calls 
 
G2: G1 plus the partners 
received telephone 
counseling and support 
guide (partners who smoked 
received cessation aids and 
counseling)  
 
C1: Usual Care: provider 
583 Pregnant 
women and 
their partners
No statistically 
significant difference 
between groups at any 
follow up point 
 
In late pregnancy, more 
partners abstinent in G2 
group (15%) than C1 
group (5%) P = 0.02 
Fair 
Peterson 2004120 
* 
 
United States 
 
Hospital 
RCT 
 
3 months 
 
12 months 
G1:Brief physician 
counseling and usual care 
plus nurse managed, 
cognitive behavioral relapse 
prevention intervention given 
pre-discharge, <5 structured 
telephone contacts 
discharge, and relapse 
management counseling as 
needed 
 
C1: Brief physician 
counseling, a self-help 
pamphlet, and list of 
community resources 
277 adults 
women  
No significant 
differences between 
groups at 12 month 
follow ups 
Fair 
Quist-Paulsen et 
al., 2003123 † 
 
Norway 
 
Hospital – 
cardiac ward 
RCT 
 
5 months 
 
12 months 
G1: Self-help booklet on how 
to quit smoking plus cardiac 
nurse consultation during in-
patient days and phone 
consultation for up to 5 
months following  discharge 
 
C1: Group sessions with 
nurses with minor emphasis 
on smoking cessation and no 
further advice or instruction 
on how to quit  
240 adults At one year, the quit 
rate was far greater 
(57%) in the intensive 
nurse intervention 
versus the minimal 
intervention group 
(37%) (absolute risk 
reduction 20%, 95% CI 
6.4-33.0; P = 0.004)  
Good 
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Table 11. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Author  
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Ratner et al 
2004124 † 
 
Western Canada 
 
Teaching 
hospital 
Randomized 
pretest-posttest 
control group 
experiment 
 
NR 
 
6 and 12 
months 
G1: 2 face to face 
counseling sessions and 9 
telephone counseling 
sessions 
 
C1: Standard hospital 
treatment 
237 surgical 
patients 
Those receiving the 
counseling (73%) were 
more likely to be 
abstinent than the 
controls (53%) (P = 
0.003) at 6 months but 
the difference is not 
significant at 12 months 
after surgery 
Fair 
Reid et al 
2003125 † 
 
Canada 
 
Hospital, tertiary 
care cardiac 
facility 
RCT 
 
8 weeks 
 
3 months and 1 
year 
G1: Self-help booklet given 
in the hospital, then follow-
up by nurse counselor at 4 
weeks after discharge; if 
patient  smoking, nurse 
provides 3 twenty minute 
face to face sessions over 8 
weeks and offered nicotine 
patch therapy 
254 coronary 
artery 
disease 
hospitalized 
patients 
Smoking cessation 
rates increased from 
42% at hospitalization 
to 53% at 3 month 
follow up (P = 0.05), but 
not significant at 1 year 
follow up 
Good 
Simon et al., 
2004101 
 
United States 
 
Hospital 
RCT 
 
7 weeks 
 
7 weeks, 3, 6 
and 12 months 
G1: 7 week course of 
Bupropion, 2 months 
transdermal nicotine 
replacement therapy, 1 visit 
with counselor (30-60 
minute session), and 5 
telephone follow-up calls  
 
C1: Same as G1 except 
participants received 
placebo instead of 
Bupropion  
244 adults 
(86% male) 
No statistically 
significant differences in 
smoking cessation rates 
at end of medication 3, 
6, and 12 months 
 
The addition of 7-week 
treatment with 
Bupropion did not 
significantly increase 
quit rates over NRT and 
counseling 
Fair 
Swan et al; 2003 
and 2003102,103  
 
United States  
 
Practice/ 
provider  
settings 
 
RCT 
 
12 months 
 
3 and 12 
months 
All participants received 
Bupropion SR for 7 weeks 
 
G1: 150 mg Bupropion SR, 
brief counseling call day 
after quit date, personalized 
intervention materials, and 
access to 24 hour 
automated support line 
 
G2: G1 except 300 mg 
Bupropion SR 
 
G3: 150 mg Bupropion SR, 
self-help materials, support 
materials for family and 
friends, an in-depth 
telephone counseling 
session, 4 brief telephone 
counseling calls, and 
access to toll free quitline 
for 1 year 
 
G4: G3 with 300 mg of 
Bupropion SR 
1524 adults Abstinence significantly 
greater at both 3 
months and 1 year for 
those receiving  
intensive counseling 
and higher dose of 
bupropion (G4) vs (G1, 
G3) and (G3) at higher 
dose with brief 
counseling  
 
The 300 mg dose was 
associated with more 
adverse events 
Fair 
64 
counseling, self-help materials, and follow-up contact either in person or by telephone, and all 
interventions were compared with usual care of brief advice to quit smoking, related self-help 
materials, or both. In the trial for women admitted to hospital with cardiovascular or peripheral 
vascular disease, the nicotine patch was offered (if not contraindicated) to those women who 
were smoking more than 19 cigarettes per day and who had not succeeded after trying to quit at 
least once.119 
One hospital-based study examined the effects of three smoking cessation counseling 
interventions for inpatients. Interventions included modified usual care, brief advice, and brief 
advice plus more extended counseling during and after hospitalization.112 Pharmacological aids 
were not provided. Inpatients in four hospitals were randomly assigned to each condition and 
followed up at 7 days and 12 months after discharge. Another hospital-based intervention 
involved smoking cessation and relapse prevention among women admitted to the hospital with 
cardiovascular or peripheral vascular disease.119 Neither of these hospital-based interventions 
increased biochemically verified abstinence rates at 12 months postdischarge, although self-
reported abstinence rates were significantly higher for the most comprehensive intervention 
group.112  
In the combined-setting study of diabetic patients seen in primary clinics and hospitals 
compared with a control group, those receiving nurse-managed assistance in quitting were, at 6-
month followup, significantly more likely to quit smoking.119 This work, biochemically 
validated, produced quit rates of 17.0 percent for the intervention group and 2.3 percent for the 
control group (P = 0.001). Among those who did not quit, the intervention significantly 
decreased the mean number of cigarettes smoked per day (for the experimental group, 20.0 at 
baseline and 15.5 at followup; for the control group, 19.7 and 18.1, respectively, at the two 
measurements; P < 0.001).  
The two different interventions for adults in private practices showed no significant 
differences in quit rates at 12-month followup.105,121 One of these studies also showed no 
significant differences in quit rates at 3 months or in continuous abstinence between 3- and 12-
month followups.121 The other study found no significant differences in biochemically confirmed 
quit rates between intervention and control groups at 6-month followup, 6-month sustained 
abstinence, or 12-month followup.105 
The three studies in this section among hospitalized patients are also included in a separate 
section of this report about interventions among hospitalized patients.112,119,120  
Single pharmaceutical therapy. Five studies examined the effect of a single pharmaceutical 
treatment on smoking cessation.100,101,106,107,114 Three studies evaluated the effect of bupropion, 
one studied the effect of nicotine gum and of different doses of nicotine gum, and one the 
comparative efficacy of transdermal nicotine and nicotine nasal spray. Two studies were based in 
hospitals: one accepting adults age 20 and over101 and the other involving adults employed by the 
hospital.106 Three studies were population-based and enrolled only adults.100,107,114 One study 
examined efficacy of bupropion use in the indigenous Maori population in New Zealand.114 
A 6-month, multicenter, parallel group, randomized, double-blind, placebo-controlled study 
compared 7-week treatment with bupropion SR (Zyban®) with placebo as an aid to smoking 
cessation in health care workers.106 All participants were motivated to quit smoking and received 
behavioral counseling. Continuous smoking abstinence at week 7 was achieved by 43 percent in 
the bupropion group and 18 percent in the placebo group (P < 0.001). Side effects, although 
frequent, were simple and reversible in both groups and generally consistent with the findings of 
65 
previous studies. Dizziness, insomnia, and pruritus appeared more frequently in the bupropion 
group than in the placebo group. 
A randomized blinded trial examined the efficacy of bupropion SR for smoking cessation 
among an outpatient population. Of the 244 participants, 121 received a 7-week course of 
bupropion and 123 received placebo.101 All participants received 2 months of transdermal 
nicotine replacement therapy and 3 months of cognitive behavioral counseling. During treatment 
the investigators observed a trend toward increased quit rates among participants randomized to 
bupropion. The self-reported end-of-medication quit rates were 64 percent for the bupropion 
group and 57 percent for the placebo group (P = 0.23). The trend favoring bupropion persisted at 
3 months of followup (P = 0.12) but was not apparent at 6 months and 1 year of followup (both 
P = 0.78). The 12-month quit rates, validated by either saliva cotinine or spousal proxy, were 22 
percent in the bupropion group and 28 percent in the placebo group (P = 0.31). Based on 
biochemical validation, 19 percent of the bupropion group and 24 percent of the placebo group 
had quit smoking by 1 year (P = 0.36). 
Holt et al. attempted to determine whether bupropion combined with smoking cessation 
counseling was effective for the indigenous Maori population of New Zealand.114 At 3- and 6-
month followup, rates of abstinence in the bupropion group were significantly higher than rates 
in the placebo group. A model-based secondary analysis found a risk ratio of 2.44 in favor of 
bupropion for all time points. Bupropion was also safe and generally well tolerated, although 
three subjects did not complete treatment with bupropion because of a rash. 
Garvey et al. used the Heaviness of Smoking Index, a subset of the Fagerstrom Test for 
Nicotine Dependence, to classify smokers planning a cessation attempt as low or high in nicotine 
dependence.107 Subjects within each level of dependence were then randomly assigned to 
placebo, 2-mg, or 4-mg nicotine gum treatment. Subjects were also provided brief (5 to 10 
minutes per visit) behavioral counseling during a 1-year period of followup. At 1 year 
postcessation, quit rates were 11.2 percent, 19.5 percent, and 18.4 percent for low-dependence 
smokers receiving placebo, 2-mg, and 4-mg gum, respectively (P linear trend = 0.20). For high-
dependence smokers, quit rates at 1 year were 6.1 percent, 15.7 percent, and 20.7 percent for the 
placebo, 2-mg, and 4-mg gum conditions, respectively (P linear trend = 0.002). The interaction 
of nicotine-gum dose and dependence group was not significant (P = 0.42). The 2-mg and 4-mg 
doses did not differ significantly in effectiveness, although both doses were significantly more 
effective than placebo gum. Other variables related to abstinence at 1 year postcessation were a 
longer period of abstinence on a prior quit attempt, being married, higher education level, and 
having a nonsmoking spouse or significant other. Results indicate that nicotine gum is a 
significant aid to smoking cessation, more than doubling the odds of successful cessation 
compared with the odds for placebo gum users. The 4-mg dose provided a nonsignificant 
increase in cessation rates for high-dependence smokers.  
Lerman et al. conducted a randomized, open-label clinical trial to evaluate the comparative 
efficacy of transdermal nicotine and nicotine nasal spray and identify predictors of treatment 
outcome in two university-based smoking cessation research programs.100 Intervention consisted 
of behavioral group counseling and 8 weeks of therapy with nicotine nasal spray or transdermal 
nicotine. Abstinence rates for the transdermal nicotine and nicotine nasal spray groups were not 
significantly different at 6-month followup (15.0 percent vs. 12.2 percent, respectively; P > 0.2). 
Interactions in abstinence rates for subgroups of smokers were statistically significant (P < 0.05).  
Smokers who had low to moderate dependence levels, were not obese, and were white achieved 
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higher abstinence rates with transdermal nicotine, whereas smokers who were highly dependent, 
obese, or members of minority groups achieved higher abstinence rates with nasal spray. 
Combined pharmacotherapies. Three studies examined the effect of combined 
pharmacotherapies on smoking cessation.91,99,116  
In one, Bohadana and colleagues recruited subjects through a local newspaper and 
randomized them to either the intervention group (which received a nicotine inhaler and nicotine 
patch) or a control group (which received a nicotine inhaler and placebo patch).91 Smoking at 
intake was defined as smoking 10 or more cigarettes per day for 3 or more years and an expired 
CO level of 10 ppm or more.  
Abstinence rates at 6 weeks, measured as expired CO of 10 ppm or more, were significantly 
higher for those receiving the nicotine inhaler and the nicotine patch than for those receiving the 
nicotine inhaler and placebo patch (60.5 percent vs. 47.5 percent, P = 0.09).91 At 6-month and 
12-month followup, however, the groups did not differ significantly in continuous abstinence. 
One-year survival analysis showed a significant association between abstinence and treatment 
with nicotine inhaler plus nicotine patch (P = 0.04). In an examination of weight gain, subjects in 
the intervention group had gained less weight than the control group by week 2 (P < 0.01), but 
after 12 months, differences in mean weight gains were not significant. Mean nicotine 
substitution at week 6 was 60.1 percent in the intervention group and 24.6 percent in the control 
group (P < 0.001). At 12 months, the frequency of respiratory symptoms in abstinent subjects 
had fallen significantly compared with their baseline (for morning cough, P < 0.001; for morning 
phlegm, P = 0.002; for wheezing, P < 0.001; and for shortness of breath, P < 0.001). A trend 
toward improved lung function was observed but not significant at 12-month followup compared 
with baseline. Subjects in the control group reported significantly more intense withdrawal 
symptoms at week 1 (P < 0.001) and craving symptoms at week 6 (P = 0.04) than those in the 
intervention group. The most common adverse events were throat irritation (from the inhaler) 
and itching (from the patch).  
Jorenby et al. recruited adult subjects through media advertisements.116 They randomized 
those in the intervention group to three conditions: bupropion only, nicotine patch only, or both 
bupropion and nicotine patch. Subjects in the control group received placebo pills and a placebo 
patch. Smoking at intake was defined as smoking at least 15 cigarettes per day. Self-report of 
smoking status and expired CO were used to assess smoking status at 6- and 12-month 
followups.  
The abstinence rates at 12 months were 15.6 percent in the placebo group compared with 
16.4 percent in the nicotine patch group, 30.3 percent in the bupropion-only group (P < 0.001), 
and 35.5 percent in the group given bupropion and the nicotine patch (P < 0.001).116 Abstinence 
rates were higher with combination therapy than with bupropion alone, but the difference was 
not statistically significant. By week 7, participants in the placebo group had gained an average 
of 2.1 kg. Weight gain in the other groups was 1.6 kg in the nicotine patch group, 1.7 kg in the 
bupropion-only group, and 1.1 kg in the combined treatment group (P < 0.05). Subjects in the 
combined therapy group had gained significantly less weight than those in the placebo group  
(P < 0.05) or the bupropion-only group (P < 0.05). Groups did not differ significantly in mean 
weight changes after week 7. Adverse events were rare and tolerable; they included insomnia 
and headache.  
In the third trial, Killen and colleagues recruited participants by placing program 
announcements in local newspapers and examined the efficacy of a smoking cessation treatment 
that combined nicotine replacement therapy via a transdermal system (TNS) with the 
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antidepressant paroxetine (a selective serotonin reuptake inhibitor [SSRI]).99 Smokers (N = 224) 
were randomized to one of three groups: (1) TNS and placebo; (2) TNS and 20 mg paroxetine; 
and (3) TNS and 40 mg paroxetine. Assignment to treatment was double-blind. TNS treatment 
was provided for 8 weeks; paroxetine or placebo was provided for 9 weeks.  
Abstinence rates at weeks 4, 10, and 26 were as follows: (1) TNS and placebo: 45 percent, 36 
percent, and 25 percent; (2) TNS and 20 mg paroxetine: 48 percent, 33 percent, and 21 percent; 
and (3) TNS and 40 mg paroxetine: 57 percent, 39 percent, and 27 percent.99 The differences 
were not statistically significant. The combined treatment was more effective in reducing both 
craving and depression symptoms associated with smoking cessation. A subgroup analysis 
compared outcomes only among compliant participants. Abstinence rates at weeks 4, 10, and 26 
were as follows: (1) TNS and placebo: 46 percent, 35 percent, and 24 percent; (2) TNS and 20 
mg paroxetine: 64 percent, 43 percent, and 33 percent; and (3) TNS and 40 mg paroxetine: 74 
percent, 51 percent, and 38 percent. The differences between paroxetine groups and the control 
group at week 4 were statistically significant.  
Pharmacotherapy and psychological interventions. We identified six studies designed to 
examine the effect on cessation rates of interventions that had both pharmacotherapy and 
psychological counseling.97,98,102-104,113 Four studies were population-based studies of adults; two 
studies included members of a large health care system. 
The population-based trial examined the effectiveness of the combination of fluoxetine 
(another SSRI antidepressant) and cognitive behavioral treatment (CBT).113 One and 3 months 
after the quit date, fluoxetine increased the likelihood of abstinence, as compared with placebo, 
among smokers with minor depression but not among those with little or no depression. As an 
adjunct to CBT, fluoxetine increased cessation by selectively benefiting medication-compliant 
smokers who displayed even subclinical levels of depression. Investigators were unable to 
predict cessation outcome on the basis of drug assignment, individual differences, or their 
interaction. Thus, they would not suggest that an interventionist could simply use the personal 
attributes they studied to predict which smokers might benefit from adjunctive fluoxetine before 
knowing something about whether a smoker is likely to adhere to an intensive treatment regimen 
involving medication plus CBT. 
No evidence suggested that the more nicotine-dependent smokers derived special benefit 
from fluoxetine.113 The moderating effect of depression on fluoxetine responsiveness was 
independent of the effect of nicotine dependence; this effect persisted even after the variance 
explained by nicotine dependence was removed. These findings suggest that adjunctive 
antidepressant treatment offers little selective benefit for highly nicotine-dependent smokers.  
Carpenter et al. studied the efficacy of smoking reduction aided by nicotine replacement 
therapy compared to motivational advice or no treatment by using a telephone-only intervention 
among smokers not currently interested in quitting.98 They randomized these smokers (N = 616) 
to receive (1) telephone-based reduction counseling plus nicotine replacement therapy plus brief 
advice to quit, (2) telephone-based motivational advice plus brief advice, or (3) no treatment.  
Over 6 months, more smokers in the reduction-counseling arm (43 percent) and the 
motivational arm (51 percent) made a 24-hour quit attempt than smokers in the no-treatment arm 
(16 percent; P ≤ 0.01).98 The two active intervention groups, however, did not differ on this 
outcome variable (P ≥ 0.05). Similarly, 18 percent, 23 percent, and 4 percent in each group were 
abstinent (7-day point prevalence) at 6 months (P ≤ 0.01). Results indicated that smoking 
reduction using nicotine replacement does not undermine cessation; rather, it increases the 
likelihood of quitting to a degree similar to that from motivational advice.  
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Using a chronic disease model of smoking, Hall et al. undertook to determine the effects of 
long-term antidepressant and psychological treatment.97 They randomly assigned 160 subjects 
who smoked at least 10 cigarettes a day to one of four treatment groups in a two-by-two design 
(nortriptyline [a tricyclic antidepressant] versus placebo by brief versus extended treatment). All 
subjects received 8 weeks of a transdermal nicotine patch, five group counseling sessions, and 
active drug or placebo treatment. Interventions for subjects in brief treatment ended at this point. 
Subjects in extended treatment continued taking nortriptyline or placebo to week 52 and received 
9 monthly counseling sessions, with checkup telephone calls midway through each session. 
Subjects were assessed at baseline and weeks 12, 24, 36, and 52.  
At week 52, point-prevalence abstinence rates with missing subjects imputed as smokers 
were 30 percent for placebo brief treatment, 42 percent for placebo extended treatment, 18 
percent for active brief treatment, and 50 percent for active extended treatment.97 With missing 
subjects omitted, these rates were 32 percent, 57 percent, 21 percent, and 56 percent, 
respectively. Differences were significant for the active extended condition at each of 24, 36, and 
52 weeks. 
In a randomized controlled trial, Macleod et al. investigated the effectiveness of telephone 
counseling as an adjunct to nicotine replacement therapy by transdermal patch in smoking 
cessation.104 Smokers were randomized to either replacement therapy alone or replacement 
therapy plus telephone counseling (five sessions spaced according to a relapse-sensitive call 
schedule). Continuous abstinence rates over 28 days among participants receiving telephone 
counseling were significantly greater than among those not receiving telephone counseling at 
both 3 and 6 months (31.6 percent vs 25.1 percent; P = 0.04 at 3 months; and 30.1 percent vs 
22.4 percent; P = 0.01 at 6 months). Similarly, 90-day continuous abstinence rates at 6 months 
were significantly greater for participants receiving counseling (26.7 percent v 18.6 percent;  
P = 0.004).104  
Two studies from the same research team examined characteristics associated with more 
clinically relevant smoking endpoints following treatment with bupropion SR in a large health 
care system.102,103 In both studies, the researchers randomized smokers to receive one of four 
combinations of bupropion (150 mg or 300 mg) and behavioral counseling (tailored mailings or 
proactive telephone counseling); they assessed point-prevalent smoking status at 3 and 12 
months. The Swan, Jack, et al. study focused on predictors of outcome;102 the Swan, McAfee, et 
al. study focused on group differences.103  
Findings related to smoking abstinence were the same in both studies. Bupropion dose was 
not associated with rates of smoking at 12 months. However, the odds ratio for 12-month 
smoking was 24 percent higher for those who received the tailored mail program than those 
enrolled in the proactive telephone-counseling program (OR, 1.24; 95% CI, 1.06-1.47).  
Strategies to Improve the Success Rate for Quit Attempts for Special 
Populations 
Synthesis of prior systematic reviews. Hospitalized patients. In a meta-analysis of four 
studies meeting selection criteria and relevant to the analysis comparing augmented smoking 
cessation treatment with usual care for hospitalized patients, Fiore et al. found that smoking 
cessation treatments have been shown to be effective for hospitalized patients.5 Augmented 
smoking cessation interventions among hospitalized patients increased rates of smoking 
abstinence. Because the meta-analysis was limited to four studies, the investigators made no 
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attempt to categorize the augmented treatment with respect to type or intensity. For reference 
only, the augmented interventions in the analyzed studies included elements such as self-help via 
brochure or audio/videotape, chart prompts that reminded physicians to advise smoking 
cessation, pharmacotherapy, hospital counseling, and postdischarge counseling telephone calls.  
In the Rigotti et al. review of interventions for smoking cessation in hospitalized patients, 
intensive intervention (inpatient contact plus followup for at least 1 month) was associated with a 
significantly higher quit rate than control (Peto OR, 1.82; 95% CI, 1.49-2.22, six trials).63 
Interventions with less than a month of followup produced no significant benefit (Peto OR, 1.09; 
95% CI, 0.91-1.31, seven trials). They found no evidence to judge the effect of very brief 
interventions (<20 minutes) delivered only during the hospital stay. Longer interventions 
delivered only during the hospital stay were not significantly associated with a higher quit rate 
(Peto OR, 1.07; 95% CI, 0.79-1.44, three trials). Although the interventions increased quit rates 
irrespective of whether nicotine replacement therapy was used, the results for replacement 
therapy were compatible with other data indicating that it increases quit rates.63 
Pregnant women. Prior reviews included studies with substantial variation in the intensity of 
the intervention and the extent of reminders and reinforcement through pregnancy. All three 
reviews concluded that participants in intervention conditions experienced significant reduction 
in continued smoking in late pregnancy.5,37,61 
Racial and ethnic minorities. A prior review of interventions specifically designed for 
particular racial or ethnic groups demonstrated the efficacy of a variety of smoking cessation 
interventions for minority populations. The resultant recommendation is that members of racial 
and ethnic minorities should be provided treatments shown to be effective in the Treating 
Tobacco Use and Dependence guideline.5 
Synthesis of current literature. We identified 13 studies not covered by prior reviews 
dealing with special populations; 10 studies dealt with hospitalized patients,112,115,119,120,123-128 
two studies dealt with pregnant women,122,129 and one with indigenous Maori.114 We described 
one of these studies in the self-help portion of this chapter and two in the counseling portion, but, 
because they dealt with hospitalized patients, we included them here as well.115,119,120 Of these, 
we rated four articles as poor quality (three for hospitalized patients126-128 and one for pregnant 
women129) and do not discuss them further in this section. Detailed data on all studies can be 
found in Evidence Table 5. 
Hospitalized patients by diagnosis. Three studies focused on improving cessation rates 
among hospitalized patients with specific smoking-related diagnoses.119,120,123 One study 
involved smoking cessation and relapse prevention among women admitted to the hospital with 
cardiovascular or peripheral vascular disease,120 one included diabetic smokers,119 and one 
involved patients under the age of 78 years admitted for myocardial infarction, unstable angina, 
or care after coronary bypass surgery performed at other hospitals.123 All interventions included 
nurse counseling, self-help materials, and follow-up contact either in person or by telephone, and 
all interventions were compared with usual care of brief advice to quit smoking and/or related 
self-help materials. In the trial for women admitted to hospital with cardiovascular or peripheral 
vascular disease, the nicotine patch was offered (if not contraindicated) to those women who 
were smoking more than 19 cigarettes per day and who had not succeeded after trying to quit at 
least once.119  
All three of these hospital-based interventions failed to increase biochemically verified 
abstinence rates at 12 months after discharge. One, however, showed significant differences in 
self-reported abstinence at 12-month followup.123 
70 
Hospitalized patients by intensity of intervention. Four studies examined the effect of varying 
the intensity of smoking cessation intervention among hospitalized patients.112,115,124,125 One 
study involved patients recently discharged from intensive care units (ICUs).115 This intervention 
included (1) verbal encouragement to remain nonsmoking at ICU discharge and at 8-week and 6-
month clinic follow-up visits, (2) instructions for patient’s immediate family not to smoke in the 
same room as the patient, and (3) a 6-week self-help ICU rehabilitation manual for the patient 
and his or her relatives that emphasized the importance of remaining abstinent and provided 
practical tips for smoking cessation along with other general tips. In the study of recently 
discharged ICU patients, those receiving the intervention were much less likely to return to 
smoking after discharge from the ICU than control patients who received only the first 
component of the intervention. Investigators could not determine whether the smoking cessation 
advice in the ICU rehabilitation package or the whole package in general was responsible for the 
high quit rate.115 Including an exercise program in the package may have enhanced the likelihood 
of quitting smoking.  
Reid et al. evaluated the efficacy of a stepped-care approach to smoking cessation treatment 
among smokers with coronary artery disease (CAD).125 Stepped care refers to the practice of 
initiating treatment with low-intensity intervention and then exposing treatment failures to 
successively more intense interventions. Smokers hospitalized with CAD were provided a brief 
cessation intervention. The participants then were assigned randomly to either a more intensive 
stepped-care treatment (counseling and nicotine patch therapy) or no additional treatment.  
In the second study of this type, Ratner et al. designed an intervention to help smokers 
abstain from smoking before surgery, maintain abstinence postoperatively, and achieve long-
term cessation.124 Their intervention included counseling and nicotine replacement therapy. 
Finally, one study examined the effects of three smoking cessation counseling interventions for 
hospital patients: (1) modified usual care, (2) brief advice, and (3) brief advice plus more 
extended counseling during and after hospitalization.112 Pharmacological aids were not provided. 
Inpatients in four hospitals were randomly assigned to each condition and followed up at 7 days 
and 12 months postdischarge.  
None of these studies showed significant differences in 12-month abstinence. In two studies, 
significant differences in abstinence emerged for the short term (i.e., 3 months and 6 months). In 
the stepped-care intervention study, treatment increased smoking cessation rates from 42 percent 
to 53 percent during a 3-month follow-up period (P = 0.05).125 In the Ratner et al. study, 
treatment group participants (73.0 percent) were more likely to abstain from smoking before 
surgery than were controls (53.0 percent) (X2 [1, N = 228] = 8.89; P = 0.003), and they were also 
more likely to be abstinent 6 months after surgery (31.2 percent vs. 20.2 percent) after 
controlling for covariates in a logistic regression analysis.124  
Pregnant women. A three-group randomized controlled trial was conducted from 1996 to 
2001, with 583 women and their partners randomized to usual care (UC), a woman-only (WO) 
intervention, or a partner-assisted (PA) intervention.122 Followups occurred at 28 weeks of 
pregnancy and 2-, 6-, and 12-months postpartum. Women in the UC condition received provider 
advice to quit and a self-help guide. The WO group received UC components plus a late-
pregnancy relapse prevention kit (booklet and gift items) and six counseling calls (three in 
pregnancy and three postpartum) initiated by a health advisor. Women in the PA group received 
the WO intervention, and their partners received telephone counseling and a support guide 
emphasizing skills to help the woman build and maintain her confidence to quit smoking. 
Partners who smoked also received cessation aids and related counseling.  
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Intent-to-treat analyses showed no significant differences by condition in women's reports of 
abstinence at any followup.122 In late pregnancy, more partners were abstinent in the PA 
condition (15 percent) than in the UC condition (5 percent) (P = 0.02).  
Racial and ethnic minorities. In a study of whether bupropion combined with smoking 
cessation counseling was effective in treatment of tobacco use in indigenous Maori in New 
Zealand, the investigators found quit rates similar to those observed in other trials of bupropion 
and no special problems related to bupropion use.114   
KQ 3. Implementation of Proven Population-Level Tobacco 
Use Cessation Strategies 
Understanding and implementing evidence-based interventions remain major challenges for 
public health and clinical practice. Adoption and implementation of population-level tobacco use 
cessation strategies are no exception. Here we summarize current research on the efficacy of 
community and health care systems interventions to increase the implementation of such 
strategies. As elsewhere, we present information from prior systematic reviews and then 
summarize current literature. We start first with population-based strategies and then consider 
strategies based in provider settings and health care systems.  
Population-Based Strategies 
Tobacco users are more likely to quit using tobacco if they are engaged in community-wide, 
comprehensive programs that use multiple channels to engage individuals.7,130 Comprehensive 
evidence-based programs usually include cessation services, policy initiatives such as smoke-
free environments, increases in the unit price of tobacco products, worksite initiatives to increase 
cessation, and mass media education campaigns.7 Cessation services range broadly: widespread 
mass media campaigns to encourage quitting, provision of printed self-help materials, and 
intensive group or individual-based cessation therapies offered in-person or over the telephone or 
Internet.131 
Synthesis of prior systematic reviews. A Cochrane review was the only previous report that 
evaluated the effectiveness of community-wide interventions to increase the implementation of 
proven population-level strategies for tobacco use cessation. The report defined a community 
intervention as a coordinated, multidimensional program aimed at changing adult smoking 
behavior, which involves several segments of the community and is conducted in defined 
geographical areas, such as town, city, county, or other administrative district. The aim was to 
identify factors in the design, implementation, or evaluation of such programs that may have 
influenced the smoking behavioral outcomes. The review included 32 studies that met inclusion 
criteria and two additional studies that compared more intensive with less intensive interventions 
but not with an “untreated” community.  
The authors examined changes in smoking prevalence using cross-sectional follow-up data in 
27 studies. For all adults, the net decline in smoking prevalence ranged from –1.0 percent to +3.0 
percent per year in 10 studies.36 Analyses for women showed a net decline ranging from –0.2 
percent to +3.5 percent per year (11 studies); those for men indicated a net decline ranging from 
–0.4 percent to +1.6 percent per year (12 studies). The authors were unable to provide estimates 
for changes in cigarette consumption or quit rates because their included studies reported such 
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measures in different ways and, in the case of quit rates, over different time periods. In sum, little 
convincing evidence exists that community interventions reduce smoking among adults. 
Synthesis of current literature. We identified three new studies that met inclusion criteria 
(Table 12). Two randomized trials aimed to deliver effective strategies to large numbers of 
smokers at a low cost.131,132 A pretest-posttest controlled group study investigated the effects of 
community intervention on smoking behavior and its determinants.133  
Table 12. Community strategies to increase the implementation of proven population-level tobacco use 
cessation strategies  
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Borland et al., 
2003131 
 
Australia 
 
Population-based 
 
RCT 
 
6 months 
 
3, 6, and 12 
months 
baseline 
 
G1: Offered self-help “Quit 
Pack”; 3 computer-
generated tailored letters 
 
G2: Offered self-help “Quit 
Pack”; 3 computer-
generated tailored letters; 
callback counseling service
 
C1: Offered printed, self-
help “Quit Pack” 
528 
adolescents, 
young adults, 
and adults 
No difference in 
smoking prevalence at 
12-month followup  
Good 
Maguire et al., 
2001132 
 
United Kingdom 
 
Community-based 
 
RCT 
 
3 months 
 
3, 6, 9, and 12 
months 
 
G1: Initial interview with 
pharmacist; smoking 
cessation contract; NRT 
offered if appropriate; 
leaflet; weekly followup for 
4 weeks, then monthly 
followup for 3 months 
 
C1: Normal pharmaceutical 
service (including the 
provision of NRT, as 
appropriate) provided by 
pharmacist 
484 adults 
 
 
Significantly more 
participants in G1 had a 
validated (urinary 
cotinine) nonsmoking 
status at 12 months 
(G1: 14.3% 
C1: 2.7%; P ≤ 0.001) 
Fair 
Ronda et al., 
2004133 
 
Netherlands, 
Western  
Europe 
 
Community-based 
Pretest-
posttest 
control 
G1: Regional mass Media-
led smoking cessation 
campaign; local activities 
organized by local 
interested working groups  
 
C1: Older mass media-led 
smoking cessation 
campaign, no local 
activities  
8,939 adults No significant 
differences between 
interventions regarding 
smoking status and 
determinants of 
smoking behavior 
 
Fair 
C, comparison group; G, intervention group(s); NRT, nicotine replacement therapy; RCT, randomized controlled trials.  
One RCT (rated good) examined the effectiveness of a computer-tailored advice program for 
callers to a reactive telephone help line service in Australia. The RCT assessed whether the 
computer-tailored advice enhanced a series of callback telephone counseling sessions as an 
alternative and complementary effort to proactive telephone callbacks.131 This strategy was 
designed not only to reach larger numbers of smokers but also to test whether varying the 
intensity of the intervention and personalizing cessation assistance influenced cessation. Slightly 
more of the participants who received a combined intervention, namely, the computer-tailored 
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advice plus callback telephone counseling, made an attempt between baseline and 3-month 
followup than did the other two groups (computer-tailored advice only; control group receiving 
no extra help).131 Significantly more people in the combination program who tried to quit in fact 
succeeded. The difference in point prevalence between the groups declined over time. It was not 
significant at the 12-month followup because of a nonsignificant trend among the groups that did 
not receive callbacks to start quitting.  
Use of nicotine replacement therapy varied across the groups.131 The group receiving only 
computer-tailored advice reported significantly lower use rates than the other two groups (i.e., 
the control and the group that received the combination intervention). The investigators analyzed 
the potential effect of replacement therapy on smoking status at 3 months using logistic 
regression. Nicotine replacement significantly improved outcomes (OR, 2.04; 95% CI, 1.22-
2.73; P < 0.001), as did callback telephone counseling (OR, 1.84; 95% CI, 1.36-3.02; P < 0.001); 
computer-tailored advice had no effect (OR, 1.11; 95% CI, 0.72-1.72; P = 0.63).  
The results indicate the questionable value of computer-tailored cessation materials, but they 
are largely consistent with other research showing an association between the greater likelihood 
of quitting smoking and the use of nicotine replacement therapy or callback counseling. The 
ineffectiveness of the computer-tailored advice program was most probably attributable to the 
fact that the program did not meet the needs of smokers who were already motivated to quit and 
actively seeking help.131 No evidence suggested that combining the two interventions (i.e., the 
computer advice and telephone counseling) was effective because, in an earlier trial of the 
callback service, the quit rates were marginally higher than those observed in this study.131 
The other trial (rated fair), seeking to deliver effective strategies to large numbers of people, 
evaluated whether a structured smoking cessation program based in community pharmacies in 
Northern Ireland and London would result in a higher smoking cessation rate compared with ad 
hoc advice from pharmacists.132 The intervention package, “Pharmacists’ Action on Smoking” 
(PAS), used a one-to-one counseling format with structured followup; the intervention was 
compared with brief, unstructured advice. Study site pharmacies displayed a poster on smoking 
cessation throughout the study; television, radio, and newspaper media were used to advertise the 
project to the general public. Smoking cessation was promoted to those using the pharmacy for 
nonmedical reasons, those asking for advice on minor ailments, and those being dispensed 
medicine by prescription. 
Significantly more subjects assigned to the PAS intervention had abstained for 12 months 
(cotinine-confirmed) than those not assigned to the PAS intervention: 14.3 percent vs. 2.7 
percent (X2 = 16.2; P < 0.001).132 Use of nicotine replacement therapy was similar in both groups 
initially, but data were insufficient to estimate the contribution of either replacement therapy or 
counseling about replacement therapy use (or both) to overall cessation rates. Pharmacy type and 
size had no impact on the 12-month cessation rates. 
The pretest-posttest control group design with two posttests (rated fair) evaluated the effects 
of a regional Dutch Heart Health Community intervention on smoking behavior and its 
determinants.133 The community intervention included a regional mass media-led smoking 
cessation campaign (“Congratulations!”) using radio commercials, advertisements, and messages 
in papers, billboards, posters, and postcards in waiting rooms and public buildings. Smaller local 
activities arranged by representatives of local organizations supplemented these regional efforts. 
The investigators hypothesized that this combination of regional and local strategies would be 
more effective than a national mass media-led smoking cessation campaign consisting of various 
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television programs, an information line, nonsmoking courses, mailings to various organizations, 
billboards in bus shelters, brochures, posters, and other materials.  
The researchers found no significant differences between the intervention region and the 
control region on smoking behavior and its determinants at either 24 months or 36 months after 
baseline.  
Provider and Health Care System-Based Strategies 
Interventions in health care systems focus on two main approaches. One approach involves 
changing provider behavior relative to offering tobacco treatment services through provider 
education alone or with feedback and assessment. Another approach involves changing health 
care systems so that health care providers will be more likely to offer effective strategies either 
proactively or in response to client demand.37  
Synthesis of prior systematic reviews. Two reviews provide information on this issue in 
terms of interventions based in settings other than full communities. One report is from the Task 
Force on Community Preventive Services;7 the other is the 2000 update of the 1996 AHCPR 
guideline.5 
Zaza et al. reviewed six interventions that health care systems can use to increase cessation of 
tobacco use by their members.7 They reported “strong” evidence of effectiveness for provider 
reminder systems with provider education, with or without client education, and for 
multicomponent interventions that include client telephone support. Provider reminders with 
provider education include efforts to educate and prompt providers to identify and intervene with 
tobacco-using clients and to provide supplementary educational materials when appropriate. 
“Sufficient” evidence of effectiveness enabled the Task Force to recommend use of health care 
provider reminders alone and reductions in patient out-of-pocket costs. Provider reminders can 
carry various types of information and can be delivered by a variety of methods, including chart 
stickers, vital sign stamps, medical record flowsheets, and checklists. Lowering patient out-of-
pocket costs reduces financial barriers that impede access to effective cessation therapies. 
Finally, the authors reported “insufficient” evidence of effectiveness to recommend provider 
education alone and provider feedback and assessment. 
To facilitate adoption of effective tobacco treatment in health care settings, the AHCPR 
guideline update used meta-analyses to identify six effective systems strategies.5 These included 
(1) implementing a tobacco user identification system in every clinic; (2) providing education, 
resources, and feedback to promote provider intervention; (3) dedicating staff to provide tobacco 
dependence treatment and assessing the delivery of this treatment in staff performance 
evaluations; (4) promoting hospital policies that support tobacco dependence services; (5) 
including tobacco dependence treatments (both counseling and pharmacotherapy) identified as 
effective as paid or covered services for all subscribers or members of health insurance packages; 
and (6) reimbursing clinicians and specialists for delivery of effective tobacco dependence 
treatments and including those interventions among the defined duties of the clinicians.  
Synthesis of current literature. Twelve new studies met all inclusion criteria  
(Table 13).134-145 Of these studies, three were RCTs;140,142,144 four, cluster RCTs;134,138,139,145 four, 
cross-sectional designs,135,136,141,143 and one, a time series design.137   
Four randomized trials, three rated fair quality and one rated good, investigated efforts to 
train providers in effective strategies.134,140,142,144 One study also trained general medicine 
residents.134 Eight studies describing interventions conducted in health care systems to improve 
use of effective cessation strategies met all inclusion criteria and received quality ratings of  
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Table 13. Strategies to increase implementation of population-level tobacco use cessation: provider-based 
and health care settings 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Cornuz et al., 
2002134 
 
Switzerland, 
Western Europe 
 
Practice/provider 
settings 
RCT with cluster 
randomization 
 
3 months 
 
1 year 
G1: Active learning 
training program for 
residents; received 
the control training 
4 months later 
 
C1: Traditional 
didactic training 
program on 
management of 
dyslipidemia; 
received the 
intervention training 
4 months later 
251 young 
adult and 
adult 
patients 
 
35 residents 
Those patients seen by 
intervention group 
residents more likely to 
be abstinent for at least 1 
week at 1-year followup 
(P = 0.005) 
Fair 
Goldstein et al., 
2003141 
 
United States 
 
Practice/provider 
settings, 
community-based 
Cross-sectional 
 
NR 
 
6, 12, 18, and 24 
months 
G1: Physicians 
provided “4 As” to 
patients 
 
G2: Smokers 
provided with 
computer-
generated, stage-
tailored cessation 
information at home
 
G3: Physician 
delivered “4 As” to 
patients, and 
patients received 
computer-
generated, stage-
tailored smoking 
cessation 
information at home
 
C1: No intervention 
2,346 
adults 
At 2-year followup, 
patients who received the 
“4 As” were significantly 
more likely to quit 
smoking (P = 0.006) 
Fair 
Joseph et al., 
2004143 
 
United States 
 
Practice/provider 
settings 
RCT  
 
2 days 
 
6 and 12 months 
G1: Organizational 
support, 2 day 
training sessions, 
smoking cessation 
medication 
 
C1: NR 
5,678 adults No effect on change 
scores between groups 
reporting whether their 
physician asked about 
smoking or provided 
counseled  
Fair 
“4 As” approach to tobacco-cessation counseling: (1) ask about tobacco use; (2) advise to quit; (3) assist with quitting; and (4) 
arrange for followup; C, control group; FP, family practitioner; G, intervention group; GP, general practitioner; NR, not reported; 
RN, registered nurse; WIC, Women, Infants, and Children program 
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Table 13. Strategies to increase implementation of population-level tobacco use cessation: provider-based 
and health care settings (continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Katz et al., 2004142 
 
United States 
 
Practice/provider 
settings 
 
Community-based 
RCT 
 
2 months 
 
Immediate 
G1: Study personnel 
worked with intake 
clinicians to 
implement guideline 
intervention; 
clinicians completed 
survey prior to 
implementation; 
After clinic visit, 
study personnel 
interviewed patients 
to evaluate whether 
they received 
cessation 
counseling  
 
C1: Intake clinicians 
completed survey 
just before tutorial 
session at end of 
intervention period, 
but had no help with 
guideline 
implementation 
1,221 adult 
patients 
 
72 clinicians 
Intervention group RNs 
were the most likely to 
ask about smoking, 
assess willingness to 
quit, advise patients to 
quit, and assist patients 
in quitting (P = NR)  
Fair 
Katz et al., 2004144 
 
United States 
 
Practice/provider 
settings 
 
 
RCT 
 
10.5 months 
 
2 and 6 months 
G1: Multicomponent 
office based 
intervention 
including a tutorial 
for intake clinicians 
on the AHRQ 
Guideline, 
performance 
feedback, offer of 
free NRT, and 
proactive counseling
 
C1: Staff received 
general information 
on the AHRQ 
Guideline 
2,163 adult 
patients 
Significantly more 
patients from practices 
who received the 
intervention were more 
likely to be asked by their 
clinician about their 
smoking status, 
willingness to quit, given 
literature about quitting, 
assisted in setting a quit 
date, engaged in a 
discussion about 
pharmacotherapy, or 
remain abstinent    
Good 
Pbert et al., 
2004139 
 
United States 
 
Practice/provider 
settings 
RCT with cluster 
randomization 
 
10 months 
 
End of 
pregnancy, 1, 3, 
and 6 months 
postpartum  
G1: Clients visited 
community health 
centers and WIC 
offices that received 
provider training, an 
office reminder 
system, and 
establishment of 
program boards to 
coordinate the 
transfer of 
documentation 
among clinics 
 
C1: Usual care 
550 adult 
pregnant 
women 
 
Women in the 
intervention group more 
likely than those in the 
control to be abstinent at 
the end of pregnancy 
(G1: 26%; C1: 12%; OR: 
2.57; P = 0.05) and 1 
month postpartum  
(G1: 26%; C1: 11%; OR: 
3.01; P = 0.04) 
No effect remained at 3- 
and 6-month followup 
Fair 
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Table 13. Strategies to increase implementation of population-level tobacco use cessation: provider-based 
and health care settings (continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Pieterse, 2001140 
 
The Netherlands, 
Western Europe 
 
Practice/provider 
settings 
RCT with simple 
randomization 
 
NR 
 
1 and 12 months 
G1: Brief physician 
counseling; self-help 
manual; follow-up 
sessions 
 
C1: Usual 
treatment—no 
counseling or advice 
on smoking except 
when initiated by the 
patient or when 
indicated by the 
contact reason 
530 young 
adults, adults
At 12 months, smoking 
abstinence rates were 
greater among those in 
the intervention 
compared with controls 
(G1: 13.4%; C1: 7.3%; 
OR = 1.51, CI: 1.1, 2.1;  
P < 0.05), as were 
consecutive abstinence 
rates (G1: 8.2%; C1: 
3.1%; OR = 3.04, CI: 1.7, 
5.6l; P < 0.001) 
Fair 
Piper et al., 2003145 
 
United States 
 
Practice/provider 
settings 
RCT 
 
NR 
 
12 months 
G1: Smoking added 
to vital sign stamp 
 
C1: Usual vital sign 
stamp without 
smoking 
1,611 adult 
smokers 
Significant increase 
(31%) in asking behavior 
of physicians in the 
smoking plus vital sign 
clinics (P = 0.0002); no 
difference in abstinence 
rates 
Fair 
Russos et al., 
1999135 
 
United States 
 
Practice/provider 
settings 
Cross-sectional 
 
2 years 
 
2 years 
postbaseline 
G1: Orthodontists 
given antitobacco 
materials, training 
session on tobacco 
prevention, written 
antitobacco 
prescriptions and 
reimbursement for 
distribution, 
quarterly visits and 
calls; office staff 
asked to make 
office tobacco-free  
 
C1: Orthodontists 
given no training, 
materials, or visits, 
nor asked to change 
their offices or 
practices 
126 adults 
 
In a typical week more 
clinicians in G1 vs. C1 
provided prevention 
counseling to patients 
(Mean: 25.4% vs. 3%, 
Mann-Whitney U = 
696.5, z = -7.0, P < 0.01) 
and at least some 
cessation counseling 
(91% vs. 72%, Χ2 = 8.4, 
P < 0.01) 
Fair 
Slama et al., 
1999136 
 
France, Western 
Europe 
 
Practice/provider 
settings 
Cross-sectional 
 
NA 
 
1 and 12 months 
G1: NA 
 
C1: NA 
372 adult 
patients 
 
2,680 
general 
practitioners 
 
None of the GPs’ 
smoking-related attitudes 
and reported behaviors 
were significantly related 
to their participation in 
the study or to their 
patients’ rates of 
smoking cessation at 1 
or 12 months 
Fair 
78 
Table 13. Strategies to increase implementation of population-level tobacco use cessation: provider -based 
and health care settings (continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Smith et al., 
2002137 
 
United States 
 
Hospital 
 
Time series 
 
3 months 
 
1 year 
G1: During 
hospitalization: 
physician advice on 
smoking cessation, 
bedside education 
and counseling with 
nurse, take-home 
materials, NRT if 
requested or 
indicated, 4 nurse-
initiated 
postdischarge 
phone counseling 
calls  
 
C1: NA 
1,077 
adults 
Including only those who 
were reached at 12 
months, 49% reported 
being smoke-free for the 
previous 7 days.  
Including the 211 who 
were not reached at 12 
months (intent to treat) 
and counting them as 
smokers, self-reported 
smoking cessation rate 
was 35% 
Fair 
Young et al., 
2002138 
 
Australia 
 
Practice/provider 
settings 
RCT with cluster 
randomization 
 
4 months 
 
6 months 
postbaseline 
G1: Family 
physicians received 
three academic 
detail visits, 
resources for FPs, 
resources for 
practices. and 
resources for 
patients 
 
C1: Similar 
intervention to G1 in 
terms of intensity 
and format, but 
focused on cervical 
screening 
1,788 adult 
patients 
 
60 
family 
practitioners 
 
Improvements between 
baseline and posttest in 
patient recall of FP 
advice about nicotine 
replacement patches and 
gum were significantly 
greater in the 
intervention than the 
control group  
(P = 0.0056 and  
P = 0.0002, respectively) 
Fair 
 
fair.135-139,141,143,145 Six of these studies used some variation of an academic detailing approach 
(i.e., personal educational visits to clinicians in their own practice setting) to increase system 
support for cessation interventions.135,138,139,141,143,145 One study examined the effect of physician 
attitudinal and behavioral variables on participation and effectiveness of general practitioners in 
offering a minimal smoking cessation intervention.136 The group effectiveness study evaluated 
how a previously proven effective smoking cessation intervention is integrated into standard 
hospital practice.137 
Provider-based interventions. Researchers in one study designed training programs to help 
general practitioners and their practice assistants140 and general medicine residents.134 The aim 
was to help providers acquire and apply skills to help their patients quit smoking. Two other 
studies implemented AHCPR strategies5 in practice and internal medicine clinics to facilitate 
adoption of effective tobacco treatment in health care settings.142,144  
Both training programs included skills training in counseling approaches tailored to smokers’ 
readiness to quit smoking and instruction in the use of written self-help materials for patients. 
General practitioners’ office assistants were also trained to apply the randomization and 
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informed consent procedures.140 To evaluate the effects of the training, Pieterse et al. randomized 
eligible smokers into two groups.140 One group received brief (10-minute) counseling sessions 
with the physician that are based on the stages of change model, a self-help manual, and follow-
up sessions led by practice assistants; the other group received usual care consisting of no 
counseling or advice on smoking except when initiated by the patient or when indicated by the 
contact reason (in which case, counseling was limited to straightforward stop-smoking advice 
and possibly referral to local municipal health organizations). 
At 1-month followup, smoking abstinence rates were greater among those in the intervention 
group than among controls (OR, 2.56; 95% CI, 1.8-3.8).140 This relationship held at the 12-
month followup (OR, 1.51; 95% CI, 1.1-2.1). Continuous abstinence was also greater among 
intervention group subjects than among controls (OR, 3.04; 95% CI, 1.7-5.6). 
In evaluating training for general medicine residents, Cornuz et al. stratified residents by 
clinic either in an intervention group trained in smoking cessation or in a control group trained in 
dyslipidemia.134 The control group received training in the intervention 4 months later, after the 
3-month patient recruitment period had ended. Eligible patients identified as smokers were 
randomly assigned to intervention (i.e., residents trained in smoking cessation) or control clinics 
(i.e., residents trained in managing dyslipidemia).  
According to smokers’ self-reports, trained residents used all counseling strategies 
significantly more often than control residents.134 These strategies included assessing motivation 
to quit (29 percent vs. 19 percent, P = 0.05), offering help to quit (23 percent vs. 7 percent,  
P = 0.003), discussing benefits of cessation (21 percent vs. 12 percent, P = 0.05) and obstacles to 
cessation (16 percent vs. 6 percent, P = 0.01), giving a brochure (14 percent vs. 1 percent,  
P < 0.001), discussing strategies to prevent relapse (15 percent vs. 6 percent, P = 0.01), and 
setting a quit date (8 percent vs. 2 percent, P = 0.02). Compared with control residents, trained 
residents expressed significantly higher self-confidence (mean scores of 7.7 vs. 5.2; P = 0.002) 
and also a nonsignificantly higher level of self-perceived effectiveness in smoking cessation 
counseling (mean scores of 6.8 vs. 5.4; P = 0.09) 3 months after training.134 At 12-month 
followup, 1-week smoking abstinence was significantly higher in the intervention group than in 
the control group (13 percent vs. 5 percent, cluster-adjusted OR, 2.8; 95% CI, 1.4-5.5). The 
proportion of smokers willing to quit was significantly higher in the intervention group than in 
the control group (94 percent vs. 80 percent; P = 0.007). Daily cigarette consumption tended to 
be lower in the intervention than in the control group, but the groups did not differ significantly. 
The groups also did not differ significantly in the proportion of smokers in the precontemplation 
stage or the proportion of smokers who moved forward one stage, applying the principles of 
educational outreach to improve clinical decisionmaking.  
Katz et al. tested the effectiveness of a multimodality intervention to implement the AHCPR 
Smoking Cessation Clinical Practice Guideline in six family practice and two internal medicine 
clinics.144 The intervention consisted of a tutorial for intake clinicians that instructed them on 
how to assess the patient’s smoking status and how to provide brief smoking cessation messages 
to each smoker with feedback on performance, real-time reminders (i.e., modified vital sign 
stamp), onsite pharmacotherapy, and proactive telephone counseling.  
Face-to-face interviews were conducted with clinic patients immediately after their office 
visit to assess how the clinic staff had performed guideline-recommended activities. In addition, 
clinic patients were contacted by telephone by study personnel, blinded to treatment group, and 
asked about their smoking habits at 2 and 6 months following the exit interview. Clinic patients 
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who reported not smoking at 6 months were mailed kits for saliva collection to verify 
biochemically self-reported abstinence.144 
During the intervention period, more patients at intervention clinic sites were asked about 
their smoking status (OR, 3.1; 95% CI, 1.2-8.2; P = 0.02) and their willingness to quit smoking 
(OR, 6.4; 95% CI, 3.7-10.8; P < 0.001), were given literature about quitting (OR, 21; 95% CI, 
8.8-49; P < 0.001), were assisted with setting a quit date (OR, 33; 95% CI, 11-100; P < 0.001), 
or were engaged in a discussion about pharmacotherapy (OR, 3.9; 95% CI, 2.5-6.3; P < 0.001). 
Among patients treated during the intervention period, those at intervention clinic sites were 
more likely than those at control sites to report being abstinent at the 2-month mark (16.4 percent 
vs. 5.8 percent, adjusted OR, 3.3; 95% CI, 1.9-5.6; P < 0.001) and the 6-month mark (15.4 
percent vs. 9.8 percent; adjusted OR, 1.7; 95% CI, 1.2-2.6; P = 0.009) and to report continuous 
abstinence (10.9 percent vs. 3.8 percent). Although planned collection of confirmatory salivary 
cotinine tests of self-report cessation had very low response rates, the confirmed abstinence rates 
at 6 months showed no difference between intervention clinics and controls.144 
A secondary analysis142 of data from the same RCT of guideline implementation determined 
whether intake clinicians (registered nurses [RNs] and less costly personnel (licensed practical 
nurses [LPNs] and medical assistants [MAs]) are similar when performing smoking cessation 
activities that AHCPR guidelines had recommended.5 Using patient exit interviews, the 
investigators obtained information on differences in performance among RNs compared with 
MAs, RNs compared with LPNs, and LPNs compared with MAs. Patients were queried whether 
their intake clinician asked about their smoking, assessed their willingness to quit, gave them 
advice about quitting, and assisted them in quitting. 
Performance of all guideline-recommended counseling activities was significantly greater for 
all types of nursing personnel at test sites than at control sites.142 MAs were significantly less 
likely to assess willingness to quit (adjusted OR, 0.4; 95% CI, 0.2-0.8, P = 0.005); they also 
tended to offer advice and assistance in quitting less often than RNs. Similar findings were 
observed for LPNs assessing willingness to quit (adjusted OR, 0.5; 95% CI, 0.3-1.0; P = 0.03). 
After accounting for personal beliefs, self-efficacy, and role satisfaction in cessation counseling, 
subset analysis in subjects with complete survey data revealed that being seen by an MA was no 
longer associated with statistically significant differences in performance. These results indicate 
that MAs and LPNs were less likely than RNs overall to perform actions recommended by the 
AHRQ smoking cessation recommendations.  
Health care systems interventions. Practice sites for academic detailing interventions 
included community health centers, clinics in the Women, Infants, and Children (WIC) program, 
orthodontists’ offices, primary care clinics, and family physician practices. Specific elements of 
an academic detailing approach varied across the six studies, but included 
 
• An in-service training for staff members on how to asses and document smoking status as 
a part of regular collection of vital signs;145 
• A 1.5-hour workshop, antitobacco materials, reimbursement for provision of antitobacco 
prescriptions, and quarterly check-up visits;135 
• Provider training to deliver a smoking intervention based on national clinical practice 
guidelines tailored to the woman’s stage of change and delivered through three channels 
(obstetric, pediatric, and WIC providers);139  
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• An office practice management system to routinely screen for smoking status, 
prompt/remind providers to intervene, document the encounter, distribute materials and 
arrange followup;139   
• Establishment of program boards to coordinate the transfer of documentation among 
clinics, including periodic meetings with representatives from all clinics;139  
• Two to three day site visits designed to communicate with Directors, Pharmacy Service 
Chief, smoking cessation coordinators and primary care nurses about barriers to  
implementation of AHCPR Smoking Cessation Guidelines;143 
• Audit, feedback, and academic detailing for family physicians;138 and  
• Four or five physician-centered office visits in the intervention counties to encourage 
physician adoption of a smoking cessation strategy based on the “4As” model from the 
National Cancer Institute (NCI) and distribution of a copy of the NCI manual How to 
Help Your Patients Stop Smoking.141 
 
Studies examined whether significant effects were achieved on clinician uptake and use of 
cessation strategies, on cessation rates among patients served by these clinicians, or both. 
Investigators used various approaches to assess clinician uptake and use of cessation guidelines 
and other evidence-based strategies, including exit, telephone, and other interviews of patients, 
medical record audit, and mail or telephone provider surveys. Study designs included three 
randomized trials with cluster randomization,138,145 two cross-sectional139 studies,135,143 and a 
community-based quasi-experimental study.141  
A multifaceted, practice-based intervention involving audit, feedback, and academic detailing 
to improve family physicians’ use of evidence-based smoking cessation strategies enrolled 60 
family physicians from 39 practices.138 Their provision of smoking cessation advice was 
measured by patient recall, medical record audit, and self-report. Improvements between baseline 
and posttest in patient recall of physician advice about nicotine replacement patches and gum 
were significantly greater in the intervention group (P = 0.0056) than in the control group  
(P = 0.002).138 Substantial increases occurred in patients’ recall of assessment of smoking status 
and family physicians’ use of quit dates, behavioral advice, and written materials in the 
intervention group, but these changes were not significantly greater than those in the control 
group. Notation of patient’s smoking status and smoking cessation advice in medical records 
remained suboptimal in both groups.  
Providers in community health centers and WIC offices received training to deliver a 
smoking intervention based on national clinical practice guidelines.139 The program included  
(1) provider training tailored to the woman’s stage of change and delivered through three 
channels (obstetric, pediatric, and WIC providers); (2) an office practice management system to 
screen routinely for smoking status, prompt/remind providers to intervene, document the 
encounter, distribute materials, and arrange followup; and (3) establishment of program boards to 
coordinate the transfer of documentation among clinics, including periodic meetings with 
representatives from all clinics. Providers in control clinics provided usual care. Five community 
health centers were randomized to intervention or usual care. Subjects were pregnant or 
postpartum women who were current smokers or smokers who had quit during pregnancy.  
The intervention and usual care groups differed significantly in 30-day abstinence rates at the 
end of pregnancy among women who had not quit spontaneously upon learning of their 
pregnancy (26 percent vs. 12 percent; OR, 2.57; P = 0.05).139 This effect remained at 1 month 
postpartum but was lost at 3- and 6-month postpartum followups.  
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Staff members in outpatient primary care clinics who usually take vital signs for each patient 
received in-service training on how to assess and document smoking status as part of the regular 
collection of patient information.145 On exiting the clinic, patients were asked questions about 
their smoking habits and smokers were asked to participate in a follow-up telephone interview in 
1 year. These later interviews revealed no statistically significant difference between either the 
intervention or control clinics for point-prevalence abstinence from baseline to the intervention 
phase. Chi square analysis indicated that abstinence was independent of being asked about 
smoking, receiving advice to quit, being prescribed nicotine replacement therapy, or having a 
follow-up appointment.  
Orthodontists in private practice offices participating in a controlled trial to decrease the 
incidence of tobacco use among adolescents were enrolled in a cross-sectional interview study to 
determine the rate and determinants of tobacco prevention and cessation counseling to youth.135 
The experimental group received a 1.5-hour workshop, antitobacco materials, reimbursement for 
provision of antitobacco prescriptions, and quarterly check-up visits. Control group clinicians did 
not receive training materials or visits.  
Orthodontists in the experimental group were more likely than those in the control group to 
ask their patients whether they use tobacco (4.8 percent vs. 2.9 percent; P < 0.01), to provide at 
least some cessation counseling to their patients who smoked (91 percent vs. 70 percent; X2, 8;  
P < 0.01), and to report mostly positive reactions from tobacco users for cessation counseling 
(X2, 7.8; P < 0.05).135 Demographic, office, and clinic practice variables were not associated with 
cessation counseling. Higher rates of cessation counseling were associated (all P < 0.05) with 
asking patients whether they used tobacco, belief that counseling is important, belief that 
clinicians should receive counseling training, intention to attend training, and disagreement that 
counseling is not part of their job description.  
The study that tested implementation of the tobacco guideline randomized 20 Veterans 
Affairs Medical Centers to an intervention or control group.143 A multicomponent intervention 
was designed to increase three specific guideline recommendations: (1) documentation of 
tobacco use status in medical records, (2) delivery of cessation intervention to all smokers, and 
(3) liberal use of pharmacotherapy for smoking cessation. In a 2-day training meeting, the three 
target strategies were presented to physicians, nurses, psychologists, and pharmacists. The 
training recommended using electronic medical records to identify smokers, giving smoking 
cessation treatment within the primary care setting rather than using referral-based care, and 
removing restrictions to prescriptions of smoking cessation aids. Site visits by an interventionist 
provided academic detailing on barriers to implementation strategies.143  
Cross-sectional surveys were conducted at baseline and 1 year later (i.e., after the 
intervention) among a sample of randomly selected patients who had seen their primary care 
provider within 6 weeks.  A cohort of current cigarette smokers identified at baseline also 
completed a follow-up survey 1 year after the intervention. At the 1-year point, medical records 
showed a significant effect on smoking status documentation (intervention medical records were 
more likely to document smokers than were those of the control group, 67 percent vs. 60 percent, 
P = 0.0007).  The groups did not differ in quit rates, providers asking about smoking status, or 
being counseled to quit smoking.  
In a community-based quasi-experimental study, Goldstein et al. delivered an academic 
detailing intervention to physicians in intervention counties during a 15-month period. The 
multicomponent office-based intervention aimed to increase primary care physicians’ adoption, 
implementation, and maintenance of the NCI “4As” as a smoking cessation strategy. The 
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intervention included four or five physician-centered visits and distribution of a copy of the NCI 
manual How to Help Your Patients Stop Smoking. The program was implemented through 
personal educational visits to clinicians in their own practice settings.141 
Among smokers reporting a physician visit during the study period, the investigators reported 
a borderline significant effect at 24-month followup for those residing in intervention areas 
compared with those residing in control areas (OR, 1.35; 95% CI, 0.99-1.83; P = 0.057).141 
Patients of experimental group physicians reported that about 60 percent of their doctors talked 
to them about smoking and advised them to quit; the figure was about 55 percent for control 
group physicians (X2, 13.8; P = 0.000 [sic]).141 In a subgroup analysis, after controlling for 
confounding factors, Goldstein et al. also reported that, among smokers who visited an enrolled 
physician, those residing in physician intervention counties were significantly more likely than 
those residing in control counties to quit smoking at 24 months (adjusted OR, 1.80; 95% CI, 
1.16-2.75, P = 0.008). Stage of change at baseline was the only other significant predictor of 
smoking cessation at 24 months (adjusted OR, 2.75; 95% CI, 1.89-3.98; P = 0.000 [sic]).  
One interview-based study (rated fair) examined the effect of physician attitudinal and 
behavioral variables on participation and effectiveness of general practitioners (GPs) to offer a 
minimal smoking cessation intervention.136 Attitudinal variables included (1) individual GP 
assessments of the influence of GPs in general, and of themselves in particular, on prevention 
efforts aimed at both smokers and other patients and (2) assessments of the potential that modern 
medicine has to affect disease outcome through screening and treatment. Behavioral variables 
included individual reports of knowing their own cholesterol level, being careful about diet, 
exercising regularly, and watching their weight. Matched pairs of smoking and nonsmoking GPs 
were invited to participate in a regional smoking cessation intervention.  
Among the GPs who initially accepted, a significantly higher proportion of GP nonsmokers 
than GP smokers participated in the study (54.1 percent vs. 45 percent, X2, 5.147; P < 0.05).136 
Nonetheless, those GP smokers who did participate achieved results similar to those of 
nonsmokers when comparing the success or lack of success in their patients’ reports of quitting 
smoking. The smoking status of GPs was not significantly related to either point prevalence 
smoking status at 1 and 6 months or to sustained abstinence. These findings suggest that when 
minimal advice has an effect, that effect can be attributed more to the systematic nature of the 
intervention provision than to the attitudes or reported practices of the provider offering the 
advice. 
A group effectiveness study (rated fair) evaluated how an RCT smoking cessation 
intervention, previously proven effective, was integrated into standard hospital practice.137 
Although this study had no comparison group, it provides useful, detailed data about 
continuation of a smoking cessation program. The intervention examined a nurse-managed 
smoking cessation program for general hospitalized patients, which continued for 3 years after 
trial completion. The intervention included physician advice, bedside education and counseling 
by a nurse specially trained in smoking cessation techniques, take-home materials (i.e., a 
videotape, workbook, and relaxation audiotape), nicotine replacement therapy if requested or 
indicated, and four nurse-initiated, postdischarge telephone counseling calls.  
Of the patients identified as smokers, 50 percent enrolled in the program, 18 percent wanted 
to quit on their own, 20 percent did not want to quit, and 10 percent were ineligible.137 The 12-
month self-reported cessation rate (7-day point prevalence) was 35 percent if patients lost to 
followup were considered smokers and 49 percent if they were not. Patients hospitalized for 
cancer, cardiovascular, or pulmonary reasons were most likely to participate, and they had the 
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highest self-reported cessation rates (cancer: 63 percent, cardiovascular: 57 percent, and 
pulmonary: 46 percent).  
KQ 4. Effect of Smokeless Tobacco Product Marketing and 
Use on Population Harm from Tobacco Use  
In our systematic review of the effects of smokeless tobacco product marketing and use on 
population harm from tobacco use, we specifically examined three issues: (1) whether 
substituting smokeless tobacco for smoking leads to less smoking-related harm on a population 
basis, (2) whether smokeless tobacco marketing leads to greater use or substitution of smokeless 
tobacco for smoking (or both), and (3) whether data on harms and harm reduction associated 
with smokeless tobacco are used to model the potential health effects of substituting smokeless 
tobacco for smoking. As elsewhere, we present information from prior systematic reviews and 
then summarize current literature. 
Effects of Smokeless Tobacco Product Marketing and Use 
Adolescents and young adults continue to be a strategically important market segment for the 
tobacco industry.15 During 2001, the largest tobacco manufacturers spent $236.7 million on 
smokeless tobacco advertising and promotion, using images that portray the attractiveness of 
tobacco products.18 Growth in sales of smokeless tobacco moist snuff has been attributed to 
advertising and marketing campaigns that encourage young nonusers to experiment with low-
nicotine starter products. Once adolescents or young adults begin to use smokeless tobacco, the 
tobacco companies’ intent is to move new users to higher nicotine brands as nicotine dependence 
progresses.2 An estimated 7 percent of high school students are current users of smokeless 
tobacco; males are the primary consumers.20 Adolescents who use smokeless tobacco are more 
likely than nonusers to become smokers.15 
Recently, tobacco companies have begun to market their smokeless tobacco products as less 
harmful alternatives to smoking tobacco, emphasizing that smokeless tobacco does not carry the 
same risks to others that are associated with smoking (i.e., secondhand and environmental 
tobacco smoke).46 We believe it is too early to determine whether these harm reduction 
approaches to smokeless tobacco marketing are effective in increasing product use; however, we 
have included this issue in our literature search for KQ 4.  
Synthesis of past literature reviews. Two types of smokeless tobacco are sold in the United 
States: chewing tobacco (i.e., loose leaf tobacco, plug, or twist) and snuff (i.e., finely ground 
tobacco that can be dry, moist, or in sachets).18,19 Smokeless tobacco can lead to nicotine 
addiction and dependence.17 Evidence from the Surgeon General and others has linked 
smokeless tobacco causally with oral leukoplakia and oral cancers.2,39 Since 1964, the Surgeons 
General reports have continuously examined the role cigarettes and smokeless tobacco play in 
developing cancers of the oral cavity and pharynx. As research has progressed, conclusions 
indicate that all forms of tobacco use (i.e., cigarettes, pipes, cigars, snuff, chewing tobacco, betel, 
and other smoked and smokeless products) can cause malignancies in any part of the oral cavity 
and pharynx except the salivary glands.1,2,6 Specific risks associated with the use of smokeless 
tobacco products are advanced periodontal disease, tooth decay, leukoplakia, stomach and 
pancreatic cancers, and heart disease.1 
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Treating nicotine addiction (from cigarettes, pipes, cigars, and smokeless tobacco) will help 
prevent most of the approximately 30,200 new cases of cancer and 7,800 deaths from these 
cancers that occur annually in the United States. Eliminating smokeless tobacco use will prevent 
12,300 new cases of esophageal cancer alone and 12,100 deaths from esophageal cancer 
annually.1 
Limited research indicates that increases in smokeless tobacco prices will reduce the use of 
smokeless tobacco, particularly by adolescents and young adults. Nonetheless, the tax on 
smokeless tobacco is well below that on cigarettes. Although increases in cigarette prices may 
reduce smoking among youth, increases may also boost the likelihood of smokeless tobacco 
use.2  
Recommendations from the updated AHCPR tobacco cessation guideline advise treating 
users of smokeless tobacco with the same counseling cessation interventions recommended for 
smokers.5 Studies of pharmacotherapies to address nicotine dependence on tobacco have not 
provided sufficient evidence showing long-term abstinence among users; specifically, gum and 
nicotine patches have not increased abstinence rates.5 Because oral lesions caused by smokeless 
tobacco use are common, dental clinicians are in a suitable position to use minimal interventions 
to reduce smokeless tobacco use.2,5 Recently, behavioral interventions by dental clinicians using 
oral examinations with feedback about the mucosal changes associated with smokeless tobacco 
use have had positive effects on abstinence (OR, 2.41; 95% CI, 1.79-3.24).57 This finding 
suggests that dental health clinicians are in an opportune position to deliver brief but efficacious 
interventions to smokeless tobacco users.  
Prior systematic reviews did not address issues relevant to KQ 4. Past reviews focused on 
risks associated with the use of smokeless tobacco and on the potential offered by smokeless 
tobacco cessation treatments. Information on tobacco product marketing is more likely to be 
disseminated in editorials, summary articles, and newspaper articles that were excluded from this 
review.  
Synthesis of current literature. Our review of smokeless tobacco product marketing and 
use found no studies evaluating whether substituting smokeless tobacco for smoking results in 
less smoking-related harm; we also did not identify any studies indicating that any researchers 
have used data on harm and harm reduction associated with smokeless tobacco to model the 
potential health effects of substituting smokeless tobacco for smoking. We found two studies 
(both rated fair) that assessed whether smokeless tobacco marketing leads to greater use of these 
products or to substitution of smokeless tobacco for smoking (Table 14).146,147 Both studies were 
population-based, used a cross-sectional design, and recruited only adolescent boys or young 
adult males. 
In the larger study (N = 3,996 responders; response rate 62 percent), adolescent and young 
adult males 11 to 19 years of age provided information on their smoking and smokeless tobacco 
use behavior through responses on the Teenage Attitudes and Practice Survey (TAPS-I and -II) 
in 1989 and 1993.147 The investigator used responses on these US-wide surveys to assess 4-year 
initiation rates of smokeless tobacco use and cigarette smoking in relation to each other; the 
investigator also examined switching between products. 
In a multiple logistic regression analysis, which was adjusted for age and race, males who 
had been regular users of smokeless tobacco were more than three times as likely as never-users 
of smokeless tobacco to become smokers (OR, 3.45; 95% CI, 1.84-6.47). Current smokers were 
not different from never-smokers in the rate of initiating current regular use of smokeless 
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Table 14. Characteristics and results of studies assessing the effects of smokeless tobacco marketing 
Author 
Year 
Setting Design Survey N Results 
Quality 
Rating 
Choi et al., 
1995146 
 
California 
 
Population-
based 
Cross-sectional Youth 
Attitudes 
and 
Practice 
Survey 
2,814  
adolescents, 
young adult 
males 
Among adolescent boys, recall of 
smokeless tobacco advertisements was 
associated with smokeless tobacco use:  
OR, 7.5; 95% CI, 3.1-18.1 
Fair 
Tomar et al., 
2003147  
 
United States 
 
Population-
based 
Cross-sectional Teenage 
Attitudes 
and 
Practice 
Survey 
(TAPS-I 
and -II) 
3,996 
adolescents, 
young adult 
males 
Significantly more users than nonusers 
of smokeless tobacco became smokers 
during 4 years of followup:  
OR, 3.45; 95% CI, 1.84-6.47  
Fair 
CI, confidence intervals; OR, odds ratio. 
tobacco (OR, 1.45; 95% CI, 0.5-4.22). Among males who were regular smokeless tobacco users 
but not smokers at baseline, 44.8 percent continued to exclusively use smokeless tobacco at 
followup, 25.5 percent switched to smoking at followup, 14.3 percent continued to use 
smokeless tobacco while also smoking at followup, and 15.2 percent were no longer using 
tobacco. Of the smokers at baseline who were not users of smokeless tobacco, 78.7 percent were 
still smokers 4 years later, 0.8 percent switched to using smokeless tobacco exclusively, 3.6 
percent continued to smoke but also used smokeless products, and 16.9 percent stopped using 
tobacco altogether.147 
The other study (N = 2,814) assessed susceptibility to smokeless tobacco advertising in terms 
of risk factors in a study among adolescent and young adult males in California.146 This analysis 
used the Youth Attitudes and Practice Survey (conducted in 1990, 1992, and 1993); the majority 
of the analysis was based on data from 1993. The investigators contacted a stratified random 
sample of young adults and adolescents 12 to 17 years of age through random-digit dialing and 
interviewed them to assess trends in smokeless tobacco use. The researchers specifically 
identified risk factors that distinguished youth who used or were at risk of using smokeless 
tobacco. Risk factors included current tobacco use, exposure to tobacco advertising and other 
smokeless tobacco users, susceptibility to use smokeless tobacco, level of rebelliousness, peers’ 
use of drugs or alcohol, and peer norms.  
Findings from the 1993 survey documented that the highest rate of smokeless tobacco use 
occurred among subjects 16 and 17 years of age (6.6 percent; 95% CI, 4.1-9.1). Exposure to 
smokeless tobacco advertisements was twice as high among males 16 to 17 years of age than 
among those 12 to 13 years of age (43.8 percent [95% CI, 38.8-48.8] and 21 percent [95% CI, 
17.4-24.6], respectively). Recall of smokeless tobacco advertisements was significantly 
associated with smokeless tobacco use (AOR, 7.5; 95% CI, 3.1-18.1; P < 0.001). In addition, 
cigarette smokers were at greater risk of being smokeless tobacco users than youth who did not 
smoke (AOR, 3.3; 95% CI, 1.9-5.7; P < 0.001).146 
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KQ 5. Effectiveness of Prevention and Cessation 
Interventions in Populations with Co-Occurring Morbidities 
and Risk Behaviors 
Our final systematic review investigated smoking prevention and cessation interventions in 
populations with co-occurring morbidities and risk behaviors. For this report, we define a person 
with co-occurring disorders as one who has a psychiatric condition and a nicotine addiction. 
Psychiatric conditions include depression, anxiety, personality disorders, traumatic stress 
disorder, attention deficit disorder, eating disorders, disruptive behavioral disorders, and 
schizophrenia. We also identify risk behaviors as behaviors that trigger or exacerbate tobacco 
use, such as alcohol abuse and other chemical dependencies.  
As with other sections, we present information on previous systematic reviews as the 
background or context for recommendations to date. We then examine specific studies identified 
over and beyond those reviews.  
Populations with Psychiatric Conditions  
People with psychiatric conditions are twice as likely to smoke as the general population and 
to smoke more heavily than other smokers.30 As many as 30 percent of smokers seeking 
cessation treatment have a history of depression.5 Smoking cessation rates reported for the 
psychiatric population are lower than rates reported for the nonpsychiatric population.30  
People with psychiatric conditions may use nicotine to self-medicate. Neurobiological and 
psychosocial factors reinforce the use of nicotine in populations with co-occurring disorders. 
Traditional antipsychotics used for certain psychiatric conditions may result in increased 
smoking, whereas patients taking atypical antipsychotics may smoke less.148 Smoking improves 
processing of auditory stimuli in patients and may lessen negative symptoms by increasing 
dopamine in the prefrontal and frontal cortex.148 Smoking is also an integral part of psychiatric 
culture because it provides a daily pastime for patients who may otherwise have few activities to 
pursue.30 With new smoking bans enforced in health care facilities, more information on the 
outcomes of smoking cessation strategies tailored to these specific populations is needed. 
Synthesis of prior systematic reviews. Approaches to increase quit rates among individuals 
with psychiatric conditions include medications, educational strategies, and cognitive behavior 
modifications.30 Smoking behavior in psychiatric populations remains a challenge, with health 
concerns and costs similar to those for nonpsychiatric populations. Although psychiatric 
populations have lower smoking cessation rates than nonpsychiatric populations, in the absence 
of relevant RCTs on smoking cessation for populations with psychiatric comorbidities, experts 
agree that clinicians should use smoking cessation treatments recommended for the general 
population, such as pharmacotherapies and counseling.5,30  
Synthesis of current literature. We found six studies related to KQ 5; all relate to cessation 
efforts.113,149-153 We found no studies on prevention per se; as this question is phrased, the 
populations of interest are already smoking. Table 15 presents information on five of these six 
studies. One study153 was graded as poor because of postrandomization of exclusions and other 
major flaws, so it is not discussed further. Detailed information is presented in Evidence Table 9 
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Table 15. Tobacco cessation interventions for persons with co-occurring morbidities and risk behaviors 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Studies in Psychiatric Populations 
Brown et al., 
2001150 
 
United States 
 
Population-based 
 
RCT 
 
6 weeks 
 
1, 6, and 12 
months 
G1: Group CBT for 
smoking cessation 
plus additional CBT 
on coping for 
depression 
 
C1:  Group CBT for 
smoking cessation 
alone 
179 formerly 
depressed 
adults 
In the main analysis, 
smoking abstinence 
did not differ when 
CBT tailored for 
depression was added; 
in a secondary 
analysis CBT tailored 
for depression had 
significant interactions 
with both  heavy 
smoking and recurrent 
depression 
Fair 
Brown et al., 
2003151 
 
United States 
 
Psychiatric hospital 
RCT 
 
Variable, 
dependent 
upon the 
length of stay 
 
1,3,6,9, and 
12 months 
G1: In-person 
motivational 
interviewing 
sessions, offer of 
nicotine patch, 
postdischarge 
telephone counseling 
(MI) 
 
C1: Brief in-person 
advice, on cessation, 
pamphlet and shorter 
course of nicotine 
patch (BA) 
191 
hospitalized 
adolescents 
for 
psychiatric 
disorders 
7-day point prevalence 
rates 
At 1 month 
• MI arm: 11% 
• BA arm: 11% 
 
At 6 months 
• MI arm: 13.3% 
• BA arm: 8.5% 
 
At 12 months 
• MI arm: 14%  
• BA arm: 9.9%  
P = NS  
 
Anxiety disorders 
increased odds for quit 
attempts in 
adolescents with 
psychiatric disorders 
(AOR, 1.99; 95% CI, 
1.08-3.71) 
Fair 
Hitsman et al., 
1999113 
 
United States 
 
Population-based 
RCT 
 
10 weeks 
 
1 week; 1, 3, 
and 6 months 
 
G1: Individual 
behavioral therapy; 
fluoxetine 30mg; quit 
date set, compliance 
level at 150ng/ml 
 
G2: Same as G1 
except fluoxetine is a 
60mg dose and 
compliance level set 
at 300ng/ml  
 
C1: Same as G1 
except received 
placebo 
253 adults At 1 and 3 months, for 
treatment-compliant  
patients, fluoxetine had 
a positive association 
with degree of 
depression and 
likelihood of 
abstinence (OR, 1.35; 
95% CI, 1.00-1.81) 
 
Fair 
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Table 15. Tobacco cessation interventions for persons with co-occurring morbidities and risk behaviors 
(continued) 
Author 
Year 
Setting 
Design 
Exposure 
Followup Intervention N Results 
Quality 
Rating 
Studies in Substance-Addicted Populations 
Joseph et al., 
2004149  
 
United States 
 
Residential 
substance use 
disorder treatment 
program 
RCT 
 
10 weeks 
 
3, 6, 9,12, 
and 18 
months 
G1:  Individual 
behavioral therapy; 
recommended 
nicotine patches (21 
mg for 6 weeks, 14 
mg for 2 weeks, and 
7 mg for 2 weeks) for 
smokers; 
combination of 
patches and nicotine 
gum for smokers of 
>20 cigarettes per 
day 
 
C: Temporary control 
group with treatment 
delayed for 6 months
499 
substance 
use disorder 
adults 
At both 3 and 6 
months, smoking 
abstinence rates were 
significantly greater in 
the treatment groups 
than the temporary 
control group  
(P < 0.000 and  
P = 0.02, respectively) 
 
 
Good 
Joseph, 1993152 
 
United States 
 
Hospital 
Prospective 
cohort study  
 
3 weeks 
 
1 year after 
hospitalization 
G1: No specific 
information on 
smoking or 
cessation; smoking 
allowed in 
designated rooms 
and not during group 
sessions 
 
G2: Upon admission, 
patient signed 
contract to abstain 
from nicotine during 
stay; cessation 
program provided; 
clonidine patches 
available 
706 adults 
enrolled in a 
substance 
abuse 
treatment 
program 
Patients who want to 
quit smoking 
At 3-week followup 
• Prepolicy: 24%  
• Postpolicy: 61%  
(P < 0.001) 
 
Patients who quit 
smoking 
At 1-year followup  
• Prepolicy: 3%  
• Postpolicy: 8%  
(P < 0.05) 
 
Fair 
AOR, adjusted odds ratio; C, control group; CBT, cognitive behavioral therapy; G, intervention group(s); ng/ml, nanogram per 
milliliter; NS, not significant; OR, odds ratio; RCT, randomized controlled trials. 
(Appendix C).§ Of the studies discussed for KQ5, we rated one as good and the other four as fair.  
Three studies addressed smoking cessation interventions for populations with co-occurring 
morbidities.113,150,151 These RCTs, all rated fair, were conducted in the United States. One study 
implemented a smoking cessation intervention in a psychiatric hospital;151 the others were 
population-based interventions.113,150 One trial included adolescents and the other two enrolled 
adults; the sample sizes ranged from 179 to 253. 
Brown and colleagues compared the efficacy of a standard CBT smoking cessation treatment 
with standard smoking cessation treatment combined with CBT for depression.150 Through 
newspaper, radio, and television advertisements, the study recruited regular smokers (i.e., 
smoked cigarettes for at least 1 year and currently smoke 10 cigarettes each day) between ages 
                                                 
 
§ Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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18 and 70 years with a history of major depressive disorder (MDD) determined by structured 
interviews using the DSM-III-R. The 179 participants enrolled in the study received eight group 
counseling sessions over 6 weeks and standard CBT. Participants in the treatment group received 
“The Coping with Depression Course,” which served as the basis for the CBT.150   
Self-report of smoking status was collected and verified by expired CO at each treatment 
session from the quit date to the end of treatment; follow-up data were collected by telephone at 
1, 6, and 12 months. No statistical differences were identified in 7-day point prevalence 
abstinence rates at 1, 6, and 12 months for the standard CBT (30.1 percent, 24.7 percent, and 
24.7 percent, respectively) compared with the depression-based CBT (39.5 percent, 24.4 percent, 
and 32.5 percent, respectively). In the final steps of the generalized estimating equations (GEE) 
analysis, significant interactions occurred between treatment and heavy smoking (OR = 3.73;  
P = 0.02) and between treatment and recurrent depression (OR = 3.62; P = 0.02).150   
A second study from Brown and colleagues randomly assigned adolescent smokers between 
13 and 17 years of age who had been hospitalized for psychiatric and substance use disorders 
into either a motivational interviewing (MI) or a brief advice (BA) tobacco cessation 
intervention.151 The MI arm consisted of two in-person, 45-minute motivational interviews 
during hospitalization.151 Participants in the MI arm received comprehensive manuals about 
relapse prevention and coping skills for mood management. Additionally, two courses of free 
transdermal nicotine patch therapy were offered to medically eligible participants. At the end of 
the MI intervention, participants received up to six postdischarge telephone counseling sessions, 
and their parents received up to four brief telephone counseling sessions. BA participants 
received 5 to 10 minutes of advice to quit smoking by one of the student therapists, a copy of the 
“I Quit!” self-help pamphlet, and (for those who were eligible) a one-time offer of a transdermal 
nicotine patch treatment regime. 
The MI arm had 116 participants and the BA arm had 75 participants. The population was 
primarily female (62.3 percent) and white (94.8 percent). The mean age of participants was 15.4 
years, and 68.6 percent met the Diagnostic and Statistical Manual for Mental Disorders, Fourth 
Edition (DSM-IV) criteria for nicotine dependence. Psychiatric disorders included mood, 
anxiety, disruptive behavior, attention deficit, and substance-related disorders. The investigators 
assessed nicotine dependence at 1, 3, 6, 9, and 12 months. Smoking abstinence, measured by 
self-report, was confirmed through biochemical verification using saliva cotinine.151 
To assess whether MI would lead to more and longer quit attempts, reduced smoking, and 
more abstinence from smoking, Brown et al. employed hierarchical linear modeling, GEE 
analyses, and logistic regression.151 The findings did not show higher quit attempts for those 
receiving MI than those receiving BA (mean quit attempts = 1.1 vs. 1.3, P = not significant 
[NS]). Seven-day point prevalence abstinence at 1, 6, and 12 months was not significantly 
different between the groups (see Table 15 for point prevalence rates). The mean number of days 
for the longest quit attempt was 48.2 days for the MI group and 60.9 days for the BA group; 
however, this difference was not significant.  
Two findings were associated with significantly less smoking among adolescent psychiatric 
patients.151 Examination of covariates revealed that having an anxiety disorder increased the 
odds for quit attempts (AOR, 1.99; 95% CI, 1.08-3.71); in the hierarchical linear model, higher 
discharge self-efficacy scores were associated with less smoking during followup (b1 = -0.02, 
standard error = 0.007; P = 0.007). MI and BA were equally ineffective smoking cessation 
interventions for this population.  
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Hitsman et al. hypothesized that smokers with greater depressive symptoms and those with 
elevated weight concerns would be more likely to achieve tobacco abstinence when receiving 
fluoxetine (combined with CBT) than when receiving a placebo (and CBT).113 The first arm 
involved nine 1-hour, individual CBT sessions plus 30 mg fluoxetine for a total of 10 weeks. 
Participants were required to set a quit date within 2 weeks of drug treatment initiation. 
Participants quit smoking at the third CBT session, and medication stopped at the ninth CBT 
session, at which time the 6-month follow-up period began. Patients with fluoxetine levels less 
than or equal to 150 ng/ml were considered compliant. The second arm was the same as the first 
arm except that the fluoxetine dose was 60 mg, and fluoxetine blood levels less than or equal to 
300 ng/ml were considered compliant. The third arm of the trial was also the same as the first 
except that participants received a placebo.  
Participants were considered to be smoking if expired CO was greater than 8 ppm and saliva 
cotinine values were greater than 10ng/ml. Level of depression, nicotine dependence, weight 
concerns, and self-efficacy about quitting were also assessed. Baseline measures were similar 
across all treatment groups. Hitsman et al. applied predictive models using logistic regression 
with a hierarchical approach to variable selection to analyze the data. Separate hierarchical 
logistic regression using intent-to-treat analysis failed to yield any stable predictive models for 
smoking status at 1 week and 1, 3, and 6 months after the quit date.113 
An interaction between fluoxetine treatment and the depression score occurred at 1- and 3-
month followup for treatment-compliant patients only (n = 169). Participants treated with 
fluoxetine had a positive association between degree of depression and likelihood of abstinence 
(OR, 1.35; 95% CI, 1.00-1.81); for controls, the opposite was true, and increasing depression 
scores were associated with decreasing likelihood of abstinence. The fluoxetine effect was 
greater for individuals with depression scores in the upper quartile of the depression scale 
(Hamilton Rating Scale for Depression [HRSD], 3; OR, 2.0; 95% CI, 0.85-4.7) than for 
individuals in the lower quartile of the depression scale (HRSD, 1; OR, 1.10; 95% CI, 0.38-
3.19). At 3 months, the interaction effect was sustained; fluoxetine selectively benefited smokers 
with higher initial levels of depression (OR, 1.39; 95% CI, 1.02-0.89) and patients receiving 
fluoxetine showed a positive association between degree of depression and likelihood of 
abstinence (highest quartile HRSD = 3; OR, 1.44; 95% CI, 0.53-3.91). Smoking characteristics 
predicting treatment compliance were nicotine intake at baseline, saliva cotinine (Χ2, 11.4;  
P < 0.001), and expired CO (Χ2, 5.3; P < 0.05).113 
Populations with Substance Addictions 
Smoking rates for alcohol and drug users are well above those for the average population, 
exceeding 70 percent.5 The risk of death is significantly higher for individuals with concurrent 
addictions of alcohol and nicotine than for individuals who abuse only alcohol or tobacco. 
Consequently, alcoholics are thought to be more likely to die from cigarette-related diseases than 
from alcohol-related diseases.154  
The best way to approach smoking cessation treatment with people who have chemical 
addictions remains controversial. Additionally, some in the substance abuse treatment 
community argue (on the basis of untested assumptions) that smoking cessation treatment 
threatens the process of alcohol rehabilitation.154 Others claim that the opportunity to engage this 
population in smoking cessation treatment may be lost by delaying treatment until after 
sobriety.24 
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Synthesis of prior systematic reviews. Multimodal strategies using nicotine replacement 
therapy in conjunction with psychosocial intervention strategies are effective in treating tobacco 
addiction in patients with alcohol and other substance abuse problems.9 Fiore et al. report that 
people with chemical and nicotine dependency should receive counseling and pharmacotherapy 
to assist with smoking cessation.5 Although these types of interventions had positive short-term 
effects for stopping smoking, maintaining long-term abstinence was not successful.9 Evidence is 
clear that smoking cessation treatment does not interfere with recovery from chemical 
dependency.9 This finding eliminates obstacles to providing this population with concurrent 
treatment for substance abuse and nicotine dependency.  
Synthesis of current literature. Three studies examined smoking cessation treatments for 
alcohol and substance abusers; we excluded one study from this discussion because of a quality 
rating of poor.149,152,153 The other two studies, both conducted in the United States, received a 
good149 and a fair152 rating. One study used a prospective cohort study design;152 the other was a 
RCT.149  Both enrolled adults in substance use disorder programs; the samples size ranged from 
706 to 499.  
To examine long-term smoking cessation outcomes, Joseph evaluated the feasibility of a 
smoke-free policy and a nicotine treatment program implemented in a drug and alcohol treatment 
hospital.152 Patients admitted to the treatment facility were consecutively enrolled in the study. In 
1988, before implementation of the smoke-free policy, patients were not provided with specific 
information about smoking or cessation. Patients in the facility when the smoke-free policy 
changed (i.e., those admitted to the hospital between May and July 1988) were excluded from the 
study. After implementation of the smoke-free policy, patients were required upon admission to 
acknowledge the smoke-free policy, sign a contract agreeing to abstain from nicotine during their 
treatment period, and agree to attend a smoking cessation program specifically designed for 
substance use patients. The program included (1) didactic lectures on the pharmacology of 
nicotine, (2) films, and (3) a discussion group. 
Joseph used a one-page, standardized, self-administered questionnaire to assess smoking 
status and motivation to quit at admission and again during the third week of hospitalization.152 
Structured telephone interviews at 1 year after hospitalization assessed substance use other than 
nicotine. The prepolicy patients (n = 156) completed posthospitalization telephone interviews at 
16.2 months, and postpolicy patients (n = 163) at 10.7 months. Approximately 55 percent of the 
sample was lost to followup. The telephone interview assessed the long-term outcome of the 
patient’s chemical dependency. Improvement in chemical dependency was defined as less or no 
use of the substance for which patients were treated at the time of hospitalization. Other 
outcomes were smoking status, motivation to quit, and use of substances other than nicotine. 
At 3-week followup, the 24 percent of patients in the prepolicy group and 61 percent in the 
postpolicy group “want[ed] to quit” smoking (P ≤ 0.001).152 The proportion of patients who 
abstained from smoking for more than 1 week was significantly higher in the postpolicy group 
than in the prepolicy group (41 percent vs. 9 percent, P < 0.001). Postpolicy patients cut down 
significantly more on the number of cigarettes smoked while in the hospital than did the 
prepolicy patients (93 percent vs. 46 percent, P < 0.001). At the 1-year follow-up interview, 8 
percent of the postpolicy patients and 3 percent of the prepolicy patients had quit smoking  
(P < 0.05). The groups did not differ significantly at the 1-year followup for nonnicotine 
substance use. 
Joseph and colleagues compared the effects of treatment for nicotine dependence and 
intensive treatment for alcohol dependence, delivered concurrently, with the same nicotine 
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dependence treatment delayed by 6 months.149 Eligible participants included both men and 
women between the ages of 21 and 75 who met the criteria for alcohol dependence or abuse 
according to the DSM-IV and who smoked more than five cigarettes each day for a year. 
Participants with no interest in quitting were excluded from the study.  
The nicotine dependence intervention included a combination of behavioral and 
pharmacological treatments. A 1-hour individual counseling session and up to three followup 
sessions conducted in person or by telephone were offered to participants. Participants in the 
action stage of change received a free prescription for nicotine replacement therapy unless they 
declined or had a medical contraindication. A combination of patches and nicotine gum was 
offered to participants who smoked more than 20 cigarettes per day. The intervention was 
identical in both treatment arms but delayed in one, which effectively established a temporary 
control group.149 
Biochemically validated self-reports were collected for both smoking and alcohol outcomes. 
Seven-day point prevalence abstinence rates were assessed at 3, 6, 12, and 18 months; 30-day 
and 6-month alcohol abstinence was measured at 6, 12, and 18 months. Using a simple 
likelihood ratio chi-square test and intent-to-treat analysis, the 7-day point prevalent smoking 
abstinence rates at 3 months were 15.5 percent in the concurrent treatment group and 4.4 percent 
in the delayed group (P < 0.0001). At 6 months, abstinence rates were 10.5 percent in the 
concurrent treatment and 5.2 percent in the delayed treatment group (P = 0.02); the delayed 
group, however, had not received the intervention at 3 and 6 months. Thereafter, at 9 and 12 
months, the treatment groups did not differ significantly. The rate of prolonged smoking 
abstinence at 18 months for both groups was similar: 8.8 percent for concurrent treatment and 
8.9 percent for delayed treatment. However, the participation rate in the concurrent treatment 
was significantly higher than in the delayed treatment (78.5 percent vs. 64.5 percent, P = 0.005; 
OR = 2.01; 95% CI, 1.35-2.99). 
The alcohol abstinence outcomes at 6, 12, and 18 months for 6-month alcohol abstinence was 
lower in the concurrent treatment group (41 percent, 33 percent, and 41 percent, respectively) 
than in the delayed treatment group (56 percent, 42 percent, and 48 percent; P = 0.004, P = 0.11, 
and P = 0.01, respectively).  
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Chapter 4. Discussion 
This chapter reviews the quality of the literature and strength of the evidence base for 
selected outcomes relating to tobacco prevention, smoking cessation intervention, and smokeless 
tobacco marketing. The confidence that readers can have in our findings, conclusions, and 
recommendations is contingent on the quality of the research reviewed and the overall robustness 
of the evidence. Key question (KQ) 6, addressed in this chapter, concerned limitations in the 
literature and gaps in the knowledge base that point to needed future research. Our information 
and suggestions pursuant to this question will be especially pertinent to participants at the 
National Institutes of Health (NIH) State-of-the-Science Conference on Tobacco Use on  
June 12−14, 2006. 
Quality of Literature and Strength of Evidence 
As described in Chapter 2 and documented in the evidence tables (Appendix C§§), we 
selected articles for this review using rigorous criteria and assessed them using a component 
quality rating scale of “good,” “fair,” and “poor.” The prior systematic reviews that we used for 
several key questions or parts of questions were all of good or fair quality.  
We also evaluated the strength of the body of evidence based on the suitability and quality of 
execution of the study design, the amount of evidence available, and the coherence or 
consistency of available evidence. The strength-of-evidence categories were strong, sufficient, 
and insufficient. The suitability of the study design for assessing effectiveness is based on how 
well the study design protects against potential threats to validity.56 Concurrent comparison 
groups, prospective measurement of exposure, multiple outcome measurements conducted over 
time, and assessment of exposure that precedes assessment of outcome are ways to avoid 
potential threats to validity. Suitability of the study design was contingent on whether the study 
had concurrent comparison groups, no comparison group but multiple prepost measurements, or 
single prepost measurements and was assessed as greatest, moderate, or least, respectively. For 
assessing the quality of study execution (see Chapter 2), we considered the following areas that 
posed possible threats to validity: (1) study population, (2) intervention descriptions,  
(3) sampling, (4) exposure and outcome measurement, (5) data analysis, (6) interpretation of 
results, (7) followup, (8) bias, and (9) confounding. We evaluated studies based on limitations in 
one or more of these areas. The number of studies needed to assess the strength of the body of 
evidence is variable and depends on the suitability and execution of the studies. 
KQ 1. Effective Population- and Community-based Interventions to 
Prevent Tobacco Use in Adolescents and Young Adults 
Population-based tobacco prevention interventions. Two studies implemented population-
based tobacco prevention interventions.73,79 Thomson et al. examined the effects of statewide 
youth tobacco access ordinances in Massachusetts and had one result in the expected direction.79 
Residents of towns with fewer free-standing tobacco product displays were less likely to 
perceive tobacco as easy to purchase. The study found an association between increased attempts 
                                                 
 
§§ Appendixes cited in this report are provided electronically at http://www.ahrq.gov/clinic/tp/tobusetp.htm. 
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to purchase tobacco and being older and male, but the study did not determine whether 
adolescents in towns with more tobacco access ordinances and regulations had less tobacco 
initiation. The second population-based study conducted within families was time intensive and 
required many resources to implement,73 but it was successful at reducing tobacco initiation for a 
subset of the population (i.e., non-Hispanic whites). These two studies alone provided little 
evidence to draw conclusions about population-based tobacco prevention interventions.  
Prior systematic reviews reported strong evidence of effectiveness for two approaches to 
tobacco use prevention among adolescents and young adults: (1) increasing the unit price of 
tobacco products, and (2) mass media campaigns run concurrently with other interventions such 
as increased excise taxes or school- and community-based tobacco prevention programs.7 We 
found no other research to add to existing evidence on increasing unit price for tobacco products 
or on mass media campaigns alone or in conjunction with other tobacco prevention efforts.  
Sufficient evidence of effectiveness was determined for tobacco prevention strategies that 
mobilize community support in conjunction with restricting tobacco product distribution, 
regulating the mechanisms of sale, enforcing access-to-minors laws, and educating and training 
merchants.7 The findings from the Massachusetts study on statewide youth tobacco access 
ordinances augments the already sufficient evidence of effectiveness for tobacco prevention 
strategies that coordinate community-wide interventions to regulate and enforce access-to-
minors laws.79  
Community-based tobacco prevention interventions. Ten studies implemented school-
based tobacco prevention programs.68-72,74-76,81,82 The studies had adequate sample sizes and used 
appropriate cluster analysis for school-level data. Limitations of school-based tobacco prevention 
studies include high attrition rates, lack of long-term follow-up assessments, and inconsistent 
definitions of smoking status and abstinence.  
Programs done over a single school year provided mixed results. At the end of the 
interventions or shortly afterwards, two studies, one using classroom instruction and the other 
using personalized letters, reduced tobacco initiation.68,71 Two other studies, however, both using 
classroom instruction (with one incorporating extracurricular activities and parent involvement), 
were effective only for boys.75,81  
Interventions done over multiple school years, which provide longer or repeated exposure to 
prevention treatment, also produced mixed results. Two studies significantly reduced tobacco 
initiation rates,72,74 one study reduced tobacco uptake for boys but not girls,70 and two other 
studies had no effect.76,82 No school-based study reported long-term effects.  
Past systematic reviews report limited support for community- and school-based tobacco 
prevention programs for reducing tobacco initiation.34,64 Long-term effects (i.e., greater than 2 
years) have not been found with school-based interventions. Although educational strategies 
conducted together with population and community tobacco prevention efforts have postponed 
tobacco initiation,2 this result was not evident in our studies. Existing evidence is sufficient to 
demonstrate that tobacco prevention measures conducted in school settings have positive short-
term effects on preventing adolescents from initiating tobacco use.68,70-72,74,75,81 Without 
definitive findings, evidence is insufficient to draw conclusions on the effectiveness of school-
based programs to produce long-term effects. These results are consistent with past reviews that 
suggest school-based prevention strategies show limited effectiveness over the long run.34  
Provider-based tobacco prevention interventions. The only provider-based study we 
reviewed found no intervention effects.80 Therefore, existing evidence is insufficient to 
determine whether tobacco prevention conducted in provider settings is effective for preventing 
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tobacco use among adolescents. Past systematic reviews have not evaluated provider-based 
tobacco prevention strategies in health care settings.  
Gaps in Tobacco Prevention Literature 
Population-based tobacco prevention interventions. With the exception of tobacco 
industry and product restriction, earlier systematic reviews had extensively evaluated tobacco 
prevention strategies and provided intervention recommendations that included increasing 
tobacco product prices, enforcing tobacco laws and regulations, and conducting mass media 
education campaigns. Our review identified two population-based studies (only one related to 
past reviews and recommendations). Population-based tobacco prevention research lacks tobacco 
industry and product restriction interventions. More research is needed on the effects of price 
increases in combinations with other strategies. Too few studies of good and fair quality report 
on the effects of enforcing tobacco youth access laws and regulations aimed at retailers, and 
many studies do not use reduced initiation as the outcome variable. More rigorous research on 
the enforcement of youth access laws and regulations and their impact on smoking initiation 
among adolescents and young adults is needed to help build the evidence base.  
Limited information is available on the effectiveness of implementing several population-
based interventions simultaneously. Implementing tobacco prevention strategies that we know 
are effective concomitantly may greatly influence the uptake of tobacco use among adolescents 
and young adults.  
Community-based tobacco prevention interventions. The body of evidence for school-
based tobacco prevention is large; our review found several recent school-based tobacco 
prevention studies. Improving this body of evidence entails producing more rigorous research 
through adequate use of randomization, using control groups without contamination or 
confounding issues, achieving low attrition rates, and consistently using operationally defined 
outcome variables. The lack of long-term effects of school-based programs is problematic, so 
sustainability of effects remains unknown.  
Additionally, we found no research about comprehensive interventions that include 
combining school-based prevention programs with other effective interventions such as media 
campaigns or enforcement of tobacco youth access laws and regulations. More research on 
community-based tobacco prevention interventions is needed, because our review found no other 
community-based interventions beyond what has been reported in prior systematic reviews.  
Provider-based tobacco prevention interventions. Virtually no evidence is available to 
report on provider-based tobacco prevention for adolescents. Provider-based tobacco prevention 
may be practical only for dental or orthodontic practices, where many adolescents have repeated 
visits. Research in this area has focused on measuring implementation, content of counseling, 
and frequency of counseling, but studies did not report on our outcome variable for KQ 1 (i.e., 
reduced initiation of tobacco use).135 Additional evidence is needed to assess whether provider 
settings are a viable place to implement tobacco prevention for this age group. 
KQ 2. Effective Strategies for Increasing Consumer Demand for and 
Use of Proven Individually Oriented Cessation Treatment 
Multicomponent strategies to increase the number of users who attempt to quit. 
Telephone counseling. Findings from recent reviews show that proactive telephone counseling is 
effective in increasing tobacco use cessation for adults, especially when combined with other 
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counseling formats. We identified three studies of fair quality that focused on telephone 
counseling with related print materials.84-86 These studies, on their own, yielded insufficient and 
inconsistent evidence to draw conclusions about the efficacy of telephone counseling. Two trials 
reported significant increases in cessation in the short term among those using telephone 
counseling;85,86 one trial reported no difference in either abstinence at each followup or in 
continuous abstinence.84 When considered within the context of recent systematic reviews and 
meta-analyses, results from two studies in our review were consistent with that body of evidence; 
each demonstrated a positive effect of telephone counseling along with relevant printed materials 
on quitting smoking.85,86 
We found only two studies targeting youth and young adults with telephone counseling. Both 
showed that telephone counseling for youth and young adults resulted in quit rates comparable to 
those for adults. The small number of studies led us to conclude that, although promising, the 
evidence is currently insufficient to draw conclusions with regard to the effect of telephone 
counseling on adolescents and young adults.  
We found no study evaluating other multiple formats for increasing the number of users who 
attempt to quit. One study that evaluated counseling enhanced by providing information on 
genetic susceptibility to lung cancer showed a short but unsustained effect on cessation rates. 
Results of studies evaluating persistence of effect in the long term were inconsistent.  
Numerous design and measurement issues complicate the interpretation of study findings for 
this portion of the review. Smokers were defined in various ways in these studies; no two studies 
applied the same definition. The trials evaluated very different interventions; they also used 
different measures of smoking status and abstinence and different follow-up intervals. The five 
studies using continuous abstinence as an outcome, however, did consistently define it as 
abstinence at all reporting periods.  
Strategies to improve the success of quit attempts. Our review included studies evaluating 
the efficacy of cessation strategies such as self-help, counseling, single pharmaceuticals, 
combined pharmacotherapies, and pharmacotherapies combined with psychological counseling. 
Three studies were determined to be of good quality; all others were fair. Our findings for self-
help strategies were consistent with those of earlier reviews. We found insufficient evidence of 
the efficacy of self-help strategies given the small number of new studies and discrepancies 
across their reported effects. In the one study that showed an effect, we could not estimate the 
independent effect of practical tips for smoking cessation compared with other components of 
the intervention such as tips on exercise.115 These findings were consistent with those of other 
recent reviews showing the marginal efficacy of self-help when offered without any person-to-
person intervention.  
Our review of counseling showed mixed results. Two studies reported increased abstinence 
with counseling treatment; three showed no effect. This evidence is insufficient on its own to 
make a recommendation differing from those of prior reviews indicating that even brief 
individual cessation counseling is efficacious.  
In our review of pharmaceutical approaches to increasing the success of quit attempts, we 
reviewed five studies, all of fair quality. Three studies evaluated the effect of bupropion, one 
studied the effect of nicotine gum and of different doses of nicotine gum, and one examined the 
comparative efficacy of transdermal nicotine and nicotine nasal spray.  
Findings are consistent with those of prior reviews showing that nicotine gum is a significant 
aid to smoking cessation, more than doubling the odds of successful quitting. No differences in 
dose response (2 mg vs. 4 mg) for nicotine gum were found in one study.  
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Results were mixed for bupropion. Two studies showed a significant benefit of bupropion 
compared with placebo at 6-month assessment. Patients ready to quit participated in one study;106 
participants at all stages of readiness in an indigenous population group were enrolled in 
another.114 In the final study, bupropion use in outpatients regardless of stage of readiness to quit 
showed a nonsignificant trend in favor of abstinence in the short term (3 months) but not at 
longer periods (e.g., 6 and 12 months).101 These mixed findings for bupropion are insufficient on 
their own to warrant a change in findings from previous reviews concluding that bupropion is a 
first-line pharmacotherapy for smoking cessation.  
In a trial evaluating the comparative efficacy of transdermal nicotine and nicotine nasal 
spray, abstinence rates for the two groups were not significantly different at 6-month followup 
(15.0 percent vs. 12.2 percent, respectively; P > 0.2).100 These results are consistent with 
estimates of significant effect for transdermal nicotine and nicotine nasal spray found in prior 
reviews. Smokers with low to moderate dependence levels, who were not obese, and who were 
white achieved higher abstinence levels with transdermal nicotine. By contrast, smokers who 
were highly dependent, obese, or members of minority groups achieved higher abstinence rates 
with nasal spray.100 These findings provide useful information for those offering these 
pharmaceuticals to their patients.  
Three studies assessed the efficacy of combined pharmaceutical therapy. Two of these 
studies showed a significant increase in long-term cessation (i.e., 12 months) compared with one 
pharmacotherapy alone. One of these studies was consistent with prior reviews showing that a 
combination of nicotine patch with a self-administered form of nicotine replacement therapy was 
more effective than a single form of replacement therapy. The other study showed the significant 
benefit of bupropion alone and in combination with the nicotine patch over the long term (12 
months) compared with placebo. The third study showed no overall benefit of the patch and 
paroxetine combined, but did demonstrate significant differences between paroxetine groups and 
placebo in the short term (4 weeks). 
We identified six studies combining pharmacotherapy and psychological interventions; 
interventions varied by type of pharmacotherapy and by content, format, and intensity of 
counseling. Five of these studies demonstrated a significant improvement in abstinence in 
treatment groups receiving combination pharmacotherapy and psychological interventions. 
These studies provide sufficient evidence of the efficacy of combined pharmacotherapy and 
psychological interventions and add to findings from previous reviews that pharmacotherapy 
either alone or in combination with counseling is effective.5,30 The single study on fluoxetine is 
not sufficient to add it to the list of efficacious pharmacotherapies. 
Strategies to improve the success of quit attempts for special populations. Nine studies 
evaluated strategies to increase the success of quit attempts among special populations. Three 
studies focused on hospitalized patients in different diagnostic categories;119,120,123 four examined 
the impact of varying the intensity of interventions for hospitalized patients;112,115,124,125 one dealt 
with pregnant women122 and one with the indigenous Maori population in New Zealand.114  
Hospitalized patients. When considering interventions for hospitalized patients by diagnosis, 
two studies of fair quality and one of good quality found results similar to those in prior studies; 
that biochemically validated abstinence rates at 12 months postdischarge, although reported as 
higher for the intervention group, were not statistically significant.119,120,123 In one study, 
significant differences at 12 months in compliant patients did not hold with intent-to-treat 
analysis.123 Overall, studies in our review were in agreement with findings of the Rigotti, et al. 
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review showing that there was no strong evidence that clinical diagnosis affected the likelihood 
of quitting.63  
Four studies considered whether cessation varied with counseling intensity for hospitalized 
patients.112,115,124,125 All three studies compared an intensive intervention (defined as inpatient 
contact plus followup for at least 1 month) with usual care and/or a less intensive intervention. 
One study showed significant differences in self-reported, but not biochemically validated, 
abstinence at 12-month followup. Two studies showed significant increases in abstinence at 3- or 
6-month assessments but not at 12-month assessments. One study found a significant increase in 
abstinence but was unable to attribute it directly to the intervention. 
Pregnant women. One study using enhanced counseling to prevent postpartum relapse, 
telephone counseling during and after pregnancy, and partner assistance in quitting demonstrated 
no significant improvement in abstinence.122 
Ethnic groups. In a study of whether bupropion combined with smoking cessation counseling 
was effective in treatment of tobacco use in indigenous Maori in New Zealand, the investigators 
found quit rates similar to those observed in other trials of bupropion.114 They also reported no 
data to suggest that the Maori encountered any special problems related to bupropion use.   
Gaps in the Literature for Increasing Demand for and Use of 
Cessation Treatments 
Very few studies examined the relative population impact of proven cessation interventions. 
For example, information on how proactive telephone counseling support compares with a face-
to-face intervention would be useful; similarly, whether nicotine replacement therapy is offered 
in either of these (or other) situations would be useful for those designing combination 
interventions. Little is known about differential rates of success of and enrollment in various 
programs and how each may either offset or enhance the other. These research questions are 
especially important given the move toward provider referral to quit-line services. 
We found no studies comparing the specific aspects of telephone counseling with each other. 
Issues about the number and timing of calls and the role of feedback to the caller’s primary 
provider have not been studied sufficiently.  
We did not identify sufficient studies of the role of mass media in increasing use of cessation 
services among specific subsets of the population. Research on specific messages and their 
effectiveness in reaching and motivating target audiences such as adolescents, young adults, and 
persons with low income and educational status could improve the impact of such interventions. 
We found very few studies examining the effectiveness of multiple intervention formats, of 
combination pharmacotherapy, or of adjuncts other than pharmacotherapy to individual 
counseling in increasing the success of smoking cessation interventions. Similarly, very few 
studies examined differences in either withdrawal symptoms or side effects associated with 
continuation or success of pharmacotherapy. Persistence of effect on smoking status over time 
was reported by only two studies; larger, prospective trials are likely needed to increase the 
evidence base for this issue. Finally, very few studies focused on ways to reach or treat special 
populations such as adolescents and young adults. 
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KQ 3. Effective Strategies for Increasing the Implementation of Proven 
Population-Level Tobacco Use Cessation Strategies, Particularly by 
Health Care Systems and Communities 
Population-based implementation strategies. We found insufficient evidence to suggest 
that community-based interventions increase implementation of proven cessation strategies. 
Three studies, one of good quality and two of fair quality, focused on very different strategies 
and populations and produced inconsistent results.131-133 Positive results were shown only in a 
trial using community-based pharmacists to discuss smoking cessation with smokers coming to 
their pharmacies for a variety of services.132 The positive results observed with pharmacist-led 
interventions suggest that further research into how pharmacists might be engaged in and support 
community-based strategies would be useful. 
Provider- and health care system-based tobacco use cessation strategies. One prior 
systematic review reported “strong” evidence of effectiveness for provider reminder systems 
with provider education, with or without client education, and for multicomponent interventions 
that include client telephone support; “sufficient” evidence of effectiveness for provider 
reminders alone and reductions in patient out-of-pocket costs; and “insufficient” evidence of 
effectiveness to recommend provider education alone and provider feedback and assessment.7  
A meta-analysis identified six systems strategies to facilitate adoption of effective tobacco 
treatment in health care settings: (1) implementing a tobacco user identification system in every 
clinic; (2) providing education, resources, and feedback to promote provider intervention;  
(3) dedicating staff to provide tobacco dependence treatment and assessing the delivery of this 
treatment in staff performance evaluations; (4) promoting hospital policies that support and 
provide tobacco dependence services; (5) including tobacco dependence treatments (both 
counseling and pharmacotherapy) identified as effective as paid or covered services for all 
subscribers or members of health insurance packages; and (6) reimbursing clinicians and 
specialists for delivery of effective tobacco dependence treatments and including those 
interventions among the defined duties of the clinicians.  
Four studies showed that provider training improved provision and uptake of smoking 
cessation strategies.134,142,144 When examining the effect of these changes on smoking abstinence, 
two studies reported significant increases in abstinence compared with control, and one reported 
no differences at 6-month followup after biochemical verification of self-reported abstinence.144 
Our review supports the efficacy of provider-based strategies to increase the implementation of 
proven cessation strategies, but falls just short of providing sufficient evidence that these 
improvements in implementation will increase cessation.  
In our review of interventions carried out in health care systems, we found sufficient 
evidence that academic detailing approaches improved provider delivery of effective smoking 
cessation treatments. Family physicians and other providers in office-based private practices, 
public clinics, hospitals, and orthodontist offices improved their knowledge and use of effective 
strategies as a result of personal educational visits in their own practice setting that included 
education, audit, and feedback.  
The evidence was insufficient, however, to suggest that these improved treatment practices 
lead to significant, long-term increases in cessation among those being treated. Too few studies 
reported quit rates for the population served. Those studies reporting quit rates showed no 
consistent effects on cessation in the long term. One study found significant improvement in 
cessation in the short term; this occurred among pregnant women.139 This finding is especially 
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important given the immediate positive health outcomes associated with quitting in the short 
term for a pregnant woman and her fetus.  
No evidence was found to conclude that provider attitudes and smoking behavior have an 
effect on uptake and use of effective interventions. The only study to test this relationship found 
no effect.136 
Evidence was also insufficient to suggest that interventions proven effective in earlier trials 
could be sustained as a part of routine care. Only one study examined this important aspect of 
improving the odds of maintaining an effective program.86 The investigators found that 
successfully implementing a proven strategy after completion of the original trial is possible; 
they also determined that the sustained program produced quit rates comparable to those 
observed in the trial and that success was more likely among cancer, cardiovascular, and 
pulmonary patients.  
Gaps in the Literature for Increasing Implementation of Cessation 
Strategies 
We found inconsistencies in the literature evaluating academic detailing as an approach to 
improving implementation of cessation strategies. Additional studies are needed that use a 
standard definition of academic detailing, that observe changes not only in practice patterns but 
also in related smoking cessation outcomes, and that systematically assess the impact of 
academic detailing across and within practice types. At a minimum, all subsequent studies 
should incorporate all proven components of an academic model, such as provider reminder 
systems. 
We found only one study describing how provider attitudes and smoking behavior affected 
provider use of effective interventions. Similarly, we found only one study examining the factors 
affecting incorporation of effective interventions into usual care. Many studies reported on 
implementation strategies to improve smoking cessation services in practice settings, but few 
studies collected data on whether these system-based improvements translate into increased quit 
rates.  
KQ 4. Effect of Smokeless Tobacco Product Marketing and Use on 
Population Harm From Tobacco Use 
Smokeless tobacco product marketing and use. Two studies with quality ratings of fair 
focused on smokeless tobacco use.146,147 They investigated (1) how smokeless tobacco use 
affects smoking behaviors and (2) how exposure to smokeless tobacco advertising affects use. 
Tomar reported that smokers were more likely to quit smoking than become users of smokeless 
tobacco.147 More importantly, users of smokeless tobacco were significantly more likely than 
nonusers of tobacco to become smokers.147 One study does not provide sufficient evidence to 
draw conclusions on whether smokeless product marketing results in substituting smokeless 
tobacco for smoking.  
Our review found one study that indicates smokeless tobacco marketing may lead to greater 
use at least for adolescents.146 Choi et al. found that exposure to advertising increased 
adolescents’ susceptibility to smokeless tobacco. One predictor of current use of smokeless 
tobacco is exposure to smokeless tobacco advertising, resulting in a sevenfold increase in current 
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use.146 Again, one study does not provide sufficient evidence to determine whether tobacco 
marketing increases smokeless tobacco use. 
Prior systematic reviews did not address issues relevant to KQ 4. Past reviews focused on 
risks associated with the use of smokeless tobacco and on the potential offered by smokeless 
tobacco cessation treatments.1,2,5  
Gaps in Smokeless Tobacco Product Marketing and Use 
Smokeless tobacco product marketing and use. The gaps in research on smokeless tobacco 
product marketing and use are substantial. No studies addressed two of three concerns presented 
in this review: (1) whether substituting smokeless tobacco for smoking results in less smoking-
related harm on a population basis, and (2) whether data on harms and harm reduction associated 
with smokeless tobacco are used to model the potential health effects of substituting smokeless 
tobacco for smoking. Additional evidence is necessary to determine how smokeless tobacco use 
affects smoking behaviors and how exposure to smokeless tobacco advertising affects use. 
KQ 5. Effectiveness of Prevention and of Cessation Interventions in 
Populations with Co-Occurring Morbidities and Risk Behaviors 
Tobacco cessation for persons with co-occurring morbidities. Three studies evaluated 
smoking cessation for persons with psychiatric conditions.113,150,151 Hitsman et al. hypothesized 
that smokers with greater depressive symptoms would be more likely to achieve abstinence when 
receiving fluoxetine combined with cognitive behavioral therapy (CBT) than when receiving a 
placebo and CBT.113 Brown et al. compared standard CBT with CBT tailored for depression for 
adults with a history of major depressive disorder (MDD).150,151 A second study by Brown and 
colleagues treated adolescent smokers hospitalized for psychiatric and substance use problems 
with either motivational interviewing or brief advice tobacco cessation interventions.151 Two of 
the three studies113,151 used some form of pharmacotherapy. Hitsman et al. achieved significant 
results in an adult population, but Brown et al. did not in an adolescent population.113,151 
Counseling paired with CBT produced smoking cessation rates for people with a history of MDD 
but depression-based CBT did not significantly increase smoking cessation rates over standard 
CBT for this population.  
Consistent with prior reviews, pharmacotherapy was effective.5,30 Participants treated with 
fluoxetine had a higher likelihood of abstinence than did participants treated with placebo, and 
fluoxetine benefited smokers with higher initial levels of depression.113 The effects of counseling 
and CBT are also congruous with the prior reviews, but depression-based CBT does not 
statistically increase abstinence rates above standard CBT abstinence rates.150 Neither 
motivational interviewing nor brief advice tobacco cessation interventions were effective for 
adolescents hospitalized for psychiatric and substance use problems.151 Prior reviews did not 
report effective smoking cessation interventions for adolescents in this population.  
Our review of the effect of smoking cessation interventions for persons with co-occurring 
morbidities supports prior reviews. Nonetheless, because we found only a limited number of 
studies and inconsistent results, it does not provide sufficient evidence to make further 
recommendations about the effectiveness of smoking cessation interventions in populations with 
psychiatric conditions.  
Tobacco cessation for persons with substance abuse addictions. Two studies investigated 
smoking cessation among alcohol and substance abusers.149,152 Joseph evaluated the feasibility of 
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a smoke-free policy and a nicotine treatment program implemented in a drug and alcohol 
treatment hospital.152 In another study, Joseph et al. investigated the effects of concurrent versus 
delayed smoking cessation intervention in substance use and abuse treatment centers.149 These 
studies used some form of counseling or classroom smoking cessation instruction with 
pharmacotherapy; compared with control groups, these approaches produced significant results. 
Joseph et al. found no difference in smoking cessation rate between concurrent and delayed 
interventions, a point that suggests that the intervention is effective for smoking cessation 
regardless of when it is implemented. However, alcohol abstinence was negatively affected (i.e., 
lower) in the concurrent treatment group compared with the delayed treatment group.149 
Consistent with prior systematic reviews,9 pharmacotherapy and psychological counseling 
significantly influence abstinence rates compared with control interventions in this population. 
The evidence is not consistent regarding the impact of smoking cessation treatment on non-
nicotine substance use.149,152 Although the two studies reported significant short-term effects for 
smoking cessation, only one study reported long-term (i.e., 12-month) abstinence rates. More 
than 50 percent of the participants were lost to followup in this study.152 The studies support 
findings from past reviews on the positive short-term effects of such interventions;30 however, 
the body of evidence in our review is insufficient to point to further recommendations. 
Gaps in the Literature for Effectiveness of Prevention and of 
Cessation Interventions in Populations with Co-Occurring Morbidities 
and Risk Behaviors 
The gaps in this evidence base remain significant for these populations. We found no 
research publications on tobacco prevention for populations with co-occurring morbidities and 
risk behaviors. Although the term co-occurring suggests that these populations are already 
smoking, tobacco prevention efforts, typically directed at adolescents, need to consider testing 
prevention strategies tailored for psychiatric and substance-addicted populations.  
Additional studies need to determine whether smoking cessation treatment should be done at 
the same time as, at the beginning, or at the end of treatment for psychiatric and substance-
addicted populations. Research to rule out any possibility of adverse effect from concurrent 
treatment regimes of psychiatric or substance use conditions and nicotine addiction is necessary 
to move forward with smoking cessation treatment for this population. More research explaining 
interaction effects among depression and smoking cessation interventions is needed.  
Several studies allude to negative perceptions and attitudes of treatment center staff as 
barriers to treating nicotine addiction simultaneously with psychiatric conditions, especially, with 
substance abuse problems. Research exploring the legitimacy of these statements should be 
pursued. We believe the current opportunity to contribute to this area of tobacco research is 
extensive. 
Limitations of Evidence Base 
Inadequate Randomization and Concealment Allocation 
Randomization procedures were rated inadequate in more than 25 percent of the randomized 
controlled trials (RCTs) we reviewed. Few studies used methods that ensured a chance 
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assignment of participants in the treatment and control groups. Preset plans, alternation method, 
and hospital numbers were used in randomization schemes. Many studies failed to report how 
investigators achieved randomization. Only 25 percent of the RCTs reported adequate 
concealment allocation.  
Deficient Study Designs  
In the absence of RCTs, particularly for studies on the effects of smokeless tobacco 
marketing on use and population harm, we accepted cross-sectional and cohort study designs. 
RCTs are the ideal, but, in some instances, more suitable study designs were appropriate for 
answering the KQs. Other study design deficiencies concerned control groups, recruiting, and 
power analyses. In about one-quarter of the studies, the control group was not adequately 
described. Studies lacked descriptions of comparison or control groups. A small number of 
studies employed convenience and volunteer samples, and studies rarely reported a power 
analysis.  
Refusal and Attrition Rates 
Both refusal rates and attrition rates for tobacco cessation studies are quite high. Participants 
not ready to stop tobacco use will not participate, and those who do participate often drop out of 
studies because of noncompliance. Other issues contributing to refusal and attrition rates were 
parental refusal (i.e., tobacco prevention studies), relocation, discharge from hospital, and side 
effects of drugs. Investigators used intent-to-treat analysis in about two-thirds of the studies. 
Construct Validity Problems 
Some intervention studies assessed tobacco use behaviors with a single item (e.g., “Have you 
smoked in the past 7 days?”). A single question measuring tobacco use may not provide adequate 
information about the key construct, tobacco use. Multiple items measuring tobacco use help to 
determine whether the behavior measured is actually the intended behavior. 
Studies often used a single version of the prevention or cessation intervention in comparison 
with a control group. This creates a “mono-operation bias,” in which the results of the study 
reflect only the particular version of the intervention and not the actual construct. Implementing 
a single version of a program, in a single place at a single point in time, may not capture the full 
breadth of the concept of the program. Arguably, the results of the study reflect only the peculiar 
version of the intervention implemented, not the actual construct proposed. 
Reliability of Results 
Biochemical verification was rarely used for tobacco prevention studies with adolescents. 
Randomized controlled trials, particularily pharmacotherapy studies, used biochemical 
verification such as expired carbon monoxide or salivary cotinine to verify self-reported tobacco 
use. Low response rates for expired carbon monoxide or salivary cotinine were reported. 
Although the reliability of self-reported data is assumed to be adequate for population-based 
studies on other topics, such data will typically underrepresent smoking status. Studies that used 
biochemical verification of smoking status did not routinely report statistics on discrepancies 
between self-report and biochemical verification. Often, investigators who used surveys and 
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questionnaires to assess tobacco use, self-efficacy regarding quitting, perceived quitting 
intentions, and other variables did not document whether they (or others) had tested the 
instrument for reliability or other psychometric properties.  
Inconsistent Terminology 
Studies lacked consistent and clear definitions of tobacco use. The definition of nonsmokers 
in KQ 1 ranged from “never smoked even one cigarette or a puff of one” to “no smoking in past 
30 days” or “past 12 months” to “no intention of smoking in high school.” The definition of 
cigarette smoking in the other KQs ranged from “10 cigarettes per day on average over last year” 
to “having smoked greater than 100 cigarettes during a subject’s lifetime” and “having smoked at 
least 1 cigarette in the last week.” This degree of variation in the dependent variable in smoking 
cessation studies makes comparing effect sizes across studies challenging if not impossible.  
Characteristics of Poor-Quality Studies 
Table 16 documents the principal reasons for rating studies that we included and reviewed as 
poor quality. Only KQ 4 had all good or fair studies; KQ 2 had the highest number of poor 
studies. Problems with studies varied considerably, but we note in particular problems with study 
design (including selection of participants), lack of reporting of basic data (baseline; group 
comparisons), and attrition.  
Future Research Recommendations 
Our review highlighted several gaps in the literature that could be addressed by future 
research and by improvement in methods. Future research should address the issues highlighted 
below. 
KQ 1. Effective Population- and Community-based Interventions to 
Prevent Tobacco Use in Adolescents and Young Adults 
Population-based tobacco prevention programs. Future research in population-based 
tobacco prevention for adolescents and young adults needs to examine tobacco industry and 
product restrictions. In particular, how laws that regulate the content, labeling, promotion, and 
advertising of tobacco products affect adolescent and young adult tobacco use warrants greater 
attention. However, before tobacco prevention research in this area can move forward, changes 
in legislation are required. Continued research on whether enforcing tobacco youth access laws 
and regulations, when they are implemented community wide, can significantly reduce tobacco 
use support is important to build this body of evidence.  
Other research using various combinations of population-based interventions may show that 
their effectiveness is greater than using interventions independently. Most important, future 
population-based studies on price increases, tobacco youth access laws and regulations, mass 
media campaigns, or tobacco industry and product restriction need to use control or comparison 
groups in their study designs to measure the impact that the intervention strategies have on the 
uptake of tobacco use among adolescents and young adults. 
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Table 16. Characteristics of studies rated poor quality 
Intervention 
Design*  
Sample Size Reasons for Rating 
Key Question 1 
Group counseling, social support77 
RCT 
450 
All methods (e.g., randomization, sampling) not well 
delineated 
No baseline data reported 
analytical methods not well described 
Video, classroom instruction78 
RCT 
3,038 
No baseline data reported  
No treatment versus comparison data reported 
Post randomization exclusions 
Key Question 2 
Self-help materials129 
RCT 
918 
High attrition rate 
No intention-to-treat analysis 
No power analysis 
Baseline differences 
Self-help, computer-based program, telephone 
counseling, group counseling, social support, media 
campaign, individual counseling by health 
professional111 
Quasi-experiment  
538 
Intervention group volunteer sample 
Control group care not reported 
Exposure to intervention low 
Findings not generalizable†  
High attrition 
Self-help, individual counseling by health professional, 
social support118 
Cohort study 
110 
Self-selected sampling technique 
Baseline differences regarding motivation to quit  
Incomplete reporting of data 
Self-help, group counseling108 
Before/after study 
119 
Self-selection of intervention  
Small group sample sizes 
High attrition rate 
No report of comparison of groups 
Findings not generalizableH 
Individual counseling,  
Acupuncture92 
RCT 
141 
High attrition rate 
Completers analysis  
 
Pharmaceuticals110 
RCT 
1,384 
High rate of noncompliance 
High overall rate of attrition 
Pharmacotherapy93 
RCT 
134 
Removed study participants perceived not to be motivated 
(similar to a “run-in period”) 
Attrition moderately high 
Limited reporting on adverse events 
Randomization not described 
Pharmacotherapy126 
RCT 
245 
Attrition rate not reported 
Allocation to groups predictable 
No adverse events reported 
Poor randomization 
Pharmaceuticals, group counseling117 
RCT 
5,887 
Large differences in baseline comparisons between white 
and black participants negate any conclusions from findings 
Pharmacotherapy, cognitive behavioral counseling96 
RCT 
150 
Randomization not reported 
No power analysis 
High attrition rate 
No adverse events reported 
Pharmacotherapy, cognitive behavioral counseling127 
RCT 
248 
High attrition rate 
Randomization not reported 
No adverse events reported 
No power analysis 
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Table 16. Characteristics of studies rated poor quality 
Intervention 
Design*  
Sample Size Reasons for Rating 
Pharmacotherapy, self-help, counseling128 
RCT 
137 
High attrition rate 
Lacked power 
Significant baseline differences not reported 
Telephone quit line94 
Cohort study 
1594 
High attrition rate 
Confounded by “additional support” 
Baseline data not reported for Proactive Treatment group 
No reliability or validity measures for instruments 
Inclusion/exclusion criteria not reported  
Telephone counseling, group meetings95 
RCT 
756 
No true control group 
Randomization not reported 
Population not described 
Inclusion/exclusion criteria not reported 
Intention-to-treat analysis not reported 
Key Question 3 
Video, telephone counseling, individual counseling by 
health professional, group counseling, social support, 
pharmaceuticals155 
Before/after study 
299 
Sampling not explained 
No control group 
Limited generalizability† 
Self-help, individual counseling by health professional, 
telephone counseling, video156 
RCT 
1,173 
Inadequate allocation of concealment and blinding 
Contamination of usual care group 
Attrition not reported 
Key Question 5 
Group counseling, pharmaceuticals153 
RCT 
3,976 
Sampling technique not reported 
Study criteria changed after one-third of participants 
recruited; post-randomization 
Attrition not reported 
Adverse events not reported 
No systematic measure of nicotine replacement therapy use 
among participants 
* RCT, randomized controlled trial.  
† Generalizability is noted but did not figure directly in the quality rating. 
Community-based tobacco prevention programs. More community-based research that 
integrates an array of strategies such as community empowerment, dissemination of health 
education materials, media advocacy, youth antitobacco activities (e.g., contests, peer leadership 
programs), and letters to schools, parents, and tobacco retailers is urgently needed. Although 
sufficient evidence exists on the positive short-term effects of school-based tobacco prevention 
programs, more (and better-designed) studies demonstrating positive long-term effects will 
improve understanding of how best to prevent adolescents from initiating tobacco use. The 
approaches to tobacco prevention need to be comprehensive (e.g., combining school-based 
interventions with community mobilization, media campaigns, and enforcement of tobacco youth 
access laws and regulations). In general, the body of evidence for community-based tobacco 
prevention requires more rigorous research through adequate use of randomization, use of 
control groups without contamination or confounding issues, low attrition rates, and consistent 
and universal utilization of operationally defined outcome variables.  
Provider-based tobacco prevention programs. Future research using providers as a 
conduit for tobacco prevention education should assess whether such settings are a viable place 
to implement tobacco prevention for adolescents and young adults. Because dental clinicians 
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may be better suited for tobacco prevention, particularly in the case of smokeless tobacco use 
and for younger subjects, additional research in these settings is warranted. 
KQ 2. Effective Strategies for Increasing Consumer Demand for and 
Use of Proven Individually Oriented Cessation Treatment 
Increasing the number of users who attempt to quit. Additional research will further our 
understanding of how to increase consumer demand for and use of individually oriented 
cessation treatment. The role of mass media in driving individuals to quit-line and other 
cessation services should be examined. Audience research on the effectiveness of specific 
messages in reaching and motivating target audiences such as adolescents, young adults, and 
persons with low income and educational status can inform and increase the impact of mass 
media. For expanding the use of quit-line or other telephone support services, future research 
should compare specific components of telephone counseling and their relative impact on 
enrollment and continuation in these services as well as their impact on individual motivation to 
quit and smoking status. Future research could investigate issues related to suitability and 
appropriateness of the services such as the number and timing of calls, the role of feedback to the 
caller’s primary provider, and the participants’ satisfaction with cessation services.  
The relative population impact of various proven cessation interventions should also be 
examined. One example is to determine how proactive telephone counseling support compares 
with in-person intervention, regardless of whether nicotine replacement therapy is offered. 
Documenting whether differential rates of success and enrollment offset or enhance each other 
on a population basis will also be an important addition to the knowledge base. These research 
questions are especially important given the move toward provider referral to quit-line services. 
Strategies to improve the success rate for quit attempts. To improve the success rate of 
cessation services, well-designed studies should examine the effectiveness of multiple 
intervention formats, of combination pharmacotherapy, and of adjuncts other than 
pharmacotherapy in comparison with individual counseling for all smokers and for special 
populations of smokers. Adjuncts to counseling could include patient incentives, biomarker 
feedback, and other approaches designed to increase the likelihood of quitting. Future studies 
should also examine ways to reduce withdrawal symptoms and cravings among those attempting 
to quit using tobacco products. Research on ways to minimize the side effects associated with 
use of various individual pharmacotherapies and combined pharmaceutical regimes is also 
needed. Identifying ways to increase the persistence of effect on smoking cessation over time 
also warrants further study. 
KQ 3. Effective Strategies for Increasing the Implementation of Proven 
Population-Level Tobacco Use Cessation Strategies, Particularly by 
Health Care Systems and Communities 
Population-based implementation strategies. Some evidence, albeit inconsistent, suggests 
that interventions at the community level increase the implementation of tobacco use cessation 
strategies at the population level. Well-designed investigations should examine ways to reach out 
to smokers in the general population and to special populations such as adolescents and young 
adults with messages that motivate smokers and nonsmokers to become aware of, promote, and 
use existing cessation services. 
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Provider- and health care system-based tobacco use cessation strategies. Future research 
to improve strategies that providers and health care systems might employ should focus on well-
designed studies of effective ways to change not only provider practice patterns but also related 
smoking cessation outcomes. To provide more awareness about what does and does not work 
with academic detailing, studies should assess the impact of academic detailing across and within 
practice types. At a minimum, future studies should incorporate all proven components of an 
academic model such as provider reminder systems.  
Either within or separate from the academic detailing research, studies should explore how 
provider attitudes and smoking behavior affect provider use of effective interventions. Research 
is also needed to understand how other institutional barriers might hamper the adoption of 
effective strategies in health care settings and among providers. Better appreciation of the factors 
that affect incorporation of effective interventions into usual care is critical. More studies are 
also needed to understand how implementation of effective interventions by providers and/or 
health systems translates into increased abstinence from smoking. 
KQ 4. Effect of Smokeless Tobacco Product Marketing and Use on 
Population Harm From Tobacco Use 
Smokeless tobacco marketing and use. The field of smokeless tobacco marketing and use 
is wide open for new research. Future research should investigate whether new tobacco industry 
marketing strategies are increasing use of smokeless tobacco, and, if so, whether the observed 
increase applies differentially to specific user populations. Of special importance is examining 
possible links between point-of-purchase tobacco promotion and advertising and increased use of 
smokeless tobacco among adolescents and young adults. We see many opportunities to build 
evidence in the area of smokeless tobacco product marketing; we advise researchers to advance 
this research with rigorous study designs.  
Robust research has established links between use of smokeless tobacco and certain cancers.1 
For that reason alone, future research should move away from investigating whether smokeless 
tobacco is a viable substitute for smoking and toward developing strategies to reduce its use. 
Research should continue to pursue possible treatments (i.e., counseling, pharmacotherapy) to 
assist or complement efforts aimed at smokeless tobacco cessation.  
KQ 5. Effectiveness of Prevention and of Cessation Interventions in 
Populations with Co-Occurring Morbidities and Risk Behaviors 
Populations with psychiatric comorbidities and risk behaviors. Specifying the best 
approaches for smoking cessation treatment in populations with co-occurring morbidity and risk 
behaviors remains controversial. Because populations with these additional ailments and risk 
behaviors smoke at higher rates than others,9,30 successfully accomplishing therapy may require 
pharmacotherapy and tailored treatments.9,113  
Investigators need to examine the effects of pharmacotherapy, particularily antidepressants 
alone or in combination with counseling, not only for people with a history of depression but 
also for people currently diagnosed with clinical depression. Additional pharmacotherapy studies 
using antidepressants such as fluoxetine alone or in combination with other nicotine replacement 
therapy will help determine whether rates of smoking cessation in psychatric and substance 
abuse populations can be improved (relative to those in the general population).9 
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Comprehensive research on concurrent versus delayed treatment for smoking cessation and 
chemical dependency is warranted in light of recent inconsistent results regarding adverse effects 
on sobriety or other drug use.9,149,152 Investigators need to determine the benefits gained from 
higher participation rates with concurrent treatment against the cost of the adverse effects and the 
lost opportunity to engage this elusive population with delayed smoking interventions.  
Finally, barriers to smoking cessation treatment in patients with other health problems, such 
as contraindications of pharmacotherapy, and the validity of concerns on the part of clinicians 
about hindering sobriety should also be investigated. 
Methods Recommendations 
Apart from the topics recommended above, we emphasize the need for investigators to use 
markedly better and more rigorous methods for all new research into tobacco prevention, control, 
and cessation. Essential scientific and technical improvements cut across many aspects of study 
design and conduct. Among the more critical are the following:  
 
• Improved study designs using rigorous research methods such as control or at least 
adequate comparison groups, adequate randomization procedures, and tobacco use as the 
dependent variable for specific tobacco prevention strategies; 
• Consistent definitions and measurement of baseline smoking status, abstinence, and 
continuous abstinence;  
• Clear descriptions of interventions and comparison and control groups; 
• Use and reporting of psychometrics of reliable and valid assessment instruments; 
• Consistent definition of academic detailing; 
• Use of biochemical validation of self-reported smoking status as appropriate; 
• Use of intent-to-treat analysis; and  
• Better methods of addressing drop-out and attrition, reporting power calculations, and 
taking loss to followup more into account in statistical analyses.  
Finally, we note the absence of important documentation of study design, conduct, and other 
details in much of the literature reviewed. We hope that both investigators and those publishing 
their studies can find a way to provide more detail on methods, study populations, interventions, 
and the like, if not in published form then through web-based media. 
Conclusions 
This review updates the literature found in previous systematic reviews. In most instances, 
the evidence in our review was consistent with that in those publications. On its own or in 
combination with findings from earlier reviews, the information from newer work is insufficient 
to draw new conclusions or conclusions different from those that prior reviews offered.  
The new studies examining tobacco prevention for adolescents and young adults in our 
review found short-term effects for school-based interventions but no evidence to draw 
conclusions for long-term effects. Insufficient new evidence exists on population-, community-, 
and provider-based interventions for reducing tobacco initiation among adolescents and young 
adults.  
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Findings from studies in our review, although insufficient in number and quality to draw 
conclusions on their own about the effectiveness of multicomponent strategies such as telephone 
counseling, are consistent with previous reviews indicating the efficacy of these approaches. 
Studies in our review of strategies to improve the success of quit attempts were consistent 
with previous reviews. Fundamentally, self-help strategies alone are not efficacious; counseling, 
pharmacotherapies either alone or in combination, or pharmacotherapies combined with 
psychological counseling all increase the likelihood of successful quitting.  
When considering interventions for special populations, we found results both consistent and 
inconsistent with prior reviews. When evaluating interventions with hospitalized patients by 
diagnosis, studies in our review agreed with findings of a prior review showing that there was no 
strong evidence that clinical diagnosis affects the likelihood of quitting.63 Results of our review 
were inconsistent with two prior reviews indicating that hospitalized patients were more likely to 
quit smoking as intensity of the intervention increased.5,63 Although some studies in our review 
found significant gains in abstinence in the short term, all studies showed an absence of effect at 
12-month assessment. The findings of our review remain consistent with those of prior reviews 
showing that counseling does increase the likelihood of abstinence among pregnant smokers. 
Investigators found quit rates for indigenous Maori in New Zealand to be similar to those 
observed in other trials of bupropion.114  
Consistent with earlier findings, we also found insufficient evidence of effectiveness for 
population-based interventions to increase implementation of proven cessation strategies. 
Sufficient evidence in our review indicated that implementing provider-based interventions, such 
as training, and health systems-based interventions, such as academic detailing, improved 
provider delivery of cessation treatment, but the information was insufficient to conclude that 
implementing these approaches leads to higher quit rates. 
We found no evidence on how smokeless tobacco product marketing affects population harm 
and only insufficient evidence on whether smokeless tobacco product marketing increases use 
and leads users to substitute smokeless tobacco for smoking.  
Our review found no evidence for tobacco prevention in populations with co-occurring 
morbidities and risk behaviors. Consistent with other reviews, we found some support for 
pharmacotherapy and/or counseling, but the evidence was insufficient in number and quality to 
draw conclusions about the effectiveness of smoking cessation interventions in comorbid 
populations. Taken as a whole, this clearly illuminates the need for better studies to close these 
gaps.  
We documented numerous gaps in the existing knowledge base and deficiencies in the design 
and conduct of currently available studies and recommend a variety of research initiatives to 
overcome these limitations. 
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Appendix A 
Search Strategies by Database 

 Appendix A. Search Strategy 
#1 Search "Tobacco Use Cessation"[MeSH] OR "Smoking 
Cessation"[MeSH] OR "Smoking/prevention and control"[MeSH] 
17017
#2 Search "Smoking"[MeSH] AND "Primary Prevention"[MeSH] 479
#3 Search #1 OR #2 17275
#4 Search #1 OR #2 Limits: Adolescent: 13-18 years, Adult: 19-44 years, 
Middle Aged: 45-64 years, English, Humans 
7383
#5 Search ("Community Networks"[MeSH] OR "Community Health 
Services"[MeSH] OR "Community Health Planning"[MeSH] OR 
"Community Health Aides"[MeSH] OR "Community Health 
Nursing"[MeSH] OR "Community Health Centers"[MeSH] OR 
"Community Mental Health Services"[MeSH] OR "Community 
Medicine"[MeSH] OR "Community Mental Health Centers"[MeSH]) 
345024
#9 Search ("Randomized Controlled Trial"[Publication Type] OR 
"Randomized Controlled Trials"[MeSH]) OR "Single-Blind 
Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random 
Allocation"[MeSH] 
310410
#10 Search #4 AND #5 AND #9 402
#11 Search ("Consumer Satisfaction"[MeSH] OR "Consumer 
Participation"[MeSH]) OR "Health Services Needs and 
Demand"[MeSH] 
84543
#12 Search #4 AND #11 129
#13 Search "Health Plan Implementation"[MeSH] OR "Diffusion of 
Innovation"[MeSH] OR "Patient Education"[MeSH] 
52494
#14 Search #4 AND #13 334
#15 Search "Tobacco, Smokeless"[MeSH]OR "spit tobacco" OR "chewing 
tobacco" OR "dip tobacco" OR "oral tobacco" 
1893
#16 Search #4 AND #15 160
#17 Search ("Marketing"[MeSH] OR "Social Marketing"[MeSH]) OR 
"Choice Behavior"[MeSH] OR "Advertising"[MeSH] 
39557
#18 Search #4 AND #17 402
#19 Search "Comorbidity"[MeSH] OR ("Risk-Taking"[MeSH] OR "Risk 
Factors"[MeSH]) OR ("Depressive Disorder"[MeSH] OR 
"Depression"[MeSH]) OR "Bipolar Disorder"[MeSH] OR "Attention 
Deficit Disorder with Hyperactivity"[MeSH] OR "Stress Disorders, 
Post-Traumatic"[MeSH] OR "Diabetes Mellitus"[MeSH] OR 
"Hypertension"[MeSH] OR "Heart Diseases"[MeSH] OR 
"Asthma"[MeSH] OR "Obesity"[MeSH] 
1406831
#20 Search #4 AND #19 1742
#21 Search #20 AND #9 250
 
A-1 
  
 
 
Cochrane and the CCTR 
 
(smoking or tobacco) AND (tobacco or quit) AND community 
 
Reviews = 3 
 
Trials = 89 
 
 
Psychological Abstracts 
 
(smoking or tobacco) AND (cessation or quit) AND community = 79 
 
 
Sociological Abstracts 
 
 (( smoking or tobacco )and( cessation or quit )) and (( community )and( intervention or Program 
or plan )) = 48 
 
 
 
Cumulative Index for Nursing and Allied Health 
 
(smoking AND (cessation OR quit) ) AND community AND trial  = 36 
 
 
 
1237 unduplicated records 
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Appendix B 
Sample Review Forms/ 
Quality Rating Forms 
 
 Title Abstraction Form 
 
1. Original research (no editorials, letters to the editor) published in English after 1980 or 
a Cochrane review?  
Yes 
No 
Cannot determine  
 
 
2. Study located in any of the following countries: USA, Canada, United Kingdom, 
Western Europe, Australia, New Zealand  
Yes 
No 
Cannot determine  
 
 
3. Addresses one or more of the following (check all that apply):  
Population and Community based interventions for preventing tobacco use (KQ1) 
Strategies for increasing consumer demand for and use of individually oriented 
cessation treatments (KQ2) 
Strategies for increasing the implementation of population-level cessation strategies 
(KQ3) 
Effects of smokeless tobacco product marketing and use on population harm (KQ4) 
Effectiveness of interventions in populations with co-morbidities and risk behaviors 
(KQ5) 
Future research (KQ6) 
Cannot determine by the title or abstract 
None of the above  
4. Study design is one of the following:  
RCT (n>30) 
RCT (n=?) 
Meta-analysis 
B-1 
  
Observational Study (n=?) 
Observational Study (n>100) 
Case series 
Case report 
Cannot be determined 
Observational Study (n<99) 
Model or simulation study 
None of the above designs (Flag this response)
Cochrane systematic review  
5. If an RCT is excluded because of small sample size check here:  
Yes  
 
 
6. Use for background ? If Yes, check here and flag article.  
Yes  
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 Full Text Review Form 
1. Is this article   
a) referenced in a systematic review, or an editorial or comment? 
b) Cochrane systematic review or meta analysis? 
Yes 
No  
 
 
2. Study is located in any of the following countries:  
 USA, Canada, United Kingdom, Western Europe, Austrailia, New Zealand  
Yes 
No  
 
 
3. The study is one or more of the following:  
KQ1 - Population and community based interventions for preventing tobacco use in 
adolescents and young adults (RCTs published Jan 2000 & later only) or refers to 
tobacco industry and product restriction (1980 to present) 
KQ2 - A 6mo or longer intervention designed to increase the number of tobacco 
users (i.e. adults/diverse pops) who seek individually-oriented treatments or 
increase use of proven intervention strategies {i.e., counseling, behavorial, & 
Pharmo} (published Jan 1999 & later only) 
KQ3 - A 6 mo or longer study of strategies to increase the implementation & use of 
proven pop-level tobacco cessation interventions, particularly those in communities 
& healthcare settings (published Jan 1999 & later only) 
KQ4 - Influence of smokeless tobacco marketing on initiation & use, and the effects 
on population harm 
KQ5 - 6 mo or longer study of effectiveness of cessation interventions in pops with 
co-morbidities & risk factors 
KQ6 - Future research 
None of the above  
4. Study design is one of the following:  
RCT (n>30) 
B-3 
 Cohort Study (n>100) - Smokers & non-smokers followed over time to compare 
outcomes 
Case Control (n>100) - Subjects who have a certain condition are compared with 
people who don't 
Cross Sectional (n>100) - Like case-control studies, but more than two categories 
(such as just "smoker" & "non-smoker")  
None of the above (please flag if meta-analysis or systematic review) 
Cochrane Systematic review or meta analysis  
 
 
5. If an RCT is excluded because of sample size <30, please check here and flag:  
Yes  
 
 
6. Use for background?  If yes, please check & flag (write background in flag box)  
Yes 
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 Abstraction Form for Systematic Review or Meta-analysis 
 
1. Is this a systematic review of meta-analysis?  
Systematic Review 
Meta-analysis  
 
 
2. Author et al, date  
 
  
3. Geographic Area  
United States 
Canada 
United Kingdom 
Western Europe 
Australia 
New Zealand  
 
 
4. Funding Source  
 
  
5. Aim of Review  
 
  
6. Time Period Covered  
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7. Inclusion Criteria  
 
 
8. Population  
 
 
9. Characteristics of studies (Interventions)  
 
 
10. Method of Review  
 
 
11. What studies are included in the Meta analysis? 
 
    
12. Study Design  
 
 
13. Main Results  
 
 
14. Adverse Events  
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 No 
Yes 
Not Applicable   
 
 
15. Quality Rating  
Good 
Fair 
Poor 
 
Comments:   
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 Abstraction Form for Articles 
1. Abstractor Initials  
 
      
2. If the article should have been excluded in level 2 exclude and provide reason in text box...otherwise 
include.  
Exclude Enter Reason  
Include   
 
 
3. Key Question  
KQ1 
KQ2 
KQ3 
KQ4 
KQ5 
KQ6  
4. Author/Year  
 
      
5. Geographic Area  
United States 
Canada 
United Kingdom 
Western Europe 
Australia 
B-8 
 New Zealand  
6. Funding Agency  
    
7. Study Objective  
      
8. Population  
Adolescents,  
Young Adults, 
Adults, 
Men (only), 
Women (only), 
Pregnant women, 
African Americans, 
American Indians, 
Latino, 
Low SES, 
Describe 
 
9. Risk Behavior(s)  
  
  
10. Psychiatric condition(s)    
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11. Study Setting  
School-based 
Community-based 
Population-based 
Hospital 
Worksite 
Practice/provider settings 
Describe 
 
12. Study Design  
RCT with simple randomization  
RCT with systematic randomization  
RCT with stratified randomization  
RCT with cluster randomization  
Cohort Study 
Case Control 
Before and after study 
Time series 
Control trial 
Cross-sectional 
    
13. Describe study design  
  
14. Sampling Technique  
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15. Sample Size  
Total sample 
I1 
I2 
I3 
C1 
 
16. Inclusion Criteria:  
 
  
17. Exclusion Criteria:  
  
18. Intervention Methods  
Self-Help 
Individual Counseling by Health Professional 
Individual Counseling by non Health Professional 
Group Counseling 
Telephone Counseling 
Computer-based Program 
Social Support 
Video 
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 Media Campaign 
Pharmaceuticals 
Parent involvement 
Extra-curricular activities 
Classroom instruction 
Community-Activities 
Describe 
  
19. Intervention  
I1 
I2 
 
I3 
C1 
  
20. Method of Assessment  
   
21. Definition of Smoking  
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 Cigarettes 
Smokless tobacco
NR   
22. Baseline Data  
      
23. Statistical Analysis  
      
24. Data verification  
  
25. Results  
Dependent Variables 
Outcome measures 
 
26. Adequate Randomization  
Yes 
No 
NR   
 
 
27. Attrition Rates  
B-13 
  
28. Quality Rating  
Good 
Fair 
Poor 
Comments 
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 Quality Review Form for RCT Studies 
1. Is this a drug study?  
Yes 
No  
 
 
2. Was randomization adequate?  
Yes 
No 
Not Randomized 
NR  
 
 
3. Was allocation of concealment adequate?  
Yes 
No 
Not randomized 
NR  
 
 
4. Are the groups similar at baseline?  
Yes 
No 
NR  
 
 
5. Was the eligibility criteria specified?  
Yes 
No  
 
 
6. Was blinding adequate?  
Yes 
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 No 
Yes, but method not described
NR 
NA  
 
 
7. The outcome assessor (Researcher) was blind to the study participants.  
Yes 
No 
Yes, but method not described
NR  
 
 
8. Are participants blind to the study treatment?  
Yes 
No 
Yes, but method not described
NR  
 
 
9. Reporting of crossovers, adherence, and contamination.  
Yes 
 No  
10. Was attrition less then 25%?  Please report percentage.  
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 Yes 
No 
Not 
Reported 
Percentage 
 
11. Was the differential attrition less than 15%?  
Yes 
No 
NR 
Percentage 
 
12. Was a power analysis calculated for the study?  
Yes 
No 
NR  
 
 
13. Did the study use Intention To Treat analysis (impute missing responses)?  
Yes 
No 
14. Did post randomization of exclusions occur in the study?   
 
 
 
Yes 
No 
Unable to determine 
NR  
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15. What is the quality rating for this study? Please provide a rational in the comment 
box.  
Good 
Fair 
Poor 
comments: 
 
Quality Assessment for External Validity  
16. The control group standard of care was described?  
Yes 
No 
Comments: 
 
17. Is the study population representative of the population of interest?  
Yes 
No 
Comments: 
 
e next questions are for drug studies only. 
18. Non-bias selection?  
Quality Assessment for Adverse Events  
Th
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 Yes 
No 
Not clear  
19. Low overall attrition at follow-up (less than 25%)?  
Yes 
No 
Not clear  
20. The adverse events were pre-specified and defined?  
Yes 
No 
Comments:  
21. Ascertainment techniques (instruments) were non-biased and adequately described?  
Yes 
No 
Comments: 
 
22. Statistical analysis of potential confounders?  
Yes 
No 
Comments: 
 
23. Was there adequate duration of follow-up (at least 6 months)?  
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 Yes 
No 
Comments: 
 
24. What is the overall adverse event assessment quality?  
Good 
Fair 
Poor 
Comments: 
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 Quality Review Form for NonRCT Studies 
 
Study quality is evaluated using six categories (Descriptions, Sampling, Measurement, 
Analysis, Interpretation of Results, and other). Some problems with a study can be 
included under several of the categories. Use your best judgement to list the problems 
under the most appropriate category.  
Answer the questions based on the quality of execution of the study's design.  
Always provide comments for limitations.  
External Validity (Generalizability of the Study Results)  
1. Was the study population well described? (Study should describe both intervention and 
comparison populations and all relevent characteristics such as age, gender, SES)  
Yes 
No 
NR 
Limitations  
2. Was the intervention well described? (What was done?, how was it delivered?, who 
was targeted?, and where it was done?)  
Yes 
No 
NA 
NR 
Limitations:  
3. Did the authors specify the sampling frame or universe of selection for the study 
population?  
Yes 
No 
NR 
NA 
Limitations:  
4. Did the authors specify the screening criteria for study eligibility?  
Yes 
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 No 
NR 
NA 
limitations:  
5. Was the population that served as the unit of analysis the entire eligible population or a 
probability sample?  
Population 
Probability 
Sample 
Limitations:  
6. Are there other selection bias issues not identified above? (This might include a very 
low participation rate (or a high refusal rate), a volunteer sample (as opposed to a 
convenience sample selected by the investigators), an inappropriate control or 
comparison group, or extremely restricted sampling inappropriate for measuring the 
effectiveness of the intervetion being studied.  
Yes 
No 
NA 
Limitations:  
Internal Validity and Reliability  
7. Did the authors attempt to measure exposure to the intervention? (observation, 
interviews, self administered questionnaire, Record review, lab test)  
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 Yes 
No  
NA 
Limitations:  
8. Was the exposure variable valid?  (i.e., measured exposure in different ways, 
consistency checks for self-reports)  
Yes 
No 
NA 
limitations:  
9. Was the exposure variable reliable? (meausres of internal consistency were used, 
Cronbach's alpha, inter rater reliability)  
Yes 
No  
NA 
Limitations:  
10. Were the outcome and other (or predictor) variables valid?  
Yes 
No 
NA 
NR 
Limitations:  
11. Were the outcome and other (or predictor) variables reliable?  
Yes 
No 
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 NA 
NR 
Limitations:  
12. Did the authors conduct appropriate statistical testing by: (Select all that apply)  
B-24 
 Conducted statistical testing when 
appropriate.  
Reported which statistical test were 
used.  
Controlled for design effects in the 
statistical model.  
Controlled for repeated measures in 
populations that were followed over time.   
Controlled for differential exposure to 
the intervention.  
Used a model designed to handle mult-
level data when they included group-level 
and individual covariates in the model. 
 
Describe other problems with the data 
is. analys   
13. Was the attrition greater then 25% (if a survey, please write in the response rate)?  
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 Yes 
No 
NA 
Survey response rate  
14. Did the author assess whether the unit of analyses were comparable prior to exposure 
to the intervention?  
Yes 
No 
NA 
 
 
 
  
15. Did the author correct for controllable variables or institute study procedures to limit 
bias apporpriately (e.g., randomization, restriction, matching, stratification, or statistical 
adjustment)?  
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 Ye
s 
No 
NA 
 
 
 
  
16. Based on your overall impression of the study please rate quality of article. Important 
issues: who are the participants and how are they selected, are good instruments used to 
measure the results, are the results analyzed using appropriate methods. Finally can the 
results be replicated and are the outcomes generalizable...if not, this study may have a 
fatal flaw.  
Good studies (an outstanding study, one to two minor limitations) 
Fair studies (limitations but mostly minor limitations) 
Poor studies (the study had fatal flaws in sampling, assessment measures, or statistical 
analysis)  
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 Good 
Fair 
Poor 
Comment 
 
 
  
 
17. New Text Box Question  
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 Quality Review Form for Systematic Reviews and Meta-analysis 
1. Is this a systematic review or meta-analysis?  
Systematic Review 
Meta-analysis  
 
 
2. Is the systematic review based on a focused question of research?  
Yes 
No 
Not reported  
 
 
3. Are the eligibility criteria for the studies clearly described?  
Yes 
No 
Not reported  
 
 
4. Did the search strategy employ a comprehensive, systematic literature search?  
Yes 
No 
Not reported  
 
 
5. Did at least 2 people independently review studies?  
Yes 
No 
Not reported  
 
 
6. Did the authors use a standard method of critical appraisal before including studies? 
Yes 
No 
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 Not reported  
 
 
These questions are for meta-analysis only  
7. Was publication bias assessed?  
Yes 
No 
Not reported  
 
 
8. Was heterogeneity assessed and addressed?  
Yes 
No 
Not reported  
 
 
9. Did statistical analysis maintain trials as the unit of analysis?  
Yes 
No 
Not reported  
 
 
10. What is the quality rating for this study? Please provide rational for response.  
Good 
Fair 
Poor 
Rational: 
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Evidence Tables 
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Glossary 
#  number 
% percent 
2x 2 times or twice 
3x three times or thrice 
ACS American Cancer Society 
ALSAC American Lebanese Syrian Associated Charities 
ANOVA Analysis of Variance 
AOR adjusted odds ratio 
ASH Action on Smoking and Health database 
ASSIS Applied Social Sciences Index and Abstracts 
b regression coefficient 
b/w between 
BA Brief Advice 
C Control group 
Calif California 
CBT cognitive behavioral therapy 
CD cardiovascular disease 
CDC Centers for Disease Control 
C-DISC Clinical Data Interchange Standards Consortium 
Chi sq Chi square 
CI confidence intervals 
CNS central nervous system 
CO carbon monoxide 
COPD Chronic Obstructive Pulmonary Disease 
CSAHS Central Sydney Area Health Services 
CT computed topography 
CVD CD 
d.f. degrees of freedom 
DARE Drug abuse resistance education 
Dec December 
DHSS Department of Health and Social Services 
DSM-IV Diagnostic and Statistical Manual – Fourth Edition 
dz diagnosis 
et al. et alia 
FEV forced expiratory volume 
FP family physician 
FTQ Fagerstrom Tolerance Questionnaire 
FVC forced vital capacity 
g grams 
G Group 
GEE generalized estimating equations 
GLIMMIX General Linear Model for Mixture Distributions 
GP general practitioner 
GSTM1 glutathione s-transferase, MU-1 
C-4 
HDRS Hamilton Depression Rating Scale 
HMO Health Maintenance Organization 
HPS health promoting schools 
HPS Health Promotion School 
hr(s) hour(s) 
HRSD Hamilton Rating Scale for Depression 
HS high school 
HSPP Hutchinson Smoking Prevention Project 
ICU intensive care unit 
IG immunoglobins 
ITT intent to treat 
kg kilogram 
LCS Lung Cancer Substudy 
LHS 1, 2, or 3 Lung Health Study 
LPN licensed practical nurse 
MA medical assistant 
mg milligram 
MI Motivational Interviewing 
mo(s) month(s) 
N number 
NA not applicable 
NCCTG North Central Cancer Treatment Group 
NCI National Cancer Institute 
ng/ml nanograms per millileter 
NHLBI National Heart, Lung, and Blood Institute 
NHS National Health Services 
NIAS National Institute Against Smoking 
NIDA National Institute on Drug Abuse 
NNS nicotine nasal spray 
NP nicotine patch 
NR not reported 
NRT nicotine replacement therapy 
NS not significant 
NSW New South Wales 
OR odds ratio 
P  p-value 
pg page 
ppm parts per million 
PTSD posttraumatic stress disorder 
RCT randomized controlled trial 
RN registered nurse 
RR relative risk 
RS Spearman’s Rank Correlation 
SAS statistical package 
SD standard deviation 
SEQ Self-Efficacy Questionnaire 
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SES socioeconomic status 
SI smoking intervention 
SLF Smoke Free Leitrim 
SLT social learning theory 
SPSS Statistical Package for the Social Sciences 
ST smokeless tobacco 
SE Standard error 
t time 
TN Tennessee 
TTM Transtheoretical Model 
txt treatment 
UCSF University of Calif San Francisco 
UK United Kingdom 
US US 
VA Veterans Administration 
v. versus 
w/ with 
WIC Women, Infants, and Children 
wk(s) week(s) 
Χ2 Chi sq 
yr(s) yr(s) 
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Evidence Table 1. Effective population-based interventions 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Ennett et al., 2001 
Geographic area: 
US 
Funding agency: 
National Institute on Drug 
Abuse 
Study setting: 
Population-based 
 
Research objective: 
To identify mediators through which the 
Family Matters Program influenced 
adolescent smoking and drinking 
Population: 
• Adolescents  
• 12 to 14 yr olds and their families  
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
Families had to have an adolescent age 12 
to 14 yrs old and live in contiguous 48 
states 
Exclusion criteria: 
NR 
Sampling plan: 
• Probability sample of families 
throughout 48 contiguous States of 
US entered into a randomized trial  
• Partcipants identified through 
random-digit dialing 
• Eligible families screened 
• Offered opportunity to participate in 
study and told that they had a 50/50 
chance of receiving Family Matters 
program 
• 1,316 adolescent–parent pairs 
agreed to enrolled in study 
• Pairs completed baseline interviews 
by telephone, matched w/ another 
pair by date and time of completion, 
and then randomly assigned either to 
receive Family Matters or to serve as 
controls 
Sample size: 
Total: 1,316 adolescent-parent pairs 
G1: NR 
C1: NR 
Definition of smoking: 
Cigarettes 
• Non-user: never smoked, not even a 
puff 
• User: smoked even a puff 
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Evidence Table 1. Effective population-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
w/ parents 
Intervention:  
G1: Family Matters 
consists of successive 
mailings 4 mailings over 
14 mos of 4 booklets to 
parents of 12- to 14-yr-old 
adolescents and telephone 
discussions b/w parents 
and health educators after 
each mailing 
C1: NR 
Method of assessment: 
3- and 12-month followup 
via telephone interview w/ 
parent/guardian and 
adolescent 
Baseline data: 
Fewer non-Hispanic 
Whites in G1 than in C1 
Statistical analysis:  
• Repeated measures 
logistic regression w/ 
GEE using a one 
sided tail test 
• Mediation analysis 
follows approach 
outlined by Baron and 
Kenny to assess 
whether extent to 
which change in 
behavioral outcomes 
as a result of Family 
Matters program is 
accounted for by 
change in proposed 
mediators 
Data verification: 
Self-report 
Dependent variables: 
• Smoking status 
• Global family 
mediators 
(supervision, support, 
communication and 
involvment) 
• Substance specific 
mediators (expected 
consequences, 
parental attitude, 
parental 
encouragement, 
parent substance use, 
rules about use, 
monitoring, availability, 
nonfamily influences) 
 
• Adolescents in C more than 
1.5 times likely to smoke at 
follow up than family matters 
group (OR = 1.59, P = 0.008, 
lower bound CI, 1.19) 
• Program parents significantly 
more likely to discuss peer and 
media influences (b = -.76,  
P < 0.01), set rules about 
smoking (b = -0.46, P < 0.01) 
• Non Hispanic white 
participants only, program 
parents significantly more 
likely to encourage their 
children not to smoke  
(b = -0.42, P < 0.01), 
improvements in parent 
involvement  
(b = -0.10, P < 0.05), and 
positive effect on adolescent’s 
intentions to smoke (b = -0.15, 
P ≤ 0.01) 
Mediating effects for full model: 
stricter parent supervision (b = 
0.16, P < 0.01) and decreased 
parental use of tobacco (b = 
0.60, P < 0.01) 
Expected consequences and 
intention to use (b = 1.82, and b 
= 0.85, P < 0.01) decreased 
smoking 
Quality rating: 
Fair 
Comments: 
• No description of 
control 
intervention 
• Sample size for 
G1 and C1 NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
26%  
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Evidence Table 1. Effective population-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Thomson et al., 2004 
Geographic area: 
US 
Funding agency: 
NCI, Flight Attendant 
Medical Research Institute 
Study setting: 
Population-based 
 
Research objective: 
To test whether community-level youth 
access ordinances reduce adolescents' 
perceived access to tobacco, purchase 
attempts, and tobacco use 
Population: 
• Adolescents, 12 to 17 yrs 
Study type: 
Cross-sectional 
Describe study design 
• Representative sample of youth from 
across Massachusetts 
Inclusion criteria: 
• Age 12 to 17 
• Resident of Massachusetts 
• Parental consent 
• Youth assent 
Exclusion criteria: 
• Youth report of resident town disagreed 
w/ ZIP code and phone exchange 
indicators 
• Towns having no identified youth 
Sampling plan: 
• University of Massachusetts obtained 
a statewide random sample of 
households by random-digit dialing  
• Interview conducted w/ an adult 
resident to collect demographic data 
• Requested permission to interview all 
youth in household b/w ages 12 to 17 
yrs 
• Screen interviewers completed 66% 
of sample and 6,006 eligible youths 
identified 
Sample size: 
• Total: 3,831 
Definition of smoking: 
Cigarettes 
• Ever smoker: smoked or puffed 
cigarette in lifetime 
• Current smokers: smoked at least 
one cigarette inpast 30 days 
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Evidence Table 1. Effective population-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Parent involvment 
• Implementation of state 
wide youth tobacco access 
ordinances 
Intervention:  
G1: Community-level 
tobacco ordinances 
C1: NA 
Method of assessment: 
Phone survey 
 
Statistical analysis:  
X2uare 
GEE 
Data verification: 
Self-report 
Dependent variables: 
• Youth perceived access 
to tobacco 
• Attempts to purchase 
tobacco 
• Tobacco use  
Baseline data: 
White: 78%  
HispaniC1: 9%  
Other: 13% 
• 37% of youth perceived easy 
access to purchase tobacco 
• Less likely to perceive easy to 
purchase w/ ban on free displays 
AOR = 0.6, 95% (CI 0.5-0.9; P = 
0.007) 
• Youth reported easy access in 
towns that required tobacco 
vendors to have a license OR = 
1.3, 95% (CI 1.1 – 1.5, P = 0.009) 
• Increased perceived access 
associated w/ being older (P < 
0.0001) and male, (P ≤ 0.002) 
• 33% of 512 youth who smoked a 
cigarette in past 6 mos reported 
purchasing cigarettes 
• Result associated w/ bans on free 
samples and single cigarette sales 
in unadjusted model only 
• Attempts to purchase cigarettes: 
AOR = NS for all ordinances 
• Tobacco use: NS in adjusted 
model 
Quality rating: 
Fair 
Comments: 
Strengths: accounted 
for clustering in 
analyses 
Limitations: moderate 
participation rate; 
generic data on 
ordinance 
enforcement; cross-
sectional data 
Adequate 
randomization: 
NR 
Attrition rate: 
76% of eligible youth 
had parental consent 
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Evidence Table 2. Effective school-based interventions 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Ausems et al., 2004 
Geographic area: 
Western Europe 
Funding agency: 
European Commission and 
the Dutch Cancer 
Foundation  
Study setting: 
School-based  
 
Research objective: 
To compare effects on smoking prevention 
among Dutch first grade vocational school 
children using a newly developed computer-
tailored (personalized messages/letters) 
out-of-school program, an existing in-school 
program, and a combined approach 
including both in-school and out-of-school 
programs 
Population: 
• Adolescents  
• Vocational school children in the 
Netherlands  
Study type: 
• RCT w/ cluster randomization  
• Six out of 8 area health departments 
agreed to participate, and within these 
areas local vocational schools invited to 
participate 
Inclusion criteria: 
Dutch vocational schools 
Exclusion criteria: 
NR 
Sampling plan: 
• 19 schools already participating in 
Healthy Schools and Stimulant 
Program  
• Randomly assigned within regionally 
defined blocks to in-school and out-of 
school conditions 
• Remaining 17 schools randomlly 
assigned to out-of school or control 
conditions 
Sample size: 
G1: 9 schools 
G2: 8 schools 
G3: 10 schools 
C1: 9 schools 
Definition of smoking: 
Cigarettes 
• Never-smokers: students who have 
never smoked even one cigarette or a 
puff of one 
• Non-current smokers: students who 
have smoked in past, but not during 
past month 
• Current smokers: students who have 
smoked during past month 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Computer-based program 
• Classroom instruction 
• Computer generated 
letters 
Intervention:  
G1: In-school intervention:  
• Three lessons, each 
lasting about 50 min, 
student and teacher 
manuals available 
• Each lesson consisted of 
general introduction by 
teacher, reading text in 
workbook, classroom 
discussion, workbook task 
and additional task that 
summarized main points of 
lesson  
• First lesson explained 
ingredients of tobacco, 
and physical and mental 
reactions of smoking, 
while second discussed 
norms concerning 
smoking, and third 
emphasized pressures to 
smoke and skills that are 
helpful in resisting 
cigarettes 
 
Statistical analysis:  
• All effect analyses done 
separately for posttests 
1–2–3 
• Since running large 
regression models w/ 
MIXOR might cause 
problems, model 
reduction first applied, 
using SPSS 9.0 to 
determine final models 
containing significant 
covariates and 
interaction terms for 
prediction of smoking at 
posttests 1–2–3 
Data verification: 
Self-reports 
Dependent variables: 
Smoking rates, based on 
both smoking initiation 
among never-smokers and 
smoking continuation 
among ever-smokers 
Baseline data: 
• Smoking behavior:  
• Ever smoking: 59.7% 
• Current smoking: 19.5% 
• Mean age (yrs): 13.1 
• Gender (%, male): 52.1 
• Origin (w/ both parents 
Dutch): 73.0% 
• Religious (adhering to a 
religion): 61.4%  
• Family composition (w/ 
two parents): 82.1% 
• Father’s occupation 
(paid job): 68.7% 
• Pocket money (%, > 6.8 
euro): 23.5  
 
• Twelve months after pretest 
(posttest 2), in-school 
intervention successful in 
preventing vocational school 
students from continuing to 
smoke, compared w/ students in 
control condition OR = 0.49; 95% 
CI 0.29–0.84 
• Eighteen months after pretest 
(posttest 3), tailored out-of-
school intervention successful in 
preventing smoking initiation, 
compared w/ students in control 
(OR = 0.42; 95% CI, 0.18–0.96) 
• Effect of combined approach not 
larger than sum of effects of in-
school and out-of-school effects. 
Quality rating: 
Fair 
Comments: 
• Refusal rate NR 
• Randomization 
description unclear 
regarding number 
of schools in txt 
groups 
• Out-of-school 
intervention poorly 
implemented (65% 
of personalized 
letters read by 
participants) 
Adequate 
randomization: 
Yes 
Attrition rate: 
School level  
• Posttest 1: 5.6%  
(2 schools) 
• Posttest 2: 8.3%  
(3 schools) 
• Posttest 3: 18.5% 
(NR) 
Student level: 
• Posttest 1: 17.3% 
• Posttest 2: 5.4%  
• Posttest 3: 24.6%  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Ausems et al., 2004 
(continued)  
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
G2: Out of school 
intervention:  
• Three tailored letters w/ 
smoking prevention 
messages, sealed in 
envelopes and mailed to 
students’ homes at 3-wk 
intervals; researchers 
signed letters and added 
telephone numbers; 
students’ pretest smoking 
behavior not disclosed in 
letters; to prevent 
arguments in students’ 
families, letters tailored to 
individual characteristics 
• Pretest questionnaire on 
attitudes, social norms, 
self-efficacy, smoking 
intention and smoking 
behavior used to create a 
database file containing 
personal information 
• Computer program 
combined database file w/ 
message file using 
decision rules that linked 
students’ answers to 
personal messages; all 
messages thus selected 
combined in a letter 
format; letters illustrated w/ 
a picture puzzle and 
several cartoons; and 
competition included 
where students could win 
one of two CD vouchers 
G3: Combination of in- and 
out-of-school interventions 
C1: Control 
Method of assessment: 
• Questionnaire for students 
at 6, 12 and 18 months  
• After a pretest, teachers 
questioned about 
effectiveness of process 
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Aveyard et al., 2001 
Geographic area: 
United Kingdom 
Funding agency: 
NR 
Study setting: 
School-based 
 
Research objective: 
To re-evaluate whether addition of a TTM-
based intervention to existing health 
education school curriculum would protect 
young people from becoming smokers and 
help those who smoked quit compared w/ 
unknown effect of existing health 
educationRe-evaluation employed different 
periods of followup and fully exploring 
effects of using an ITT analytical approach 
Population: 
• Adolescents, ages 13 to 16  
• Living in West Midlands, UK 
Study type: 
RCT w/ cluster randomization  
Inclusion criteria: 
Yr 9 student (age 13 to 14) in participating 
school, assented and parents consented 
Exclusion criteria: 
• Parent or student refusal 
• Smoking status could not be assessed at 
followup(s) 
Sampling plan: 
• Sampling description referenced from 
previous study (Aveyard et. al., 1999) 
• Once schools agreed to participate 
individuals randomly allocated to 
intervention or control 
• Arms balanced by ordering schools 
into five groups based on numbers of 
students in yr 9; allocated each 
school a number b/w 1 and n 
(maximum number in group) 
• Computer program generated n/2 
random numbers b/w 1 and n, and 
schools allocated to intervention 
• One school allocated to intervention 
dropped out after randomisation and 
before baseline questionnaires 
administered  
All Yr 9 students (aged 13 to 14) in 
participating schools invited to 
participate 
Sample size:  
G1: 4,125 
C1: 4,227 
Definition of smoking: 
Cigarettes 
• Regularly smoking at least one 
cigarette per wk 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis 
and Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Computer-based program 
• Video 
• Classroom instruction 
Intervention:  
G1: During Yr 9, received  
• Three whole class 
lessons and three 
interactive computer 
sessions (including video 
clips of young people 
discussing their smoking)  
• Followed by 
questionnaires assessing 
stages of change, 
smoking uptake or 
cessation 
• Feedback on results of 
questionnaire, counseling 
about how to move 
forward in stages, and 
feedback on progress 
over time points 
C1: Standard lessons on 
smoking as part of English 
national curriculum, possibly 
up to three additional 
lessons on smoking (already 
available from teaching 
resources), which included 
quizzes and group work on 
health effects of smoking 
and different methods of 
persuading someone to quit 
smoking, all unrelated to 
TTM; no data collected on 
receipt of information 
Method of assessment: 
Self-report questionnaire 
administered at baseline, 1 
yr and 2 yr followups 
 
Statistical analysis:  
• Random effects 
logistical regression 
• Logistical regression 
• Bivariate analysis, 
• Frequencies 
• Kappa assessment 
• Sensitivity analysis 
Data verification: 
Self-report 
Dependent variables: 
• Movement in stage of 
change 
• Smoking status 
Baseline data: 
• NR, but stated no 
large differences b/w 
groups in these 
predictors of smoking 
at baseline 
• Predictors included: 
smoking status, 
stage of change, and 
potential 
confounders, i.e., risk 
factors for smoking in 
future 
No evidence of change of stage 
at either 1 yr or 2 yr followup:  
G1 vs C1 
• 1 yr AOR = 1.13, 95% (CI, 
0.91 - 1.41); 
• 2 yr AOR = 1.25, 95% (CI, 
0.95 - 1.64) 
No change in regular smoking at 
either follow up:  
• G1 vs C1:  
1 yr AOR = 1.14,  
(95% CI, 0.93, 1.39) 
• 2-yr AOR = 1.06,  
(95% CI, 0.86, 1.31)  
Subgroup analysis by initial 
smoking status NS for benefit for 
prevention of smoking or 
smoking cessation 
Quality rating: 
Fair 
Comments: 
40% refusal rate; 
no details on 
baseline data; C 
exposure to other 
prevention 
programs not 
assessed 
Adequate 
randomization: 
Yes 
Attrition rate: 
Yr 1:  
G1: 11%  
C1: 10.7%  
Yr 2:  
G1: 14% 
C1: 16.9%  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Brown et al., 2002 
Geographic area: 
Canada 
Funding agency: 
NHLBI  
Study setting: 
School-based 
 
Research objective: 
To evaluate an extracurricular HS tobacco 
control intervention developed by teachers 
and students 
Population: 
• Adolescents 
• Cohort followed from 7-8th grade through 
9-10th grade 
Study type: 
• RCT w/ cluster randomization and paired-
matching 
• Matched pairs prior to randomization 
• Randomized within pairs to Intervention 
and Cs 
Inclusion criteria: 
• School board participated in prior 
elementary school smoking prevention 
study 
• At least 30 students from elementary 
school cohort projected to attend HS 
Exclusion criteria: 
NR 
Sampling plan: 
30 high schools 
Matched pairs prior to randomization by: 
• Size of school 
• Number of students projected to 
attend who participated in an 
elementary school study 
• Proportion of cohort students from 
elementary school study control 
condition 
Sample size: 
G1: 1,563 
C1: 1,465 
Definition of smoking: 
Cigarettes 
• Experimental smoker: smoked less 
than once a wk 
• Regular smoker: smoked weekly 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis 
and Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Extra-curricular activities 
• Mobilization of staff and 
students to involvement in 
anti-smoking activities 
Intervention:  
G1: Extracurricular 
activities: Quit and win 
contests, poster contests, 
displays, health fairs, 
smoking surveys 
• Average of 3.8 
intervention activities in 
9th grade and 3.5 
activities in 10th grade 
• A teacher facilitated 
students, staff, and 
community members in 
planning and 
implementing prevention 
and cessation activities 
tailored to each 
intervention school to 
build committment and 
strengthen not smoking 
as a school social norm 
• Research staff provided 
consultation, conducted 
semiannual workshops for 
teachers and student 
leaders, developed 
resources for 
dissemination to all 
intervention schools, 
produced newsletters, 
and provided a $1000 per 
school annual budget 
C1: Usual care, details NR 
Method of assessment: 
Surveys completed by 
cohort at end of their 9th 
and 10th grade yrs; data 
collectors blind to txt status 
 
Statistical analysis:  
Cluster-randomized 
designs (as discussed 
in Donner) and applied 
a procedure that uses a 
variance term 
appropriate to 
randomization of 
schools (Liang) 
Data verification: 
• Bogus CO breath 
samples collected to 
enhance validity of 
self-reported 
smoking behavior 
• Data collected from 
absent students by 
mail or phone, but no 
bogus CO samples 
collected  
Dependent variables: 
• Social model risk 
score 
• Elementary school 
risk score 
• Smoking status 
Baseline data: 
Baseline data similar 
except proportion of HS 
students in elementary 
school study 
intervention cohort : 
G1: 84% 
C1: 75%  
(P = 0.10) 
Grade 10 smoking rates for 
never smokers:  
• Male regular smoking rates 
lower  
G1: 9.8% 
C1: 16.4% 
P = 0.02 
Smoking rates despite baseline 
status (NS):  
• Females: 
G1: 28.3% 
C1: 24.8% 
P = NR 
• Males:  
G1: 21.1% 
C1: 26.4% 
P = NR 
• Overall:  
G1: 24.9% 
C1: 25.7% 
P = NR 
Quality rating: 
Fair 
Comments: 
• Randomization 
technique 
incomplete 
• Control schools 
received “usual” 
care but not 
described 
• Some slight 
baseline data 
differences 
• Limited 
generalizability 
Adequate 
randomization: 
Yes 
Attrition rate: 
G1: 5% 
C1: 5%  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Crone et al., 2003 
Geographic area: 
Western Europe 
Funding agency: 
None 
Study setting: 
School-based 
 
Research objective: 
To assess effect of a peer pressure based 
antismoking intervention on adolescents in 
lower secondary (middle) school 
Population: 
• Adolescents  
• 1st grade of lower secondary education in 
the Netherlands (mean age 13) 
Study type: 
RCT w/ stratified randomization 
Inclusion criteria: 
• Adolescents in lower secondary 
education in the Netherlands 
Exclusion criteria: 
• If already participating in another study 
Sampling plan: 
Community Health Sources  
• 48 school identified;  
18 willing to participate; 
8 additional schools recruited  
• Schools stratified by size and use of 
national drug education  
• Randomized to intervention or control 
by toss of coin by independent 
person 
Sample size: 
G1: 14 schools, 1,444 students 
C1: 12 schools, 1,118 students 
Definition of smoking: 
Cigarettes 
• Smoker: all students who experiment 
w/ smoking or who smoke weekly or 
daily 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Video 
• Classroom instruction 
• Competition by NIAS 
that reward class w/  
< 10% smokers 
Intervention:  
G1: Three lessons on 
knowledge, attitudes, and 
social influence, followed 
by a class agreement not 
to start smoking or to stop 
smoking for next 5 months 
• Two extra video lessons 
on smoking and social 
influence were available 
as an optional extra 
during the 5 months  
• A competition 
administered by the 
NIAS that rewarded 
classes that had fewer 
than 10% smokers at 
the end of the 5 month 
period 
• A photography contest 
to pick best photos that 
expressed a non-
smoking class 
C1: Used drug prevention 
program normally given to 
students (which 
intervention schools used 
as well) 
• Given option to use 
intervention program 
one yr after study 
Method of assessment: 
Surveys administered at 
baseline, at end of 
intervention, and at 1 yr 
followup 
 
Statistical analysis:  
• Used multilevel 
techniques to account 
for clustering; 
• Compared intervention 
and Cs in terms of 
proportions of smokers 
before and after 
intervention and 
proportion who started 
smoking, controlling 
for differences at 
baseline 
• Performed ITT 
analysis 
Data verification: 
Self-report 
Dependent variables: 
Smoking status 
• Changes in attitude 
toward smoking 
• Perceived social 
influence 
• Self-efficacy 
• Intention to remain a 
smoker 
Baseline data: 
Males (%): 
G1: 49.5 
C1: 60.9 
P = < 0.001smoker 
Mean age: 13 yrs 
Proportion increase at end of 
intervention:  
• Nonsmokers:  
G1: 9.6% 
C1: 14.2% 
OR 0.61  
(95% CI, 0.41-.90) 
• Smokers:  
G1: 2.6% 
C1: 7.9% 
OR = 0.62  
(95% CI, 0.43 - 0.90) 
Perceived social pressure:  
• More likely to be smokers  
OR = 2.21  
(95% CI, 1.53 - 3.18) 
• Effects at one yr followup: NS 
Quality rating: 
Fair 
Comments: 
• Refusal rate 
(62.5%) 
• Not generalizble 
• Significant 
differences in 
baseline data 
• Very high 
attrition but used 
ITT 
Adequate 
randomization: 
Yes 
Attrition rate: 
Schools:  
Overall attrition: 
11.5% (3/26) 
G1: 7.1% (1/14)  
C1: 16.7% (2/12) 
Student attrition:  
Overall: 63.3% 
(1,621/2,562)  
G1: 61.4% 
(887/1,444)  
C1: 63.9% 
(714/1,118) 
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Ellickson et al., 2003 
Geographic area: 
US 
Funding agency: 
NIDA, the BEST Foundation 
for a Drug-Free Tomorrow; 
the Conrad N. Hilton 
Foundation 
Study setting: 
School-based 
 
 
Research objective: 
To evaluate revised Project ALERT drug 
prevention program across a variety of 
Midwestern schools and communities 
Population: 
• Adolescents, 7th and 8th graders in 
South Dakota (Urban and rural 
communities) 
Study type: 
RCT w/ stratified randomization  
Inclusion criteria: 
• Middle schools in South Dakota  
• Parental consent obtained 
Exclusion criteria: 
NR 
Sampling plan: 
• 48 school clusters (high schools and 
their feeder middle schools) 
• Schools organized in 3 strata by 
community size and type (city, town, 
rural) 
• Blocks of school clusters consisted of 
3 clusters from same stratum located 
in same geographic region of state., 
within each block, 1 school cluster 
randomly assigned to each 
experimental condition 
• Results are combined through 8th 
grade for this study w/ one C 
Sample size: 
G1: 34 middle schools, 2,553 students 
C1: 21 middle schools, 1,723 students 
Definition of smoking: 
Cigarettes 
• Cigarette use: ever, past month, and 
weekly 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
Classroom instruction 
Intervention:  
G1: 11 lessons in 7th 
grade and 3 lessons in 8th 
grade that, using 
interactive teaching 
methods, they sought to 
change students' beliefs 
about drug norms and 
social, emotional, and 
physical consequences of 
using drugs, to help 
students identify and resist 
pro-drug pressures from 
parents, peers, media, and 
others, and to build 
resistance self-efficacy; 
followed by booster 
lessons in 9th and 10th 
grades 
G2: 11 lessons in 7th 
grade and 3 lessons in 8th 
grade that, using 
interactive teaching 
methods, they sought to 
change students' beliefs 
about drug norms and 
social, emotional, and 
physical consequences of 
using drugs, to help 
students identify and resist 
pro-drug pressures from 
parents, peers, media, and 
others, and to build 
resistance self-efficacy; 
not followed by any 
booster lessons 
C1: Did not receive 
experimental program; 
schools could continue 
other prevention curricula 
already in place 
Method of assessment: 
Students completed 
surveys at baseline and 18 
months later 
 
Statistical analysis:  
• Adjusted for multiple 
baseline covariates, 
including covariates 
for school geographic 
location and 
enrollment size to 
account for blocking 
• Used Bayesian model 
to impute missing data 
for covariates; a 
generalized estimating 
equation that assumed 
a linear model for 
natural logarithm of 
the odds of use and 
constant correlation 
among responses 
from students from 
same schools used to 
account for possible 
intraschool correlation 
Data verification: 
Self-reported smoking 
status validated by 
assessing salivary 
cotinine levels for a 
random subsample of 
654 students 
Dependent variables: 
Cigarette, marijuana, and 
alcohol use; beliefs 
about consequences, 
prevalence and 
expectations of use, self-
efficacy 
Baseline data: 
• Non-white: 12.5% 
(largely Native 
American) 
• Female: 50% 
• Students in C1 less 
likely to be White and 
more likely to have 
used marijuana than 
students in G1 and G2 
At 18-month followup, cigarette 
use in the past month:  
• Baseline non-users:  
G1+G2:8.6% 
C1: 11.1% 
P = < 0.01 
• Baseline experimenters: 
G1+G2:28.9% 
C1: 36.6% 
P = < 0.05  
• Baseline users:  
G1+G2:56.8% 
C1: 70.8% 
P = < 0.05 
At 18-month followup, weekly 
cigarette use: 
• Baseline non-users: 
G1+G2:4.0% 
C1: 6.6% 
P = < 0.05 
• Experimenters:  
G1+G2:18.0% 
C1: 23.5% 
P = < 0.05 
• Users:  
G1+G2:45.1% 
C1: 56.0% 
P = < 0.10 
Quality rating: 
Fair 
Comments: 
• Slight baseline 
differences but 
controlled for in 
analysis 
• Clear description 
of school 
assignment 
• Possible 
disruption of 
randomization 
process 
Adequate 
randomization: 
Yes 
Attrition rate: 
9%  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Josendal et al 2005 
Geographic area: 
Western Europe 
Funding agency: 
Norwegian Cancer Society 
Study setting: 
School-based 
 
Research objective: 
To evaluate the BEsmokeFREE school-
based, smoking-prevention program for 
adolescents in Norway 
Population: 
• Adolescents 
• Norwegian 7th, 8th , and 9th grade (mean 
age 13) 
Study type: 
• RCT w/ cluster randomization  
Inclusion criteria: 
After being sampled by technique 
described, the school had to agree to 
participate 
Exclusion criteria: 
NR 
Sampling plan: 
• Nationally representative sample of 
99 secondary schools from a list of all 
secondary schools in Norway 
• Schools sorted by ascending postal 
code number, every 11th school 
included in study; schools allocated to 
groups by investigators choosing a 
random number b/w 1 and 44 
• Starting w/ that number, every 44th 
school selected for C and next three 
schools on list of comparable size (+/- 
10%) allocated to three intervention 
groups 
Sample size: 
G1: 25 schools, 1,125 students 
G2: 25 schools,  933 students 
G3: 25 schools, 1,005 students 
C1: 25 schools, 1,092 students 
Definition of smoking: 
Cigarettes 
• Smokers: daily smokers, and weekly 
smokers 
• Nonsmokers: smoking less than once 
a wk, and not smoking at all 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Video 
• Parent involvment 
• Classroom instruction 
Intervention:  
G1: Intervention 
administered by teachers 
and other staff at school 
• Given to students in 
grades 7 and followed 
cohort through 7, 8, 9 
grade 
• Number of hrs of 
intervention: grades 7 thru 
9 were 8, 5 and 6 hrs, 
respectively 
• Classroom instruction 
contained non-traditional 
school activities such as 
video, games, and group 
work 
• During grade 8 
adjustments to intervention 
were requested by 
students and teachers 
• In grade 9, students 
developed and carried out 
and evaluated their own 
campaign to promote a 
smoke free lifestyle among 
the 7th graders  
• Classroom curriculum, 
teacher in-service course, 
and parental involvement 
G2: Same as G1 Classroom 
curriculum and parental 
involvement but teacher did 
not receive in-service 
training on intervention 
G3: Same as G1 Classroom 
curriculum w/ teacher in-
service course but no parent 
involvement 
C1: Education on smoking 
and health about half the 
number of hrs as intervention 
Method of assessment: 
Surveys administered in 
classroom by teachers at 
end of each academic yr 
(7th, 8th, and 9th grades), 
then mailed to evaluators. 
 
Statistical analysis:  
Multilevel, multiple logistic 
regression analyses used 
to examine odds of 
smoking among students in 
intervention groups 
compared w/ students in 
C1, adjusted for gender 
and smoking habits at 
baseline 
 
Significance tested w/ 
Pearson's Χ2, corrected for 
design effect; correction 
implies chi sq value 
converted to an F-value w/ 
number of d.f. that may 
deviate from integer values
Data verification: 
Self-report 
Dependent variables: 
• Frequency of smoking 
• Number of cigarette hrs 
• Number of cigarettes 
smoked per wk 
• Use of cannabis 
• Frequency of cannabis 
use 
Baseline data: 
Baseline data reported but 
limited to smoking 
frequencies 
Mean age: 13 yrs 
Proportion of smokers higher in C1 
vs G1 for 3 followup yrs: 
• 1995: F(d.f. = 2.61; 125.49) = 
5.66; P < 0.01 
• 1996: F(2.34; 114.46) = 7.19;  
P < 0.001 
• 1997: F(2.39; 112.42) = 4.05;  
P < 0.05 
In G2 and G3, proportion of 
smokers on all followup occasions 
higher than G1 but lower then C1  
• 1995: F(d.f. = 9.74; 886.65) = 
2.84; P < 0.01 
• 1996: F(7.87; 739.55) = 3.98 
P < .001 
• 1997: F(6.00; 485.98) = 2.46;  
P < .05 
Odds of becoming a smoker during 
intervention period statistically 
lower in G1 compared to C1:  
• Daily smoking (Wald’s 9.81, d.f. 
= 3, P = 0.02) 
• Weekly smoking (Wald’s 15.65, 
d.f. = 3, P = 0.0001) 
• Any smoking (Wald’s 16.54, d.f. 
= 3, P = 0.0001) 
Quality rating: 
Good 
Comments: 
• Study design and 
randomization 
technique clearly 
described 
• Intervention 
theoretically 
anchored; 
description of 
scales reported in 
referenced article 
• Explored attrition 
by surveying drop 
outs 
Adequate 
randomization: 
Yes 
Attrition rate: 
• G1+G2+G3: 11.2%
C1: 5.8% 
• Smokers more 
likely to drop out 
than non-smokers  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Perry et al., 2003 
Geographic area: 
US 
Funding agency: 
NIDA  
Study setting: 
School-based 
 
 
Research objective: 
To evaluate effect of middle and junior HS 
D.A.R.E. and D.A.R.E. Plus programs on 
drug use and violence 
Population: 
• Adolescents, 7th and 8th grade 
• Junior High Schools and communities in 
Minneapolis-St Paul region, Minnesota 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
Minnesota school district, 7th graders in Fall 
1999 
Exclusion criteria: 
NR 
Sampling plan: 
• Targeted Minnnesota school districts 
w/ schools w/ 7th grade populations 
of at least 200 
• 24 Junior high schools matched on 
SES, drug use and size; schools 
randomly assigned to 1 of 3 
conditions DARE only, DARE Plus, or 
C 
Sample size: 
G1: 8 schools; 2226 students 
G2: 8 schools; 2221 students 
C1: 8 schools; 1790 students 
Definition of smoking: 
NR 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Parent involvment 
• Extra-curricular activities 
• Classroom instruction 
• Community-activities 
Intervention:  
G1: D.A.R.E. middle and 
junior HS curriculum 
• 10 sessions taught by 
police officers in 1999-
2001 
G2: D.A.R.E curriculum 
and D.A.R.E. Plus 
program in 1999-2001:  
• Classroom sessions, 
peer led, parent 
involvement 
• Community leader 
involvement program 
consisting of extra 
curricular anti-smoking 
activities in and out of 
school, including 
neighborhood activities 
to address 
neighborhood issues 
related to drug use and 
violent behavior 
C1: Delayed program: 
Schools could receive 
D.A.R.E. Plus programs in 
2001-2002, after final 
followup 
Method of assessment: 
Self-administered 
questionnaire 
 
Statistical analysis:  
Growth curve analysis; 
3-level linear, random-
coefficients model 
Data verification: 
Self-report 
Dependent variables: 
• Use of cigarettes, 
alcohol, and 
marijuana; multidrug 
use; violent behaviors; 
expectations 
concerning drug use, 
perceived access/offer 
of drugs, parental 
rules and 
communication about 
drugs 
• Outcome expectations 
about tobacco 
Baseline data: 
Male: 51.6% 
White: 67.3% 
African American: 7.5%  
Asian American: 12.7% 
HispaniC1: 3.6%  
American Indian: 4.0%  
Mixed or other: 4.9% 
Using growth curve analysis: 
D.A.R.E. Plus less likely than 
control to show an increase in 
current smoking for boys 
G2: (.28) std = 0.05 
C1: (.31), std = 0.05  
D.A.R.E. Plus less likely than 
D.A.R.E. curriculum alone to 
show an increase in tobacco use 
behavior and intentions. 
G1: (.95), std = 0.11  
G2: (.68), std = 0.11 
C1: (.96), std = 0.12  
NS outcomes for females 
Quality rating: 
Fair 
Comments: 
• Randomization 
and sampling 
technique 
incomplete 
• No baseline 
comparison data 
Adequate 
randomization: 
No, group-
randomization 
method NR; exactly 
8 schools per 
intervention 
Attrition rate: 
• 16% overall 
• Minimal 
differential 
attrition per 
authors  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Schofield et al., 2003 
Geographic area: 
Australia 
Funding agency: 
National Health and Medical 
Research Council 
(Australia); Hunter Centre 
for Health Advancement 
Study setting: 
School-based 
 
 
Research objective: 
To determine whether HPS intervention 
program led to lower smoking uptake and 
improved knowledge and attitudes among a 
cohort of students, and to examine factors 
independently predicting posttest smoking 
status 
Population: 
• Adolescents  
• 7th -8th grade cohort followed 2 yrs to 
grades 9-10 in New South Wales 
Study type: 
• RCT w/ cluster randomization (cohort 
prepost design) 
• Students followed over two yr period; 
cohort prepost design used to evaluate 
intervention effectiveness 
Inclusion criteria: 
Students in Yr 7-8 at one of participating 
schools who gave assent, whose parent(s) 
gave active consent, and whose pre and 
posttests could be matched for comparison 
Exclusion criteria: 
NR 
Sampling plan: 
• Intervention randomly allocated to 
selected secondary schools 
• Randomly selected 24 of 31 
secondary schools in Hunter and 
Taree schools districts of New South 
Wales 
• 22 of 24 schools participated, w/ 12 
schools assigned to intervention, 10 
to control 
Sample size:  
G1: 1,007 
C1: 845 
Definition of smoking: 
Cigarettes 
• Smoking status at posttest: having 
smoked any amount of cigarettes 
within past 7 days 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Group counseling 
• Social support 
Intervention:  
G1: Each school had 
liaison office responsible 
for introducing minimum 
set of actions and 
facilitating tailoring and 
implementation of the 
following actions:  
• Ensure curriculum 
covers smoking effects, 
distribute parent 
smoking pamphlet, 
implement school 
smoking policy, 
distribute letters to 
tobacco retailers, 
discussion group/survey 
w/ parents, followup 
action from discussion 
group, and training of 
SRC/peer leaders to 
deal w/ smoking issues 
• Schools also 
encouraged to take over 
other additional anti 
smoking activities of 
their choice 
C1: Control schools not 
offered any of the 
resources or actions to 
reduce smoking that 
intervention schools 
received, but if they 
requested assistance, 
project team offered 
support for other health-
related issues and 
promised smoking-specific 
support at completion of 
study period 
Method of assessment: 
Self-reported retrospective 
diary (of having smoked 
within past 7 days), as 
assessed via 
questionnaire 
 
Statistical analysis:  
Univariate analysis 
Bivariate analysis 
Multivariate analysis 
Logistic regression 
Data verification: 
Self-report 
Dependent variables: 
• Smoked in last wk 
• Smoking knowledge 
• Smoking attitudes 
towards schools 
Baseline data: 
Large variations in 
baseline smoking rates 
(11-33%) so smoking 
and school controlled for 
in regression (details 
NR)  
 
At pretest, smokers had:  
• Less positive attitudes 
than nonsmokers 
(mean for smokers: 
4.3; mean for non-
smokers 4.7, mean 
difference = 0.4, 95% 
CI-0.3, 0.5) 
• Fewer perceived 
negatives about 
smoking (smokers' 
mean: 3.6, non-
smoker's mean = 3.9, 
mean difference = 0.2, 
95% CI, 0.1, 0.3) 
Posttest results:  
Smoked in last wk: NS 
G1: 17.5% 
C1: 20.5% 
Crude OR for G1 = 0.82 (0.65, 
1.04) 
Maximum knowledge score:  
G1: 64% 
C1: 60% 
Prepost change: 
G1: 12%  
C1: 7%  
P = 0.001 
Smoking attitudes:  
NS at pre or posttest 
Solely among smokers (from 
combined groups), positive 
attitudes to smoking 
decreased from pretest to 
posttest (P = 0.01), but not 
among non-smokers 
Quality rating: 
Fair 
Comments: 
• Refusal rate: 40% 
• High attrition 
• Intervention not 
consistently 
implemented across 
schools, though 
high fidelity in 
implementing "key 
components" of 
intervention, 
authors mention 
potential 
contamination via 
control schools w/ 
personnel 
supportive of HPS 
intervention 
program, but no 
data to 
support/refute 
• Study properly 
addressed 
clustering issue 
through analytical 
methods 
Adequate 
randomization: 
Yes 
Attrition rate: 
G1: 48% 
C1: 52% 
(Authors mention 
more smokers than 
non-smokers lost to 
follow up)  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Share et. al., 2004 
Geographic area: 
Western Europe 
Funding agency: 
Europe Against Cancer 
Programme 
Study setting: 
School-based 
 
Research objective: 
To evaluate impact of a school-based 
intervention-SFL-which aimed to involve the 
community, increase tobacco knowledge, 
strenghthen refusal skills, and improve 
decision-making ability 
Population: 
• Adolescents, ages 13 to 15 
• Leitrim, Sligo, and Donegal County, 
Ireland students  
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• SLF program participants 
• Aged 9 to 10yrs attending 4th grade 
(1996-97) in North Western Health Board 
area (not defined) 
Exclusion criteria: 
NR 
Sampling plan: 
SLF program participant cohort 
matched w/ a C located in North 
Western Health Board area (not 
defined) 
Sample size: 
G1: 450 
C1: NR 
Definition of smoking: 
NR 
 
C-29 
Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
Classroom instruction 
Intervention:  
G1: Primary school phase: 
materials about smoking, 
healthy lifestyle, and 
growing up provided for 
classroom instruction; 
• Teachers determined 
order/timing of lessons; 
visits from health 
promotion staff,and yr 
end celebration;  
• Postprimary school 
phase: quizzes, 
competition, visits by 
health promotion staff, 
newsletter, website, 
peer education project, 
smoke free school 
buses campaign, and 
annual events day(no 
classroom materials 
provided) 
C1: NR 
Method of assessment: 
Self-report questionnaire 
at study's end 
(administered face to face 
in intervention group and 
11 control schools; 
"posted" (mailed) to other 
control schools) 
 
Statistical analysis:  
• SPSS 
• Pearsons chi sq 
• Spearman's Rank 
correlation 
Data verification: 
Self-report 
Dependent variables: 
• Smoking 
experimentation 
• Current smoking 
• Smoking knowledge 
• Attitudes about 
smoking 
• Family member 
smoking 
• Reasons for continued 
smoking 
Baseline data: 
Baseline data (i.e: at age 
9 to 10) NR 
Male 
G1: 52% 
C1: 45% 
Age 13: 
G1: 12% 
C1: 14% 
Age 14: 
G1: 72% 
C1: 77% 
Age 15+: 
G1: 16% 
C1: 9% 
Tried smoking: 
G1: 59% 
C1: 55% 
Current smoking:  
G1: 19% 
C1: 24% 
Females in C 2x as likely to 
smoke everyday and 50% more 
likely to currently smoke than 
females in intervention group, (P 
< 0.05) 
Feel grown if smoke: 
G1: 30% 
C1: 43% 
(P < 0.01) 
Don't mind if friends smoke:  
G1: 72% 
C1: 67% 
(P < 0.05) 
Family: correlation b/w student 
smoking experimentation and 
parent/sibiling smoking: 
• Mother (rs = 0.165, P < 0.01) 
• Father (rs = 0.172, P < 0.05) 
• Both parents (rs = 0.346,  
P < 0.01) 
• Brother (rs = 0.162, P < 0.01) 
• Sister (rs 0.277, P < 0.01) 
Quality rating: 
Poor 
Comments: 
• No information 
on selection of 
subjects from 
primary 
intervention 
• Unable make 
inferences from 
original baseline 
data because 
followup 
instrument not 
compatible 
• No reliability 
testing of 
instrument 
• No information 
on 
randomization, 
or C 
• No baseline data 
and analytical 
methods not well 
described 
Adequate 
randomization: 
NR 
Attrition rate: 
G1: 22% 
C1: NR  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Simons-Morton et al.,2004 
Geographic area: 
US 
Funding agency: 
NR 
Study setting: 
School-based 
 
Research objective: 
To examine associations b/w initial and 
continuing peer affiliation and parent 
influences and smoking stage progression 
Population: 
• Adolescents, 6th, 7th, and 8th graders 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• 6th grader in 1996 or 1997 at one of 7 
schools in un-named Maryland School 
District 
• Consent by parents 
Exclusion criteria: 
Special education students 
Sampling plan: 
• Seven middle schools (in 1 Maryland 
school district) recruited and 
randomized:  
o 3 to txt condition and 4 to control 
• Starting w/ 1996 school yr., 2 
successive cohorts of 6th-grade 
students recruited and followed 
through 9th-grade 
Sample size: 
Total: 3,039 at start, 1,320 final  
C1: NR 
Definition of smoking: 
Cigarettes 
• Never: no smoking in past 30 days or 
past 12 months + no intention of 
smoking in HS 
• 12-month smoker: smoking in past 12 
months but not in past 30 days 
• Recent smoker: smoking 1 to 2 times 
in past 30 days 
• Frequent smoker: smoking 3+ times 
in past 30 days 
• Intent to smoke: none in past 30 days 
or past 12 months but intent to smoke 
in HS 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Video 
• Classroom instruction 
Intervention:  
G1: The Going Places 
Program: parent education 
(materials sent home), 
school media, social skills 
curriculum (to increase 
school engagement and 
prevent multiple problem 
behavior such as 
substance use, 
aggression, and antisocial 
behavior) 
• 18 class sessions in 6th 
grade, 10 in 7th grade, 6 
in 8th grade 
C1: NR 
Method of assessment: 
• Students surveyed at 
beginning and end of 
6th grade, toward end 
7th & 8th grades, and 
beginning of 9th grade 
• Two trained proctors 
collected data; teachers 
not involved w/ survey 
Baseline data: 
NR 
 
Statistical analysis:  
LGC analysis (Curran, 
2000): structural 
equation modeling + 
hierarchical linear 
modeling 
Data verification: 
Self-report 
Dependent variables: 
• Background variable 
• Smoking 
• Friends w/ problem 
behaviors 
• Parenting practices 
 
Final sample:  
• White: 66%  
• Black: 25%  
• Other: 9% 
 
• Variance of intercept factor in 
linear LGC model 2.23 (SE = 
2.05; P < 0.001) indicating 
significant differences in 
tobacco use at beginning of 
6th grade 
• Variance of slope factor 0.289 
(SE = 0.038; P < 0.01) 
indicating significant 
differences in smoking stage 
progression over time 
• Path coefficients: intercept of 
adolescent smoking to slope of 
friends who smoke variable = 
0.31(P < 0.01) indicating 
adolescents at higher initial 
smoking stages had increased 
# of friends smoking over time 
• Path coefficient b/w parent 
involvement and adolescent 
smoking = -0.15, (P < 0.01) 
indicating parent monitoring 
and expectations overtime are 
negatively associated w/ 
smoking stage progression 
• Path coefficient directly leading 
from parent involvement (-.15) 
and indirectly to the slope of 
adolescent smoking stage (-
.46) through the slope of 
friends who smoke (.66) 
indicating that parenting 
practices overtime protect 
against smoking progression 
both directly and indirectly by 
limiting the adoption of friends 
that smoke P < 0.01 
Quality rating: 
Poor 
Comments: 
• Baseline data 
NR 
• C sample size 
NR 
• No txt vs 
comparison 
group data 
reported 
• 151 special 
education 
students 
excluded after 
assessment 1, 
suggested 
possibility of post 
randomization of 
exclusions 
Adequate 
randomization: 
NR 
Attrition rate: 
36.3%  
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Evidence Table 2. Effective school-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Unger et al., 2004 
Geographic area: 
US 
Funding agency: 
National Institutes of Health 
and the Calif Tobacco-
Related Disease Research 
Program  
Study setting: 
School-based 
 
Research objective: 
Determine whether a multicultural 
curriculum prevents initiation of smoking 
among middle school children at 1-yr 
followup 
Population: 
• Adolescents 
Study type: 
RCT w/ cluster randomization  
Inclusion criteria: 
Students participated if they and their 
parents provided active written consent 
Exclusion criteria: 
NR 
Sampling plan: 
Sixteen middle schools in Southern 
Calif randomly assigned to receive 
multicultural curriculum or standard 
curriculum (8 schools in each group) 
Sample size: 
G1: 1,040 students, 8 schools 
C1:  930 students, 8 schools 
Definition of smoking: 
Cigarettes 
• Smokers: trying smoking b/w 6th and 
7th grade 
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Evidence Table 2. Effective school-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
Classroom instruction 
Intervention:  
G1: Project FLAVOR (Fun 
Learning about vitality, 
origins, and respect) 
provided 8 weekly 
classroom sessions 
conducted by health 
educators that addressed 
smoking-related 
psychosocial concepts 
through activities such as 
role-playing, trivia games 
and art projects, relating 
these issues to values of 
several cultures, such as 
Asian Yin-Yang concepts, 
and telenovela (soap 
opera) role play 
C1: 8 weekly classroom 
sessions conducted by 
health educators that 
addressed smoking-
related psychosocial 
concepts through activities 
such as role-playing, trivia 
games and art projects, 
but without cultural 
references 
Method of assessment: 
Surveys at baseline and 1 
yr followup 
Statistical analysis:  
• X2 and ANOVA 
analyses assessed 
prevention 
equivalence of 2 
groups 
• Logistic regression 
used to examine 
attrition based on 
experimental 
condition, baseline 
smoking, and 
experimental condition 
x baseline smoking 
• Multi-level logistic 
regression w/ school 
as a random effect to 
control for intraclass 
correlation assessed 
effect of intervention 
on smoking initiation 
b/w sixth and seventh 
grades 
Data verification: 
Self-report 
Dependent variables: 
Smoking status 
Baseline data: 
• Groups similar at 
baseline 
• No significant 
differences in 
demographics or 
lifetime smoking 
prevalence b/w 
intervention and Cs 
• HispaniC1: 57% 
• Asian American: 27% 
• Other: 16% 
Initiation among never smokers 
(yr 1 followup):  
G1: 8% 
C1: 11% 
P = NR 
Among male, Hispanic, never 
smokers, OR of smoking 
intitation by 7th grade: OR = 0.49 
(95% CI, 0.27 -.88) 
Overall intervention effect NS: 
OR = 0.75 (95% CI, 0.48, 1.18) 
Quality rating: 
Fair 
Comments: 
• Randomization 
scheme NR 
• No ITT analysis 
Adequate 
randomization: 
NR 
Attrition rate: 
G1: 16.83% 
C1: 16.77% 
Higher among 
baseline ever 
smokers (22%) 
than never 
smokers (16%),  
P = < 0.05  
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Evidence Table 3. Effective provider-based interventions  
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Tyc et al., 2003 
Geographic area: 
US 
Funding agency: 
NCI, ALSAC  
Study setting: 
Practice/provider settings 
 
Research objective: 
To evaluate efficacy of a tobacco risk 
counseling intervention vs standard care for 
preadolescent and adolescent cancer 
survivors 
Population: 
• Adolescents who were cancer survivors 
age 10 to 18 (treated at St. Jude 
Children's Research Hopital, Memphis, 
TN) 
Study type: 
RCT w/ stratified randomization  
 
Inclusion criteria: 
• Between 10 to 18 yrs old 
• Survivor of pediatric cancer 
• Currently disease-free 
• At least 1 yr from completion of 
antineoplastic therapy at St. Jude 
Children's Research Hospital (TN) 
Exclusion criteria: 
Patients who had brain tumors (due to 
cognitive, functional impairments that often 
result from txt) 
Sampling plan: 
• Stratified RCT w/ patients who were 
pediatric cancer survivors treated at 
St. Jude Children's Research 
Hospital, Memphis, TN, currently 
receiving txt there  
• Recruited during outpatient visits 
• Asked to participate and told 
participation did not depend on 
smoking status 
• On enrollment patients randomly 
assigned (stratified by age, sex, race, 
and self-reported smoking status) 
• Randomization scheme proposed by 
Zelen (1974) 
Sample size: 
G1: 53 
C1: 50 
Definition of smoking: 
NR 
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Evidence Table 3. Effective provider-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Telephone counseling 
• Video 
Intervention:  
G1: Administered in single 
session w/ periodic 
reinforcement of tobacco 
goals by telephone 
• Educational video 
discussed short- and 
long-term physical and 
social consequences of 
tobacco use 
• Late effects risk 
counseling focused on 
potential chemotherapy 
and radiation txt related 
toxicities exacerbated by 
tobacco use and 
survivors’ increased 
vulnerability to tobacco-
related health risks 
relative to their healthy 
peers 
• Goal setting involving 
tobacco abstinence or 
cessation depending on 
survivor’s smoking 
status 
• A physician feedback 
letter that reinforced 
antitobacco message 
delivered in intervention 
• Tobacco literature and 
followup telephone 
counseling at 1 and 3 
months after 
intervention 
• Face-to-face counseling 
component of 
intervention conducted 
by a master’s level 
psychologist over a 50- 
to 60-minute period, and 
followup telephone 
counseling conducted 
by a research nurse 
trained by V.L.T.  
 
Statistical analysis:  
• Descriptive 
• Multivariate analysis of 
variance,  
• Repeated measures  
• Mixed-model analysis 
of variance and 
regression 
Data verification: 
Self-report 
Dependent variables: 
• Knowledge (of 
adverse 
consequences of 
tobacco use generally 
and for cancer 
survivors) 
• Perceived Vulnerability 
(to tobacco related 
health risks) 
• Intentions (I) (to use 
tobacco) 
• Perceived PPE 
Baseline data: 
Baseline demographic 
and questionnaire data 
collected for both groups 
w/ no significant 
differences b/w groups 
 
Mean K score: 
G1: 24 
C1: 22.7 
Mean PV score: 
G1: 35.9 
C1: 32.5 
I scores: 
G1: 7.8 
C1: 10.0 
P = 0.002 
No significant differences in PPE 
at 12 mos, nor in any of 
dependent variables at 6 months 
Quality rating: 
Fair 
Comments: 
• No psychometric 
validation of 
researcher-
designed scales 
to measure 
knowledge and 
perceived 
positive effects 
of tobacco 
• No verification or 
definition of 
tobacco use 
• Limited 
generalizability 
to primarily white 
cancer patience  
• Possible ceiling 
and floor effects 
on Knowledge 
and intention 
measures makes 
it difficult to 
access 
meaningful 
changes 
Adequate 
randomization: 
Yes 
Attrition rate: 
At 6 months:  
Overall: 30% 
(31/103)  
G1: 32.1% (17/53) 
C1: 28% (14/50) 
At 12 months:  
Overall: 21.5% 
(22/103) 
G1: 20.1% (11/53) 
C1: 22% (11/50) 
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Evidence Table 3. Effective provider-based interventions (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Tyc et al., 2003 
(continued) 
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Evidence Table 3. Effective provider-based interventions (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention delivered 
using scripted protocol 
tailored to patients’ 
individual responses to 
questions posed during 
intervention and individual 
goal setting. 
C1: Patients asked about 
their tobacco use and 
briefly advised about 
health risks associated w/ 
tobacco use; all tobacco 
users advised to stop and 
nonsmokers encouraged 
to continue to resist 
tobacco 
Method of assessment: 
Knowledge scale:  
• 25 true-false questions 
regarding adverse 
effects of tobacco use 
and w/ questions 
focused on increased 
risks of youth treated for 
cancer 
• 8-item scale measuring 
patients' perceptions of 
their vulnerability to 
tobacco-related health 
risks 
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Evidence Table 4. Multi-component interventions to increase the number of users who quit smoking 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Bauman et al., 2000 
Geographic area: 
US 
Funding agency: 
NIDA Grant  
Study setting: 
Population-based 
 
Study objective: 
To report effectiveness of a universal family-
directed program (Family Matters) for 
reducing/eliminating cigarette and alcohol 
use by adolescent users 
Population: 
Adolescents 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• In contiguous US state 
• Consent 
• Child age 12 to 14 yrs 
• Completion of baseline interview 
Exclusion criteria: 
NR  
Sampling plan: 
• Eligible parent-adolescent pairs 
matched (by date and time of baseline 
interview) then randomly assigned to 
either Family Matters or C 
• Random digit dialing and basic query 
used to identify families w/ 12- to 14-
yr old children 
Sample size: 
G1: 37 baseline tobacco users 
C1: 48 baseline tobacco users 
Definition of smoking: 
Cigarettes 
• Use on one or more days during past 
30 days 
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Evidence Table 4. Multi-component interventions to increase the number of users who quit smoking 
(continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
Intervention:  
G1: Family Matters:  
• Successive mailing of 4 
booklets and telephone 
discussion w/ health 
educator 2 wks after each 
mailing 
• Adult family members 
read booklets and do 15 
activities w/ adolescent 
• Booklet topics: (1) 
motivation, (2) family 
characteristics, (3) 
tobacco and alcohol 
variables,  
(4) variables outside 
family 
C1: NR 
Method of assessment: 
Telephone interviews at 3 
and 12 months 
postcompletion or dropout 
 
Statistical analysis:  
GEE method, one-tailed 
test (alpha 0.05), 
controlled for background 
variables. 
Data verification: 
NR 
Dependent variables: 
Smoking 30 days before 
interview 
Baseline data: 
Groups similar on all 
measures except txt had 
younger and fewer non-
Hispanic white participants 
Overall:  
12 yrs: 30.6% 
13 yrs: 35.3% 
14 yrs: 34.1% 
Male: 49% 
Non-Hispanic white: 73.4% 
In 2-parent home: 78.8%  
 
Among smokers:  
• 21.6%, 40.5%, and 
37.8% were 12,13, and 
14 yrs old respectively in 
txt 
• 10.4%, 29.2%, and 
60.4% were 12,13,and 
14 yrs old respectively in 
control 
• 35.1% male (txt) vs 
47.9% male (control);  
• 70.3% vs 95.8% non-
Hispanic white in txt vs 
control 
• 75.7% vs 68.8% in 2-
parent home in txt vs 
control 
Of 85 baseline smokers, 74 
completed followup at 3 months 
(62.2% still smoked) and 80 
completed followup at 12 months 
(66.3% still smoked) 
No statistically significant 
difference in tobacco use b/w 
control and txt for baseline 
cigarette users (OR = 1.42, lower 
bound CI, 0.57, P = 0.2846). 
Quality rating: 
Fair 
Comments: 
• Include only 
baseline users in 
analyses in order 
to focus on 
cessation 
• Only compare 
entire baseline 
groups to US or 
previous study 
population rather 
than each other 
• Used one-tailed 
tests 
• Attrition high 
among tobacco 
users 
• No biochemical 
measure of use 
• Small sample size 
Adequate 
randomization: 
No 
Groups not similar at 
baseline by age and 
race 
Attrition rate: 
14% overall; 40.5% 
among tobacco 
users in txt 
group(Control NR) 
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Evidence Table 4. Multi-component interventions to increase the number of users who quit smoking 
(continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Etter et al., 2004 
Geographic area: 
Western Europe 
Funding agency: 
Swiss National Science 
Foundation, the Swiss 
Cancer League, the Swiss 
Federal Office of Public 
Health, and the Health 
Authority of the Canton of 
Geneva 
Study setting: 
Population-based  
 
Study objective: 
To determine whether effects of a computer-
tailored smoking cessation program were 
maintained at 2-yr followup 
Population: 
Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• 18 to 60 yrs old 
• Resident of French-speaking Switzerland 
• More than an occasional smoker 
• Have a postal address 
Exclusion criteria: 
NR  
Sampling plan: 
• Baseline questionnaire sent to 20,000 
18-60 yr old residents of French-
speaking Switzerland, 3,124 agreed 
to participate in study 
• 2,934 randomized to txt or Cs 
Sample size: 
G1: 1,467 
C1: 1,467 
Definition of smoking: 
Cigarettes 
• 1 mo Abstinence: not smoking even a 
puff of a tobacco cigarette, cigar, or 
pipe in last 4 wks 
• 1 wk Abstinence: not smoking even a 
puff of a tobacco cigarette, cigar, or 
pipe in last 7 days 
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Evidence Table 4. Multi-component interventions to increase number of users who quit smoking (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
Self-help 
Intervention:  
G1: After baseline 
questionnaire:  
• Received 8-pg personal 
counseling letters 
written by a computer 
according to answers 
given by participants on 
a 62 item questionnaire 
• Received 2 16-pg 
booklets corresponding 
to their current stage of 
change and next stage 
of change 
• Two, four, and 12 mos 
after entering study, 
participants could 
answer tailoring 
questions again to 
receive new letter  
C1: After completing 
baseline questionnaire, C 
participants received a 
letter telling them that they 
were in C, and not 
contacted again until 6- 
and 23-mo followup 
surveys 
Method of assessment: 
Surveys at 7- and 24-mos 
postbaseline 
 
Statistical analysis:  
X2 to compare 
proportions; t-tests to 
compare means 
Data verification: 
NR 
Dependent variables: 
• Demographic 
characteristics 
• Stage of change 
• Level of tobacco 
dependence 
• Perceived drawbacks 
of smoking 
• Self efficacy 
• Use of self help 
strategies 
• Current use 
• Intention to use NRT 
Baseline data: 
Groups similar at 
baseline 
At 7 mo followup: 
1 mo abstinence rates:  
G1: 5.8% 
C1: 2.2% 
P = < 0.001 
1 wk abstinence rates:  
G1: 8.0% 
C1: 3.3% 
P = < 0.001 
At 24-mo followup: 
1 mo and 1 wk abstinence 
rates similar for both groups, 
differences NS 
Proportion of those who quit 
for at least 1 mo during study:  
G1: 30.9% 
C1: 24.7% 
P = < 0.001 
Proportion of those who used 
> 1 nicotine replacement 
product:  
G1: 24.9% 
C1: 20.8% 
P = < 0.008 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
NR 
Attrition rate: 
7-mo followup: 16% 
24-mo followup: 12% 
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Evidence Table 4. Multi-component interventions to increase number of users who quit smoking (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Lipkus et al., 2004 
Geographic area: 
US 
Funding agency: 
NCI grant  
Study setting: 
Community-based  
 
Study objective: 
To test efficacy of self-help materials w/ or 
without proactive telephone counseling to 
increase cessation among teen smokers. 
Population: 
Adolescents 
Study type: 
RCT w/ simple randomization  
• 2-arm randomized intervention trial 
•  
Inclusion criteria: 
• Age 15 to 18 
• Smoked a cigarette within last wk 
• Gave verbal consent 
• Obtained parental consent if < 18 yr 
Exclusion criteria: 
NR  
Sampling plan: 
• Teen smokers recruited from 11 
shopping malls and 1 amusement 
park in Southeastern US  
• Teens stratified on stage of readiness 
to quit, then randomized to (1)self-
help materials + video (C) or (2) self-
help materials + video + telephone 
counselors (experimental group). 
Sample size: 
G1: 193 
G2: 209 
Definition of smoking: 
Cigarettes 
• Smoked 1 or more within last wk 
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Evidence Table 4. Multi-component interventions to increase number of users who quit smoking (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
• Video 
Intervention:  
G1: Two self-help booklets 
by mail and 6 minute video 
and 3 telephone counseling 
sessions 
C1: Two self-help booklets 
by mail , 6 minute video, no 
telephone counseling 
Method of assessment: 
6-item revised Fagerstrom 
Nicotine Tolerance Scale; 
self report (validated by 
saliva cotinine if denied 
smoking in last wk); Shadel 
and Mermelstein's 5-item 
scale 
 
Statistical analysis:  
ITT; logistic regression 
Data verification: 
Saliva cotinine kit mailed at 
month 4 postbaseline if teen 
denied smoking in last 7 
days; otherwise selfreport. 
 
Saliva kits retruned by 40% 
of those reporting cessation; 
rates of return did not differ 
by group 
Dependent variables: 
Point-prevalent abstinence 
at 4 and 8 mos 
postbaseline; sustained 
abstinence (proportion 
reporting not smoking at 
both followups) and 
predictors of cessation 
Baseline data: 
No arm differences on 
sample characteristics 
Age 17 or older: 
G1: 55% 
C1: 59% 
Male: 
G1: 47% 
C1: 51% 
High School: 
G1: 85% 
C1: 78% 
82% white, 10% black in 
both groups 
3 (SD 2) mean yrs smoking 
in both groups 
No group differences 
observed in abstinence at 
either time point or for 
sustained abstinence 
G1: Abstinence rates: 16% 
and 21% for 4 and 8 mos, 
respectively  
C1: Abstinence rates: 11% 
and 19% for 4 and 8 mos, 
respectively 
Outcome Measures 
unchanged after adjusting 
for multiple variables 
Sustained abstinence rates 
(C1) 7% and (G1) 9%  
Participants completing 
more counseling calls more 
likely to report cessation at 
4 and 8 mos postbaseline 
w/ ITT: (OR = 1.59, 95% CI, 
1.14-2.22 for 4 mos and OR 
= 1.54, 95% CI, 1.15-2.07 
for 8 mos) and to have 
sustained abstinence (OR = 
2.03, 95% CI, 1.14-2.22  
Intervention group less likely 
to watch some/all of video 
(44% vs 62%, P < 0.05) and 
read some/all of booklet 
(57% vs 78%, P < 0.01) 
Teens completing more 
calls more likely to report 
quitting at 4 and 8 mos (4 
mos: OR = 1.59, 95%CI, 
1.14-2.22, P < 0.007; 8 
mos: OR = 1.54, 95% CI, 
1.15-2.07, P < 0.007) and 
have sustained abstinence 
(OR = 2.03, 95%CI, 1.14-
2.22, P < 0.006) 
The more calls teens 
accepted, the more negative 
they felt about smoking (r = 
0.23, P < 0.05) and the 
more they reported wanting 
to stop (r = 0.23, P < 0.05) 
 
Quality rating: 
Fair 
Comments: 
• Methods described in 
good detail (except 
randomization scheme) 
• Major limitation is high 
attrition rates 
Adequate randomization: 
NR 
Attrition rate: 
Control: 49%  
Intervention: 66% 
Abstinence rates: 
4 mos: 
G1: 16% 
C1: 11% 
8 mos: 
G1: 21% 
C1: 19% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Lipkus et al., 2004 
(continued) 
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(continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
  
Compared w/ teens who 
smoked more than the 
median number of cigarettes 
per day (>8), teens who 
smoked equal to or less 
than the median number of 
cigarettes a day more likely 
to have quit smoking at 4-
mo (OR = 3.3, 95% CI, 1.7-
5.0, P < 0.0004) and at 8-
mo followup (OR = 2.0, 95% 
CI, 1.2-3.3, P < 0.007) and 
to have sustained 
abstinence at both followups 
(OR = 2.5, 95% CI, 1.2-5.0, 
P < 0.01) 
Teens in preparation stage 
more likely than 
precontemplators to have 
quit at 4-mo (OR = 2.4, 95% 
CI, 1.0-5.4, P < 0.05) and at 
8-mo (OR = 2.9, 95% CI, 
1.4-6.0, P < 0.005) 
followups  
Stage of readiness not 
related to sustained 
abstinence 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
McBride et al; 2002 
Geographic area: 
US 
Funding agency: 
NCI 
Study setting: 
Practice/provider settings 
 
Study objective: 
To assess whether a multicomponent 
intervention that included feedback about 
genetic susceptibility to lung cancer 
increased risk perceptions and rates of 
smoking cessation compared w/ a standard 
cessation intervention 
Population: 
• Adults 
• African Americans 
• Low SES 
Study type: 
NR 
Eligible smokers randomized in a 1:2 ratio 
to enhanced usual care group or biomarker 
feedback (that included tailored feedback of 
genetic susceptibility to lung cancer based 
on presence or absence of GSTM1 and 
telephone counseling) group 
Inclusion criteria: 
• Self-identify as African American 
• Smoked at least one cigarette/day in prior 
7 days 
• Would consider genetic testing for 
GSTM1 
Exclusion criteria: 
• Not African American; being treated for 
substance abuse 
• Smoked less than 7 cigarettes/wk 
• Did not have a telephone 
• Have medical conditions that 
contraindicate participation, e.g., 
Alzheimer’s disease, alcohol dependence
• Non-English speaking 
• < 18 yrs of age 
Sampling plan: 
African-American patients (seen in adult 
medicine, dental, urgent care and 
specialty clinics) current smokers, and 
identified by chart abstraction and 
provider referral 
Those eligible and agreed to participate 
called within 7 days of visits to complete 
participant intake assessment 
Sample size: 
G1: 185 
G2: 372 
Definition of smoking: 
Cigarettes 
• Smoking: At least 1 cigarette in past 7 
days 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Telephone counseling 
• Pharmaceuticals 
• Genetic susceptibility 
feedback 
Intervention:  
G1: Enhanced Usual Care: 
participants received 
provider advice to quit 
smoking and referred to 
smoking specialist who 
assessed stage of 
readiness to quit and 
appropriateness of NRT 
• Within 2 wks after clinic 
visit, all smokers sent a 
self-help smoking 
cessation guide 
especially designed for 
African-American 
smokers, “Pathways to 
Freedom”  
• If eligible (smoked at 
least five cigarettes/day 
and in preparation stage 
of readiness to quit), a 
14-day supply of 15 mg 
nicotine patches 
• Refill kits included a 7-
day supply of patches 
provided as needed;  
• Participants allowed to 
request up to eight refills 
over study period (for a 
total of 10 wks of 
therapy) 
 
Statistical analysis:  
• Baseline characteristics 
compared by intervention 
arm w/ Χ2 statistic for 
discrete variables and t-
tests for normally 
distributed continuous 
and ordinal variables 
• Wilcoxon test statistic 
used when variables not 
normally distributed 
• Logistic regression used 
for main binary outcomes 
of trial, abstinence from 
smoking in prior 7 days at 
6- and 12-mo followups, 
and continuous 
abstinence (not smoking 
at both 6- and 12-mo 
followups) 
• All analyses done twice, 
first unadjusted and then 
adjusted by adding 
baseline variables that 
differed (P < 0.05) by arm 
and known to be 
associated w/ smoking 
cessation, including 
number of chronic 
illnesses (0 v. 1 or more), 
smoking within 30 min of 
rising (no v. yes), and 
desire to quit (below or 
equal to median v. above 
median) 
Data verification: 
• Salivary cotinine levels 
assessed for self-report of 
not smoking at 12-mo 
followup 
• Efforts to biochemically 
confirm self-reported 
cessation unsuccessful 
• 39% (24/61) of those who 
reported abstinence and 
agreed to provide a saliva 
sample returned one 
• Rates of return did not 
differ b/w two arms (P = 
0.78) 
Proportion of participants not 
smoking at 6-mo followup:  
G1: 10% 
G2: 19% 
Unadjusted P = 0.006 
Adjusted P = 0.03 
Proportion of participants not 
smoking at 12-mo followup is 
NS:  
G1: 10% 
G2: 15% 
Unadjusted P = 0.12 
Adjusted P = 0.34 
Continuous abstinence of 
participants:  
G1: 5% 
G2: 11% 
Unadjusted P = 0.02 
Adjusted P = 0.08 
Rates of prevalent and 
sustained abstinence for 
those w/ enzyme missing or 
present did not differ 
significantly at followup:  
• 6 mos, 17 and 23%, 
respectively 
• 12 mos, 18 and 15%; 
sustained, 12 and 12%  
Among those who declined 
test, rates of prevalent 
abstinence at 6 and 12 mos 
and sustained abstinence 
substantially lower (11, 11, 
and 5% for each outcome and 
time point, respectively 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
• 6-month 
followup: 26% 
• 12-month 
followup: 36% 
No difference in 
attrition b/w groups 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
McBride et al; 2002 
(continued) 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
G2: Biomarker Feedback:  
• Participants offered 
opportunity to have their 
blood tested for GSTM1 
• Within 2 wks after clinic 
visit, participants priority 
mailed an eight-pg test 
result booklet written at 
a fifth grade reading 
level that included test 
result, information about 
chemical constituents of 
tobacco smoke and 
harms of exposure, 
regardless of genetic 
make-up 
• Those who declined test 
were sent an identical 
booklet that included 
same graphical displays 
along w/ a generic 
description of test and a 
question mark in result 
box 
• Within 1 wk after test 
result booklet mailed, 
participants called to 
discuss GSTM1 test and 
their result; counselors 
attempted a total of four 
calls w/ each participant 
over a 12-wk period; b/w 
first and second calls, 
participant sent 
“Pathways” selfhelp 
guide and nicotine 
patches, if appropriate 
C1: NR 
Method of assessment: 
Self-report of 7-day point 
prevalence smoking status 
Salivary cotinine levels 
assessed at 6 and 12-mo 
followup 
Blood analyzed for G2 
group to evaluate whether 
or not GSTM1 present 
 
Data verification: 
Salivary cotinine levels 
assessed for those who 
self-reported not 
smoking at 12-mo 
followup 
 
Efforts to biochemically 
confirm self-reported 
cessation unsuccessful; 
39% (24 of 61) of those 
who reported abstinence 
and agreed to provide a 
saliva test 
Dependent variables: 
Primary:  
• smoking status 
Secondary:  
• risk perceptions 
• worry 
• depression 
Baseline data: 
Groups similar at 
baseline except: G1 arm 
participants had:  
• more chronic illnesses 
• less desire to quit 
smoking 
• more likely to smoke 
within 30 min of 
waking  
than those in G2 arm 
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(continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Murray et al., 2002 
Geographic area: 
US 
Canada 
Funding agency: 
NIH 
Study setting: 
Practice/provider settings 
 
Study objective: 
To evaluate long-term persistence of effects 
on smoking and quitting on participants in 
the LHS intervention aimed at smoking 
cessation and to describe characteristics 
that distinguish those who quit smoking 
from those continuing to smoke 
Population: 
• Adults 
Study type: 
RCT w/ systematic randomization  
Inclusion criteria: 
• Smokers who had some evidence of lung 
function impairment (at baseline, their 
ratio of FEV to FVC less than 0.70 and 
their FEV b/w 55 and 90% of predicted 
normal for their age, gender, height, and 
race) 
• Willingness to participate in a smoking 
cessation program if randomized to 
smoking intervention 
Exclusion criteria: 
• Serious health conditions likely to affect 
participation in followup visits and lung 
function measurement 
• Use of prescribed medications that might 
alter lung function  
Sampling plan: 
Original LHS recruited, in 10 clinics in 
U.S. and Canada, 5,887 adult volunteer 
smokers w/ some evidence of lung 
function impairment 
Following LHS 1, LCS enrolled 5,008 of 
original cohort, and followed at 6-mo 
intervals w/ telephone interviews to 
ascertain smoking status and morbidity 
Recruits randomized equally to three 
study arms 
Sample size: 
G1: 3,040 
C1: 1,477 
Definition of smoking: 
Sustained abstainers:  
• participants who had been sustained 
quitters in LHS 1 
• gave no report of smoking during 
LCS 
• if not enrolled in LCS, recalled no 
month w/ as much as one cigarette 
per day in interval b/w LHS 1 and 
LHS 3 
• ex-smokers at LHS 3 baseline, 
validated by expired air CO levels 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
Pharmaceuticals 
Intervention:  
G1: SI(described in other 
articles) w/ ipratropium 
bromide inhaler and SIwith 
placebo inhaler - both 
groups combined for 
analysis because 
ipratropium bromide 
inhaler had no effect on 
smoking cessation 
C1: usual care (described 
in other articles) 
Method of assessment: 
• Interviews in-person and 
via telephone 
• Expired air CO levels 
 
Statistical analysis:  
Comparisons b/w groups 
for quantitative variables 
are based on t-tests, 
while those for 
categorical variables are 
based on Χ2 or Fisher’s 
exact test; Logistic 
regression used to 
analyze multiple 
predictors of LHS 3 
cross-sectional smoking 
status and sustained 
abstinence status 
Data verification: 
Expired air CO levels 
used to validate non-
smoking status 
Dependent variables: 
Smoking status 
Baseline data: 
Groups similar at 
baseline 
Biochemically validated smoking 
status at LHS 3 baseline - 
Percent quit:  
G1: 51.7 
C1: 42.9 
P = < 0.001 
Sustained abstinence since LHS 
1 baseline:  
G1: 21.9% 
C1: 6.0% 
P = < 0.001 
OR of abstinence in participants 
assigned to G1 as opposed to  
C1 = 4.45 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
16.7% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Rabius et al., 2004 
Geographic area: 
US 
Funding agency: 
ACS 
Study setting: 
Population-based 
 
Study objective: 
To examine effects of telephone counseling 
on smoking cessation among smokers 18 to 
25 yrs old and smokers over 25 yrs old 
Population: 
• Young adults 
• Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
Of those who called a toll-free ACS number 
to inquire about cessation, adult current 
daily smokers willing to make a quit attempt 
in next two wks 
Exclusion criteria: 
NR  
Sampling plan: 
• Cessation assistance offered to 
smokers from anywhere in US that 
called ACS' general toll-free number 
for information about cessation 
• Adult current daily smokers willing to 
make a quit attempt in next 2 wks and 
gave consent , interviewed and 
randomized to 2 txt or control 
• All participants received three ACS 
booklets that provide standard advice; 
half of participants randomized to 
receive an offer of telephone 
counseling 
Sample size:  
Total: 3,522 
G1: Half of participants; exact N NR 
C1: Half of participants; exact N NR 
Definition of smoking: 
Cigarettes 
• Current smoking: any smoking within 
last 48 hrs 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
Intervention:  
G1: Three ACS booklets w/ 
standard advice plus up to 
five sessions of proactive 
telephone counseling 
C1: Three ACS booklets w/ 
standard advice 
Method of assessment: 
Interview at 15 wks after 
enrollment (approximately 3 
mos postquit date); if 
participants reported 
abstinence at 3 mo 
interview, then interviewed 
again at 6 mos postquit date 
 
 
Statistical analysis:  
• Logistic regression for 
studies of factors 
predicting study 
retention and quitting 
success, t-tests for 
comparing means 
• Χ2 for comparing 
proportions 
Data verification: 
NR 
Dependent variables: 
Study retention by 
intervention; abstinence; 
use of NRT or Zyban 
Baseline data: 
Proportion of participants 
in younger age group (18-
25 yrs old):  
12% (n = 420), similar to 
larger population 
Women outnumbered men 
overall 
Proportion of men:  
18-25 yrs: 39% 
Over 25 yrs: 33% 
P = < 0.01 
Proportion of married men: 
18-25 yrs: 19% 
over 25 yrs: 49% 
P = < 0.001 
Frequency of cigarette 
use:  
18-25 yrs: 18 cigarettes 
Over 25 yrs: 24 cigarettes 
P = < 0.001 
Prevalence of reported 48 hr 
abstinence at 3 mo followup 
among 18-25 yr olds:  
G1: 19.6% 
C1: 9.3% 
P = < 0.005 
Prevalence of reported 48 hr 
abstinence at 3 mo followup for 
over-25 yr olds:  
G1: 15.1% 
C1: 9.6% 
P = < 0.001 
Proportion of 18-25 yr olds 
reporting 48 hr abstinence at both 
3 and 6-mo followups:  
G1: 9.8% 
C1: 3.2% 
P = < 0.01 
Proportion of over-25 yr olds 
reporting 48 hr abstinence at both 
3 and 6-mo followups:  
G1: 8.8% 
C1: 5.3% 
P = < 0.005 
Estimate of prolonged abstinence 
at 6 mo followup (reported 48 hr 
abstinence plus 5 or fewer 
• Logistic regression analysis 
examining relationships b/w 
demographic variables, smoking 
behavior and history, and txt 
condition found the following: 
among 18-25 yr olds, txt 
condition only significant 
predictor of 48 hr abstinence at 
3-mo followup  
(P = < 0.01) 
• Among over-25 yr olds, 48 hr 
abstinence at 3-mo followup 
significantly higher in txt group 
(P = < 0.001), those w/ more 
education  
(P = < 0.01), and those w/ lower 
baseline smoking rates  
(P = < 0.001) 
 
Quality rating: 
Fair 
Comments: 
Adequate 
randomization: 
NR 
Attrition rate: 
Overall: 36% 
Attrition at 3-mo 
followup:  
18-25 yr olds: 48% 
Over-25 yr olds: 34%
P = < 0.001 
Attrition among those 
abstinent and eligible 
for followup at 6 mos: 
18-25 yr olds: 36% 
Over-25 yr olds: 15%
P = < 0.001 
Logistic regression 
found that 
successfully followed 
participants more 
likely to be female (P 
= < 0.01) and better 
educated (P = < 
0.01) than those not 
retained in study 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Smith et al.; 2004 
Geographic area: 
Canada 
Funding agency: 
Ontario Ministry of Health; 
Heart and Stroke 
Foundation of Ontario 
Study setting: 
Population-based 
 
Study objective: 
To examine options for use, efficiency, and 
effectiveness of telephone counseling for 
structuring a population-based telephone 
smoking cessation service 
Population: 
• Adults 
Study type: 
RCT w/ stratified randomization  
Inclusion criteria: 
• Current smokers 
• At least 18 yrs of age 
• Daily smokers 
• Non pregnant 
• Intend to quit within 7-20 days 
• Live in specified geographic recruitment 
areas 
• Consent to participate in study 
Exclusion criteria: 
NR  
Sampling plan: 
Counselors answered incoming toll-free 
calls and determined study eligibility of 
callers; ineligible callers sent cessation 
materials designed to respond to their 
needs (e.g., pregnancy); eligible callers 
randomized (stratified within 
communities) to one of five conditions 
Sample size: 
Total: 632 
Definition of smoking: 
Cigarettes 
• Point abstinence: 7-day abstinence at 
time of followup call 
• Continuous abstinence: 7-day 
abstinence at all followup calls 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
• Pharmaceuticals 
Intervention:  
G1: Initial 50 minute 
telephone counseling, 2 
five to 10 minute followup 
calls, booklet  
G2: Initial 50 minute 
telephone counseling, 2 
five to 10 minute followup 
calls, pamphlet 
G3: Initial 50 minute 
telephone counseling, 6 
five to 10 minute followup 
calls, booklet  
C1: Print materials only 
Method of assessment: 
Research staff, blind to txt 
conditions, called 
participants in all 5 
conditions at 3,6, and 12 
mos to assess smoking 
status; 7 attempts made at 
each followup call before 
recording it as missed 
 
Statistical analysis:  
NR 
Data verification: 
No biochemical 
validation of self-reported 
smoking status 
performed 
Dependent variables: 
• Smoking status 
• Participant rating of 
print materials 
• Participant rating of 
telephone counseling 
Baseline data: 
No significant differences 
across the 5 groups at 
baseline 
Point abstinence at 3 mos:  
G1: (1, 2, 3, 4 collapsed) = 15% 
C1: 13% 
P = < 0.05 
Point abstinence at 6 mos:  
G1: (1, 2, 3, 4 collapsed) = 15% 
C1: 14% 
P = < 0.05 
Point abstinence at 12 mos:  
G1: (1, 2, 3, 4 collapsed) = 17% 
C1: 20% 
P = < 0.05 
Continuous abstinence:  
G1: (1, 2, 3, 4 collapsed) = 5% 
C1: 1% 
P = < 0.05 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
Attrition: 30.6% 
• Died: 0.003% 
• Withdrew: 7.1%  
• Lost to followup: 
23.2%  
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Aveyard et al., 2003  
Geographic area: 
United Kingdom 
Funding agency: 
West Midlands health 
authorities 
Study setting: 
Practice/provider settings 
 
Research objective: 
To examine the population impact and 
effectiveness of the Pro-Change smoking 
cessation course based on the 
Transtheoretical Model (TTM) compared to 
standard self-help smoking cessation 
literature  
Population: 
Patients of general pracitioners employed at 
65 West Midlands general practices   
Study type: 
RCT  
Inclusion criteria: 
Current smokers 
Exclusion criteria: 
All selected patients were eligible unless 
terminally ill, violent or other unusual 
circumstances pertained  
Sampling plan: 
• 3 wave recruitment process – wanted 
to estimate the proportion of smokers 
that could be recruited from British 
general practice 
• 1st wave: used random sampling. 
West Midlands GP practices were 
selected with probability proportional 
to size and then a fixed number of 
patients (300) were selected for 
invitation  
• From wave 1, became clear that 
insufficient patients would be recruited 
so invited originally recruited practices 
to repeat the process (2nd wave) 
• When 2nd wave failed to reach target 
number, non-randomly selected new 
practices approached to participate. 
• In all waves, potential participants 
were sent invitation packs containing 
a cover letter from GP to patients 
expressing concern about smoking, 
assuring patients never to late to quit, 
and offering to help stop smoking at 
the surgery, if not by trial entry. 
• Participants signaled consent by 
returning baseline questionnaire 
• On receipt of baseline questionnaire, 
participants then randomly assigned 
either to control group (standard self-
help literature), manual intervention 
group (received Pro-Change system), 
the telephone group (received Pro-
Change system plus 3 telephone 
calls) or the nurse group (received 
Pro-Change system, 3 telephone calls 
and 3 visits to practice nurse  
Sample size: 
G1: 683 
G2: 685 
G3: 413 
C1: 690 
Definition of smoking: 
Cigarettes 
• Current Smoker - NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help quit guides and 
tip cards 
• Workbook and 
questionnaires 
• Telephone counseling 
• Nurse visits 
Intervention:  
G1: Pro-Change self-help 
system with workbook and 3 
questionnaires to generate 
tailored feedback 
G2: G1 plus three telephone 
calls 
G3: G1 plus three nurse 
visits 
C1: 2 standard self-help quit 
guides and 2 tip cards 
Method of assessment: 
Asked the question “are you 
currently a smoker?” at 12 
months post baseline -  
verified by salivary cotinine, 
obtained by visit to 
participant’s house or by 
mail 
Baseline data: 
No significant differences 
b/w any of the groups 
Statistical analysis:  
• Recruitment of new 
practices in wave 3 
where participants only 
allocated to 3 arms (no 
one allocated to G3) 
complicated analysis, 
b/c no guarantee overall 
that participants’ 
characteristics balanced 
b/w arms – therefore, 
analyzed the data as 2 
separate trials – 
calculated the 
percentage quitters in 
each arm and performed 
an overall chi-square 
test to calculate 
differences between 
arms 
• Odds ratios for the risk 
of quitting relative to 
control arm and the 
percentage and OR for 
quitting in 3 intervention 
groups (G1, G2, G3) 
combined vs. control 
arm were calculated 
• To examine if difference 
b/w 4-arm and 3-arm 
trials in effectiveness of 
intervention arms 
relative to control arm, 
added a multiplicative 
term for trial x trial arm 
to a logistic regression 
model 
• The study reported 
results using intent-to-
treat analysis, as well as 
results that used only 
those that followed-up 
Data verification: 
Self-report, salivary 
cotinine (values >14.2 
ng/ml taken as indicative 
of active smoking) 
Dependent variables: 
• Point prevalence of 
being quit at 12 months 
• Point prevalence of 
sustained abstinence of 
at least 6 months 
No statistically significant 
difference in quit rates between 
intervention and control groups 
(G1=11%, G2=12%, G3=10%, 
C1=10%) in biochemically-
confirmed abstinence for 6-months 
sustained abstinence and  
12-months point prevalence 
 
Quality rating: 
Fair 
Comments: 
• Authors conclude 
Pro-Change 
system unlikely to 
provide important 
alternative to 
current network of 
smoking cessation 
clinics and 
prescription of 
NRT 
Adequate 
randomization: 
Yes 
Attrition rate: 
29% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Bier et al., 2002 
Geographic area: 
NR 
Funding agency: 
Arizona Disease Control 
Research Commission 
Study setting: 
NR 
Research objective: 
To examine the effect of acupuncture alone 
and in combination with education on 
smoking cessation and cigarette 
consumption 
Population:  
Age 18 years or older 
Study type: 
Prospective, quasi factorial design 
Inclusion criteria: 
• Aged 18 years or older 
• Attempted to stop smoking at least once 
without success 
Exclusion criteria: 
• Actively psychotic 
• Suffering from any neurological or 
physical illness or other impairment that 
would prevent understanding of research 
consent form 
• Not able to read and write sufficiently to 
understand and complete the forms 
• Not willing to participate in a treatment 
protocol involving acupuncture 
• Currently taking phenothiazine, tricyclic 
antidepressants, lithium carbonate or beta 
blocking medication 
• Chronically using sympathomimetic drugs 
such as ephedra, ephedrine, 
amphetamines, or sedative medication 
 
Sampling plan:  
Blind random assignment to groups 
Sample size: 
G1: 38 
G2: 45 
C1: 58 
Definition of smoking:  
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
Individual counseling by 
health professional 
Intervention:  
G1: Acupuncture, 20 
sessions over 4 weeks (5 per 
week) 
G2: Same as GI, but also 
received 5 weeks 
educational smoking 
cessation program 
(multisession, 
multicomponent behavioral 
training, education, social 
support, relapse prevention, 
1.5 hours  twice per week for 
first week, then once per 
week for next 4 weeks) 
C1: Sham accupuncture, 20 
sessions over 4 weeks (5 per 
week) plus 5 weeks 
educational smoking 
cessation program 
(multisession, 
multicomponent behavioral 
training, education, social 
support, relapse prevention, 
1.5 hours  twice per week for 
first week, then once per 
week for next 4 weeks) 
Method of assessment: 
Cigarette pack self 
monitoring chart, recording 
number and times cigarettes 
smoke in past 7 days, pre 
and post intervention; asked 
about smoking at clinic visit 
Baseline data: 
No significant differences 
Statistical analysis:  
• Power analyses for 
sample size (.05 for power 
of .80) 
• Mixed model with 
repeated measures 
• Covariance between any 
2 periods considered 
autoregressive 
Data verification: 
Self report 
Dependent variables:  
• Beck Depression 
Inventory score 
• Zung Self-Rating Anxiety 
Scale 
• # of cigarettes smoked per 
day 
• Age of initiation 
• # of years smoking 
• Smoking or not smoking 
at visit 
• % decrease in smoking 
• Decrease in # of 
cigarettes smokes 
• VAS Score 
• Pack year history 
Not Smoking (%) at 18 
months 
G1: 20% 
G2: 40% 
C1: 53% 
NS 
Greater the estimated pack 
year history before treatment, 
the greater the decrease in 
total number of cigarettes 
smoked per day following 
treatment 
Quality rating: 
Poor 
Comments:  
• Very high attrition rate 
• Group has a higher pack 
year history than in other 
studies 
Adequate randomization: 
Yes 
Attrition rate:  
At 18 months 
Total: 66% 
G1: 68% 
G2: 65% 
C1: 66% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Bohadana et al; 2000 
Geographic area: 
Western Europe 
Funding agency: 
Pharmacia and Upjohn 
Consumer Healthcare 
Study setting: 
Practice/provider settings 
 
Study objective: 
To investigate whether short-term (6-wk) 
addition of a NPto nicotine inhaler txt 
improves early smoking cessation rates, and 
whether this txt combination improves 
likelihood of abstinence at 6 and 12 months 
Population: 
• Adults 
Study type: 
• RCT w/ systematic randomization  
• Double-blind, randomized, placebo-
controlled trial 
Inclusion criteria: 
• Aged 18 to 70 yrs 
• Smoked 10 or more cigarettes per day for 
3 or more yrs 
• Expired CO level of 10 ppm or more 
• Made 1 or more previous attempts to quit 
• Personally motivated to stop smoking 
• Fluent in French 
Exclusion criteria: 
• History of myocardial infarction within past 
3 mos 
• Unstable angina 
• Severe cardiac arrhythmia 
• Serious renal, pulmonary, endocrine, or 
neurological disorders 
• Pregnancy or breastfeeding 
• Use of any form of ST or nicotine 
substitution 
• Participation in any smoking cessation 
program during past 6 mons 
• Alcoholic or illegal drug user 
• Use psychoactive drugs 
• Have generalized dermatological 
diseases 
Sampling plan: 
• Subjects from Nancy, France, and 
surrounding towns recruited by means 
of local newspaper 
• First subject enrolled in March 1996, 
and followup completed in February 
1998 
• Approximately 1,000 people who 
contacted the Centre Hospitalier 
Universitaire de Nancy-Brabois, 462 
underwent a prospective telephone 
screen to enroll 400 subjects who met 
inclusion criteria 
Sample size: 
Total: 400 
Definition of smoking: 
Cigarettes 
• 3-mo cessation rate, rate of 
continuous abstinence at all time 
points: self-reported nonsmoking b/w 
wk 2 and mo 12 and an expired CO 
level less than 10 ppm at each 
followup visit 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Individual counseling by 
health professional 
• Pharmaceuticals 
Intervention:  
G1: Nicotine inhaler 
(plastic tube containing a 
perforated plastic plug 
impregnated w/ 10 mg of 
nicotine, approximately 4 
mg of which is available for 
inhalation, and menthol to 
reduce irritant effect of 
nicotine) plus 30-cm2 
NPcontaining 0.83 mg of 
nicotine per square 
centimeter, delivering 15 
mg per 16 hrs 
C1: Nicotine inhaler 
(plastic tube containing a 
perforated plastic plug 
impregnated w/ 10 mg of 
nicotine, approximately 4 
mg of which is available for 
inhalation, and menthol to 
reduce irritant effect of 
nicotine) plus placebo 
patch that contained no 
nicotine 
Method of assessment: 
Baseline assessments 
included patient 
characteristics, vital signs, 
patient weight, smoking 
history, expired CO, blood 
cotinine, psychological 
status, SES, pulmonary 
measures (symptoms and 
function) and medical 
history; during txt and 
followup, weight 
measured, smoking history 
and expired CO assessed, 
blood cotinine measured, 
craving and withdrawal 
symptoms and all adverse 
events; pulmonary 
measures (symptoms and 
function) collected at 12 
mos 
Statistical analysis:  
• Data analyzed on an 
ITT basis (ie, all 
subjects who entered 
study and received 
medication, 
irrespective of 
medication use or 
outcome); Intergroup 
differences in ITT 
abstinence rates at all 
time points calculated 
by Χ2 (or Fisher exact 
test if necessary) 
• Proportions of 
participants remaining 
abstinent over time 
calculated by 
comparing relapse w/ 
smoking curves of 2 
groups by means of 
log rank test 
• Continuous variables 
compared b/w groups 
by parametric t-tests 
whenever possible, 
and Mann-Whitney 
rank sum test used for 
data non-normally 
distributed 
Data verification: 
Self-reported smoking 
status validated by blood 
cotinine levels and 
expired air CO levels 
Dependent variables: 
3-mo cessation rate, rate 
of continuous abstinence 
at all time points, nicotine 
inhaler use, nicotine 
substitution, incidence of 
withdrawal symptoms, 
adverse events, and 
changes in body weight 
Baseline data: 
No significant differences 
b/w 2 groups except for a 
greater number of 
cigarettes per day in G1 
Percentage of participants 
completely abstinent at 6-wk 
followup: 
G1: 60.5 
C1: 47.5 
P = 0.009 
3-mo followup: 
G1: 42.0 
C1: 31.0 
P = 0.02 
No significant difference in 
complete abstinence b/w G1 and 
C1 at 6- and 12-mo followups 
Pulmonary findings confirm 
beneficial respiratory effects of 
smoking cessation and that 
slowing down of decline in FEV 
volume in 1 second appears to 
be relatively rapid in those who 
quit smoking 
Mean body weight gain 
significantly higher in C1 than G1 
by wk 2 (0.49 kg v. 0.99 kg)  
(P = 01) 
No significant difference in mean 
body weight gain at 1 yr (4.22 kg 
and 5.06 kg P = 0.14)  
Subjects in C1 reported 
significantly more intense 
withdrawal symptoms at wk 1 (P 
< 0.001) and craving symptoms 
at wk 6 (P = 0.04) than those in 
G1 
Adverse events rare and 
tolerable 
 
Quality rating: 
Fair 
Comments: 
Attrition rate NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
1 person withdrew 
from study due to a 
serious adverse 
event, but overall 
attrition rate NR 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Canga et al., 2000 
Geographic area: 
Western Europe 
Funding agency: 
NR 
Study setting: 
Hospital 
Practice/provider settings 
 
 
Study objective: 
Evaluate effectiveness of a nurse-managed 
smoking cessation intervention aimed at 
helping diabetic smokers quit smoking 
Population: 
• Young adults 
• Adults 
Study type: 
RCT w/ systematic randomization  
Inclusion criteria: 
• Type 1 and 2 diabetic patients registered 
in centers under study who were either 
current smokers or who had quit  
< 1 yr ago 
Exclusion criteria: 
• Had quit smoking for over 1 yr or was 
misclassified in medical record as a 
diabetic smoker 
Sampling plan: 
• Type 1 and 2 diabetics at 2 hospitals 
and 15 primary care clinics 
randomized to receive either usual 
care or a nurse-led, face-to-face 
cessation counseling intervention 
• All clinical records of Type 1 & 2 
diabetics registered at 15 primary 
care clinics and 2 hospitals b/w Dec 
1997 and Dec 1998 reviewed to 
confirm smoking status 
• Smokers contacted through a letter 
and telephone call to participate in a 
general lifestyle study of diabetic 
patients 
• Smokers randomly assigned to 
intervention or C using computer-
generated allocation; randomized 
assignment blinded 
Sample size: 
G1: 147 
C1: 133 
Definition of smoking: 
Cigarettes 
Current smoking: having smoked > 100 
cigarettes during a subject's lifetime and 
having smoked at least 1 cigarette in 
last wk 
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Intervention Details 
Statistical Analysis 
and Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Pharmaceuticals 
Intervention:  
G1: Initial 40 min face-to-
face interview w/ a research 
nurse that included 
personalized advice about 
benefits of quitting and 
strategies that may be 
useful, based on patient's 
clinical condition, smoking 
history, and personal 
interests; self-help materials 
w/ quitting cues; 3 months of 
transdermal NRT offered to 
those w/ no 
contraindications who 
smoked > 19 cigarettes per 
day and those who had not 
succeeded after trying to 
quit at least once; followup 
program of 5 contacts 
scheduled according to 
negotiated cessation date: 
1) telephone call the day 
before quit date, 2) a 
followup visit 2 wks post quit 
date, 3) a letter 3 wks post 
quit date, 4) a followup visit 
2 months post quit date, and 
5) a final evaluation carried 
out 6 months post quit date 
C1: Usual care for diabetic 
smokers that is routinely 
provided by hospital or 
primary care clinic and is 
established in the Navarre 
diabetes care program, 
including advice to quit 
smoking 
Method of assessment: 
Followup interview 
conducted by a nurse at 6 
months after initial interview; 
urinary cotinine levels 
obtained from those who 
self-reported quitting 
Statistical analysis:  
• Two-tailed Fisher's 
exact tests used to 
compare proportion 
of quitters b/w both 
groups 
• Two-tailed t-tests 
used to compare 
change in average 
number of cigarettes 
smoked daily 
• Incidence ratio, 
incidence difference, 
and number needed 
to treat w/ their 
respective 95% CIs 
used to estimate 
effect of intervention 
Data verification: 
Urinary cotinine levels 
obtained from self-
reported quitters and 
analyzed using method 
developed by Jarvis, et 
al 
Dependent variables: 
• Urinary cotinine 
validated cessation 
• Mean number of 
cigarettes smoked 
daily 
• Stage of change 
according to 
Prochaska's model 
Baseline data: 
Intervention and Cs 
similar at baseline in 
demographic 
characteristics, 
diabetes history, and 
history of tobacco use 
Proportion of smokers who quit 
at 6-month followup (validated):  
G1: 17.0% 
C1: 2.3% 
Difference: 14.7 (CI, 8.2, 21.3) 
P = < 0.001 
6-mo followup, change in mean 
cigarettes per day:  
G1: -4.6 (CI, -3.2, -6.0) 
C1: -1.6 (CI, -0.4, -2.8) 
Difference: -3.0 (CI, -1.1, -4.9)  
P = < 0.001 
6-mo followup, patients in 
precontemplation stage:  
G1: 39.5% 
C1: 56.4% 
Difference: -16.9%  
(CI, -5.3, -28.9) 
P = < 0.001 
6-month followup, patients in 
contemplation stage:  
G1: 9.5% 
C1: 29.3% 
Difference: -19.8%  
(CI, -10.7, -34.1) 
P = < 0.001 
6-mo followup, patients in action 
and maintence stages:  
G1: 17.0% 
C1: 2.3% 
Difference: 14.8%  
(CI, 8.2, 21.3) 
P = < 0.001 
6-mo followup, patients in 
relapse stage:  
G1: 33.3% 
C1: 10.5% 
Difference = 22.8%  
(CI, 13.6, 32.0) 
P = < 0.001 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
Overall = 0.71% 
G1: 0.68% 
C1: 0.75% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Carpenter et al., 2004 
Geographic area: 
USA  
Funding agency: 
National Institute on Drug 
Abuse 
Study setting: 
Population-based 
Research objective: 
To assess whether a behavioral treatment to 
reduce smoking combined with NRT 
followed by brief advice to quit versus 
motivational advice plus brief advice to quit 
produces a greater incidence of quit 
attempts 
Population:  
NR 
Study type: 
RCT 
Inclusion criteria: 
• Not Interested in quitting 
Exclusion criteria: 
• No current smoker in household (96%) 
• Smokes less than 10 cigarettes a day 
• Less than 18 years of age 
• Secondary Exclusion 
• Nursing, pregnant, planning to become 
pregnant in next 9 months 
• Cardiovascular disease or high blood 
pressure not controlled by medication 
• Currently taking prescription medications 
for depression or asthma (79%) 
• Not accessible by telephone throughout 
duration of the study 
 
Sampling plan:  
Randomized 
Sample size: 
G1: 212 
G2: 197 
C1: 207 
Definition of smoking:  
Abstinence: greater than or equal to 3 
cigarettes per day 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
Telephone counseling 
Intervention:  
G1: Telephone based 
reduction counseling and 
NRT and brief advice to quit 
G2: Motivatiiona advide 
(5Rs) and brief advice 
C1:  No treatment  
Method of assessment: 
Mailed questionnaire at 
0,3,6,12 and 24 weeks 
Baseline data: 
• Smoking habits 
• Urine cotinine levels 
• Fagerstrom Test for 
Nicotine dependence 
• Stage of change 
• Demographics 
• Parity 
• Proportion having a 
partner 
• Proportion whose partner 
smoked  
• Educational achievement 
• Household net income 
 
Statistical analysis:  
• Logistic regression 
Data verification: 
Self report 
Dependent variables:  
• # of cigarettes per day 
over previous 7 days 
• Intention to quit in next 1 
to 6 months 
• Stage of change 
• Self-efficacy 
• Quit attempts within past 
24 hours 
• Point prevalence 
abstinence (no smoking 
at all in past 7 days) 
Percentage with “24-hour Quit 
Attempts” over 6 months 
G1: 43% 
G2: 51% 
C1: 16% 
G1 vs G2: NS 
G1 + G2 vs C1: P < 0.01 
Percentage with “24-hour Quit 
Attempts”  at  6 weeks (when 
intervention was completed) 
G1: 36% 
G2: 18% 
C1: NR 
Percentage with “24-hour Quit 
Attempts” after 6 weeks (when 
intervention was completed) 
G1: 64% 
G2: 82% 
C1: NR% 
Abstinence Rates 
G1: 18% 
G2: 23% 
C1: 4% 
Seven-day Point Prevalence at 
6 months:  
P<0.01 
Smoking reduction using NRT 
does not undermine cessation 
but rather increases likelihood of 
quitting to a degree similar to 
motivational advice 
 
Quality rating: 
Fair 
Comments:  
• Source of database 
used to recruit 
people for study is 
unclear 
• No biochemical 
verification 
Adequate 
randomization: 
NR 
Attrition rate: 
NR 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Chalmers et al., 2001 
Geographic area: 
Canada 
Funding agency: 
Health Canada, Tobacco 
Programs Unit, Health 
Promotion Directorate and 
the Canadian Lung 
Association 
Study setting: 
Practice/provider settings 
 
 
Study objective: 
Smoking reduction and cessation program 
implemented w/ registered nurses 
Population: 
• Adults 
• Women (only) 
Study type: 
Self-selected intervention 
Inclusion criteria: 
• RN 
Exclusion criteria: 
• No other type of nurses 
Sampling plan: 
Advertised study in a variety of medium 
and participants allowed to select 
intervention type 
Sample size: 
G1: 75 
G2: 44 
Definition of smoking: 
Cigarettes 
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Group counseling 
Intervention:  
G1: Group participation 
G2: Self-study 
G3: NR 
C1: NR 
Method of assessment: 
Questionnaires administered 
prior to and at end of 8-wk 
interventions and at 6 and 12 
months postintervention 
 
Statistical analysis:  
• SAS and Excel used 
• Descriptive statistics 
obtained and t-tests 
used in pre and posttest 
analyses  
• Variance difference 
considered across 4 time 
periods  
• Duncan's Multiple Range 
test implemented for all 
post hoc comparisons 
• Time-study analysis 
techniques used to 
organize data and 
observe and test for 
trends 
Data verification: 
None 
Dependent variables: 
Stage of quiting 
Baseline data: 
No comparisons made 
 
Statistically significant changes at 8 
wks in nurses' smoking practices 
found on number of nurses 
continuing to smoke, mean number 
of cigarettes smoked, and 
movement in stage of behavioral 
change 
Quality rating: 
Poor 
Comments: 
No ITT, self-selection 
of intervention, no 
comparisons b/w 
groups. 
Adequate 
randomization: 
No 
Not randomised! 
Attrition rate: 
Pretest: 0 (0%) 
8 wks: 27 (23%) 
6 months: 47 (40%) 
12 months: 62(53%) 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Clark et al; 2004 
Geographic area: 
US 
Funding agency: 
NCI 
Study setting: 
Hospital 
Practice/provider settings 
 
Study objective: 
To examine effectiveness of standard 
written self-help materials for nicotine 
dependence compared to written materials 
consisting of internet-based resources on 
smoking abstinence rates in a lung cancer 
screening population 
Population: 
• Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• Asymptomatic  
• Men and women 50 yrs of age or older  
• Current cigarette smokers w/ at least a 20 
pack-yr history of smoking 
• Access to a computer w/ Internet service 
• Written informed consent to participate 
Exclusion criteria: 
• History of any cancer within five yrs, other 
than non-melanomatous skin cancer, 
cervical cancer in situ, or localized 
prostate cancer 
• Mentally incompetent 
• Not healthy enough to potentially undergo 
pulmonary resection (i.e., have 
congestive heart failure or disabling 
dyspnea at time of enrollment) 
• Serious illness that decreased life 
expectancy to less than 5 yrs 
Sampling plan: 
Community informed about low-dose 
fast spiral chest CT screening study by 
local and regional television and 
newspaper coverage carrying 
information on general outline of study 
and eligibility requirements, as well as 
funding by NCI 
Sample size: 
Total: 171 
Definition of smoking: 
Cigarettes 
• Abstinence: no cigarettes in last 7 
days 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Computer-based 
program 
Intervention:  
G1: Received handout w/ 
a list of 10 Internet sites 
related to stopping 
smoking and a brief 
description of each site; 
Web sites included: the 
American Heart 
Association, ACS, NCI, 
Cancer Information 
Service, CDC Tips, 
Tobacco 
Information/Prevention 
Source, Mayo Clinic 
Nicotine Dependence 
Center, Quit Now! (the 
National Tobacco 
Campaign), the No Smoke 
Caf, Massachusetts 
Quitline, Nicotine 
Anonymous, and the 
American Lung 
Association; these sites 
include information on 
health risks related to 
tobacco use, benefits of 
stopping smoking, specific 
behavioral strategies, 
support for stopping, 
review of stop smoking 
medications, and 
references to local 
resource 
C1: Received a copy of 
Clearing the Air: How to 
Quit Smoking and Quit for 
Keeps (24-pg self-help 
manual describing multiple 
behavioral strategies for 
stopping smoking), a 
publication of the National 
Cancer Institute; 
participants also given the 
American Lung 
Association booklet, Quit 
Smoking Action Plan, 
which provides up to date 
information on available 
pharmacotherapies for 
nicotine dependence 
Statistical analysis:  
Responses from 1-mo 
followup survey, and 
tobacco use variables 
collected at 1-yr 
followup, compared b/w 
txt groups using Χ2 
For 1-yr smoking 
abstinence outcome, 
subjects that missed the 
visit or failed to provide 
tobacco use information, 
classified as smoking 
All other analyses 
performed using 
available data w/ no 
imputation of missing 
values 
For biochemically 
confirmed 7-day smoking 
abstinence, exact binary 
confidence intervals 
calculated for each txt 
group and a logistic 
regression analysis 
performed using smoking 
abstinence as dependent 
variable and txt group as 
independent variable 
Logistic regression used 
to assess whether 
screening 
recommendations 
associated w/ 1-yr 
tobacco use outcomes 
In all cases, two-sided 
tests performed w/ P-
values; < 0.05 used to 
indicate statistical 
significance 
Data verification: 
Self-reported smoking 
status confirmed w/ 
expired air CO levels at 1 
yr followup 
 
No statistically significant 
differences in smoking status 
found at 1-mo (13 vs 7%, P = 
0.248) or 1-yr followup (5 vs 
10%, P = 0.166, OR = 0.4, 95% 
CI, 0.1-1.4) 
At yr 1 followup more subjects 
receiving internet-based 
resources, compared to C1, 
reported that they had made an 
attempt to stop smoking in last yr 
(68 vs 48%, P = 0.011) 
Recommendation of additional 
followup from chest CT screening 
exam not found to be associated 
w/ abstinence (OR = 0.5, P = 
0.267), making a quit attempt 
(OR = 0.8, P = 0.412) or 
advancement in state of change 
from baseline to 1-yr (OR = 0.6, 
P = 0.222) 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
No attrition at 1-yr 
followup (study 
followup coincided 
w/ 1-yr followup for 
lung cancer 
screening) 
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Baseline Data  Outcome Measures 
Quality 
Comments 
Method of assessment: 
Questionnaire at 1-mo 
followup: 
• Smoking status self-
reported 
In-person visit at 1 yr 
followup: 
• Smoking status and 
expired air CO levels 
assessed 
 
Dependent variables: 
Biochemically-confirmed 
smoking status 
Baseline data: 
Both groups similar at 
baseline 
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Author: 
Covey et al., 2002 
Geographic area: 
US 
Funding agency: 
Pfizer, Inc  
Study setting: 
Population-based 
 
Research objective: 
To evaluate sertraline as an effective aid to 
smoking cessation for smokers with a 
history of major depression 
Population: 
Adults   
Study type: 
RCT, double blind, placebo control study 
Inclusion criteria: 
• Subjects required to meet DSM-III-R 
criteria for at least one episode of major 
depression, which must have remitted 
more than 6 months befor the start of the 
study 
• Age 18 to 70 
• Daily use of 20 or more cigarettes for at 
least a year 
• One prior attempt to quit 
Exclusion criteria: 
• Serious medical illnesses 
• Use of a psychotropic medication 
• Major depression, alcohol or drug 
dependence, panic disorders, post-
tramatic stress disorder, anorexia 
nervosa, or bulimia nervosa within the 
past 6 months 
• Life time diagnosis of bipolar disorder, 
antisocial or schizotypal personality 
disorder, severe borderline personality 
disorder, obsessive-compulsive disorder, 
or psychosis including schizophrenia 
• Pregnancy or lactation 
Sampling plan: 
• Respondents were first screened by 
telephone, those who met initial 
criteria were seen at the first clinical 
visit 
• Eligible participants obtained a 1 
week single-blind washout phase of 
one placebo tablet per day 
• Once medically confirmed to meet 
criteria, participants were randomly 
assigned in a double blind fashion to 
receive sertraline (50mg tablet) or 
placebo 
Sample size: 
G1: 68  
C1: 66  
Definition of smoking: 
• Smoking measured by cotinine level, 
non-smokers < 25 ng/ml  
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Intervention methods: 
Pharmacotherapy 
Intervention:  
G1: Received sertraline for 
11.3 weeks: 1 week placebo 
washout, 3 weeks for 
medication buildup before 
quit day, 6 weeks at full 
dose (200mg), and a 9 day 
taper period. 
C1: Same as G1 but used 
placebo 
Method of assessment: 
7-Day point prevelance self-
report (biochemically verified 
by cotinine levels less than 
25 ng/ml) 
Baseline data: 
Lower nicotine dependence 
scores for participants in G1; 
no other baseline 
differences 
Statistical analysis:  
Chi square and t-tests of 
significants 
Data verification: 
Self-report and cotinine 
tested 
Dependent variables: 
• Abstience  
• Nicotine dependence 
level 
• Depression 
• Withdrawal symptoms 
• Compliance with NRT 
treatment  
At the end of treatment, 
abstience rates were 28.8% 
for C1 and 33.8% for G1, this 
was not significant 
At 6 months, the abstience 
rates were G1=11.8 and 
C1=16.7%, NS 
No modifying effects of 
depressed mood at baseline, 
nicotine dependence level, or 
gender were observed 
Quality rating: 
Poor 
Comments: 
Similar to a run-in periods 
this study participants if not 
motivated to quit after week 
1 (9%) 
Adequate randomization: 
Yes 
Attrition rate: 
25.4% 
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Author: 
Croghan et al; 2003 
Geographic area: 
US 
Funding agency: 
NCI, Public Health Service 
and NCI, DHHS  
 
Medications provided by 
NcNeil Consumer Products 
Study setting: 
Community-based 
Practice/provider settings 
 
Study objective: 
To determine whether combined use of NP 
and a NNS would improve smoking 
abstinence rates compared to either therapy 
alone without behavioral counseling; to 
determine frequency and severity of adverse 
events experience 
Population: 
Adults 
Study type: 
RCT w/ stratified randomization 
• Multi-center, randomized, open-label 
clinical trial 
• Txt assignment carried out using a 
dynamic allocation procedure that 
balanced marginal distributions of 
stratification factors among three txt 
groups 
• Stratification factors used gender, number 
of cigarettes smoked per day reported at 
time of study entry (15–39 vs 40 or more 
cigarettes per day), and total yrs of 
smoking (fewer than 5 yrs vs 5–9 yrs vs 
10 or more yrs) 
• Open-label, randomized, 3-intervention, 
multi-center trial. 
Inclusion criteria: 
• 18 yrs of age or older 
• Smoking at least 15 cigarettes per day for 
past yr 
• Good health verified by medical history 
• Female subjects of childbearing potential 
had to be using contraception,  
• Ability to participate in all aspects of study
 
Sampling plan: 
After dissemination of a local news 
release (radio and print), interested 
smokers contacted their regional 
NCCTG cancer control site and 
underwent telephone screening 
 
Brief discussion of study provided, 
informed consent obtained, 
demographic information collected, and 
an interview based on inclusion and 
exclusion criteria conducted over phone 
 
Study subjects who fulfilled basic study 
entry criteria were invited to attend an 
information meeting, at which time 
details of study were explained and an 
informed consent signed 
Sample size: 
Total: 1,384 
Definition of smoking: 
Cigarettes 
• At least 15 per day over past yr NR 
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Intervention methods: 
Pharmaceuticals 
Intervention:  
G1: 15 mg transdermal 
NPfor 16 hr a day; new 
patch each morning; initiated 
within 7 days of 
randomization and 
continued for 6 wks  
G2: NNS that delivered 0.5 
mg of nicotine per spray; 
recommended dose one puff 
per nostril as needed to a 
maximum of five doses per 
hr or 40 doses per day; 
initiated within 7 days of 
randomization and 
continued for 6 wks 
G3: 15 mg transdermal 
NPfor 16 hr a day, putting on 
a new patch each morning, 
plus nicotine nasal spray 
that delivered 0.5 mg of 
nicotine per spray, 
recommended dose of one 
puff per nostril as needed to 
a maximum of five doses per 
hr or 40 doses per day; 
initiated within 7 days of 
randomization and 
continued for 6 wks 
C1: NR 
Method of assessment: 
Subjects returned to clinic at 
3 wks, 6 wks, and 6 mos 
postintervention; self-
reported smoking rates, 
expired air CO levels, and 
reports of adverse events 
collected Questionnaire 
about smoking history, 
Fagerstrom, Health Status 
Questionnaire 
 
Statistical analysis:  
Tests of balance in 
baseline characteristics 
across txt arms carried out 
via Χ2 procedures for 
categorical variables, 
Kruskal-Wallis tests for 
ordinal-level data, and 
ANOVA for interval- and 
continuous-level variables; 
effect of sociodemographic 
variables on abstinence 
rate comparison 
investigated via logistic 
regression modeling  
 
Standard equality of 
binomial proportions, 
logistic regression 
modeling 
Data verification: 
CO levels of expired air 
collected to verify self-
reported smoking status 
Expired CO < 8 ppm 
confirmed smoking 
abstinence 
Dependent variables: 
Smoking status: wk 6 
biochemically confirmed 7-
day point prevalence 
smoking abstinence rate. 
Baseline data: 
No reported differences 
among txt groups, but no 
data given 
Overall, mean age = 42.0 
(+/-10.8); 58% female; 
mean 26.2 (+/-9.8) 
cigarettes per day; mean 
23.2 (+/-10.7) yrs of 
smoking 
CO confirmed 7-day point-
prevalence smoking abstinence 
rates at 6-wks after initial quit date:  
G1: 20.7% 
G2: 13.6% 
G3: 27.1% 
P = < 0.001 
Differences in CO confirmed 7-day 
point-prevalence smoking 
abstinence rates at 6 mos were NS 
Abstinence rates (6 wks):  
G1: 20.7% 
G2: 13.6%  
G3: 27.1%  
P < 0.001 
NNS associated w/ more adverse 
events than NP (P < 0.001): 
burning in nose or throat (63% vs 
12%), watery eyes (48% vs 14%), 
sneezing (49% vs 21%) 
Quality rating: 
Poor 
Comments: 
Attrition quite high at 
6 mos (70%); overall, 
45% of participants 
non-compliant w/ 
study protocols - a 
larger proportion 
than were compliant 
(34%); study may not 
have had enough 
power 
Baseline data not 
given by txt group 
Adequate 
randomization: 
Yes 
Attrition rate: 
6 wks: 47%  
6 mos: 70%  
 
C-76 
Evidence Table 5. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Croghan et al; 2003 
(continued) 
 
Exclusion criteria: 
Exclusion criteria included  
• Recent (< 3 mos) history of myocardial 
infarctionangina pectoris, serious cardiac 
arrhythmia, or other medical conditions 
that the health care provider deemed 
incompatible w/ study participation 
• Presence of current (within 30 days) 
psychiatric disorders (major depression, 
bipolar disorder, schizophrenia); current 
use of major psychiatric 
drugs(antipsychotics, lithium) 
• Chronic nasal disorders such as nasal 
polyps, chronic nasal congestion, 
allergies, or sinusitis that would preclude 
use of a nasal spray 
• Pregnancy or current breast feeding 
• Current use of tobacco products other 
than cigarettes 
• Current use of nicotine replacement 
therapy 
• Use of an investigational drug within 30 
days of start of study 
• Concomitant use of clonidine, buspirone, 
doxepin, bupropion, or fluoxetine 
• History of skin allergies or evidence of 
chronic dermatosis 
• Participation within last 12 mos in a formal 
smoking cessation program  
 
C-77 
Evidence Table 5. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
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Author: 
Dalsgareth et al., 2004  
Geographic area: 
Denmark 
Funding agency: 
GlaxoSmithKline, Denmark 
Study setting: 
Hospital 
 
Research objective: 
To evaluate treatment with buproprion 
hydrochloride sustained release (Zyban) 
compared with placebo as an aid to smoking 
cessation in healthcare workers 
Population: 
Hospital employees from 5 hospitals in 
eastern part Denmark   
Study type: 
RCT – double-blinded  
Inclusion criteria: 
• Age ≥18 yrs old 
• Average use of ≥10 cigarettes per day 
throughout the last year 
• Motivation to quit smoking 
Exclusion criteria: 
• Use of other pharmacological support for 
smoking cessation 
• History of or current major depression 
reported by participant 
• Sever neurological, cardiopulmonary, liver 
or kidney disease 
• Epilepsy, predisposition to or former 
epidsodes of seizures 
• Use of medicine known to lower seizure 
threshold 
• Pregnancy and lack of sufficient 
contraception were additional exclusion 
criteria for fertile women. 
Sampling plan: 
• Employees were informed of study via 
E-mail, notification accompanying 
paychecks, posters and personal 
contact  
• Eligible participants screened  
• Participants underwent detailed 
baseline interview to obtain health-
disease profile and info on smoking 
behavior in general and at work 
• Subjects were given info on 
physiological and harmful effects of 
smoking as well as on the assumed 
mechanism of action and likely side-
effects of buproprion 
• All subjects received behavioral 
counseling aimed at establishing 
rational smoking cessation process 
• Each participant agreed on a target 
quit date of 8-13 days after baseline 
• Participants then randomly assigned 
either to receive buproprion 150 mg or 
placebo  
Sample size: 
G1: 222 
C1: 114 
Definition of smoking: 
Cigarettes 
• User: smoked ≥10 cigarettes daily 
• Continuous smoking abstinence: not 
even a puff 
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Intervention methods: 
• Telephone counseling 
• Clinic visits 
• Buprprion 150 mg over 7-
week period 
Intervention:  
G1: 2 motivating phone 
calls, 5 clinic visits, and 
sustained-release bupropion 
hydrochloride 
C1: 2 motivating phone 
calls, 5 clinic visits, and 
placebo  
Method of assessment: 
Clinic visits at weeks 
3,7,12,23 and 26 (post-
baseline) 
Baseline data: 
No significant differences 
b/w G1 and C1 
Statistical analysis:  
• Intent -to-treat analysis, 
in which all randomized 
patients who took ≥1 
dose of study 
medication were 
counted 
• Mantel-Haenszel chi-
square test at two-sided 
5% level of significance 
used analysis of 
smoking abstinence 
endpoints 
• Analysis of covariance 
was used for analysis of 
change in weight from 
baseline and nicotine 
dependence; treatment, 
center and baseline 
values were covariates 
• Participants with 
missing cigarette counts 
after 7-week treatment 
phase assumed to be 
treatment failures 
Data verification: 
• Self-report – completion 
of daily diary cards 
• Expired-air carbon 
monoxide  
measurements (<10 
ppm CO was the cutoff) 
Dependent variables: 
• Smoking status 
• Tobacco craving 
• Weight gain 
 
Twelve months after pretest 
(posttest 2), in-school intervention 
successful in preventing vocational 
school students from continuing to 
smoke, compared w/ students in 
control condition OR = 0.49; 95% 
CI 0.29–0.84 
Eighteen months after pretest 
(posttest 3), tailored out-of-school 
intervention successful in 
preventing smoking initiation, 
compared w/ students in control 
(OR = 0.42; 95% CI, 0.18–0.96) 
Effect of combined approach not 
larger than sum of effects of in-
school and out-of-school effects. 
Quality rating: 
Fair 
Comments: 
• Refusal rate NR 
• Randomization 
description unclear 
regarding number 
of schools in txt 
groups 
• Out-of-school 
intervention poorly 
implemented (65% 
of personalized 
letters read by 
participants) 
Adequate 
randomization: 
Yes 
Attrition rate: 
School level  
• Posttest 1: 5.6%  
(2 schools) 
• Posttest 2: 8.3%  
(3 schools) 
• Posttest 3: 18.5% 
(NR) 
Student level: 
• Posttest 1: 17.3% 
• Posttest 2: 5.4%  
• Posttest 3: 24.6%  
 
 
C-80 
Evidence Table 5. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Davies et al., 2005 
Geographic area: 
Southeastern US 
Funding agency: 
National Cancer Institute 
Study setting: 
Hospital 
 
Research objective: 
To evaluate the impact of a stage-matched 
smoking cessation intervention in a sample 
of hospitalized, low-income, African 
American smokers admitted to an indigent 
care hospital 
Population:  
• Low income hospitalized adult African 
Americans 
Study type: 
Experimental, pretest-posttest design 
Inclusion criteria: 
• Adult  
• African American 
• Admitted to medical and surgery units of 
the study hospital 
• Smoker 
Exclusion criteria: 
• Life expectancy less than one year  
• Mental conditions (not defined) 
Sampling plan:  
90 % of patients approached agreed to 
participate 
Sample size: 
248 
Definition of smoking:  
NR 
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Intervention methods:  
• Self-help 
• individual counseling 
Intervention:  
G1: Physician-delivered 
stage-specific advice to quit 
smoking; individualized 
counseling based on the 
smokers stage of readiness 
and individual smoking 
pattern; self-help materials 
tailored to the African 
American smokers and their 
support networks; and a 
follow-up booster session in 
the form of a phone call 
following the patient’s 
discharge from the hospital 
(at @6 months) 
C1: usual care (not defined) 
Method of assessment: 
In person and telephone 
survey at about 6 months 
Baseline data: 
Between group differences 
are not reported 
Statistical analysis:  
• Mann-Whitney U used to 
examine intervention 
effects by baseline stage 
• Z Test used to compare 
overall differences 
between treatment groups 
(forward movement, 
success in quitting 
smoking) 
• T tests used for 5 
measures (Pros, Cons, 
Confidence, 2 Nicotine 
Dependent measures) 
• Intention to treat analysis 
used only for cessation 
rates 
Data verification: 
Self report 
Dependent variables:  
• Sociodemographic 
characteristics 
• Smoking history 
• Present smoking habit 
• Stage of change 
• Decisional balance 
• Self-efficacy to remain 
abstinent 
• Perceived nicotine 
dependence 
• Perceived health status 
• Presence of chronic 
disease 
 
 
Intervention patients more 
likely to advance in stage than 
control patients 
Dependence score increased 
as stage of readiness 
increased 
Intervention had a higher 
proportion of subjects in the 
preparation and action stages 
at follow-up, significantly  
(P < 0.05) for those at 
contemplation stage at 
baseline 
Greater percentage of 
intervention than controls 
progressed at least one stage 
(40% vs 21.7%,  
P < 0.01) 
ITT analysis for cessation non-
significant (G1:7.9% vs C1: 
5.8%)  
Quality rating: 
Poor 
Comments:  
• 60% failed to complete 6 
month follow-up 
• ITT analysis used for 
cessation rates does not 
state that all of those with 
no follow-up data were 
categorized as smokers 
Adequate randomization: 
Not defined, plus there was 
a second adjustment made 
by assigning shared rooms 
to either the intervention or 
control groups 
Attrition rate:  
• 152 of 248 were loss to 
follow-up 
• Reasons:  
- no telephone,  
- telephones  
  disconnected,  
- changed residence,  
- became homeless,  
- went to prison 
- died 
• Several follow-up 
interviews took place well 
after 6 months 
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Author: 
Garvey et al., 2000 
Geographic area: 
United States 
Funding agency: 
National Institute on Drug 
Abuse and the Department 
of Veteran Affairs 
Study setting: 
Community-based  
Research objective: 
To investigate the long-term efficacy of 4-mg 
and 2-mg gum for smokers classified at 
baseline as low or high in dependence on 
nicotine 
Population: 
• Smokers from greater Boston area 
• ≥20 years old 
Study type: 
RCT  
Inclusion criteria: 
• Aged ≥20 years, smoke ≥5 cigarettes per 
day 
• Adequate health  
Exclusion criteria: 
• Cardiologist deemed subjects in 
“inadequate” health based on medical 
tests, including hematology analyses, 
liver-function profiles, urinalyses and if 
over 50 years old, electrocardiograms 
 
Sampling plan: 
• Recruited smokers from greater 
Boston area via newspaper ads and 
press releases 
• Subjects needed to obtain a letter 
from their doctor stating they had no 
obvious medical conditions that would 
prevent them from entering the study; 
those who didn’t have primary care 
physician required to undergo testing 
at medical lab in Boston 
• Subjects chose a quit-day and 
reported for their baseline visits a 
median of 3 days before their quit 
days – at baseline, they completed 
the Heaviness of Smoking Index and 
a 2-question subset of the Fagerstrom 
Test for Nicotine Dependence. 
Results were used to classify subjects 
as either low-dependence or high-
dependence  
• Subjects within each dependence 
group were assigned to placebo, 2-
mg, or 4-mg gum treatment using a 
randomized, double-blind procedure 
• Subjects were instructed on proper 
use of gum, recommended to use 9-
15 pieces of gum a day for 2 months, 
after which they would wean 
themselves from the gum – would be 
weaned off by 5 months post-
cessation 
Sample size: 
G1: 87 
G2: 88 
G3: 115 
G4: 115 
C1: 88 
C2: 115 
Definition of smoking: 
Cigarettes 
• Current Smoker – Smoking ≥5 
cigaretters per day  
• Relapser – if returned to a regular 
pattern of smoking at any time during 
the 1-year period of follow up 
• Regular pattern of smoking – 7 or 
more consecutive days or episodes of 
smoking 
• Day of relapse – the day post-
cessation that began the regular 
pattern of smoking  
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Intervention methods: 
• Self help booklet (all 
groups) 
• Brief behavioral 
counseling (all groups) 
• Nicotine gum – 2mg or 
4mg 
Intervention:  
G1: Low dependence 2 mg 
gum 
G2: Low dependence 4 mg 
gum 
G3: High dependence 2 mg 
gum 
G4: High dependence 4 mg 
gum 
C1: Low dependence 
placebo 
C2: High dependence 
placebo 
Method of assessment: 
Follow up visits at 1, 7, 14, 
30 days and 2, 3, 6, 9, and 
12 months post-cessation  
Baseline data: 
Placebo, 2-mg and 4-mg 
gum users were comparable 
on most baseline variables – 
those in 4-mg group had 
higher mean CO values  
(P= 0.01) and heart rates  
(P = 0.02) 
High-dependence smokers 
were more likely to be older 
and less-educated, slightly 
more likely to be males, and 
they had significantly larger 
values on other indices of 
depencence 
Statistical analysis:  
• Wilcoxon rank sum tests 
were used to compare 
percentage baseline 
cotinine replaced by 
each dose of nicotine 
gum 
• Logistic regression 
analysis and pairwise 
dose comparisons were 
used to assess 
differences in 
abstinence rates among 
groups at each post-
cessation visit. Two 
dummy variables (each 
coded 1 or 0) were used 
to represent the 3 
nicotine-gum doses in 
these analyses 
• Chi-square tests for 
binomial trends were 
used to examine the 
significance of dosage 
effects 
• Effects of nicotine gum 
dose on withdrawal 
symptoms and urges to 
smoke were assessed 
for the 1st 30 days post-
cessation using 
repeated-measures 
analysis of variance 
• For withdrawal indices, 
changes from baseline 
on various indices of 
withdrawal were 
dependent variables in 
repeated-measures 
analysis; while values 
obtained at 1,7,14,and 
30 were used to 
supplement repeated-
measures analysis 
• Because of occasional 
missing data, number of 
subjects available for 
some statistical 
analyses were reduced) 
Data verification: 
Self-report, saliva cotinine 
and CO levels 
Dependent variables: 
Quit rates  
At 1 year follow-up quit rates for 
low dependence were  
Placebo 11.2% 
2 mg gum 19.5% 
4 mg gum 18.4% (NS) 
High dependence smokers quit 
rates at 1 year 
2 mg gum compared to placebo 
(15.7% vs. 6.1%, P = 0.02) 
4 mg gum compared to placebo 
(20.7% vs. 6.1% P = 0.002) 
No statistical differences between 
2 and 4 mg gum doses. Both 2 
and 4 mg gum users significantly 
(P < 0.008) more likely to abstain 
than placebo at all post-cessation 
assessments, except for day 1 
Other variables related to 
abstinence at 1 year post-
cessation were a longer period of 
abstinence on a prior quit attempt, 
being married, higher education 
level, and having a non-smoking 
spouse or significant other 
 
 
Quality rating: 
Fair 
Comments: 
• 3 subjects 
withdrew from 
study due to 
adverse effects – 
dizziness, nausea 
and vomiting 
Adequate 
randomization: 
Yes 
Attrition rate: 
Overall attrition not 
reported but 3 left 
due to adverse 
events 
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Author: 
Hahn et al; 2004 
Geographic area: 
US 
Funding agency: 
American Legacy 
Foundation 
Study setting: 
Community-based 
 
Study objective: 
To evaluate impact of a quit and win contest 
on smoking cessation among low-income 
tobacco users 
Population: 
• Adults 
• Low SES 
Study type: 
Two-group, quasi-experimental study 
Inclusion criteria: 
Intervention group:  
• at least 18 yrs old 
• volunteered to participate in a quit-and-
win contest 
• registered for contest by September 10, 
2001 
• earned <$25,000 per yr 
C1:  
• regular tobacco user who had smoked 
cigarettes or used another form of 
tobacco in last 30 days 
• had not been exposed to promotional 
media campaign 
• earned <$25,000 per yr 
Exclusion criteria: 
NR  
Sampling plan: 
Intervention group: sample of volunteer 
registrants in a quit-and-win contest 
C1: participants randomly selected from 
outside media campaign geographic 
area using random digit dialing and 
meeting inclusion criteria 
Sample size: 
Total: 538 
Definition of smoking: 
Cigarettes 
• Quitter: not used any form of tobacco 
in last 7 days 
Smokless tobacco 
• Quitter: not used any form of tobacco 
in last 7 days 
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Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Group counseling 
• Telephone counseling 
• Computer-based 
Program 
• Social support 
• Media campaign 
Intervention:  
G1: A community quit date 
requiring participants to 
quit using tobacco for 30 
days to be eligible for a 
large cash prize lottery; 
provider advice on gender-
specific cessation 
information to participants 
through weekly mailed 
postcards during 30-day 
contest period; online 
computer registration and 
quit assistance; one-on-
one telephone quit 
assistance through a toll-
free number provided by 
Cancer Information 
Service’s smoking 
cessation call center; a 
media campaign that 
included paid radio and 
television advertisements, 
intensive billboard 
promotions, magazine or 
newspaper registration, 
newspaper features, 
registration brochures, and 
promotional flyers; and 
support from community 
organizations, work sites, 
physicians, health 
professionals, and 
community leaders 
 
Statistical analysis:  
Group comparisons 
performed using Χ2 of 
equal proportions for 
nominal variables 
Kruskal– Wallis tests for 
ordinal variables, or two-
sample t-tests for 
continuous variables 
Repeated measures 
analysis for logistic 
regression based on 
GEE approach used to 
determine predictors of 
quit status over three 
postcontest time periods 
 
Each model included 
control variables of 
baseline age, gender, 
race (Caucasian v. 
other), education (<HS v. 
>HS), marital status 
(married v. unmarried), 
and stage of change 
status to adjust for 
differences in personal 
characteristics among 
participants 
Data verification: 
All participants who 
reported quitting were 
asked to provide a urine 
sample to test for 
cotinine; cotinine level 
determined by Accutest 
NicoMeter 
Dependent variables: 
Tobacco use status 
 
Percentage of participants w/ 
self-reported 7-day point 
prevalence abstinence at 3-
month followup:  
G1: 23.3,  
C1: 3.1 
P = < 0.001 
Percentage of participants w/ 
confirmed 7-day point prevalence 
abstinence at 3-month followup: 
G1: 11.3 
C1: 0.7 
P = < 0.001 
Percentage of participants w/ 
self-reported 7-day point 
prevalence abstinence at 6-
month followup:  
G1: 21.2 
C1: 5.9 
P = < 0.001 
Percentage of participants w/ 
confirmed 7-day point prevalence 
abstinence at 6-month followup: 
G1: 9.3 
C1: 0.7 
P = < 0.001 
Percentage of participants w/ 
self-reported 7-day point 
prevalence abstinence at 12-
month followup:  
G1: 23.3  
C1: 8.7 
P = < 0.001 
Percentage of participants w/ 
confirmed 7-day point prevalence 
abstinence at 12-month followup:  
G1: 8.1  
C1: 0.7 
P = < 0.001 
 
Quality rating: 
Poor 
Comments: 
• High attrition 
• Intervention 
group volunteer 
sample 
• C care NR 
• Exposure to 
intervention low 
• Not 
generalizable 
Adequate 
randomization: 
NR 
Attrition rate: 
Loss to followup by 
12-month followup:  
G1: 41% 
C1: 44% 
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Author: 
Hahn et al; 2004 
(continued) 
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Intervention Details 
Statistical Analysis 
and Baseline Data  Outcome Measures 
Quality 
Comments 
Community organization 
support included 
promoting the contest at 
work sites and in 
community newsletters, 
recruiting participants via 
flyers at physician offices 
and health fairs, and 
coordinating group 
cessation classes to 
coincide w/ the contest. 
C1: NR 
Method of assessment: 
Telephone interviews 
conducted at baseline, 
then 3, 6, and 12 months 
after baseline interview 
 
Baseline data: 
Participants more likely 
to be married in the 
intervention group than 
in the control 
More than half of 
intervention group had at 
least some college 
education, while only 1/4 
of C had any 
postsecondary 
education; intervention 
group significantly 
younger than control 
(Median age: G1: 35.9, 
C1: 42.3, t = 5.3, 535 df, 
P = < 0.0001); those lost 
to followup at 1 yr were 
significantly younger 
than those who remained 
in study (loss to followup: 
mean age = 37.5, 
remained in study: mean 
age = 41.2, t = 3.0, P = 
0.003) 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Hall et al., 2004 
Geographic area: 
United States 
Funding agency: 
NIDA  
Study setting: 
Population-based 
Research objective: 
To determine the effects of brief versus 
extended treatment with nortriptyline and 
group counseling 
Population:  
General public 
Study type: 
RCT 
Inclusion criteria: 
Smoked >=10 cigarettes per day 
Exclusion criteria: 
• Cardiovascular disease 
• History of seizure 
• Severe allergies 
• Life-threatening disease 
• Bipolar disorder 
• Current major depressive disorder 
• Use of l-dopa 
• Migraine headaches 
• Current use of any psychiatric medication 
including bupropion 
• Suicidal or psychotic symptoms 
• Current use of NRT 
• Previous treatment for cigarettes smoking 
with nortriptyline 
• Treatment for drugs or alcohol within 6 
months 
• Psychiatric hospitalization within 1 year 
• Pregnancy or lactation 
Sampling plan:  
• Subjects were recruited through 
advertising, PSAs, and flyers 
• Interested persons completed a 
telephone screening and orientation 
meeting 
• After informed consent was obtained, 
potential subjects were invited to a 
baseline physical assessment 
• For those who did not have any 
exclusion criteria, 160 subjects 
smoking ≥ 10 cigarettes per day were 
stratified by: 
- baseline number of cigarettes 
- history of nicotine replacement  
  therapy 
- history of major depressive disorder 
• Subjects were then randomized to 
four treatment cells 
Sample size: 
160 subjects 
Definition of smoking:  
Subject must meet all three criteria to be 
considered abstinent: 
• self-report of not having had a 
cigarette in past seven days, not even 
a puff 
• carbon monoxide levels ≤ 10 ppm 
• cotinine levels of ≤ 50 ng/ml 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Transdermal nicotine 
patch 
• Group counseling 
• Bupropion 
Intervention:  
G1: Brief Nortriptyline: 
Nortriptyline for 12 weeks; 5 
counseling sessions and 
NRT patch at week 5 
C1: Brief placebo: Placebo 
for 12 weeks; 5 counseling 
sessions and NRT at week 5 
G2: Extended Nortriptyline: 
G1 + extended 
pharmacotherapy and 
counseling (1/month) for 52 
weeks 
C2: Extended placebo: G2 
but used placebo instead of 
Nortriptyline 
Method of assessment: 
• In-person self-report  
• Carbon monoxide 
• Urinary cotinine 
Baseline data: 
No significant differences 
among the intervention 
conditions 
Statistical analysis:  
• Powered at 80% with 
alpha = .05 
• Logistic regression was 
used to test the effect of 
drug/placebo dose and 
treatment duration on 
repeat 7-day abstinence 
• Generalized estimating 
equation was used to test 
hypotheses about point 
prevalence abstinence at 
weeks 24,36,52 
• Compared baseline 
variables among the four 
groups using ANOVA for  
continuous and chi-
square for categorical to 
examine if randomization 
had been compromised 
• To identify potential 
covariates, used point-
biserial correlations 
• Differences in weeks of 
medication / placebo 
dispensed were 
determined by a two-way 
ANOVA with individual 
comparisons with the 
Tukey test 
• Differences in withdrawal 
symptoms were 
determined using 
repeated measures 
ANOVA 
• Chi-square tests or 
Fisher’s exact tests were 
used to determine 
differences in side effects 
• All tests for all analyses 
were two-tailed 
Data verification: 
• Expired carbon monoxide 
and urinary cotinine were 
used at 24, 36, and 52 
week follow-ups 
• Expired carbon monoxide 
only was used at 12 week 
follow-up 
Dependent variables:  
• Abstinence 
• Nortriptyline adherence 
• Withdrawal symptoms 
• Side effects 
A duration by dose by time of 
assessment effect was significant 
(X2 = 11.90, df=3, P = 0.008) 
Brief Nortriptyline vs brief placebo 
(OR = 0.69, 96%CI; 0.49-0.92,  
P = 0.02) 
Brief Nortriptyline vs extended 
placebo (OR = 0.47, 95%CI; 
0.30-0.75, P  = 0.001) 
Extended Nortriptyline did not 
differ significantly from extended 
placebo 
Quality rating: 
Fair 
Comments:  
NR 
Adequate 
randomization: 
Unknown – did not 
state how they 
randomized 
participants 
Attrition rate:  
• 13% for brief 
nortriptyline 
• 7% for brief 
placebo 
• 10% for extended 
nortriptyline 
• 27% for extended 
placebo 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Hand et al., 2002 
Geographic area: 
UK 
Funding agency: 
Author’s endowment fund 
Study setting: 
Hospital-based 
 
Research objective: 
To investigate the effectiveness of combined 
NRT (Patch and inhaler) for smoking 
cessation in patients hospitalized for 
smoking related disease. 
Population: 
Adults  
Study type: 
RCT  
Inclusion criteria: 
• Hospitalized inpatients or outpatients with 
smoking related disease referred to 
counselor by hospital doctor 
• Age 18 or older 
Exclusion criteria: 
• Patients with alcoholism, drug dependeny, 
active psychiatric illness, preterminal or 
terminal patients, pregnant women, and 
patients who suffered a myocardial 
infarction during previous month 
Sampling plan: 
• Recruitment began on October 1, 
1998 and all patients recruited during 
this month and in any even month 
over the next 13 months were given 
NRT 
• Those patients recruited in the 
following month and in any odd month 
over the next 12 months were given 
advice and support 
• One extra month of patients were 
randomized to the NRT group 
resulting in unequal groups 
Sample size: 
G1: 136 (NRT and advise and support) 
C1: 109 (advice and support) 
Definition of smoking: 
Abstinence 
• Carbon monoxide levels less than  
10ppm 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
Pharmacotherapy 
Intervention:  
G1: Received NRT 
(combination of nicotine 
patch and inhalator) for 3 
weeks; dosage determined 
by number of cigarettes 
smoked; plus G2 
C1: Four weekly sessions 
and patient encouraged to 
set quit date (45 to 60 
minutes); followed by 3 
weekly 15-30 minute 
sessions 
Method of assessment: 
Carbon monoxide validated 
Self-report at 1 week, 3, 6 
and 12 months  
Baseline data: 
No baseline differences 
Statistical analysis:  
Chi square test of 
significants 
Data verification: 
Carbon monoxide verified 
Dependent variables: 
• Smoking status 
• Compliance with NRT 
treatment  
At week 1, abstinence rates were 
higher for G1 compared with C1 
(54% vs 33%, P < 0.001) 
At 6 months this significant 
difference disappeared between 
the two groups. 
At year 1, 14% of the total 
sample were verified as abstinent 
(G1=15%, C1=14%, NS) 
30% of G1 used the full supply of 
NRT and 43.9% of these patients 
successfully quit at year 1 
Quality rating: 
Fair 
Comments: 
NA 
Adequate 
randomization: 
No 
Attrition rate: 
0% 
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Author: 
Helgason et al., 2004 
Geographic area: 
Sweden 
Funding agency: 
NR 
Study setting: 
Population-based 
 
Research objective: 
To assess variables related to 12-months 
abstience using proactive compared to 
reactive telephone quitline smoking 
interventions 
Population: 
Adults   
Study type: 
Cohort study 
Inclusion criteria: 
Contacted toll-free Swedish quitline from 
April to October 1999 
Exclusion criteria: 
NR 
Sampling plan: 
Immediately after the first call all 
patients expressing an interest in beign 
registered as clients received a 
registration from by mail confirming their 
idenity 
Sample size: 
G1: 694 (reactive quitline) 
G2: 900 (proactive quitline) 
Definition of smoking: 
Abstience 
• Not a single puff of smoke during the 
last week 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
Telephone quitline  
Intervention:  
G1: Tailored materials to the 
patients motivation to quit 
(stage of change) is offered 
free of charge; treatment 
protocal is described as a 
combination of motivational 
interviewing, cognitive 
behavioral therapy, and 
pharmacological counseling 
G2: same as G1 with 4 to 5 
proactive counseling calls 
Method of assessment: 
Self-report at 12 to 13 
months after first contact 
Baseline data: 
NR  
Statistical analysis:  
Logistic regression was used 
to calculate Odds Ratios 
Data verification: 
Self-report  
Dependent variables: 
• Smoking status 
• Stage of change 
• NRT use 
• Exposure to second hand 
smoke 
• Treatment compliance 
• Periods of depressive 
moods 
• Use of additional support 
Additional support (i.e., being 
referred  to the quitline by a 
health professional)  was 
associated with abstience and 
persisted with the exclusion of 
patients with severe smoking 
related symptoms 
Overall abstience was not 
significantly higher in the 
proactive compared with the 
reactive group (33% vs 28%, 
NS) 
When men and women are 
assessed separately, women 
were signifcantly more likely to 
be abstinent in the procative 
compared with the reactive 
group (34% vs 27%, P.03)  
 
Quality rating: 
Poor 
Comments: 
NA 
Adequate randomization: 
NA 
Attrition rate: 
30% 
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Author: 
Hennrikus et al., 2005 
Geographic area: 
US 
Funding agency: 
NIH 
Study setting: 
Hospital 
 
Study objective: 
Evaluation of effectiveness of three smoking 
cessation interventions for a hospital-based 
population 
Population: 
Adults 
Study type: 
RCT w/ systematic randomization  
Inclusion criteria: 
• Patient smoked a cigarette in wk before 
admission and considered themselves a 
regular smoker for at least 1 mo during yr 
before admission 
• Between 18 and 75 yrs old 
• Length of hospital stay of 24 hrs or 
greater 
• Ability to understand consent process 
• Availability for telephone contact 
Exclusion criteria: 
• Pregnancy 
• Chemical dependency or psychiatric 
disturbance as primary reason for 
admission 
• Severe physical or mental distress  
Sampling plan: 
Research assistant obtained list of all 
general admissions from previous day at 
four hospitals and screened patients 
meeting age and admission dz 
requirements for smoking status and 
other eligibility requirements 
Research assistants approached 
patients for informed consent and asked 
consenting patients to complete a 
baseline interview; participants then 
randomized by research assistant by 
looking up next available group 
assignment on a list on which 3 
conditions were randomly ordered within 
blocks of 30 assignments 
Sample size: 
G1: 703 
G2: 696 
C1: 696 
Definition of smoking: 
Cigarettes 
• Regular smoker: smoked more than 
100 cigarettes in lifetime 
• Current smoker: uses cigarettes now 
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Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Individual counseling by health 
professional 
• Telephone counseling 
• Referral to community resources, 
clinician reminder 
Intervention:  
G1: Participants given 2 smoking 
cessation manuals designed for 
hospital in-patients, a directory of 
smoking cessation community 
resources, a label in medical record 
to cue doctors and nurses to provide 
brief (60 second) smoking cessation 
advice and document that advice, 
and a letter after discharge 
reiterating that their health care 
providers would like for them to quit 
and to encourage them to read 
manuals provided 
G2: Participants given 2 smoking 
cessation manuals designed for 
hospital in-patients, a directory of 
smoking cessation community 
resources, a label in medical record 
to cue doctors and nurses to provide 
brief (60 second) smoking cessation 
advice and document that advice, a 
letter after discharge reiterating that 
their health care providers would like 
for them to quit and to encourage 
them to read manuals provided, a 
more extended bedside counseling 
session in the hospital, and three to 
six telephone calls from a research 
nurse during 6 mos after discharge 
C1: Participants received 2 smoking 
cessation manuals tailored for 
hospital in-patients and a directory of 
smoking cessation community 
resources 
Method of assessment: 
Followup interviews 7-18 days and 
12 mos post discharge; for those 
who reported abstinence at 12 mo 
followup, salivary cotinine levels 
assessed 
 
Statistical analysis:  
Using SAS statistical 
package, multivariate 
logistic regression 
conducted to examine the 
outcome variable 
"abstinence from tobacco 
use; " Mantel-Haenszel 
test for homogeneity of 
effects performed for each 
outcome to determine 
whether results from 4 
hospitals could be pooled; 
Χ2 analyses of 
relationships b/w txt 
condition and outcomes 
also performed 
Data verification: 
Salivary cotinine levels 
assessed for those who 
reported abstinence at 12-
mo followup 
Dependent variables: 
Abstinence; use of NRT 
Baseline data: 
Groups similar at baseline 
 
Percentage of those self-
reporting abstinence at 7-
day followup:  
C1: 26.0% 
G1: 24.0% 
G2: 25.2% 
P = > 0.05 
Percentage of those self-
reporting abstinence at 12-
mo followup:  
C1: 15.0% 
G1: 15.2% 
G2: 19.8% 
P = < 0.05 
Percentage of those 
abstinent verified by 
salivary cotinine at 12-mo 
followup:  
C1: 8.8% 
G1: 10.0% 
G2: 9.9% 
P > 0.05 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
• 7-day followup: 
13.5% 
• 12-mo followup: 
24.1% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Hitsman et al., 1999 
Geographic area: 
US 
Funding agency: 
VA Merit Review award by 
NIDA, and Eli Lilly and 
Company 
Study setting: 
Population-based 
 
Study objective: 
To identify individual differences that predict 
cessation when fluoxetine is combined w/ 
CBT 
Population: 
• Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
Participants are: 
• 18 to 65 yrs of age 
• have smoked daily for at least one yr 
• exhibit a baseline expired CO level of 
greater than 8 ppm 
• agree to declare a quit date within 2 wks 
after second study visit (Source: Borrelli, 
et al. 1997) 
Exclusion criteria: 
• Clinically significant depression HDRS 
score greater than 14 
• Pregnancy 
• Hypertension 
• Use of psychotropic medication or current 
psychiatric illness 
• Alcohol or drug abuse in past yr 
• Current use of nicotine replacement 
• Unstable medical condition or major 
health event in past 6 months 
• Use of ST, pipes or cigars 
• Recent experience of a major life event 
(e.g., divorce or major job change) 
• Suicidal ideation 
• History of bipolar disorder (Source: 
Borrelli, et al. 1997) 
Sampling plan: 
Specific randomization scheme NR. 
Sample size: 
Total: 253 
Definition of smoking: 
Cigarettes 
• Reported smoking 
• Expired CO greater than 8 ppm 
• Saliva continine value greater than 10 
ng/ml 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Individual counseling by 
health professional 
• Pharmaceuticals 
Intervention:  
G1: Nine, 1-hr individual 
CBT sessions + fluoxetine 
30 mg for a total of 10 wks  
• Participants required to 
set a quit date within 2 
wks after drug txt began 
• Participants quit 
smoking at 3rd CBT 
session 
• Medication stopped at 
9th CBT session, at 
which time 6-month 
followup period began 
• CBT not explained 
• Patients w/ fluoxetine 
level less than or equal 
to 150 ng/ml considered 
compliant 
G2: Same as G1:, except 
fluoxetine dose of 60 mg 
and fluoxetine blood level 
less than or equal to 
300ng/ml considered 
compliant 
C1: Same as G1, except 
given placebo 
Method of assessment: 
Self report of smoking, 
expired CO, and saliva 
continine 
Also used depresion scale, 
nicotine dependence, 
weight restraint scale, and 
self-efficacy questionnaire 
 
Statistical analysis:  
Constructed predictive 
models using logistic 
regression w/ 
hierarchical approach to 
variable selection. 
Models evaluated w/ 
parallel analyses using 
stepwise selection 
procedure 
Data verification: 
Expired CO and saliva 
continine 
Dependent variables: 
Depression, nicotine 
dependence, weight 
concerns, self-efficacy 
about quitting smoking 
Baseline data: 
No significant difference 
b/w txt groups in 
baseline characteristics: 
age, gender, education, 
smoking history, baseline 
level of nicotine 
dependence, depression, 
weight concern, and self-
efficacy 
At 1 wk postcessation: higher 
levels of depression predicted 
failure to achieve abstinence (ITT 
analysis); higher levels of 
nicotine dependence and 
depression associated w/ 
decreasing likelihood of 
abstinence (analysis of txt-
compliant patients) and likelihood 
of abstinence for participants on 
fluoxetine tended to be higher 
than for those on placebo (P = 
0.06); At 1 month postcessation: 
higher levels of weight concern 
predicted lower abstinence (Χ2 
4.8, P = 0.78); patients on 
fluoxetine had positive 
association b/w degree of 
depression and likelihood of 
abstinence (highest quartile 
HRSD = 3, OR = 2, 95% CI, 
0.85-4.70); At 3 months 
postcessation: patients treated w/ 
fluoxetine had positive 
association b/w HRSD scores 
and abstinence likelihood 
(highest quartile HRSD = 3, OR = 
1.44, 95% CI, 0.53-3.91) 
Smoking characteristics 
predicting txt compliance were 
nicotine intake at baseline, saliva 
cotinine (Χ2 = 11.4, P < 0.001), 
and expired CO ( Χ2 = 5.3, P < 
0.05) 
 
Quality rating: 
Fair 
Comments: 
• Authors didn't 
report numbers 
of participants 
per arm of study, 
baseline 
demographic 
characteristics of 
those groups, 
nor 6 month 
followup results 
• Inclusion/ 
exclusion criteria 
are described in 
companion 
article, Borrelli, 
et al. 1997 
Adequate 
randomization: 
NR 
Attrition rate: 
NR 
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Author: 
Holt et al., 2005 
Geographic area: 
New Zealand 
Funding agency: 
GlaxoSmithKline 
Study setting: 
Community-based 
Population-based 
 
Study objective: 
To determine whether bupropion is effective 
in txt of smoking cessation in indigenous 
Maori population of New Zealand 
Population: 
• Adolescents 
• Young Adults 
• Adults 
Study type: 
• RCT w/ systematic randomization  
• Placebo controlled, double blind, parallel 
group study 
Inclusion criteria: 
• Self-indentified Maori 
• Age 16 to 70 
• Smoked at least 10 cigarettes per day 
over last yr 
• Desire to quit 
• Nonpregnant women w/ reliable 
contraception 
Exclusion criteria: 
History of:  
• epilepsy 
• febrile convulsion 
• CNS tumor 
• head injury 
• cerebrovascular dz 
• anorexia 
• bulima 
• CD 
• other severe illnesses 
• pregnant or lactating 
• drug/alcohol abuse 
• unwilling to quit marijuana 
Sampling plan: 
• Self-recruitment from mall 
advertisements 
• Recruited from Maori health networks
• Randomized (by computer generated 
code) 
Sample size: 
G1: 88 
C1: 46 
Definition of smoking: 
Cigarettes 
• Smoke ≥ 10 per day on average over 
last yr 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Individual counseling by 
health professional 
• Individual counseling by 
non health professional 
• Telephone counseling 
• Pharmaceuticals 
Intervention:  
G1: Bupropion 150 mg 
once daily for 3 days, then 
150 mg twice daily for 7 
wks; smoking cessation 
counseling 
Clinic visits (to assess 
smoking status, exhaled 
CO, and adverse events) 
at 3 wk, 7 wk,  
3 mo, 6 mo, 9 mo, and 12 
mo after target quit date 
C1: Same as G1 except 
given identical placebo 
pills 
Method of assessment: 
• Self-report 
• Fagerstrom score 
• exhaled CO 
Baseline data: 
Mean age (SD): 41.79 
(9.2) txt vs 38.0 (11.1) 
placebo 
Mean Fagerstrom index 
(SD): 5.8 (2.2) txt vs 5.3 
(2.0) placebo 
Mean initial weight (SD): 
85.4kg (18.9) txt vs 80.2 
(16.8) placebo; 69.3% 
female in txt vs 76.1% in 
placebo 
Statistical analysis:  
Primary: normal 
approximation to 
binomial distribution 
Secondary: GEE 
Exploratory: general 
additive model 
Data verification: 
Exhaled CO 
Dependent variables: 
Continued abstinence 
from smoking at 3 and 
12 months (or other time 
points, secondarily) 
 
Rates of continued abstinence in 
bupropion and placebo groups, 
respectively = 44.3% vs17.4% at 
3 months (RR = 2.54; 95% CI 
1.30-5.00); = 21.6% vs10.9% at 
12 months (RR = 1.99; 95% CI 
0.79-5.00). 
Bupropion group more likely to 
have insomnia (26% vs9% w/ RR 
= 3.0 and 95% CI 1.1-8.2) 
 
Quality rating: 
Fair 
Comments: 
• No ITT analysis 
• No attrition 
reported 
• Fell just short of 
sample size 
needed 
according to 
power analysis 
• No analysis for 
confounders. 
Adequate 
randomization: 
Yes 
Attrition rate: 
NR 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Jones et al., 2001 
Geographic area: 
United Kingdom 
Funding agency: 
NR 
Study setting: 
Hospital 
 
Study objective: 
Determine whether ICU patients' smoking 
cessation after critical illness is aided by 
provision of a rehabilitation program 
Population: 
• Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• Minimum 48 hr ICU admission 
• Had been ventilated 
Exclusion criteria: 
NR  
Sampling plan: 
Recovering ICU patients recruited to 
study 2 wks after ICU discharge, 
randomized to receive either usual care 
followup of unit visits and ICU clinic 
appointments or routine followup plus 
an ICU rehabilitation manual 
 
Sample size: 
G1: 31 (20 smokers) 
C1: 30 (16 smokers) 
Definition of smoking: 
Cigarettes 
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Social support 
Intervention:  
G1: Verbal encouragement 
to remain non-smoking at 
ICU discharge, at 8-wk clinic 
vist, and six month clinic 
visit; patients' immediate 
family instructed not to 
smoke in same room as 
patient; 2 wks postdischarge 
introduction to 6-wk self help 
ICU rehabilitation manual 
read by patient and relative 
that emphasized importance 
of remaining non-smoking 
and provided practical tips 
C1: Verbal encouragement 
to remain non-smoking at 
ICU discharge, at 8-wk clinic 
vist, and six-mo clinic visit; 
patients' immediate family 
instructed not to smoke in 
same room as patient 
Method of assessment: 
Followup in clinic at 8 wks 
and 6 mos postdischarge 
Baseline data: 
No significant differences in 
baseline data among C1 and 
G1  
Statistical analysis:  
NR 
Data verification: 
Smoking status verified by 
information from a close 
family member 
Dependent variables: 
• Smoking status 
• Levels of anxiety 
• Depression 
• PTSD-related symptoms
 
Of smokers preICU admission, 
those returning to smoking at 8-wk 
followup:  
G1: 2  
C1: 5  
RR = 0.24 (CI 0.03-1.84) 
Of smokers preICU admission, 
those returning to smoking at 6-mo 
followup:  
G1: 3 
C1: 10 
RR = 0.11 (CI 0.02-.64) 
No differences in anxiety, 
depression or PTSD-related 
symptoms at 6 mos b/w patients 
who continued to smoke and those 
who had quit (Mann Whitney U, 
HAD anxiety P = 0.51, HAD 
Depression P = 0.74, Impact of 
Events Scale P = 0.50) 
Quality rating: 
Fair 
Comments: 
Very small study; 
due to type of article, 
details about 
randomization and 
sampling NR 
Adequate 
randomization: 
NR 
Attrition rate: 
O% attrition 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Jorenby et al; 1999 
Geographic area: 
US 
Funding agency: 
Glaxo Wellcome 
Study setting: 
Community-based 
 
Study objective: 
To determine whether buproprion plus NPis 
more effective for smoking cessation than 
either cessation aid alone or a placebo 
Population: 
• Adults 
Study type: 
• RCT w/ systematic randomization  
• Double-blind, placebo-controlled, 
randomized control trial 
Inclusion criteria: 
• At least 18 yrs of age 
• To smoke at least 15 cigarettes per day 
• To weigh at least 45.4 kg (100 lb) 
• To be motivated to quit smoking 
• To speak English 
• Only one smoker per household allowed 
to enroll in study 
Exclusion criteria: 
Subjects excluded for following reasons:  
• Serious or unstable cardiac, renal, 
hypertensive, pulmonary, endocrine, or 
neurologic disorders, as assessed by 
study-site physician 
• Ulcers 
• Seizure or dermatologic disorders 
• A current dz of major depressive episode 
or a history of panic disorder, psychosis, 
bipolar disorder, or eating disorders 
• Use of a nrt within six mos before study 
enrollment 
• Pregnancy or lactation 
• Abuse of alcohol or a non–nicotine-
containing drug within preceding yr 
• Use of a psychoactive drug within wk 
before enrollment 
• Use of an investigational drug within mo 
before enrollment 
• Prior use of bupropion 
• Current use of other smoking-cessation 
treatments 
• Regular use of any noncigarette tobacco 
product 
Sampling plan: 
• Subjects recruited at four study sites 
by advertisements in the media  
• First subject enrolled in August 1995, 
and followup completed in March 
1997; subjects randomly assigned to 
one of four treatments w/ use of an 
unequal-cell design 
• Randomization not balanced within 
sites 
Sample size: 
G1: 245 
G2: 244 
G3: 244 
C1: 160 
Definition of smoking: 
Cigarettes 
• Abstinent: no smoking since last clinic 
visit and expired air CO 10 ppm or 
less 
• Continuously abstinent: no smoking 
since quit date at expired air CO 10 
ppm or less at every clinic visit over 
12 mos 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
Pharmaceuticals 
Intervention:  
G1: sustained-release 
bupropion (subjects received 
150 mg of bupropion in 
morning and a placebo 
tablet in evening on days 1, 
2, and 3 of txt; and one 
bupropion tablet in morning 
and one in evening on days 
4 to 63) plus NP(one patch 
per day; patches from wks 2 
to 7 each contained 21 mg 
of nicotine, those used 
during wk 8 each contained 
14 mg, and those used 
during wk 9 each contained 
7 mg) 
G2: sustained-release 
bupropion (subjects received 
150 mg of bupropion in 
morning and a placebo 
tablet in evening on days 1, 
2, and 3 of txt; and one 
bupropion tablet in morning 
and one in evening on days 
4 to 63) plus placebo patch 
G3: NP(one patch per day; 
patches from wks 2 to 7 
each contained 21 mg of 
nicotine, those used during 
wk 8 each contained 14 mg, 
and those used during wk 9 
each contained 7 mg) plus 
placebo pills 2x per day 
C1: placebo pills 2x per day 
plus placebo patch one time 
per day 
Method of assessment: 
Followup at 10 wks, 3 mos, 
6 mos, and 12 mos after 
start of study; assessment 
consisted of self-reported 
smoking status, vital signs, 
measurement of expired air 
CO, and the Beck 
Depression Inventory 
 
Statistical analysis:  
Χ2 and ANOVA used to 
test for baseline 
differences in demographic 
and smoking-history 
variables 
All statistical tests two-
sided and had an alpha 
level of 0.05 
Logistic-regression 
analysis used to determine 
pairwise differences 
among groups in 
abstinence rates 
Kaplan–Meier method 
used to analyze 
differences in rates of 
continuous abstinence; 
homogeneity among 
treatments and pairwise 
differences tested w/ log-
rank test 
Data verification: 
Expired air CO levels 
assessed to validate self-
reported smoking status 
Dependent variables: 
• Primary: smoking status 
• Secondary: withdrawl 
symptoms, body weight, 
and Beck Depression 
Inventory scores 
Baseline data: 
No significant differences 
b/w groups 
 
Proportion of participants 
abstinent at 6 mo followup: 
G1: 38.8% OR = 2.7 (95% 
CI, 1.7-4.4) P = < 0.001 
G2: 34.8% OR = 2.3 (95% 
CI, 1.4-3.7) P = < 0.001 
G3: 21.3% OR = 1.2 (95% 
CI, 0.7-1.9) P = 0.53 
C1: 18.8% 
Proportion of participants 
abstinent at 12 mo 
followup:  
G1: 35.5% OR = 3.0 (95% 
CI, 1.8-4.9) P = < 0.001 
G2: 30.3% OR = 2.3 (95% 
CI, 1.4-3.9) P = < 0.001 
G3: 16.4% OR = 1.1 (95% 
CI, 0.6-1.8) P = 0.84,  
C1: 15.6% 
All four groups had 
significant increases in 
withdrawal symptoms 
during first wk of txt (P < 
0.001) but changes 
smaller in three active-txt 
groups than in placebo 
group during first six days 
after quitting date and 
during following wks  
No txt effect on Beck 
Depression Inventory 
scores 
Subjects in combined-
therapy group had gained 
significantly less weight 
than those in placebo 
group (P < 0.05) or 
bupriopion group  
(P < 0.05) at wk 7 but no 
significant differences b/w 
groups in mean weight 
changes after wk 7 
Quality rating: 
Fair 
Comments: 
NR 
Adequate randomization: 
Yes 
Attrition rate: 
6 month followup: 30.8% 
12 month followup: 34.6% 
Adverse events: 8.8% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Killen et al., 2000 
Geographic area: 
US, San Jose, CA 
Funding agency: 
University of California 
Tobacco-Related Disease 
Research Program; 
SmithKline Beechum 
Study setting: 
Population-based 
Research objective: 
To examine efficacy of smoking cessation 
treatment that combined nicotine 
replacement therapy via transdermal system 
with antidepressant paraxetine 
Population:  
Adults 
Study type: 
RCT, double-blind 
Inclusion criteria: 
• Adults over age 18 
Exclusion criteria: 
• Pregnant, or lactating 
• History of severe liver or kidney disease, 
epilepsy, bipolar disorder, schizophrenia,  
• Receiving active treatment for or reported 
current depression or substance abuse   
• Taking antidepressants, psychotropics, or 
other drugs that could interact with 
paraxetine resulting in potentially adverse 
consequences 
• Unable to obtain permission from 
personal physician to participate in the 
study – for patients with history of heart 
disease, diabetes, thyroid disease, recent 
chest pain, very high blood pressure, skin 
conditions or peptic ulcer  
 
Sampling plan:  
• Recruitment from local newspapers, 
then telephone interview screen, then 
initial office visit screen 
• Double blind allocation 
Sample size: 
Total: 224 
About 75 in each group 
Definition of smoking:  
• Greater than or equal to 10 cigarettes 
per day 
• Abstinence: nonsmoking not even a 
puff for 7 consecutive days and saliva 
cotinine level below 20ng/ml an a CO 
level below 9ppm 
• Smokers – reported abstinence but 
failed to provide a saliva sample 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
• Self-help 
• Individual counseling 
Intervention:  
G1: NRT transdermal 
system patch for 8 weeks 
plus 20 mg paroxetine for 9 
weeks 
G2: NRT transdermal 
system patch for 8 weeks 
plus 40 mg paroxetine for 9 
weeks  
C1: NRT transdermal 
system patch for 8 weeks 
plus placebo for 9 weeks  
Method of assessment: 
• In person interview and 
biomarkers at initial clinic 
visit 
• Telephone interview at 1, 
4, 10 and 26 weeks 
• Via an interactive voice 
response system at 24 
hours, weeks 2 and 6 
Baseline data: 
• Demographics 
• Medical status questions 
• Smoking history 
• Screen for current major 
depression 
• Modified Fagerstrom 
Tolerance Questionnaire 
• Self-reported depression 
symptoms 
• Clinical diagnosis of 
depression 
• BMI 
• Blood pressure and heart 
rate  
Statistical analysis:  
• Intention to Treat analysis
• Logistic regression 
• 75% poser to detect at 
least a 20% increase in 
abstinence 
Data verification: 
• Self report 
• Saliva cotinine 
concentrations 
• Blood level to determine 
paroxetine compliance 
level 
Dependent variables:  
• Craving 
• Adverse events 
• Smoking status 
• Compliance 
• BMI 
• Heart rate 
• Blood Pressure 
• Expired air CO level 
• Depressive symptoms 
Abstinence Rates (NS) 
At 4 weeks 
G1: 48% 
G2: 57%  
C1: 45% 
At 10 weeks 
G1: 33% 
G2: 39%  
C1: 36% 
At 26 weeks 
G1: 21% 
G2: 27%  
C1: 25% 
Chemical Confirmation 
At 4 weeks: 95% 
At 10 weeks 98% 
At 26 weeks 86% 
Subanalysis of Compliant 
Persons 
At 4 weeks 
G1: 64% 
G2: 74%  
C1: 46% 
P < 0.001 
At 10 weeks 
G1: 43% 
G2: 51%  
C1: 35% 
At 26 weeks 
G1: 33% 
G2: 38%  
C1: 24% 
Those who reported greater use 
of nicotine patches and those 
with higher blood levels of  
paroxetine in Week 4 were more 
likely to be abstinent 
Quality rating: 
Good 
Comments:  
NR 
Adequate 
randomization: 
Yes 
Attrition rate:  
Not clear 
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Study Characteristics  Study Design Sample Design and Definitions 
Author: 
Lancaster et al., 1999 
Geographic area: 
United Kingdom 
Funding agency: 
NR 
Study setting: 
Practice/provider settings 
 
 
Study objective: 
To determine whether receiving brief advice 
from a GP plus extended counseling and 
followup from a trained nurse resulted in 
patients' cessation more than brief advice 
from a GP alone 
Population: 
• Adults 
Study type: 
RCT w/ systematic randomization  
Inclusion criteria: 
• Adults ages 18 and over who smoked at 
least one cigarette per day 
Exclusion criteria: 
• NR 
Sampling plan: 
• Opportunistic recruitment of patients 
attending the practice w/ unrelated 
complaints 
• Letters to patients identified as 
smokers by practice records 
• 497 patients from 6 practices 
systematically randomized to receive 
brief advice from a GP or brief advice 
from a GP plus extended counseling 
and followup from a trained practical 
nurse 
Sample size: 
G1: 249 
C1: 248 
Definition of smoking: 
Cigarettes 
• Smoker: At least one cigarette 
smoked per day and/or salivary 
cotinine levels < 113.5 nmol/l 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Pharmaceuticals 
Intervention:  
G1: Brief verbal or written 
advice to quit from the 
patients' general 
practitioners, plus: extended 
counseling and followup from 
a trained practing nurse; 
Health Education Authority 
leaflet on cessation; fact 
sheet on NRT; invitation to 
contact research nurse for 
more intensive, tailored 
counseling that included CO 
breath test and a 
personalized message about 
benefits of quitting - 
minimum one 15 min visit 
plus 1 followup, max five, 10-
min followup visits; NRT if 
necessary 
C1: Brief advice to quit from 
patients' general 
practitioners 
Method of assessment: 
Surveys administered at 3 
and 12 months post quit 
date; salivary cotinine 
assessed for self-reported 
quitters; those who did not 
provide followup information 
were assumed to be 
smokers 
 
Statistical analysis:  
• Chi sq used to test for 
differences b/w 
proportions and 95% CI 
calculated 
• ITT analysis 
Data verification: 
Salivary cotinine levels 
obtained to validate self-
reported quitters 
Dependent variables: 
• Sustained abstinence at 
3 and 12 mos 
• Biochemically validated 
• Forward movement on 
stage of change 
Baseline data: 
G1 and C1 similar at 
baseline in terms of 
demographics and 
smoking status 
Abstinence at 3 month followup:  
G1: 9.2% 
C1: 8.1%, NS 
Abstinence at 12 month followup: 
G1: 6.8% 
C1: 11.3%, NS 
Sustained abstinence (abstinent at 
both 3- & 12-month followup):  
G1: 3.6 
C1: 4.4 
Difference: -0.8%  
(CI, -4.3%, 2.6%)  
Validated (-3.3 vs4.0) 
Any forward change in stage of 
change:  
G1: 20.9% 
C1: 26.6% 
Difference: -5.7%  
(CI, -13.2%, 1.7%) 
 
Quality rating: 
Fair 
Comments: 
Adequate 
randomization: 
Yes 
Attrition rate: 
3 mo followup: 19% 
12 mo followup:25% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Lawrence et al., 2005 
Geographic area: 
West Midlands, UK  
Funding agency: 
Department of Health and 
the West Midland Health 
Authorities 
Study setting: 
Practice/provider settings 
Research objective: 
To evaluate the effect on quitting smoking at 
18 months post partum of smoking 
cessation intervention based on TTM 
delivered in pregnancy compared to current 
standard of care 
Population: 
Women patients at of antenatal clinics in 
general practices 
Study type: 
Cluster randomized trial 
Inclusion criteria: 
• At least 16 years of age 
• Still smoking at 12 weeks gestation  
Exclusion criteria: 
NR 
 
Sampling plan:  
• Recruited 16 of the 19 midwifery 
services for West Midlands 
• 100 general practices randomized into 
trial arms 
• Allocated by computerized 
minimization algorithm 
Sample size: 
G1: 305 
G2: 324 
C1: 289 
393 (42%) eligible smokers were 
followed up on 
Definition of smoking:  
• Urine cotinine of 1.5 ug/ml 
• Abstinence: declared nonsmoking and 
no cigarette consumption in last 24 
hours 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
Self-help 
Intervention:  
G1: TTM-based self help 
manuals 
G2: TTM-based self help 
manuals plus sessions with 
interactive computer 
program giving 
individualized smoking 
cessation advice 
C1: Standard care  
Method of assessment: 
Medical chart abstraction 
and follow-up telephone 
interview 
Baseline data: 
• Smoking habits 
• Urine cotinine levels 
• Fagerstrom Test for 
Nicotine dependence 
• Stage of change 
• Demographics 
• Parity 
• Proportion having a 
partner 
• Proportion whose partner 
smoked  
• Educational achievement 
• Household net income 
 
Statistical analysis:  
• Cluster randomization 
• Random effects liners 
regression 
Data verification: 
Self report 
Dependent variables:  
• Cotinine saliva 
• Continuous and point 
prevalence abstinence 
since pregnancy 
Continuous abstinence since 10 
days PP: G1+G2 vs C1: 1.20 
(95% CI: 0.29-4.88) 
Point Prevalence for Abstinence: 
G1+G2 vs C1: 1.15 (95% CI: 
0.66-2.03) 
Seven of the 54 (13%) who quit 
at end of pregnancy were still quit 
18 months later 
No evidence that TTM-based 
interventions were superior in 
preventing relapse 
18 of the 54 (33%) of those who 
had quite 10 days PP were still 
quite at 18 months, though 11 of 
these were not continuously 
 
Quality rating: 
Poor 
Comments:  
NR 
Adequate 
randomization: 
NR 
Attrition rate:  
NR  
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Lerman, et al., 2004 
Geographic area: 
United States 
Funding agency: 
National Cancer Institute; 
National Institute on Drug 
Abuse, and Public Health 
Services Research grant  
Study setting: 
Population-based 
Research objective: 
To evaluate the comparative efficacy of 
transdermal nicotine and nicotine nasal 
spray and identify predictors of treatment 
outcome 
Population:  
Adults ≥18 years old enrolled at Georgetown 
University and the University of 
Pennsylvania 
Study type: 
RCT 
Inclusion criteria: 
• 18 years of age or older  
• Had smoked 10 or more cigarettes per 
day for the previous 12 months 
Exclusion criteria: 
• Pregnancy or lactation 
• Uncontrolled hypertension 
• Unstable angina 
• Heart attack or stroke within the previous 
6 months 
• Current treatment or recent diagnosis of 
cancer, drug or alcohol dependence 
• Current diagnosis or history of a psychotic 
disorder 
• Current use of bupropion or nicotine-
containing products other than cigarettes 
Sampling plan: 
• Participants were recruited through: 
- local media ads for free smoking  
  cessation treatment  
- physician referral 
• Eligible participants randomly 
assigned to receive transdermal 
nicotine or nicotine nasal spray 
Sample size: 
299 adults  
Definition of smoking:  
• Prolonged abstinence defined as not 
having smoked for 7 consecutive days 
at any time during the follow-up period
• Point prevalence defined as 7 days of 
continuous abstinence immediately 
before the follow-up point 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
• Nicotine nasal spray 
• Transdermal nicotine 
therapy 
• Standardized behavioral 
group counseling  
Intervention:  
G1: 8 weeks of nicotine 
nasal spray and 7 sessions 
of behavioral group 
counseling  
G2: 8 weeks of transdermal 
nicotine therapy (i.e., patch) 
and 7 sessions of behavioral 
group counseling 
Method of assessment: 
8 weeks and six month 
telephone interviews plus 
biochemical verification for 
point prevalence 
Baseline data: 
Participants at the University 
of Pennsylvania site were 
significantly more likely to be 
non-white, obese, and have 
lower levels of education  
Statistical analysis: 
• Calculated sample size of 
140 per group to detect a 
between-group difference 
in quit rates of 8% or 
greater with 80% power 
(alpha = 0.05) 
• Chi square and Wilcoxon 
rank-sum tests were used 
to examine differences in 
pre-treatment variables 
• Chi square and Wilcoxon 
rank-sum tests were used 
to compare treatment 
groups on abstinence 
outcomes 
• Logistic regression 
analysis was used to 
examine the independent 
effects of treatment group 
assignment, pretreatment 
variables, and their 
interactions on prolonged 
abstinence and verified 
point prevalence 
abstinence 
• Wilcoxon rank-sum tests 
were used to examine 
differences between 
treatment group in use 
and percentage of 
cotinine replacement  
Data verification: 
• Self-report for prolonged 
abstinence 
• Self-report for point 
prevalence plus carbon 
monoxide reading < 10 
ppm 
Dependent variables: 
• Smoking status 
No statistically significant 
difference found between 
treatment groups at 6 months 
(G1: 12.2%, G2: 15%, NS)  
Abstinence rates similar to those 
achieved in other studies  
Smokers who were highly 
dependent, obese, or members 
of minority groups achieved 
higher rates of abstinence with 
nasal spray 
 
 
Quality rating: 
Fair 
Comments:  
Authors stated that 
stratification was 
done by study site but 
no mention of what 
was stratified, or how 
or why 
Adequate 
randomization: 
Yes 
Attrition rate:  
18% lost-to-follow-up 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
MacLeod et al., 2003 
Geographic area: 
Australia 
Funding agency: 
GlaxoSmithKline 
Study setting: 
Population-based 
Research objective: 
To investigate the effectiveness of telephone 
counseling as an adjunct to nicotine 
replacement therapy (NRT) by transdermal 
patch in smoking cessation 
Population: 
• Smokers from New South Wales 
• ≥18 years old 
Study type: 
RCT  
Inclusion criteria: 
• Aged ≥18 years 
• English-speaking 
• Smoking ≥10 cigarettes per day for the 
previous year 
• Ready to begin a quit attempt within 1 
week 
Exclusion criteria: 
• History of cardiovascular disease, 
diabetes or skin sensitivity 
• Currently breastfeeding, pregnant or 
intending to become pregnant 
• Using contraindicated medications 
Sampling plan: 
• Recruited smokers from New South 
Wales via newspaper ads 
• Consent forms, questionnaires on 
health, smoking history and attitudes 
to quitting were mailed to people who 
responded to the ads. 
• Responses were screened by  a 
pharmacist in accordance with the 
approved product information for 
transdermal nicotine patches and 
eligibility criteria for the study   
• Those deemed eligible were randomly 
allocated to either NRT alone or NRT 
plus telephone counseling 
• Participants were contacted by 
telephone data collectors to verify 
their understanding of the study 
(baseline) 
Sample size: 
G1: 412 
C1: 442 
Definition of smoking: 
Cigarettes 
• Current Smoker – Smoking ≥10 
cigaretters per day for the previous 
year 
• 28-day continuous abstinence (used 
at 3 and 6 month follow up calls) – 
complete abstinence, “not even a 
puff” for at least the previous 28 days 
• 90-day continuous abstinence – the 
reported date of the last cigarette 
smoked was at least 90 days before 6 
month follow-up call  
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• NRT - patch 
• Telephone counseling 
Intervention:  
G1: Nicotine Patch and 5 
telephone counseling calls, 
scheduled at 1,2,3,6 and 10 
weeks after baseline 
C1: Nicotine Patch only  
Method of assessment: 
Brief (5 minute) follow-up 
telephone questionnaires 
were administered at 1, 2, 3, 
and 6 months post-baseline 
Baseline data: 
No significant differences 
b/w the 2 groups 
Statistical analysis:  
• Intent-to-treat approach 
used, where missing 
values on smoking status 
imputed as smokers with 
0 days abstinence in that 
period, unless continuous 
abstinence between calls 
was subsequently 
reported 
• Statistical significance 
between groups was 
tested by X2  tests and 
logistical regression 
(categorical variables) or 
t tests (continuous 
variables)  
• Logistic regression 
analysis was conducted 
with both treatment group 
and duration of patch use 
included as predictors of 
90-day abstinence 
Data verification: 
• Self-report, bogus 
pipeline technique used, 
with possibility of carbon 
monoxide breath testing 
mentioned in the consent 
form and at the 3- and 6-
month monitoring calls 
Dependent variables: 
• 28-day continuous 
abstinence at 3 and 6 
months 
• 90-day continuous 
abstinence at 6 months  
 
 
Telephone counseling improves 
cessation rates when used in 
conjunction with the patch 
28-day continuous abstinence 
rates at 6-months: G1 30.6%, C1 
22.4%, P =.01 
90-day continuous abstinence 
rates G1 26.7%, C1 18.6%,  
P = 0.004 
Logistic regression analysis 
revealed the duration of patch 
use and telephone counseling 
made independent contributions 
to prediction of 90-day 
abstinence 
Odds of successful quitting 
increased with each extra week 
of patch use when treatment 
group held constant (OR=1.24,  
P < 0.05) 
When controlling for weeks of 
patch use, the odds of success 
were higher for those in the 
counseling group (OR=1.46,  
P < 0.05) 
Quality rating: 
Good 
Comments: 
No biochemical 
verification of 
abstinence – relied 
solely on self-report 
Adequate 
randomization: 
Yes 
Attrition rate: 
16% 
 
 
C-114 
Evidence Table 5. Strategies to improve success rates for quit attempts for general and special populations 
(continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
McBride et al., 2004  
Geographic area: 
United States 
Funding agency: 
National Cancer Institute 
Study setting: 
Military Medical Center 
Research objective: 
• To evaluate whether relative to usual care 
and a previously evaluated woman-only 
intevention, if training in optimal support 
behaviors and giving support to partners 
increased abstinence rates among 
pregnany women during and after 
pregnancy 
• 2nd aims – decrease postpartum relapse 
and increase rates of smoking cessation 
among partners  
Population: 
• Pregnant woman who received prenatal 
care at the Womack Army Medical 
Centers 
• Their live-in partners 
Study type: 
RCT  
Inclusion criteria: 
• Eligible women were ≤20 weeks pregnant 
• Aged ≥18 years 
• Current smokers or recent quitters 
• Living with an intimate partner 
• Willing to have the partner contacted for 
participation in the study 
Exclusion criteria: 
• >20 weeks pregnant 
• Partner not available, or refused partner 
contact 
Sampling plan: 
• Introductory letters describing the 
study were sent on behalf of WAMC 
to all women identified from 
automated appointment logs with a 
scheduled 1st prenatal visit. 
• Women who did not call study’s toll-
free number w/in 10 days to decline 
contact were called to complete 
screening survey 
• Eligible women who agreed to 
participate were stratified by smoking 
status (smoker or recent quitter), their 
partner’s smoking status (smoker or 
nonsmoker) and partner’s level of 
willingness (not at all vs somewhat or 
very)  
• Once stratified, participants were then 
randomly assigned to one of 3 
conditions: usual care (UC), woman 
only (WO) or partner assisted (PA) 
• Women and partners completed 
telephone surveys at baseline (about 
11 weeks of pregnancy) 
Sample size: 
G1: (WO): 192 
G2: (PA): 193 
C1: (UC): 198 
Definition of smoking: 
Cigarettes 
• Current Smoker – NR 
• Recent quitter – smokers in the 30 
days prior to pregnancy but not 
smoking at intake 
• Prevalent abstinence – no smoking in 
prior 7 days 
• Sustained abstinence – no smoking 
across all 4 follow-up times 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Provider advice 
• Self-help quit guides  
• Telephone counseling 
• Pregnancy relapse kit 
• Telephone counseling 
and support guide geared 
towards partners 
Intervention:  
G1: Usual care plus late 
pregnancy relapse kit, and 6 
counseling calls 
G2: G1 plus the partners 
received telephone 
counseling and support 
guide (partners who smoked 
received cessation aids and 
counseling)  
C1: Usual Care: provider 
advice to quit and self-help 
guide 
Method of assessment: 
• Telephone surveys of the 
women and partners at 28 
weeks pregnant, 
postpartum and 2, 6, and 
12 months 
• Self reported smoking 
status assessed at each 
follow up with the 
question “have you 
smoked any cigarettes in 
the past 7 days?” 
• Saliva samples collected 
by mail at 28 weeks 
pregnancy and 12 months 
postpartum from women 
and partners who 
reported not smoking in 
the previous 7 days 
Baseline data: 
No significant differences 
b/w any of the groups 
Statistical analysis:  
• Logistic regression was 
used to compare the 2 
experimental conditions 
to the control condition on 
each outcome measure, 
controlling for baseline 
smoking-specific support 
variables and predictors 
known to be associated 
with smoking cessation 
trials  
• Intent-to-treat approach 
used, where missing 
values on smoking status 
imputed as “smoker” 
• Comparison on the 
experimental conditions 
to the control condition on 
dichotomous secondary 
outcomes, such as 
postpartum relapse and 
partners’ prevalent 
abstinence, were made 
with logistic regression 
• Proportional hazards 
model was used to 
compare conditions on 
time to relapse, where 
time to relapse defined as 
the number of days b/w 
woman’s delivery date 
and the date she 
resumed smoking 
• Differences by condition 
for changes in women’s 
and partner’s smoking-
specific support and 
general support across 
time were tested with 
mixed linear-model 
repeated measures 
analysis 
Data verification: 
Self-report, salivary cotinine 
Dependent variables: 
• Abstinence at 28 weeks, 
2, 6 and 12 months 
postpartum 
• Sustained abstinence 
 
 
No statistically significant 
difference between groups at any 
follow up point 
No statistically significant 
difference between groups in the 
proportion relapsed at any 
postpartum follow-up 
In late pregnancy (28 weeks), 
more partners abstinent in G2 
group (15%) than C1 group (5%) 
P = 0.02 
Women in all groups consistently 
reported a decline in positive 
partner support from baseline to 
12-month postpartum (F=81.43, 
df=1322, P < 0.001) 
Quality rating: 
Fair 
Comments: 
By only including 
women who agreed to 
involve their partners, 
couples who were 
inclined to support 
each other and 
attentuated treatment 
effects may have 
been over-
represented 
Adequate 
randomization: 
Yes 
Attrition rate: 
19% 
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Study Characteristics Study Design Sample Design and Definitions 
Author:  
Mermelstein et al., 2003 
Geographic area:  
US 
Funding agency:  
National Heart, Lung and 
Blood Institute and National 
Cancer Institute 
Study setting:  
NR 
 
Research objective:  
To compare the relative efficacy of two types 
of proactive telephone calls following a 
group cessation program.  
Population:  
Participants completing a group smoking 
cessation program 
Study type:  
RCT 
Inclusion criteria:  
NR 
Exclusion criteria:  
NR 
 
Sampling plan:   
• Participants recruited primarily 
through paid advertisements, media 
coverage of the program, flyers and 
referrals 
• 905 smokers attended the first group 
meeting 
• 771 smokers completed the group 
program 
• 756 smokers were assessed at least 
once over the follow-up period  
Sample size: 
G1: (basic): 375 
G2: (enhanced): 381 
Definition of smoking:   
Tobacco dependence as measured by 
the Fagerstrom Tolerance Questionnaire
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:   
• Group meetings 
• Telephone counseling 
Intervention:  
G1: Enhanced: Basic 
program (see C1 below) plus 
telephone counseling call 
content varied by 
participants’ smoking status 
(i.e., still smoking, abstinent, 
slipped or relapsed); if still 
smoking or relapsed also 
received a videotape; plus 
abstinent counseling on 
keeping motivation and self-
efficacy high using a variety 
of techniques 
C1: BasiC1: 7 week group 
treatment program of 
telephone counseling giving 
only words of 
encouragement without 
specific guidance 
Method of assessment: 
3-,6-,9-,12- and 15-month 
follow-ups via telephone 
Baseline data: 
No significant differences 
between conditions on any 
variables or on percentage 
with a history of depression 
 
Statistical analysis:  
NR 
Data verification: 
Expired air carbon monoxide 
and saliva cotinine used to 
verify abstinence at each 
major assessment point for 
participants reporting 
abstinence 
Dependent variables:  
• Abstinence: no smoking at 
all in the past 7 days 
• Relapse: smoking one 
one or more days of the 
past 7 after achieving an 
initial 7-day period of 
abstinence at the end of 
the group program 
Point Prevalence of 
Abstinence: no significant 
differences by condition at any 
assessment point 
Post-hoc analysis by condition 
by gender at all assessment 
points showed that men 
receiving the enhanced 
condition were more likely to 
abstain while women were 
more likely to abstain when 
participating in the basic 
condition. 
 
 
Quality rating: 
Poor 
Comments:  
• No true control group (i.e., 
those in group program 
with no telephone follow-
up). So no true 
comparison of whether 
calls had an effect. 
• Random assignment 
method NR 
• Population not described 
• No inclusion/exclusion 
criteria specified 
Adequate randomization: 
NR 
Attrition rate:  
6-month: 1% 
15-month: 4% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Murray et al., 2001 
Geographic area: 
US 
Funding agency: 
Division of Lung Disease of 
the National Heart, Lung, 
and Blood Institute 
Study setting: 
Practice/provider settings 
 
Study objective: 
To evaluate hypothesis that Black smokers 
will respond differently than Whites to a 
smoking cessation intervention program 
where no adjustments are made in 
recognition of cultural differences 
Population: 
• Adults 
• African Americans 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• Age 35-60 yrs 
• Mild COPD 
• Current smoker 
Exclusion criteria: 
• Serious health conditions likely to to 
affect lung function or ability to stay in trial 
for 5 yrs  
• Use of regular medications that might 
alter lung function  
Sampling plan: 
NR 
Sample size: 
G1: 3,923 
C1: 1,964 
Definition of smoking: 
Cigarettes 
Defined as smoking at any clinic visit 
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Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Group counseling 
• Pharmaceuticals 
Intervention:  
G1: SI (12-wk group 
program using a quit day 
in second wk, followed by 
4 consecutive days of 
group meetings) w/ 
bronchodilator therapy 
G2: SI w/ placebo inhalers  
C1: Usual care- annual 
physician visits 
Method of assessment: 
• Interviews at baseline 
and annually for 5 yrs 
• Annual saliva collection 
 
Statistical analysis:  
Covariate data used to 
explore differences using 
regression t-tests etc. 
Data verification: 
• Salivary cotinine 
annually 
• Expired CO 
throughout 
intervention program 
and subsequently at  
4-mo intervals 
Dependent variables: 
Smoking cessation 
Baseline data: 
Baseline data 
comparisons b/w 2 
groups showed 
significant differences 
 
Black population had 
more women (46% 
vs37%) P = 0.01, less 
education, less income, 
less likely to be married 
(48% vs70%), smoked 
less (23.5 vs32.9 per 
day) 
Quitting at 1 yr G1 vs C1: 
Blacks: AOR: 1.48 
Whites: AOR: 5.99 
P = 0.002 
Quitting at 5 yrs: 
G1 vs C1 
Blacks: AOR: 1.87 
Whites: AOR: 3.34 
P = 0.06 
Significant txt effect for Blacks 
over 5 yrs of study (OR = 1.95, P 
= 0.04) 
 
Quality rating: 
Poor 
Comments: 
Large differences 
in baseline 
comparisons b/w 
white and black 
negate any 
differences that 
occur in outcomes, 
small sample size 
Adequate 
randomization: 
No 
Study not designed 
for this comparison 
Attrition rate: 
NR 
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Author: 
Peterson, 2004 
Geographic area: 
US 
Funding agency: 
National Heart, Lung, and 
Blood Institute 
Study setting: 
Hospital 
 
 
Study objective: 
To evaluate whether a nurse-managed 
smoking cessation and relapse prevention 
program reduced smoking rates at 12 mos 
in women admitted to hospital w/ CD 
Population: 
• Adults, 
• Women (only) 
Study type: 
RCT w/ systematic randomization  
Inclusion criteria: 
• Female 
• At least 18 yrs of age 
• Admitted to hospital w/ CVD or peripheral 
vascular disease 
• Had smoked cigarettes in month before 
admission 
• Willing to make a serious attempt to quit 
smoking after discharge 
Exclusion criteria: 
• Medical instability 
• Alcohol or substance abuse 
• Dementia 
• Schizophrenia 
Sampling plan: 
NR 
Sample size: 
G1: 142 
C1: 135 
Definition of smoking: 
Cigarettes 
• Abstinent: no smoking in past 7 days 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Telephone counseling 
Intervention:  
G1: Brief physician 
counseling and usual care 
plus nurse managed, 
cognitive behavioural, 
relapse prevention 
intervention given before 
discharge, <5 structured 
telephone contacts 2–90 
days after discharge, and 
relapse management 
counseling as needed 
C1: Brief physician 
counseling, a self help 
pamphlet, and a list of 
community resources 
Method of assessment: 
NR 
 
Statistical analysis:  
NR 
Data verification: 
Self-reported smoking 
status (abstinence in 
past 7 days) verified by 
cotinine levels and 
family/friends 
Dependent variables: 
Smoking status  
Baseline data: 
NR 
At 12-month followup, 7-day 
point prevalence for non-
smoking:  
G1: 48% 
C1: 42% 
RBI: 14% (95% CI, -14 to 51),  
P = NS 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
NR 
Attrition rate: 
11% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Quist-Paulsen and 
Gallefoss, 2003 
Geographic area: 
Norway 
Funding agency: 
Vest-Agder Council for 
Public Health and the charity 
Sykehuset i vaare hender 
Study setting: 
Cardiac ward of a general 
hospital 
Research objective: 
To determine whether a nurse led smoking 
cessation intervention affects smoking 
cessation rates in patients admitted for 
coronary heart disease 
Population:  
Adults under 76 yrs of age 
Study type: 
RCT 
Inclusion criteria: 
• Patients under the age of 76 admitted for 
myocardial infarction, unstable angina, or 
cardiac bypass surgery who had been 
daily smokers until the start of their 
present coronary symptoms.  Patients had 
to be sufficiently recovered to reliably 
receive the intervention and had to live in 
Vest-Agder or Aust-Agder county. 
Exclusion criteria: 
• Patients with serious illness associated 
with short life expectancies, serious 
psychiatric problems, alcoholism, and 
dementia 
Sampling plan:  
• Invited to participate in study all 
patients admitted to Vest-Agder 
Hospital for myocardial infarction, 
unstable angina, or care after 
coronary bypass surgery performed at 
other hospitals 
• 1016 patients assessed for eligibility 
• Nurses recruited patients 2-4 days 
after admission 
• Participants answered baseline 
questionnaire and were randomly 
allocated to usual care (control group) 
or intervention 
• Nurses given serially numbered 
sealed envelopes from secretary 
otherwise uninvolved in study 
• Randomization was in blocks of 
varying sizes 
• 250 patients randomized;  10 were 
later withdrawn  
Sample size: 
G1: 118 
C1: 122 
Definition of smoking:  
• Daily smoker until start of present 
coronary symptoms 
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Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
• Group sessions with cardiac 
nurses, including seeing a 
video and getting info 
booklet 
• Telephone counseling 
• Self-help 
Intervention:  
G1: Cardiac nurse consulted 
patients 1-2 times during 
hospital stay.  Intervention 
based on booklet focusing on 
fear arousal and prevention of 
relapse. Booklet emphasized 
health benefits of quitting 
smoking after coronary event, 
including illustrations showing 
mortality differences for those 
who continued smoking after 
coronary condition vs. those 
who quit, information on how to 
prevent relapse, how to stop 
smoking, how to use nicotine 
replacement.; also explained 
how to identify & cope with 
high risk situations for relapse. 
Nurses contacted participants 
by telephone 2 days, 1 week, 3 
weeks, 3 months & 5 months 
after discharge.  At 6 weeks 
aoo participants in G1 had 
consultation at outpatient clinic 
with nurse. 
C1: Patients were offered 
group sessions twice/week 
with nurses where importance 
of smoking cessation was 
mentioned; a video was shown 
and booklet distributed giving 
general information on 
coronary heart disease and 
advice on quitting smoking.  No 
further specific instructions on 
how to quit were given 
Method of assessment: 
Self report and biochemical 
verification of smoking 
cessation rates at 12 months 
Baseline data: 
• Fewer employed in C1 than 
in G1 
• More with post primary 
education in C2 than in G1  
Statistical analysis:  
• Chi-square test used to 
assess effect of 
intervention 
• NNT calculated with 
confidence intervals 
• Simple and multiple 
logistic regression 
models used to test 
relation between 
baseline characteristics 
and outcome measures 
• SPSS used for all 
analyses 
Data verification: 
Self-report and urine 
analysis 
Dependent variables:  
• Number of days spent in 
ICU 
• Myocardial infarction as 
reason for admission 
• No previous coronary 
heart disease 
• Employment 
Quit rate at 12 months:  
G1: 57% 
C1: 37% (absolute risk 
reduction 20%, 95% CI 6.4 – 
33.0; P = 0.004) 
NNT to get one additional 
person who would quit was 5 
Assuming dropouts relapsed at 
12 months, smoking cessation 
rates were:  
• G1: 50% 
• C1: 37% (absolute risk 
reduction 13%, 95% CI 0% - 
26%) 
Smokers who stated they were 
still smoking were classified as 
smokers 
Those who claimed they had 
quit and had a nicotine 
metabolite concentration in 
urine < 2.0 mmol/mol 
creatinine were classified as 
non-smokers 
G1: average of 1.6 (SD 0.7) 
consultations as inpatients and 
1.6 (SD 1.5) as outpatients; 
also received a mean of 8.5 
(SD 3.2) telephone calls 
Mean total time devoted to 
each patient was 147 minutes 
(SD 50) 
Use of nicotine replacements:  
G1: 36% 
C1: 28% (without a statistically 
significant difference) 
9% of patients who smoked 
while in hospital or at 6 wks 
were abstinent at 12 months 
 
Quality rating: 
Good 
Comments:  
• Well-reported—
interventions and methods 
fully described  
• Objective outcome 
measure (urine test) 
• Loss-to-follow up treated 
as relapsed smokers 
yielding valid ITT analysis
Adequate randomization: 
Yes 
Attrition rate:  
• 10 post-randomization 
exclusions 
• LTF at 12 months(not 
including post-
randomization 
exclusions): 9% (G1: 
15.3%, C1: 3.1%) 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Ratner et al., 2004 
Geographic area: 
Western Canada 
Funding agency: 
National Cancer Institute of 
Canada 
Study setting: 
Teaching hospital 
Research objective: 
Test an intervention to help smokers abstain 
(fast) from smoking before surgery, maintain 
abstinence postoperatively, and achieve 
long-term cessation 
Population:  
Patients admitted for presurgical 
assessment from Nov. 1999 to Oct 2001 
Study type: 
Randomized pretest-posttest control group 
experiment 
Inclusion criteria: 
• Self-identified smokers within previous 7 
days 
• Remain in hospital for at least 24 hours 
following surgery 
• Speak and write English 
• Able to be contacted by phone 
• Willing and able to participate 
Exclusion criteria: 
NR 
 
Sampling plan:  
Elective-surgical patients in  
• Cardiovascular 
• Opthalmology 
• Orthopedics 
• Plastics 
• Urology 
Sample size: 
237 
Definition of smoking:  
• Smoked in 7 days before surgery 
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Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
• Counseling  
• Nicotine replacement 
therapy 
Intervention:  
• 2 face to face counseling 
sessions 
• 9 telephone counseling 
sessions 
Method of assessment: 
• CO measure  
• Cotinine assay 
• Self-report 
Baseline data: 
Similar in both groups 
Statistical analysis:  
• Univariate descriptive 
statistics 
• Hypothesis testing using 
contingency tables and 
chi-square 
• Treatment effect- multi-
step logistic regression 
Data verification: 
• Cotinine assay 
• CO measure 
Dependent variables:  
• # days until follow-up 
• Age 
• Education 
• Self-efficacy 
• POMS 
• Fagerstrom test 
• Other household 
smokers 
• Smoking stage of 
change 
Treatment group participants 
(73.0%) were more likely to 
fast than were controls 
(53.0%):  
2(1, N = 228) = 8.89, 
P = .003, and more likely to be 
abstinent 6 months after 
surgery (31.2% vs. 20.2%). 
There was no significant 
difference in the abstinence 
rates at 12 months after 
surgery, 2(1, N = 169)  
< 0.001, P  = 1.00.  
Quality rating: 
Fair 
Adequate randomization: 
Yes 
Attrition rate:  
28.7% 
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Author: 
Reid et al., 2003 
Geographic area: 
Ottawa, Canada 
Funding agency: 
NR 
Study setting: 
Tertiary care cardiac facility 
Research objective: 
To determine whether stepped-care 
treatment helped smokers hospitalized with 
CAD to quit smoking over 3-month and 1-
year follow-up periods. 
Population:  
• Patients hospitalized with CAD 
• Age of 18 years or more 
• Motivated to quit smoking 
Study type: 
RCT 
Inclusion criteria: 
• At least 18 years or age 
• Hospitalized with coronary artery disease 
Exclusion criteria: 
• Unresolved unstable angina 
• Life-threatening arrhythmias 
• Vasospastic diseases (buerger’s disease, 
prinzmental’s variant angina) 
• Pregnant or lactating women 
• Those who lived more than 1 hour of 
travel time away 
Sampling plan:  
• 8330 patients admitted for coronary 
angiography, PTCA, MI, or CABG 
were screened 
• 1379 (16.6%) were identified as 
cigarette smokers 
• 419 individuals who met all eligibility 
criteria 
• 254 (60.6%) agreed to participate 
Sample size: 
G1: 126 
C1: 128 
Definition of smoking:  
• 5 or more cigarettes a day 
• Did not include users of pipes, cigars 
or smokeless tobacco exclusively 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
• Self-help 
• Stepped-care treatment 
Intervention:  
G1: called by a nurse-
counselor 4 weeks after 
discharge and questioned. If 
not smoking, provided positive 
reinforcement and reminded 
about relapse prevention 
information in the booklet. If 
smoking, nurse counseling was 
begun, 3 - 20 minute face to 
face sessions over 8 weeks 
and nicotine patch therapy was 
made available  
C1: no additional counseling 
after hospital discharge; free to 
seek assistance from 
community or primary care 
physician 
Method of assessment: 
Surveyed by mail 3 months 
and 1 year after hospital 
discharge. If the questionnaire 
was not returned promptly, the 
participants were called, and 
the questionnaire was 
completed by telephone 
Baseline data: 
• Groups balanced for age, 
gender, education level, 
reason for admission, 
cigarettes per day, 
Fagerstrom score, years of 
smoking, quit attempts, 
motivational readiness to 
quit smoking, self-efficacy, 
and preference for cessation 
assistance 
Statistical analysis:  
• Baseline subject 
characteristics - t tests 
for continuous variables 
and chi-square tests for 
categorical variables.  
• Primary analysis- a 
Fisher’s exact test was 
used to compare 3-
month and 1-year rates 
A secondary analysis 
univariate and 
multivariate logistic 
regression procedures  
Data verification: 
Self-reported with a 
random sample of 25 
tested for CO levels 
Dependent variables:  
• Demographic factors 
• reason for admission 
• smoking history  
• nicotine dependence 
• self-efficacy 
• motivational readiness 
variables  
 
At 3 months stepped-care 
treatment increased smoking 
cessation rates from 42% to 
53% during a 3-month follow-
up period (P = 0.05) 
1-year follow-up minimal 
intervention group of 36% 
versus 39% for the stepped-
care group (P = 0.36) 
Quality rating: 
Good 
Comments:  
• Well-thought out design 
• Well reported 
Adequate randomization: 
Yes 
Attrition rate:  
C1: 19.5% 
G1: 9.5% 
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Author: 
Rowe et al., 1999 
Geographic area: 
United Kingdom 
Funding agency: 
NR 
Study setting: 
Worksite 
 
Study objective: 
To evaluate effectiveness of offering an 
individualized approach to smoking 
cessation to qualified nurses and student 
nurses in Northern Ireland 
Population: 
• Adults 
Study type: 
Cohort study 
Inclusion criteria: 
• Qualified nurse ("nurse") or student nurse
• Smoked at least one cigarette daily 
• Expressed desire to quit smoking 
• Agreed to participate in study as an 
intervention or control participant 
Exclusion criteria: 
Did not meet all inclusion criteria  
Sampling plan: 
• Nurses and student nurses from a 
college of nursing and a large 
hospital trust who self-identified as 
smokers and wanting to quit were 
invited to participate in study 
• Participants could choose to be in 
intervention group or control 
Sample size: 
G1: 22 (nurses) 
G2: 32 (Student nurses) 
C1: 23 (nurses); 33 (student nurses) 
Definition of smoking: 
Cigarettes 
• Unclear, but to enroll, had to report 
smoking at least one cigarette daily 
(also see Dependent Variables 
section) 
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Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
Health professional 
• Social support 
Intervention:  
G1: (Qualified nurses): 
received individual 
counseling to: (1) assess 
health beliefs and motivation 
to quit smoking; (2) plan and 
implement strategy for 
quitting (set quit date, 
discuss coping strategies, 
identify social support, keep 
smoking success and failure 
diary) and make subjects 
aware follow up would occur 
at 6 wks, 6 months, 1 yr 
postintervention. 
G2: (Student nurses): Same 
intervention as G1 
C1: (Qualified nurses) and 
C2 (Student nurses) 
received no smoking 
cessation counseling or 
assistance, but were 
followed up at 6 months and 
1 yr postenrollment 
Method of assessment: 
Self-report on 
questionnaires and 
biochemical verification of 
non-smoking status 
 
Followup conducted at 6 
wks postintervention for 
intervention groups, at 6 
months and 1 yr for both 
intervention and Cs 
Definition of smoking: 
Cigarettes 
• Unclear, but to enroll, had 
to report smoking at least 
one cigarette daily (also 
see Dependent Variables 
section) 
 
Statistical analysis:  
Frequencies 
Fisher's Exact Test 
Qualitative data 
Data verification: 
Self report of smoking 
status 
For those reporting no 
smoking, verified through 
CO in expressed alveolar 
air (2-10 ppm = non-
smoker; 11-60 ppm = 
smoker) and through 
salivary cotinine 
concentrations (20 ng/ml = 
non-smoker) 
Dependent variables: 
• Verified quit rate 
• Perceptions of smoking 
and health 
• Perceptions of their 
health promotion role 
Baseline data: 
Nurses: G1 and C1 similar 
(age 23-56 yrs; 45% of G1 
and 49% of C1 had 
spouses, partners, or 
parents who smoked; 
95.5% female)  
G1 and C1 similar in 
smoking history (89% 
began smoking before 
nursing, 64% smoked 20 
cigarettes daily; 82% had 
been smoking more than 
10 yrs) 
68% G1 vs100% C1 tried 
to quit smoking previously 
(no test) 
 
Verified quit rate:  
G1: 22.7% vs 8.6% (C1) 
P < 0.05 
G2: 25% vs 6% in C2  
P < 0.05 
 
Quality rating: 
Poor 
Comments: 
Participants self-
selected to 
intervention and 
comparison group 
status; at 1 yr 
followup, participants 
self-selected whether 
to answer a 
questionnaire for 
smokers or for non-
smokers; motivation 
and determination to 
quit smoking higher 
among intervention 
groups vscomparison 
groups, factors not 
controlled for in 
analyses; not given 
all data regarding 
intervention 
vscomparison groups 
(sometimes %s 
given, but not per 
group status) 
Adequate 
randomization: 
Not a RCT, but 
problematic group 
membership 
because participants 
self-selected into 
intervention or 
comparison group 
per their desire to 
receive smoking 
cessation assistance 
(intervention groups) 
or to try to stop 
smoking on their own 
(comparison group) 
Attrition rate: 
At 1 yr, 5% overall 
(no further attrition 
detail provided and 
unable to determine 
from tables 
presented) 
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Author: 
Rowe et al., 1999 
(continued) 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
 
Student nurses: 62% b/w 
17-21, range 17-36; 60% 
had family members who 
smoked; 91% female; 91% 
single (no further detail by 
group) 
97% of G2 and 94% C2 
began smoking before 
entering nursing; range of 
smoking = 1-10 yrs, 68% 
smoked b/w 1- 6 yrs 
88% G2 and 73% C2 
smoked 10-20 cigarettes 
daily 
About 75% of each group 
had tried to stop smoking 
at least once before 
100% of G2 and C2 
accepted smoking did or 
might influence their or 
their family's/friends' health
78% of G2 and 45% C2 
experiencing some ill 
health effect of smoking 
# Perception of role as 
health promoter:  
G1: 100%  
C1: 96% 
G2: 94% 
C2: 82% (no test) 
All Groups: Motivation to 
quit smoking ("want to very 
much" or "would like to"): 
G1: 100% vs 
C1: 65%, P < 0.01 
G2: 61% vs C2: 61%  
(P < 0.01) 
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Study Characteristics Study Design Sample Design and Definitions 
Author:  
Saules, et al., 2004 
Geographic area:  
US 
Funding agency:  
National Institute on Drug 
Abuse and State of 
Michigan 
Study setting:  
Population-based 
 
Research objective:  
To test effect of fluoxetine on smoking 
cessation in the context of a program that 
includes group cognitive-behavioral therapy 
(6 weeks) and transdermal nicotine patch 
(10 weeks) 
Population:   
Adults  
Study type: 
Randomized, double-blind, placebo-
controlled trial 
Inclusion criteria:   
• Adults 21-65 
• Smoking > 15 cigarettes/day 
• Producing CO. 15ppm 
Exclusion criteria:  
• Candidates in acute psychiatric crisis 
• Met criteria for apsychieatric disorder 
within the past six months 
• Were currently taking psychiatric 
medications 
• Clinically significant medical conditions 
• Pregnant 
• Inability to comprehend and respond to 
measures 
 
Sampling plan:  
• Participants recruited by flyers and 
notics distributed throughout the 
university and through paid 
advertisements in local newspapers 
and radio stations. 
• Telephone screening of all 
respondents. 
• Candidated attended a screening visit 
at which expired CO reading were 
required to be greater ahn or equal to 
15 ppm. 
Sample size: 
G1: 51 
G2: 51 
C1: Placebo 
Note: planned sample size was 168 with 
56 participants per arm 
Definition of smoking:  
Self-reported smoking of any cigarettes 
at all (or even part of one cigarette), CO 
greater than or equal to 10 ppm  
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Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:   
• Pharmaceuticals: 
fluoxetine and transdermal 
NRT 
• Cognitive-behavioral 
counseling (CBT) 
Intervention:  
G1: Fluoxetine (20mg) 4 
weeks before quit date, 
changed to 40 mg fluoxetine 
after one week, CBT starting 
2 weeks before quit date and 
15 mg NRT patch on 
morning after quit date visit 
G2: Fluoxetine (20mg) 4 
weeks before quit date and 
for 15 weeks total, CBT 
starting 2 weeks before quit 
date and 15 mg NRT patch 
on morning after quit date 
visit 
C1: Placebo and CBT 
starting 2 weeks before quit 
date and 15 mg NRT patch 
on morning after quit date 
visit 
Method of assessment: 
NR 
Baseline data:  
No significant differences 
across groups except for 
significant differences in 
baseline depression with 
elevated levels among those 
randomized to placebo. 
 
Statistical analysis:  
Chi-square analysis 
Data verification: 
Expired CO of less than 10 
ppm obtained for self-
reported quitters 
Dependent variables:  
Documented nonsmoking: 
self-reported abstinence 
combined with CO less than 
10 ppm 
No significant differences 
observed in smoking status at 
end of trial (assuming that end 
of trial was at 12-months post 
quit date although time frame 
is not stated in the article text 
or table for these 
assessments):  
C1: 35.4% 
G1: 43.1% 
G2: 43.1% 
Change in weight was 
significant for treatment group 
(P = 0.010), smoking cessation 
(P = 0.037) and their 
interaction (P = 0.012). 
Withdrawal symptom scores 
were significantly lower in both 
fluoxetine groups as compared 
to the placebo group  
(P = 0.038) 
 
Quality rating: 
Fair 
Comments: 
Random assignment method 
NR 
Adequate randomization: 
NR 
Attrition rate:  
40% 
Drop-out was related to 
smoking status, as 90% of 
the people who did not 
complete the study had 
documented smoking at their 
last assessment whereas 
only 32% of those who 
completed the study had 
documented smoking at the 
last assessment 
(X2(1)=9.94, P = 0.002) 
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Author: 
Simon et al., 2004  
Geographic area: 
United States 
Funding agency: 
California Tobacco-Related 
Disease Research Program  
Study setting: 
Hospital 
Research objective: 
Whether the addition of bupropion to 
transdermal NRT and cognitive-behavioral 
counseling would increase quit rates 
compared with standard therapy using NRT 
and cognitive-behavioral counseling only 
Population:  
Adults  
Study type: 
RCT 
Inclusion criteria: 
• Smoked 20 or more cigarettes during the 
week prior to enrollment 
• Have a telephone and no plans to leave 
the catchment area during the study 
period 
• In the contemplation or preparation stages 
of quitting according to the Prochaska and 
DiClemente Stages of Change model 
• ≥ 20 years of age 
Exclusion criteria: 
• Contraindications to bupropion or NRT 
• Serious psychiatric illness including major 
depression 
• History of alcohol abuse within the past 
three months or consuming more than 3 
alcoholic beverages per day 
Sampling plan:  
Participants were recruited from the 
three following sources: 
• Lists of known smokers from previous 
smoking cessation clinical trials at the 
San Francisco VA Medical Center 
• Hospital-based advertising at major 
teaching hospitals 
• Local Bay Area advertising and PSAs 
Eligible smokers were assessed for their 
readiness to quit smoking 
Subjects in the contemplation or 
preparation stages of quitting were 
randomized to either treatment or 
control arm 
Sample size: 
244 adults  
Definition of smoking:  
Non-smoker 
• Self-report of no smoking for the past 
seven days during each follow-up 
counseling call 
• Follow-up self report of no-smoking in 
the past six months and twelve 
months  
• Among those who reported no 
smoking at 12 months, follow-up 
saliva cotinine level had to be less 
than 15 ng/ml   
Continous non-smoker 
• Self-reported quitting at each follow-
up assessment, and biochemical or 
proxy verification of no smoking at 12 
months 
Smoker 
• Self-reported no smoking but using 
NRT and salivary cotinine levels >= 
15 ng/ml 
• Stopped smoking cigarettes but using 
other tobacco products 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Bupropion 
• Transdermal nicotine 
replacement therapy 
• Cognitive-behavioral 
counseling 
Intervention:  
G1: 7 week course of 
Bupropion, 2 months 
transdermal nicotine 
replacement therapy, 1 visit 
with counselor (30-60 minute 
session), and 5 telephone 
follow-up calls  
C1: Same as G1 except 
participants received placebo 
instead of Bupropion   
Method of assessment: 
Follow-up at 7 weeks (end-of 
treatment), 3 months, 6 
months, and 12 months by 
telephone 
Baseline data: 
No statistically significant 
differences in any of the 
baseline demographic of 
medical characteristics 
between the samples in the 2 
study arms 
Males: 86% 
Statistical analysis: 
• 2-sample t tests and 
Wilcoxon rank sum tests 
for continuous variables
• Chi square tests for 
categorical variables 
• Calculated relative risk 
and 95% CIs 
• For multi-variate 
analysis, used backward 
stepwise procedure to 
examine relationship 
between demographic 
and historical variables 
and smoking cessation 
• Variables were retained 
in the model if they 
remained associated 
with quitting at  
P ≤ 0.20 
• All regression models 
were adjusted for 
treatment assignment 
• Hosmer-Lemeshow 
goodness-of-fit test was 
used to assess 
adequacy of the models
• 2-tailed P values < 0.05 
were considered 
significant 
Data verification: 
Self-report plus cotinine 
saliva for those who self-
reported quitting at the 12 
month followup   
Dependent variables:  
Quit rates 
No statistically significant 
differences in smoking 
cessation rates at end of 
medication 3, 6, and 12 
months 
The addition of 7-week 
treatment with Bupropion did 
not significantly increase quit 
rates over NRT and counseling 
Quality rating: 
Fair 
Comments:  
No power analysis 
Adequate randomization: 
Yes 
Attrition rate:  
• 1% lost to followup 
• 2% died 
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Author:  
Swana, et al., 2003 and 
Swanb et al., 2003 
Geographic area:  
US, Seattle 
Funding agency:  
National Cancer Institute 
Bupropion SR provided by 
Group Health Cooperative 
Pharmacy 
Study setting:  
Non-profit consumer-
governed health care 
system serving 600,000 
residents of western 
Washington (GHC) 
 
Research objective:  
Swan:a To identify individual characteristics 
predictive of more clinically relevant smoking 
end-points beyond end of treatment in 
smokers prescribed bupropion SR and 
counseling.  
Swan:b To determine the differential 
effectiveness of 2 doses of bupropion in 
combination with behavioral interventions of 
minimal to moderate intensity. 
Population:   
• 18 years of age or older 
Study type:  
• Data from a large, randomized 
effectiveness trial 
• Two dosage levels of bupropion SR 
(Zyban, 150 and 300 mg) were crossed 
with two behavioral treatment programs of 
lower or higher intensity to create a four-
cell design. 
Inclusion criteria:  
• Individuals at least 18 years of age 
• Smoking an average of 10 or more 
cigarettes per day in the 12 months prior 
to enrollment 
• Motivated to stop smoking 
• Otherwise in good general health and had 
proper GHC coverage 
Exclusion criteria: 
• Predisposition to seizure 
• Current use of medications 
contraindicated for use with bupropoion 
SR or know to lower seizure threshold 
• History of or current diagnosis of anorexia 
nervosa or bulimia or presence of any 
severe chronic medical condition 
• Use of any investigational drug within 1 
month of treatment with buropion SR 
• Participation in GHC’s Free and Clear 
smoking cessation program in the 
previous 12 months 
• Current depression 
• Recent high frequency or binge drinking 
• Abuse of other substances including 
recreational/street drugs 
• Current pregnancy or plans to become 
pregnant 
• Current nursing of a child 
Sampling plan:  
• Participants who called the study 
center were screened over the 
telephone. 
• Eligible volunteers were sent a 
pretreatment questionnaire and 
consent form. 
• Participants were randomly assigned 
to 4 treatment arms by a computer-
generated number. 
• The computer code calculated 
probabilities of group assignment that 
were dynamically modified based on 
the number of members in each group 
so that final group sizes were equal.  
• No restrictions such as stratification or 
blocking were used in the process. 
Sample size: 
G1: 382 
G2: 381 
G3: 383 
G4: 378 
Definition of smoking:  
• Any smoking within the past 7 days (7 
day point prevalence) 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
• Pharmacologic treatment 
• Tailored mail program (ZAP) 
• Proactive telephone 
counseling program (Free 
and Clear Program) 
Intervention:  
G1: 150 mg bupropion SR and 
proactive telephone counseling 
(Free and Clear Program)  
G2: 150 mg bupropion SR and 
tailored mail ( Zyban 
Advantage Plan - ZAP) 
G3: 300 mg bupropion SR and 
proactive telephone counseling 
(Free and Clear Program)  
G4: 300 mg bupropion SR and 
(ZAP) 
Method of assessment: 
3- and 12-month follow-up  
Baseline data:  
• Reported by gender not 
treatment condition. 
• Men had significantly more 
years of formal schooling, 
smoked more cigarettes per 
day, had higher number of 
previous attempts to quit.  
• Women significantly more 
likely to report perceived 
stress, social support 
depression, ever having 
depression in lifetime or 
percentage of family ever 
depressed.  
 
Statistical analysis:  
• Intent-to-treat analysis 
• Logistic regression for 
assessing pretreatment 
characteristics for their 
relationship to point-
prevalent smoking at 12 
months 
Data verification: 
Self-report 
Dependent variables:   
• Smoking: any smoking 
within the 7 days prior to 
follow-up  
 
Swan 2003a 
At 12-month follow-up, type of 
behavioral treatment had a 
strong association with point-
prevalent smoking (e.g., 
participation in the less-
intensive TM program being 
associated with a greater 
likelihood of smoking) whereas 
dose and the dose x treatment 
interaction had little or no 
association with outcome 
OR=1.21 (95% CI, 1.08 - 
1.35). 
Swan 2003b 
• At 3 months: 
300mg G3: 35% vs 150 mg  
G1: 24.4% (P=0.001);  
300mg G3: 35% vs 150mg 
G2: 24.2% (P =0.001); 
300mg  
G3: 35% vs 300mg  
G4= 26.7% (P =0.01) 
 At 12 months: 
300mg G3: 33.2% vs 
150mg G2: 23.6% (P 
=0.004) 
300mg G3: 33.2% vs 
300mg G4: 25.7% (P =0.02) 
150 mg G1: 31.4% vs 
150mg G2: 23.6% vs  
(P =0.02) 
 
 
Quality rating: 
Fair 
Comments:  
• Lack of blinding 
• No biochemical 
confirmation of self-
reported smoking status 
• No objective 
measurement of 
adherence to the 
therapeutic regime 
Adequate randomization: 
NR 
Attrition rate:   
• 3-month follow-up: 20.8% 
• 12-month follow-up: 
14.9% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Wakefield et al., 2004 
Geographic area: 
South Australia 
Funding agency: 
National Health and Medical 
Research Council 
Study setting: 
Hospital-based  
Research objective: 
To determine whether a motivational 
interviewing intervention increased 
successful smoking cessation attempts of 
patients with cancer attending a South 
Australian public hospital, as compared with 
usual care 
Population: 
• Cancer patients at South Australian public 
hospital 
Study type: 
RCT  
Inclusion criteria: 
• Participant must have a cancer diagnosis 
• Smoke tobacco more than weekly 
• Speak English 
• Be cognitively able to consent 
• Have a prognosis exceeding 6 months 
• Live close enough to maximize 
biochemical confirmation at follow-up 
assessment* (changed to include patients 
living remotely to increase participation 
numbers)  
Exclusion criteria: 
See above 
 
Sampling plan: 
• Patients were screened by doctors 
after scheduled appointments in the 
radiation therapy, medical oncology, 
and hematology departments at Royal 
Adelaide Hospital over 20 month 
period 
• After several months, accrual of 
participants too slow, so patients 
living remotely were approached to 
increase numbers 
• Once patients consented to 
participate, they completed a baseline 
questionnaire   
• 6-month follow up interviews were 
done and those who said had stopped 
smoking were asked to provide either 
a urine sample for cotinine analysis or 
a CO reading using a breath monitor 
Sample size: 
G1: 74 
C1: 63 
Definition of smoking: 
Tobacco 
• Current Smoker – Smoke tobacco at 
least weekly 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Visit with smoking cessation 
counselor 
• Booklets 
• NRT 
• Family advice to quit 
• In-person or telephone 
follow-up conversation 
Intervention:  
G1: Specific advice and 
booklets about benefits of 
quitting for patients with 
cancer, telephone and in-
person counseling using the 
framework of motivational 
counseling, supplemented with 
NRT if patient smoked ≥15 
cigarettes per day 
C1: brief advice to quit, widely-
available quit-smoking 
brochures, and info about well-
promoted state-based 
telephone quit-line service 
Method of assessment: 
In-person follow up visit or 
telephone assessment at 6 
months post-baseline 
Baseline data: 
Patients in intervention group 
were more likely than control 
patients to have ever tried to 
quit (P = 0.04) and to have 
made more quit attempts in the 
past year (P = 0.02) 
Control patients were more 
likely to live remotely (P = 0.04) 
Statistical analysis:  
• Data were analyzed 
using SPSS 
• Fisher’s exact tests and 
chi-square tests were 
used to establish 
whether groups differed 
significantly across 
categorical variables, 
and t-tests were used 
for continuous variables
• An intention to treat 
analysis was used, as 
well as an analysis 
excluding those lost to 
follow-up evaluation 
• Phi coefficients were 
calculated to determine 
the degree of 
association between the 
intervention and control 
groups across variables
• Binary logistic 
regression was used to 
examine predictors of 
smoking cessation  
Data verification: 
Self-report, urine cotinine 
and CO levels 
Dependent variables: 
• Quit rates – 3 month 
period prevalence, 7-
day period prevalence 
 
Outcome Measures: 
• At 6-month follow up, no 
difference in biochemically 
confirmed 3-month 
prevalence quit rates 
between the intervention 
(5%) and control (6%) 
groups 
• Sensitivity analysis using 
more lenient criteria 
indicated quit rates of 29% 
for intervention group and 
18% for control group  
(P = 0.32) 
• Predictors of smoking 
cessation at 6 months for all 
patients included a smoking-
related cancer site, more 
cessation attempts in the 
year before the enrollment 
study, and no radiation 
therapy 
 
 
Quality rating: 
Poor 
Comments: 
Study lacked power, had a 
high attrition rate and there 
were significant differences 
in groups at baseline 
Adequate randomization: 
No 
Attrition rate: 
36% 
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Author: 
Borland et al., 2003 
Geographic area: 
Australia 
Funding agency: 
NHMRC grant, 
supplemented by The 
Cancer Council Victoria; 
callbacks funded by Quit 
Victoria 
Study setting: 
Population-based 
 
Study objective: 
To assess effectiveness computer-
generated tailored advice for callers to 
telephone helpline; to assess if it enhanced 
series of callback telephone counseling 
sessions in aiding smoking cessation. 
Population: 
• Adolescents 
• Young adults 
• Adults 
Study type: 
RCT w/ simple randomization 
Randomization done by shuffling 
questionnaires 
Inclusion criteria: 
• English-speaking 
• No obvious psychiatric or neurological 
problems 
• Called quitline b/w October 1996 and 
August 1997 
Exclusion criteria: 
• Small # of callers who sought callback 
service proactively after self-help 
materials offered  
Sampling plan: 
Recruited eligible callers of Victorian 
Quitline telephone counseling and 
advice service 
Sample size: 
G1: 523 
G2: 528 
C1: 527 
Definition of smoking: 
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
• Computer-based 
program 
Intervention:  
G1: Offered a 'Quit Pack' 
and a series of 3 
computer-generated 
tailored letters 
G2: Offered a 'Quit 
Pack'and a series of 3 
computer-generated 
tailored letters and 
callback counseling 
service 
G3: NR 
C1: Offered a 'Quit Pack', 
printed self-help materials 
consisting of: a 30 pg 
booklet based on stage of 
disease, leaflets promoting 
smoking cessation courses 
and card w/ strategies to 
reduce cravings 
Method of assessment: 
Baseline interview; mailed 
survey at 3, 6, and 12 
months post baseline 
 
Statistical analysis:  
Data analyzed using SPSS 
ITT analysis 
Data verification: 
NR 
Dependent variables: 
• Self-reported smoking 
status at 3-, 6-,and 12-
month followups, both 
point prevalence and 9 
months' sustained 
absitinece 
• Duration of cessation 
• Use of nicotine 
replacement 
• Extent of participation in 
callback 
Baseline data: 
Smoked average of 22.8 
cigarettes/day: 
Prepartion stage: 45% 
Contemplation stage: 54%  
Groups similar at baseline 
by gender, age, education, 
level of addiction, stage of 
readiness, quit attempts in 
past yr 
Quit attempts w/ 95% CI  
G1: 56% (51.3-60.7) 
G2: 62.8% (58.2-67.4) 
C1: 57.4% (52.5-61.5) 
 
Smoking point prevalence at 
12-mo followup:  
G1: 22.6% (18.5-26.7) 
G2: 25.6% (21.3-29.9)  
C1: 22.1% (18.1-26.1) 
Chi sq 1.5, P 0.46 
Quality rating: 
Good 
Comments: 
Groups similar at 
baseline in spite of 
suboptimal 
randomziation 
scheme 
Adequate 
randomization: 
Yes 
Attrition rate: 
Overall: 23.4% 
G1: 23.1% 
G2: 25.9% 
C1: 21.1% 
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Author: 
Maguire et al., 2001 
Geographic area: 
United Kingdom 
Funding agency: 
Medical Research Council 
and the Northern Ireland 
DHSS 
Study setting: 
Community-based 
 
Study objective: 
To evaluate whether a structured 
community pharmacy-based smoking 
cessation program would result in a higher 
smoking cessation rate compared to ad hoc 
advice from pharmacists 
Population: 
• Adults 
Study type: 
• RCT w/ systematic randomization  
• Comparing a structured intervention w/ 
usual care 
Inclusion criteria: 
• More than 18 yrs of age 
• Not pregnant 
• Expressing a wish to stop smoking 
Exclusion criteria: 
• NR 
Sampling plan: 
• 100 pharmacists working in 
community pharmacies in N. Ireland 
and 24 in London participated in 
study  
• Each asked to enroll 12 smokers 
Pharmacists promoted study to:  
• People who used pharmacy for non-
medical reasons, using window 
displays, posters in-pharmacy and 
leaflets at cash registers 
• People reporting and asking for 
advice on minor ailments, e.g. chest 
cold, asking them about smoking and 
telling them about program 
• People being dispensed medicines, 
asking them about smoking and 
telling them about program 
Sample size: 
G1: 265 smokers 
C1: 219 smokers 
Definition of smoking: 
NR 
C-143 
Evidence Table 6. Community strategies to increase the implementation of proven population-level tobacco 
use cessation strategies (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Media campaign 
• Pharmaceuticals 
Intervention:  
G1: Initial interview lasting 
b/w 10 and 30 minutes; 
smoking cessation 
contract; indication for 
NRT assessed and offered 
if appropriate; leaflet; 
weekly followup for 4 wks, 
then monthly followup for 3 
months 
C1: Normal 
pharmaceutical service 
(including provision of NRT 
as appropriate) provided 
by pharmacist 
Method of assessment: 
• Telephone interviews at 
3, 6, and 12 mos 
• Urinary cotinine 
assessed to validate 
self-reported non-
smoking at 12 mos 
• Qualitative assessments 
also conducted using 
semi-structured 
telephone interviews 
and focus groups 
 
Statistical analysis:  
NR 
Data verification: 
Urinary cotinine 
assessed to validate self-
reported non-smoking at 
12 months 
Dependent variables: 
Smoking status 
Baseline data: 
Numbers given but no 
tests for significance 
Self-reported non-smoking status 
at 3-month followup:  
G1: 27.5% 
C1: 11% 
Self-reported non-smoking status 
at 6-month followup:  
G1: 18.5% 
C1: 8.2% 
Self-reported non-smoking status 
validated by urinary cotinine (50 
ng/ml) at 12-month followup:  
G1: 14.3% 
C1: 2.7% 
Χ2 = 16.2 
P = <.001 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
G1: 10.2% 
C1: 14.2% 
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Author: 
Ronda et al., 2004 
Geographic area: 
Western Europe 
Funding agency: 
Netherlands Heart 
Foundation 
Study setting: 
Community-based 
 
 
Study objective: 
To assess whether Hartslag community 
smoking cessation intervention resulted in 
increased smoking cessation in Maastricht 
region as compared to control region 
Population: 
• Adults 
Study type: 
• Cohort Study 
• A pretest–posttest C design w/ two 
posttests 
Inclusion criteria: 
• Over 18 yrs old 
• Living in intervention or control regions 
Exclusion criteria: 
• NR 
Sampling plan: 
A cohort research population of 1,200 
smokers (age 18 and over) recruited in 
each region by taking a stratified 
random sample of 6,500 inhabitants in 
each region from computerized 
telephone registers, based on number 
of inhabitants i n each municipality 
included in region 
Sample size: 
G1: 4,242 (35.4% of whom were 
smokers) 
C1: 4,697 (34% of whom were 
smokers) 
Definition of smoking: 
Cigarettes 
• Smoker: smoked at all in last 7 days 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Telephone counseling 
• Media campaign 
Intervention:  
G1: Regional mass media-
led smoking cessation 
campaign Proficiat 
(Congratulations) 
implemented in January 
and February 2000 and 
2001, consisting of radio 
commercials, 
advertisements and 
messages in papers, 
billboards along roads, and 
posters and postcards in 
waiting rooms and public 
buildings; local activities 
organised by working 
groups consisting of 
representatives of local 
organizations, such as a 
non-smoking campaign for 
parents of children in 
playgroups 
C1: National mass media-
led smoking cessation 
campaign Dat kan ik ook (I 
can do that too) 
implemented around the 
turn of the century, 
consisting of various 
television programmes, an 
info line, non-smoking 
courses, mailings to 
variousorganizations, 
billboards in bus shelters, 
brochures, posters 
Method of assessment: 
Short structured telephone 
interviews 
 
Statistical analysis:  
• Multiple logistic 
regression analysis 
conducted to identify 
potential dropout bias 
(w/ attendance v. 
dropout as the 
dependent variable 
and baseline values 
for gender, age, 
education, and 
condition as 
independent variables) 
• Multiple logistic 
regression analysis 
used to identify 
potential baseline 
differences b/w G1 
region and control 
region 
• Independent variables 
in this analysis were 
baseline values for 
gender, age and 
education 
• Only respondents who 
completed all surveys 
included 
• Analyses performed 
using SPSS 10.0 
Data verification: 
NR 
Dependent variables: 
Primary: smoking status 
Secondary: intention to 
quit, cessation self-
efficacy, perceived social 
support for cessation 
Baseline data: 
Respondents from G1 
region significantly older, 
more often female, and 
more highly educated 
than respondents from 
control region 
Outcome measures: 
No significant differences found 
b/w G1 and control regions 
regarding smoking status and 
determinants of smoking 
behavior 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
NR 
Attrition rate: 
37.9%, net attrition 
after excluding 
unreachable 
respondents from 
T0 to T2 18.7% 
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cessation (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Cornuz et al., 2002 
Geographic area: 
Western Europe 
Funding agency: 
Swiss Federal Office for 
Public Health, Swiss 
Medical Association, Swiss 
Foundation for Health 
Promotion 
Study setting: 
Practice/provider settings 
 
Study objective: 
To assess efficacy of an educational 
program based on behavioral theory, active 
learning methods and practice w/ 
standardized patients for internal medicine 
residents in helping patients abstain from 
smoking and changing counseling practices 
Population: 
• Young adults 
• Adults 
Study type: 
RCT w/ cluster randomization  
Inclusion criteria: 
• 16 to 75 yrs old 
• Understood French 
• Consulted an outpatient clinic for a 
followup or an emergency visit 
• Had smoked 1 or more cigarettes daily 
during previous wk 
Exclusion criteria: 
• NR 
Sampling plan: 
• 35 residents at 2 general medicine 
clinics randomly assigned by 
computer and stratified by clinic to 
either intervention group trained in 
smoking cessation or C trained in 
dyslipidemia 
• Patients screened for eligibility by 
research assistants 
• Eligibile patients asked for written 
informed consent to participate in a 
study about preventive care 
Sample size: 
G1: 17 residents, 115 patients 
C1: 18 residents, 136 patients 
Definition of smoking: 
Cigarettes 
• 1-wk point prevalence of abstinence: 
no smoking in last wk 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
Intervention:  
G1: Intervention training 
program for residents based 
on active learning of 
counseling skills and 
interventions that matched 
patients' readiness to quit; 
after training, residents 
supposed to reach the 
following objectives: 
Systematically identify all 
smoking patients, clearly 
advise smokers to quit, 
assess each smoker's 
readiness to quit, use 
applied counseling 
strategies and offer a 
brochure that matched 
patient's stage of readiness, 
propose an individual 
smoking cessation program, 
follow smokers in short and 
long term, and facilitate 
implementation of smoking 
cessation in routine practice; 
received control training 4 
months later, after 3 month 
patient recruitment period 
had ended 
C1: Traditional diadactic 
training program on 
management of 
dyslipidemia; received 
intervention training 4 
months later, after 3 month 
patient recruitment period 
had ended 
Method of assessment: 
Baseline information 
collected by research 
assistant immediately after a 
patient's medical visit; 1-yr 
followup survey 
administered by mail; self-
reported abstinence 
validated at one clinic by 
measurement of exhaled CO 
by a research assistant 
blinded to group allocation 
Statistical analysis:  
To compare baseline data, 
Χ2 and Fisher exact tests 
used for categorical data 
and t-test and Wilcoxon 
rank-sum test used for 
continuous data; to 
measure outcomes, 
logistic regression 
performed w/ a 
generalized estimating 
equation to stratify by clinic 
and adjust for clustering by 
resident; all statistical 
analysis performed using 
STATA 
Data verification: 
Self-reported abstinence 
validated at one clinic by 
measurement of exhaled 
CO by a research 
assistant blinded to group 
allocation 
Dependent variables: 
Primary: Smoking status 
Secondary: Counseling 
score, willingness to quit, 
daily cigarette 
consumption 
Baseline data: 
• Both groups of residents 
similar at baseline 
• Both groups of patients 
similar at baseline 
At one-yr followup, 1-wk point 
prevalence of abstinence:  
G1: 13% (95% CI, 7% to 21%) 
C1: 5% (95% CI, 1% to 9%) 
P = 0.005 
OR = 2.8 (95% CI, 1.4 to 5.5) 
Residents who recieved study 
training provided better counseling 
(mean score 4 vs2.7, P = 0.002) 
Smokers willingness to quit higher 
in IG (94% vs80%, P = 0.007) 
No significant trend toward lower 
daily cigarette consumption in G1. 
Quality rating: 
Fair 
Comments: 
No comments 
Adequate 
randomization: 
Yes 
Attrition rate: 
Loss to followup at 1 
yr:  
G1: 33% 
C1: 26.5% 
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Author: 
Goldstein et al., 2003 
Geographic area: 
US 
Funding agency: 
NCI 
Study setting: 
Community-based 
Practice/provider settings 
 
 
Study objective: 
To determine effect of a community-based 
academic detailing intervention on quit rates 
of a population-based sample of smokers 
Population: 
• Adults 
Study type: 
• Cross-sectional 
• Community-based, quasi-experimental 
study 
Inclusion criteria: 
• Physicians eligible if they practiced a 
primary care specialty (i.e., family 
medicine, internal medicine, obstetrics 
/gynecology), provided primary care for at 
least 25% of their patients, completed 
postgraduate training, and planned to 
practice in the state for the 3 study yrs 
• Patients recruited through random digit 
dialing 
• Patients must be 18 to 75 yrs old 
• Live in a household w/ a phone 
• Current smokers 
Exclusion criteria: 
• Full-time hospital-based physicians 
excluded 
• Only one smoking patient per household 
included 
Sampling plan: 
• A list of all licensed physicians 
obtained from Rhode Island 
Department of Health, Folio’s Medical 
Directory of Rhode Island, 1990, and 
local health care institutions 
• Physicians received mailed invitations 
followed by postcards, and then 
phone calls from physician recruiters 
• Principal Investigator contacted 
nonresponders to complete 
recruitment process 
• All physicians providing direct care to 
adults in Newport, Washington, and 
Kent counties targeted for 
participation in intervention and 
delayed intervention (control) arms of 
PCS trial 
Sample size: 
G1: 376 patients 
G2: 385 patients 
G3: 332 patients 
C1: 1253 patients 
Definition of smoking: 
Cigarettes 
• Smoker: currently smokes cigarettes 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Multi-component office-
based intervention 
• Academic detailing 
Intervention:  
G1: Physicians provided 4 
A's to patients 
G2: Smokers provided w/ 
computer-generated, 
stage-tailored information 
about quitting smoking at 
home 
G3: Physician delivered 4 
A's to patients, and 
patients received 
computer-generated, 
stage-tailored smoking 
cessation information at 
home 
C1: No intervention 
Method of assessment: 
Telephone survey at 6, 12, 
18, and 24 mos 
 
Statistical analysis:  
• Descriptive statistics 
(mean, median, 
proportions) used to 
characterize study 
sample at baseline 
and to examine 
demographic 
differences b/w study 
groups which might 
confound study 
outcomes at 24 
months 
• Multivariate logistic 
regressions done to 
examine differences in 
smoking status at 24 
mos 
Data verification: 
NR 
Dependent variables: 
Self-reported smoking 
status 
Baseline data: 
• Those residing in 
physician intervention 
areas (G1 & G3) less 
likely to be less than 
HS educated and 
more likely to be 
college educated than 
C 
• C more likely to be in 
preparation state of 
change for cessation 
than intervention 
groups 
• Those visiting 
physicians more likely 
to be older female, 
higher education, 
report poorer health 
Percentage of patients who quit 
smoking at 6-month followup:  
G1: 8.4 
G2: 7.6 
G3: 8.9 
C1: 7.1 
P = NR 
Percentage of patients who quit 
smoking at 12-month followup:  
G1: 17.0 
G2: 16.5 
G3: 16.9 
C1: 16.1 
P = NR 
Percentage of patients who quit 
smoking at 18-month followup:  
G1: 25.2 
G2: 24.8 
G3: 19.2 
C1: 20.0 
P = NR 
Percentage of patients who quit 
smoking at 24-month followup:  
G1: 33.3 
G2: 26.3 
G3: 25.7 
C1: 22.6 
P = 0.006 
 
Quality rating: 
Fair 
Comments: 
Adequate 
randomization: 
NR 
Attrition rate: 
At 24 mos, of 2346 
participants, 35% 
attrition in 
controlled/delayed 
G1, 35% attrition in 
physician only IG, 
35% attrition in 
physician and 
home G1 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Joseph, Arikian, et al., 2004 
Geographic area: 
US 
Funding agency: 
Veterans Administration 
Health Services Research 
and Development Service 
(CPG 97-039) 
Study setting: 
Provider-based 
 
Research objective: 
To test the effect of modest intensity, 
practical systems change that might 
increase delivery of smoking cessation 
treatment within Veterans Affairs. 
Population: 
• Adults (N = 5,678) 
• 20 Veteran Affairs Medical Centers 
(results from this analysis were not used 
because sample size too small) 
Study type: 
• Cross-sectional design (individual 
analysis) 
• RCT w/ simple randomization 
(organizational analysis) 
Inclusion criteria: 
• Existence of referral-based smoking 
cessation program that treated a minimum 
of 50 patients/year, information resource 
management capacity for data collection, 
institutional review board, and evidence of 
commitment to participation in the project 
Exclusion criteria: 
• Facilities serving predominatly psychiatric 
patients, or displayed communication 
problems. 
Sampling plan: 
• Telephone surveys were conducted 
among 3 cohorts of patients 
• A cross-sectional survey was 
conducted at baseline among a 
sample randomly selected from 
patients who had seen their primary 
care provider within 6 months 
(preintervention) 
• A second cross-sectional survey 
sample was obtained 1 year after the 
intervention using the same sampling 
technique (post intervention) 
• Preintervention smokers at baseline 
were surveyed 1 year after 
intervention 
• Medical records reviewed 6 months 
before intervention and 6 months 
following intervention for all subjects 
who provided consent and smoked 
and a random sample of equal size of 
subjects that did not smoke.   
Sample size: 
Total: 5,678 Adults 
Preintervention 
G1: 2,112 
C1: 2,142 
Post intervention 
G1: 641 
C1:783 
Definition of smoking: 
Cigarettes 
• Current smokers 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
• Multicomponent 
intervention 
Intervention:  
G1: Received 
documentation of tobacco 
use status in medical 
records; delivery of 
intervention to all smokers; 
liberal use of smoking 
cessation medication; 
organizational support; site 
visits; 2 day training 
meeting; an interventionist at 
coordinating site. 
C1: NR 
Method of assessment: 
Medical record review and 
telephone survey 
Baseline data: 
No differences at baseline 
between intervention and 
control group sites. 
Statistical analysis:  
• A McNemar odds on 
change was calculated 
to assess difference in 
change between the 
intervention groups 
• The significance of the 
resulting odds was 
computed by the 
Pearson chi square 
• For continuous variables 
measured at facility level 
a Wilcoxon rank sum 
test was used.  
Data verification: 
Self-report (no biochemical 
verification) and medical 
record review 
Dependent variables: 
• Smoking status 
• General health 
• Nicotine dependence 
• Services provided at last 
visit to primary care 
provider 
• Mood  
• Alcohol use  
• Demographics 
G1: 11.4% quit smoking 
C1 13.2% quit smoking, NS 
No effects of the intervention on 
change scores between groups for 
reporting that their provider asked 
about smoking, or being counseled 
to quit at 1 year post intervention 
Intervention had no effect on 
smokers’ report of being counseled 
to quit 
Smokers only group, 30% of 
smokers in G1 were counseled 
before the intervention and 44% 
counseled after the intervention; 
C1 smokers counseled 39.1% 
before intervention and 42.2% post 
intervention. Amomg smokers who 
had a change in counseling before 
and after the intervention, the 
subjects in the intervention group 
had 2 times the odds of being 
counseled relative to controls 
(OR=2.24, 95% CI, 1.17 to 4.28, 
P=.014). 
Medical records: Post intervention 
had a significant effect on smoking 
status documentation where 
intervention records were more 
likely to document smokers (67% 
vs 60%, P=.0007)  
Smokers were more likely to be 
documented as smokers than non 
smokers were to be documented 
as nonsmokers  
 
Quality rating: 
Fair 
Comments: 
• Organizational 
level analysis was 
not used (N = 20) 
Adequate 
randomization: 
Yes for VA hospitals 
only not individual 
subjects 
Attrition rate: 
• Pre-intervention = 
21% 
• Smokers followup 
= 13% 
• Post- intervention 
= 16%  
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cessation 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Katz et al., 2004 
Geographic area: 
US 
Funding agency: 
National Cancer Institute 
and University of Wisconsin 
Comprehensive Cancer 
Center. 
Study setting: 
Community-based 
Practice/provider settings 
 
Study objective: 
To compare MAs' and LPNs' performance 
of recommended smoking cessation 
activities w/ that of RNs 
Population: 
• Adults 
Study type: 
• Secondary analysis of data from a RCT of 
guideline implementation 
• Intake clinicians (RNs, LPNs, MAs) paired 
w/ primary care physician (PCP)  
• Clinic randomized to receive help 
implementing AHRQ cessation guidelines 
vs control 
• Patients interviewed after clinic visit 
Inclusion criteria: 
• NR 
Exclusion criteria: 
• NR 
Sampling plan: 
NR 
Sample size: 
G1: 724 patients 
By intake clinician:  
RN: 100  
LPN: 154 
MA: 470 
C1: 497 patients 
By intake clinician:  
RN: 153  
LPN: 256 
MA: 88 
Definition of smoking: 
Cigarettes 
• At least one per day on average 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Individual counseling by 
non health professional 
• Telephone counseling 
Intervention:  
G1: In original RCT: study 
personnel worked w/ 
intake clinicians to 
implement guideline 
intervention (tutorial w/ 
feedback, real-time 
reminder, self-help 
material, onsite 
pharmacotherapy, and 
proactive telephone 
counseling) 
• Survey administered to 
intake clinicians 
immediately preceeding 
intervention 
• After clinic visit, study 
personnel interviewed 
consecutive adults who 
had routine, non-
emergency appointment 
and who smoked ≥ 1 
cigarette per day 
• Patients asked whether 
they received cessation 
counseling from intake 
clinician 
C1: Intake clinicians 
completed survey just prior 
to tutorial session at end of 
intervention period, but 
had no help w/ guideline 
implementation 
Method of assessment: 
Exit interview of patients 
 
Statistical analysis:  
Two-level hierarchical 
logistic regression 
Data verification: 
NR 
Dependent variables: 
Proportion of patients 
receiving guideline-
recommended 
counseling at time of 
scheduled clinic visit 
Baseline data: 
Patients seen by MA 
vsRN at control site = 
57% vs43% male 
(P = 0.01), and 49% 
vs71% w/ regular 
clinician (P = 0.02) 
Patients seen by MA 
vsRN at test site = 57% 
vs75% w/ regular 
clinician (P = 0.001) 
Ask about smoking:  
Control RN/LPN/MA: 
67%/35%/41% vstest site 
RN/LPN/MA: 92%/86%/78%. 
Assess willingness to quit: 
control RN/LPN/MA = 
15%/8%/7% vstest site 
RN/LPN/MA = 85%/75%/60%. 
Advise to quit: control 
RN/LPN/MA = 16%/7%/9% 
vstest site RN/LPN/MA = 
41%/46%/28%. 
Assist in quitting: control 
RN/LPN/MA = 17%/8%/9% 
vstest site RN/LPN/MA = 
73%/69%/51%. 
(Also reported as difference in 
proportion (& 95% CI) b/w RNs 
and other intake clinicians). 
 
Quality rating: 
Fair 
Comments: 
Secondary 
analysis, so study 
not designed to 
answer this 
question 
Missing important 
info that's reported 
in original study 
Adequate 
randomization: 
NR 
Attrition rate: 
NR 
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Study Characteristics Study Design Sample Design and Definitions 
Author:  
Katz et al., 2004 
Geographic area:  
US 
Funding agency:  
National Cancer Institute; 
University of Wisconsin; 
GlaxoSmithKline donated 
transdermal nicotine 
patches for use in trial 
Study setting:  
Provider-based 
 
Research objective:  
To test the effectiveness of a multi-modality 
intervention to implement the AHRQ 
Smoking Cessation Clinical Practice 
Guideline in primary care settings 
Population:   
Adults  
Study type: 
RCT 
Inclusion criteria:  
Adults smoking at least one cigarette per 
day and having an appointment with a 
primary care clinician for routine, non-
emergency care and willing to complete a 
brief exit interview immediately after the 
clinic appointment 
Exclusion criteria:  
NR 
 
Sampling plan:   
• 12 eligible clinics were invited to 
participate; 9 clinics agreed to 
participate; 1 clinic participated only in 
the pilot phase 
• Matched clinic sites (8) by primary 
care discipline and health plan 
affiliation (if any)  
• For each pair of clinics, project 
statistician used a random number 
generator to randomly assign each 
clinic to receive either the intervention  
(test site, n=4) or usual care (control 
site, n=4) 
Sample size: 
G1: 4 clinics, 1141 patients 
C1: 4 clinics, 1022 patients 
Definition of smoking:   
7-day point prevalence  
 
C-155 
Evidence Table 7. Health care systems strategies to increase implementation of population-level tobacco use 
cessation (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:   
• Multicomponent office 
based intervention  
Intervention:  
G1: Tutorial for intake 
clinicians, group and 
individual performance 
feedback for intake 
clinicians, use of a modified 
vital signs stamp, an offer of 
free nicotine replacement 
therapy and proactive 
telephone counseling. 
C1: Staff received only 
general information on the 
AHRQ Guideline 
Method of assessment: 
Self-reported by telephone 
interview at 2- and 6-month 
follow-up 
Baseline data: 
No statistically significant 
differences in smoking 
cessation rates between 
participants at test and 
control sites during the 
baseline period, except in 
educational level 
During the intervention 
period, patients at test sites 
were older, had more years 
of education and smoked 
more cigarettes per day than 
patients at control sites 
No significant differences 
between characteristics of 
intake clinicians at test sites 
and those at control sites 
with one exception, intake 
clinicians at control sites had 
more years of work 
experience than those at 
test sites 
 
Statistical analysis:  
Hierarchical logistic 
regression models used to 
estimate the odds rations 
for treatment assignment 
after adjustment for patient 
characteristics 
Data verification: 
Self-report and 
confirmatory salivary 
cotinine for self-reported 
quitters 
Dependent variables:  
• Performance of 
recommended smoking 
cessation activities by 
clinic staff 
• Abstinence at 2 and 6 
months after the initial 
clinic visit (7-day point 
prevalence) 
• Continuous abstinence 
at 2 and 6 months (self-
reported abstinence at 
both 2 and 6 month 
assessments) 
During the intervention period, 
more patients at test sites were 
asked about their smoking status 
(OR = 3.1; 95%,CI; 1.2 to 8.2;  
P = 0.02) or about their willingness 
to quit smoking (OR = 6.4, 95%, 
CI; 3.7 to 10.8; P < 0.001), were 
given literature about quitting (OR 
= 21, 95%, CI; 8.8to 49;  
P < 0.001), were assisted with 
setting quit date (OR = 33, 95%, 
CI;11 to 100; P < 0.001) or were 
engaged in a discussion about 
pharmacotherapy (OR = 3.9, 95%, 
CI; 2.5 to6.3; P < 0.001). 
Among participants treated during 
the intervention period, those at 
test sites were more likely than 
those at control sites to report 
being abstinent at the 2- month 
(16.4% vs. 5.8%, adjusted OR = 
3.3, 95% CI, 1.9 –5.6, P < 0.001) 
and 6-months (15.4% vs 9.8%; 
adjusted OR = 1.7, (95% CI = 1.2-
2.6), P = 0.009) follow-up 
assessments and to report 
continuous abstinence (10.9% vs 
3.8%, adjusted OR = 3.4 (95% CI, 
1.8-6.3), P < 0.001) 
With biochemically confirmed 
abstinence at 6 months, showed 
no difference between G1 and C1 
Very low response rate for planned 
collection of confirmatory salivary 
cotinine tests of self-report 
cessation 
 
Quality rating: 
Good 
Comments:   
Failed to reach 
original enrollment 
target resulting in 
slightly lower power 
than originally 
planned to detect 
differences in 
cessation outcomes. 
Adequate 
randomization: 
Yes 
Attrition rate:   
G1: 11% 
C1: 10% 
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Study Characteristics  Study Design Sample Design and Definitions 
Author: 
Pbert et al., 2004 
Geographic area: 
US 
Funding agency: 
NHLBI 
Study setting: 
Practice/provider settings 
 
 
Study objective: 
To evaluate effect of a provider counseling 
and office systems intervention in obstetric, 
pediatric, and Special Supplemental 
Nutrition Program for WIC clinics on 
smoking and relapse rates in pregnant and 
postpartum wome 
Population: 
• Adults 
• Women (only) 
• Pregnant women 
Study type: 
RCT w/ cluster randomization  
Inclusion criteria: 
• Women receiving prenatal care and WIC 
services and planning to receive pediatric 
care at one of community health centers 
• Speaking English or Spanish 
• Having at least 2 months before their due 
date 
• Being a current smoker or spontaneous 
quitter (quit smoking after learning of 
pregnancy) 
• Planning to remain in area for at least 6 
months following delivery 
Exclusion criteria: 
• NR 
Sampling plan: 
• Five community health centers 
randomized to special intervention or 
usual care 
• Research assistants screened 
women in WIC offices 
Sample size: 
G1: 272 
C1: 278 
Definition of smoking: 
Cigarettes 
• Abstinence: not smoking within last 7 
days 
• Spontaneous quitter: quit smoking 
since learning of pregnancy and not 
smoking for at least 7 days prior to 
baseline 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
Individual Counseling by 
non Health Professional 
Intervention:  
G1: Clients visited 
community health centers 
and WIC offices that 
received: provider training 
to deliver a SIbased on 
national clinical practice 
guidelines tailored to 
woman’s stage of change 
and delivered through 
three channels (obstetric, 
pediatric, and WIC 
providers); an office 
practice management 
system to routinely screen 
for smoking status, 
prompt/remind providers to 
intervene, document the 
encounter, distribute 
materials, and arrange 
followup; and 
establishment of program 
boards to coordinate 
transfer of documentation 
among clinics, including 
periodic meetings w/ 
representatives from all 
clinics 
C1: Usual care 
Method of assessment: 
Data collected from 
participants at five time 
points during regular WIC 
appointments or by 
telephone: baseline 
interview upon enrollment, 
9-month interview before 
delivery, 1-month 
postpartum interview 
within 30 days after 
delivery, 3-month 
postpartum interview, and 
6-month postpartum 
interview 
 
Statistical analysis:  
• A mixed-effects linear 
modeling used to test 
hypotheses about txt 
conditions controlling 
for clustering of 
respondents within 
each community 
health center 
• Linear logistic 
regression analyses 
computed using 
GLIMMIX macro, 
which uses iteratively 
reweighted likelihoods 
to fit a logistic 
regression 
• PROC MIXED 
procedure in SAS 
used for analysis of 
number of cigarettes 
per day over time 
• Reported P values are 
for two-sided 
alternative hypotheses 
Data verification: 
Salivary cotinine levels  
≤ 20 ng/ml assessed to 
confirm 7 day abstinence 
Dependent variables: 
Smoking status 
Baseline data: 
Groups similar at 
baseline 
30-day abstinence rates at end of 
pregnancy among women who 
did not spontaneously quit upon 
learning of their pregnancy:  
G1: 26% 
C1: 12% 
OR = 2.57 
P = 0.05 
30-day abstinence rates at 1-
month postpartum among 
women who did not 
spontaneously quit upon learning 
of their pregnancy:  
G1: 26% 
C1: 11% 
OR = 3.01 
P = 0.04 
All other effects not statistically 
significant 
No effect remained at 3 and 6 mo 
followup 
Intent to treat at 30 day followup:  
Non-spontaneous quitters: 2.02 
P = 0.09 
Spontaneous quitters 0.95  
P = 0.95 
 
Quality rating: 
Fair 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
20% 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Pieterse, 2001 
Geographic area: 
Western Europe 
Funding agency: 
Dutch Cancer Society 
Study setting: 
Practice/provider settings 
 
Study objective: 
To test effectiveness of a minimal contact 
smoking cessation program implemented by 
Dutch general practitioners. 
Population: 
• Young adults 
• Adults 
Study type: 
• RCT w/ simple randomization 
• Randomization occurring within practice 
sites according to a "prestructured 
allocation list" 
Inclusion criteria: 
• 18 to 70 
• Self-reported smoker 
Exclusion criteria: 
• Controls exposed to txt 
• Controls w/ severe tobacco-related health 
problems (thus given intervention) 
Sampling plan: 
Smoking patients 18 to 70 recruited 
from participating Dutch general 
practitioners' clinics 
 
Only info regarding randomization 
process:  
• Occurred within clinics and used a 
prestructured allocation list 
Sample size: 
G1: 269 
C1: 261 
Definition of smoking: 
Cigarettes 
• Non-smokers at followup defined as 
consistently providing non-smoker 
responses to two questions 1) contact 
name for someone to verify smoking 
status and 2) self-reported smoking 
status 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Individual counseling by 
non health professional 
• Telephone counseling 
• Pharmaceuticals 
Intervention:  
G1: Brief (10-minute) 
counseling sessions w/ 
physician; self-help 
manual; followup sessions. 
C1: Usual txt - no 
counseling or advice on 
smoking except when 
initiated by patient or when 
indicated by the contact 
reason, in which case 
counseling limited to a 
straightforward stop-
smoking advice and 
possibly a referral to local 
municipal health 
organization 
Method of assessment: 
Self-report by 
questionnaire 
 
Statistical analysis:  
Logistic regression, 
backward stepwise 
procedures, univariate 
ANOVA, Χ2 tests 
Data verification: 
Self-report. 
No biochemical 
verification 
Dependent variables: 
• Self-reported 
abstinence from 
smoking 
• Point prevalence of 
smoking 
• Consecutive 
abstinence from 
smoking (abstinent at 
both 6- and 12-month 
followups) 
Baseline data: 
Significant difference in 
G1 vsC1 in baseline 
measures of: 
Percent smoking ≤ 10 
cigarettes per day (G1: 
13.3, C1: 20.4; F = 4.3, 
P = 0.04)  
Motivation to quit score 
(G1: 14.8, C1: 13.8, F = 
6.7, P = 0.01) 
 
Otherwise, population 
considered 
representative of 
average Dutch visitor of 
a general practice 
1-month followup smoking 
abstinence rates greater among 
those in intervention compared to 
controls (OR = 2.56; CI, 1.8, 3.8)  
Similarly, 12-month follow up 
smoking abstinence rates were 
13.4% (G1) vs 7.3% (C1), w/ an 
OR = 1.51 (CI, 1.1, 2.1), P < 0.05  
 
Consecutive abstinence greater 
among intervention group (8.2%) 
than among C (3.1%); OR = 3.04 
(CI, 1.7, 5.6), P < 0.001 
Quality rating: 
Fair 
Comments: 
Not clear about 
randomization 
procedures 
because only 
vague information 
provided 
 
Important potential 
influence identified 
by authors -- 
implementation of 
national mass-
media stop-
smoking campaign, 
which started 
shortly before 
second followup 
Adequate 
randomization: 
Yes 
Attrition rate: 
1 month:  
Overall: 26% 
G1: 33% 
C1: 19% 
6 month:  
Overall: 26% (no 
info on each 
group). 
12 month:  
Overall: 19% (no 
info on each 
group). 
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cessation (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Piper et al., 2003 
Geographic area: 
US 
Funding agency: 
National Cancer Institute 
Study setting: 
Provider-based 
Research objective: 
To test effectiveness of expanded vital sign 
stamp to identify smokers and reduce 
smoking rates 
Population:  
Adult smokers attending health care clinics 
Study type: 
Cluster RCT (clinics unit of randomization) 
Inclusion criteria: 
• Any adult smoker (older than 18 years) 
• Attended only one health care clinic 
Exclusion criteria: 
None reported 
Sampling plan:  
• Convenience sample 
• Adults exiting health clinics (n = 5) 
were approached 
• Any adult smoker willing to participate 
was enrolled 
Sample size: 
G1: 5582 
C1: 3857 
Definition of smoking:  
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods:  
Expanded vital sign stamps 
Intervention:  
G1: smoking status was 
added to the vital sign stamp 
C1: usual vital sign stamp 
without smoking status 
Method of assessment: 
Follow up questionnaire 
after 1 year  (method NR) 
Baseline data: 
Similar at baseline 
Statistical analysis:  
Chi square (response 
rates not reported) 
Data verification: 
NR 
Dependent variables:  
• Smoking cessation 
• Identification of smokers
• Rates of smoking 
counseling by 
physicians 
Proportion of all participants asked 
by any clinic staff person about 
smoking before and after 
implementation of vital sign stamp 
revealed an overall increase of 
9.6% in control group and 30.9% in 
intervention clinics 
Mean increase in asking behavior 
of physicians at vital sign clinics 
was statistically greater than that of 
physicians at control clinics  
t = -3.61; P = 0.002) 
No statistically significant 
differences in abstinence rates 
(complete abstinence during past 7 
days) between G1 and C1 after 1 
year (P = 0.27). 
Quality rating: 
Fair  
Comments:  
Response rates to 
follow up 
questionnaire at 1 
year not reported 
Adequate 
randomization: 
NR 
Attrition rate:  
NR 
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cessation (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Russos et al., 1999 
Geographic area: 
US 
Funding agency: 
Cigarette and Tobacco 
Surtax Fund of the State of 
Calif through the Tobacco-
Related Disease Research 
Program of the University of 
Calif 
Study setting: 
Practice/provider settings 
 
 
Study objective: 
To examine rate and determinants 
(especially as related to social learning 
factors) of tobacco prevention and cessation 
counseling by orthodontists participating in 
a controlled trial to decrease incidence of 
tobacco use among adolescents. 
Population: 
• Adults 
Study type: 
• Cross-sectional  
• Current study based on cross-sectional 
interview design survey of orthodontists 
randomized to intervention to enhance 
skills in delivering smoking prevention 
and cessation counseling to adolescent 
patients or to C (thus, interventions 
described relate to the RCT, not the 
cross-sectional survey) 
Inclusion criteria: 
• Orthodontist from an office in one of the 
selected Calif counties 
• Practiced at least 2 days a wk 
• Had at least 75 adolescent patients 
• Planned to remain in practice at least 2 
yrs (for survey: participated in original 
study) 
Exclusion criteria: 
• Not meeting inclusion criteria 
Sampling plan: 
Orthodontists recruited from 154 
participating orthodontic offices within 
various southern Calif counties 
Sample size: 
G1: 63 
C1: 63 
Definition of smoking: 
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
non health professional 
• Telephone counseling 
• Video 
• Media campaign 
Intervention:  
G1: Anti-tobacco materials 
(e.g., posters), 1.5 hr 
training session on 
tobacco prevention, written 
anti-tobacco prescriptions, 
reimbursement for anti-
tobacco prescription given 
to patients, quarterly visits 
and calls; office staff asked 
to make office tobacco-
free (remove ashtrays, 
distribute anti-tobacco 
materials and prescriptions 
to all youth, to remind 
patients not to begin 
tobacco use) 
C1: No training, materials, 
or visits, nor asked to 
change their offices or 
practices 
Method of assessment: 
Mailed survey requesting 
self-report from 
orthodontists 
 
Statistical analysis:  
• Nonparametric 
statistics (Kendall, 
Mann-Whitney) used 
in bivariate analyses 
• Multivariate analysis 
Data verification: 
Telephone survey of 
orthodontists 
Dependent variables: 
• Provision of prevention 
and cessation 
counseling to patients 
• Counseling content 
• Counseling 
determinants 
Baseline data: 
No significant differences 
(P > 0.05) found b/w G1 
and C1 in terms of 
demographics, clinical 
practices, office 
characteristics, history of 
tobacco use, nor training 
for tobacco counseling 
Mean age about 51, 
mean yrs in practice 
about 24 yrs, about 230 
adolescent patients, 
mean gross annual 
income 445,000 
Outcome measures: 
In a typical wk more clinicians in 
experimental vsC provided 
prevention counseling to patients 
(Mean: 25.4% v 3%, Mann-
Whitney U = 696.5, z = -7.0, P < 
0.01) and at least some 
cessation counseling (91% vs 
72%, chi sq = 8.4, P < 0.01) 
G1 asked higher % (4.8) of their 
patients whether they use 
tobacco than C1 (2.9), (U = 
1349.0, z = -3.3, P < 0.01) 
G1 more likely to report mostly 
positive reactions from tobacco 
users for cessation counseling 
(chi sq = 7.8, P < 0.05) 
C1 more likely than G1 to say 
they don't provide counseling 
because it's not their job or not 
expected of them (chi sq = 3.7, P 
= 0.05) 
G1 more likely to say lack of time 
is significant barrier to giving 
prevention counseling (chi sq = 
4.2, P < 0.05) 
Demographic, office, and clinic 
practice variables not associated 
w/ prevention or cessation 
counseling (P > 0.05) 
Higher rates of prevention and 
cessation counseling associated  
(P < 0.05) w/: asking patients 
whether they used tobacco; 
belief that counseling is 
important; belief that clinicians 
should receive counseling 
training; intent to attend training; 
and to disagree that counseling 
is not part of their jobs 
 
Quality rating: 
Fair 
Comments: 
Good, 
documentation of 
reasons for attrition 
and distribution of 
non-responders by 
group; things to 
consider when 
trying to improve 
providers' provision 
of tobacco use 
prevention and 
cessation advice 
Similar findings 
from comparison of 
results to other 
studies 
Adequate 
randomization: 
Yes 
Attrition rate: 
Survey:  
G1 and C1: 18% 
each 
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cessation (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Slama et al., 1999 
Geographic area: 
Western Europe 
Funding agency: 
French Ministry of Health; 
European Union "Europe 
Against Cancer 
Programme"; French 
Committee for Health 
Education 
Study setting: 
Practice/provider settings 
 
Study objective: 
To examine participation and effectiveness 
of GPs in offering a minimal smoking 
cessation intervention according to 
attitudinal and behavior variables 
Population: 
• Adults 
Study type: 
Cross-sectional survey w/ GPs who 
participated in a previous smoking cessation 
intervention 
Inclusion criteria: 
• Participated in previous smoking 
cessation intervention study 
Exclusion criteria: 
• NR 
Sampling plan: 
• 2,860 GPs from France interviewed 
about their attitudes and behaviors 
• From this group, 170 of 371 randomly 
selected smoking GPs and 202 of 
375 randomly selected non-smoking 
GPs participated in survey 
Sample size: 
Smokers: 170 smokers 
Non-smokers: 202 
C1: NA 
Definition of smoking: 
Cigarettes 
• Abstinent: not smoking cigarettes 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
Extra-curricular activities 
Intervention:  
G1: NA 
G2: NA 
G3: NA 
C1: NA 
Method of assessment: 
For GPs' attitudes and 
reported practices: self 
report obtained by 
telephone survey 
GPs' participation in 
intervention measured by 
patient information GP 
returned per protocol at 1 
and 12 mo followups. 
Patient smoking status: 
self report at 1 and 12 mo 
followups 
 
Statistical analysis:  
Chi sq tests 
Frequencies 
Proportions 
Data verification: 
Self report 
Dependent variables: 
• Rate of participation in 
cessation trial by GP's 
smoking status 
• Effect of GPs' 
smoking-related 
attitudes and reported 
practices 
Baseline data: 
50% of eligible GPs 
participated (45% 
smoked; 54.1% did not; 
Χ2 = 5.147, P < 0.05) 
Significant differences 
b/w participating and 
non-participating GPs in 
beliefs about usefulness 
of screening for cervical 
(96.2% vs 91.6%, Χ2 = 
6.460, P < 0.011) and 
breast cancer (98.1% v 
94.8%, Χ2 = 5.918,  
P < 0.015) 
 
Other differences NS 
Doctors who were smokers less 
likely than non-smoking GPs to 
participate in the smoking 
cessation trial, despite having 
originally consented to do so 
(45% vs 54.1%, chi sq: 5.147,  
P < 0.05) 
None of the GPs' smoking 
related attitudes and reported 
behaviors significantly related to 
their participation in the study nor 
to their patients' rates of smoking 
cessation at 1 mo, 12 mos, or 
both 
Conclusion: When minimal 
advice has an effect, it is due 
more to systematic nature of the 
provision of intervention than to 
the attitudes or reported 
practices of practioner giving 
advice 
Quality rating: 
Fair 
Comments: 
Interesting practical 
applications to 
understanding 
factors that might 
influence 
physicians' 
willingness to 
participate in 
interventions to 
address smoking 
cessation w/ 
patients; Limited 
discussion of 
intervention, 
though refers to 
previous article 
description 
Adequate 
randomization: 
NR 
Attrition rate: 
Smoking GPs (%): 
1 wk: 11.8 
2 wks: 8.2 
3 wks: 12.9 
4 wks: 32 
Non-smoking GPs 
(%):  
1 wk: 9.9 
2 wks: 10.3 
3 wks: 15.3 
4 wks: 35.5 
 
C-166 
Evidence Table 7. Health care systems strategies to increase implementation of population-level tobacco use 
cessation 
Study Characteristics  Study Design Sample Design and Definitions 
Author: 
Smith et al., 2002 
Geographic area: 
US 
Funding agency: 
NCI, Canadian Cancer 
Society 
Study setting: 
Hospital 
 
 
Study objective: 
To assess effectiveness of a nurse case-
managed smoking cessation program for 
general hospitalized patients, was continued 
for 3 yrs after completion of RCT 
Population: 
• Adults 
Study type: 
• Time series 
• Single group effectiveness study using a 
program put into standard hospital 
practice. 
• No comparison group for this study; 
instead, follows participants over time and 
assesses smoking status at various 
points postintervention 
Inclusion criteria: 
• Patients who smoked in month before 
hospital admission 
• Wanted to quit smoking 
• Agreed to participate in intervention 
Exclusion criteria: 
• Did not speak English 
• Impaired level of consciousness 
• Terminal 
• Primary reason for hospitalization was 
substance abuse 
• Hospital stay less than 36 hrs 
Sampling plan: 
Patients admitted to Stanford (Calif.) 
Hospital who smoked any amount the 
month before admission were offered a 
smoking cessation program during 
hospitalization 
Sample size: 
12 month sample = 720 
Definition of smoking: 
Cigarettes 
• 7 day point-prevalence as defined by 
NHLBI (not even a puff for a minimum 
of 7 consecutive days prior to 
assessment 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Telephone counseling 
• Video 
• Pharmaceuticals 
Intervention:  
G1: Used multiple-
reinforcement approach 
(multiple providers, 
components, and contacts) 
During hospitalization: 
Physician advice on 
smoking cessation; 
bedside education and 
counseling w/ specially 
trained nurse; take-home 
materials (video, 
workbook, relaxation 
audiotape), NRT if 
requested or indicated, 4 
nurse-initiated 
postdischarge phone 
counseling calls (2,7,21, 
and 90 days 
postdischarge) 
C1: No control or 
comparison group 
Method of assessment: 
In-person survey for 
demographic information, 
and baseline smoking 
history and alcohol 
consumption 
Postdischarge data 
collected by telephone and 
involved self-report 
 
Statistical analysis:  
• ANOVA 
• Χ2 
• Frequencies 
• Intent-to-treat analysis 
Data verification: 
• Self-report by 
telephone No 
biochemical 
assessment 
Dependent variables: 
12 mo quit rate (7 day 
point prevalence at 12 
mos) 
Baseline data: 
Mean age: 52 
Males: 58% 
 
Race/ethnicity: 
• Caucasian: 79% 
• African American: 5% 
• Asian: 9% 
• HispaniC1: 1%  
• Other race: 6%  
 
Hospitalization reasons:  
• Cardiovascular: 41% 
• Cancer: 12%  
• Pulmonary: 6% 
• Gynecological: 4% 
• Internal medicine: 19% 
• OrthopediC1: 10% 
• Other: 9%  
 
Significant (P < 0.001) 
differences in age, sex, 
ethnicity, primary reason 
for hospitalization b/w 
total smokers identified, 
ineligibles, participants, 
wanted to quit on own, 
and did not want to quit 
groups 
Including only those who were 
reached at 12 mos, 49% reported 
being smoke free for previous 7 
days 
Including 211 who were not 
reached at 12 mos (intent to 
treat) and counting them as 
smokers, self-reported smoking 
cessation rate is 35%. 
 
Quality rating: 
Fair 
Comments: 
Though no 
comparison group 
in this study, it 
provides very good 
and detailed data 
regarding 
continuation of a 
smoking cessation 
program 
implemented 
previously as part 
of a RCT; 
only 52% of eligible 
patients 
participated, but 
this is considered 
fairly high 
acceptance rate for 
the population;  
it also presents 
data both w/ and 
without intent-to-
treat approach; 
partial reasons for 
high attrition rate at 
12 mos include 
nurse not having 
time to devote to 
trying to make 
follow up calls and 
only 3 attempts 
made to reach 
participants by 
phone. Study also 
addresses practical 
hospital-related 
issues to be 
considered when 
implementing an 
inpatient smoking 
cessation program 
Adequate 
randomization: 
No 
Attrition rate: 
Excluding 42 who 
died before 
assessment, 29% 
attrition rate (not 
reached or dropped 
out) 
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Study Characteristics  Study Design Sample Design and Definitions 
Author: 
Soulier-Parmeggiani et al., 
1999 
Geographic area: 
Western Europe 
Funding agency: 
NR 
Study setting: 
Hospital 
Practice/provider settings 
 
Study objective: 
To evaluate effectiveness of a smoking 
cessation program for outpatients 
Population: 
• Adults 
Study type: 
• Before and after study 
• Patients participated in 1-hr consultation 
groups once a wk for 4 wks; patients 
interviewed at baseline and 3, 6, and 12 
months after intervention 
Inclusion criteria: 
• NR 
Exclusion criteria: 
• NR 
Sampling plan: 
NR 
Sample size: 
G1: 299 
Definition of smoking: 
NR 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Individual counseling by 
health professional 
• Group counseling 
• Telephone counseling 
• Social support 
• Video 
• Pharmaceuticals 
Intervention:  
G1: One-hr group 
consultations once per wk 
for 4 wks; followup 
individual consultations by 
telephone at 1, 3, 6, and 
12 mos after intervention; 
prescription of NRT; 
individual strategy for 
cessation discussed w/ a 
provider; family support 
recommended; video of 
benefits of cessation; 
dietitian-led session on 
preventing weight gain and 
individual diet 
recommendations; relapse 
prevention counseling 
C1: NR 
Method of assessment: 
• Questionnaires filled out 
by patients at baseline 
and 3, 6, and 12 mos 
postintervention 
• Patients' CO levels 
measured at each 
session and followup 
 
Statistical analysis:  
Proportions of smokers 
calculated at baseline 
and followup intervals 
Data verification: 
Patients' CO levels 
measured at each 
session and followup 
Dependent variables: 
Smoking status 
Baseline data: 
Collected data on 
smoking history, 
addiction level as 
measured by FTQ, and 
motivation and 
confidence to quit 
smoking 
Non-smokers at baseline and 
each followup:  
Baseline: 0% 
End of intervention: 54% 
3-mo followup: 39.4% 
6-mo followup: 25.8% 
12-mo followup: 20.9% 
Quality rating: 
Poor 
Comments: 
Sampling not 
explained, no C, 
limited 
generalizability 
Adequate 
randomization: 
NR 
Attrition rate: 
10.4% 
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Study Characteristics  Study Design Sample Design and Definitions 
Author: 
Stevens et al., 2000 
Geographic area: 
US 
Funding agency: 
NCI 
Study setting: 
Hospital 
 
Study objective: 
To evaluate implementation and 
effectiveness of hospital-based smoking 
cessation counseling delivered by 
respiratory therapists chosen from among 
hospital staff 
Population: 
• Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
• Between 18 to 70 yrs old 
• Being admitted to one of two participating 
Kaiser Permanente hospitals in Portland, 
OR 
• Reporting regular smoking anytime in 3 
months preceding hospitalization 
Exclusion criteria: 
• Obstetric patients 
• < 18 or >70 yrs old 
• Hospitalized for psychiatric or drug or 
alcohol abuse diagnoses 
• Patients w/ hospital stays less than 36 hrs
• Hospice patients 
Sampling plan: 
• Smokers b/w 18 to 70 yrs old 
identified by questionnaire upon 
hospital admission 
• Eligible smokers assigned to txt or 
usual care by a random digit in their 
HMO member number 
Sample size: 
G1: 541 
C1: 632 
Definition of smoking: 
Cigarettes 
• Abstinence from smoking considered 
as ≥ 6 months 
• Second analysis included pipes or 
cigars 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Telephone counseling 
• Video 
Intervention:  
G1: If assigned to 
intervention but did not 
agree to participate, 
received smoking 
cessation brochure only 
If agreed to participate, 
watched 12 minute video 
for hospitalized smokers; 
offered one 20-minute 
counseling session w/ RT; 
choice of written materials 
(e.g., NCI's  
C1: no information 
Method of assessment: 
Mailed questionnaire and 
follow up by phone for 
non-responders 
 
Statistical analysis:  
Χ2 tests and one logistic 
regression 
Data verification: 
Relied on self-report of 
smoking status 
Dependent variables: 
6 month abstinence from 
smoking 
Baseline data: 
• 57% women, mean 
age 47 yrs 
• Mean smoking rate 
before hospitalization: 
19 cigarettes per day 
• Similar baseline 
characteristics among 
intervention and Cs 
 
No statistically significant 
differences b/w groups at 
baseline in terms of 
demographics or 
smoking, but 
race/ethnicity NR) 
NR Quality rating: 
Poor 
Comments: 
NR 
Adequate 
randomization: 
Yes 
Attrition rate: 
NR 
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Study Characteristics Study Design Sample Design and Definitions 
Author: 
Young et al., 2002 
Geographic area: 
Australia 
Funding agency: 
CSAHS Tobacco Education 
Team. (NSW Quit 
Campaign supplied free 
"Quit Kits," Pharmacia 
Upjohn donated NRT starter 
packs; NSW Cancer 
Council supplied videos and 
workbooks at cost.) 
Study setting: 
Practice/provider settings 
 
 
Study objective: 
To evaluate a multifaceted, practice-based 
intervention involving audit, feedback, and 
academic detailing to improve family 
physicians' smoking cessation advice 
Population: 
• Adults 
Study type: 
• RCT w/ cluster randomization  
• Each family practice, representing a 
cluster, randomly allocated to receive 
either intervention in smoking cessation 
advice (G1) or an intervention of identical 
format and intensity but about cervical 
screening (C1) 
• This constituted a 2 x 2 balanced 
incomplete block design, used to equalize 
nonspecific effects of research 
participation b/w groups and thereby 
minimize Hawthorne effect 
• Data from FPs' patients used to assess 
effectiveness of intervention by 
comparing baseline and posttest 
questionnaires 
Inclusion criteria: 
• Family physicians from practices located 
within a defined geographical area in 
1999 
• Patients: Aged 18 to 70 
• Attending FPs during specified data 
collection periods 
• Spoke and read English 
• Could read questionnaire 
Exclusion criteria: 
FPs:  
• Ineligible if they worked < 2 days per wk 
• Planning to leave practice within 6 
months 
• On extended or maternity leave 
• Did not employ a receptionist 
• Already participating in a clinical audit 
• More than 50% of their patients spoke a 
language other than English at home 
 
Patients:  
• Did not read or speak English 
• Were unable to read or understand 
questionnaire 
• Were too sick or distressed to participate 
• Had participated previously 
Sampling plan: 
• All FPs in defined geographical area 
in 1999 were invited to participate 
• Following baseline data collection, 
practices stratified according to 
number of participating FPs at 
practice (1, 2-4, 5+) to ensure 
approximately equal numbers of FPs 
in each study group 
• Within each stratum, practices then 
randomly allocated to intervention or 
C using random numbers generated 
by SAS  
 
FP patients 18 to 70 recruited 
consecutively and invited to participate 
in a study about health care in a general 
practice. 
Sample size: 
G1: 30 (FPs) in 20 practices 
C1: 30 (FPs) in 19 practices 
Definition of smoking: 
Cigarettes 
• NA 
Smokless tobacco 
• NA 
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Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Self-help 
• Individual counseling by 
health professional 
• Video 
• Pharmaceuticals 
Intervention:  
G1: FP received three 
academic detail visits 
which combined audit and 
feedback; resources for 
FPs (skills training video 
and workbook package, 
clinical practice guidelines, 
prompt sheet to assist w/ 
smokers’ excuses and 
self-exceptions); resources 
for practices (patient-
mediated prompts, 
reminders for medical 
records) and resources for 
patients (patient brochures 
and free starter packs of 
nicotine replacement gum) 
• Sessions 1 and 2 
conducted by a medical 
peer 
• Session 3 conducted by 
a non-medical public 
health academic 
C1: Received similar 
intervention in terms of 
intensity and format, but w/ 
regard to cervical 
screening 
Method of assessment: 
• Baseline: Demographic 
questionnaires 
completed by 
participating FPs 
• Patients at participating 
practices also 
completed baseline and 
posttest questionnaires 
• Medical record audit 
 
Statistical analysis:  
Frequencies, 
proportions, univariate 
analysis, bivariate 
analysis, Χ2, Wilcoxon's 
rank sum tests, Fisher's 
exact test, McNemar's 
test for paired 
proportions, Wilcoxon's 
sign rank tests for paired 
ordinal data, logistic 
regression using GEE 
Data verification: 
Self-report of FP 
practices and patient 
recall of them, 
supplemented w/ patient 
medical chart review for 
verification 
Dependent variables: 
• Patient recall of 
smoking cessation-
related interactions w/ 
FP during clinic visit 
• Recall of: question 
from FP about 
smoking status 
• Smokers' recall of 
specific smoking 
cessation advice 
• Discussion of health 
risks of smoking 
• Discussion of passive 
smoking 
• Providing practical 
advice 
• Setting a quit date 
• Providing written 
materials 
• Recommending 
nicotine replacement 
patches 
• Arranging follow up 
appointment; referring 
to a smoking clinic 
Medical record audit of 
patient smoking status 
and cessation advice in 
chart for index 
consultation (for smokers 
only). 
Improvements b/w baseline and 
posttest in patient recall of FP 
advice about nicotine 
replacement patches and gum 
were significantly greater in 
intervention than C (P = 0.0056 
and P = 0.0002, respectively) 
Substantial increases in patient 
recall of assessment of smoking 
status and FP use of quit dates, 
behavioral advice, written 
materials in intervention group, 
but changes not significantly 
greater than those in C 
Medical chart review indicated 
FP notation of smoking cessation 
advice remained suboptimal after 
intervention 
100% of FPs found following 
intervention components 
Quality rating: 
Fair 
Comments: 
• Low consent rate 
among FPs 
(35%), limiting 
generalizability 
of findings 
• Some significant 
differences b/w 
patients in G1 vs 
C1 
• Though many 
comparisons of 
improvements in 
FPs' smoking 
cessation advice 
(G1 v C1) were 
NS, could be due 
to both groups 
being trained to 
be more mindful 
of addressing 
patients' health 
risks, thus 
reducing 
apparent effect 
of intervention 
• High rate of 
attrition in both 
groups and at 
both time points 
Adequate 
randomization: 
Yes 
Attrition rate: 
Baseline follow up:  
G1: 34% 
C1: 27% 
Posttest follow up:  
G1: 37% 
C1: 31% 
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cessation 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Young et al., 2002 
(continued) 
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Evidence Table 7. Health care systems strategies to increase implementation of population-level tobacco use 
cessation (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
 • Also assessed FPs 
thoughts about 
usefulness of 
intervention 
components 
Baseline data: 
FPs:  
Representative of 
reference FP population 
except for participating 
FPs more likely to be full-
time vs part-time 
 
Personal and 
professional 
characteristics of FPs 
allocated to each group 
were comparable 
G1 vs C1:  
Mean age 46.4 v. 49.8;  
Female (%): 43 v. 33; 
Mean yrs in practice: 18 
vs 19 
 
Patients:  
77% consented to 
participate 
70% response rate 
 
Less likely to respond: 
Smokers vs non-
smokers (57% v 73%, 
chi sq = 35.3, P < 0.001) 
Males (65% v 73%, chi- 
sq = 11.8, P < 0.001) 
Those from intervention 
practices (66% v 73% chi 
sq = 11.2, P < 0.001) 
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Evidence Table 8. Effect of smokeless tobacco product marketing and use on population harm from tobacco 
use 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Choi et al., 1995 
Geographic area: 
US 
Funding agency: 
UCSF, Institute for Health 
and Aging 
Study setting: 
Population-based in Calif 
 
Study objective: 
To assess trends in ST use and to identify 
risk factors that distinguish youths who use 
or who are at risk of using ST 
Population: 
• Adolescent males, ages 12 to 17 
• Young adult males, ages 18 to 24 
Study design: 
• Cross-sectional 
• Telephone survey using random digit 
dialing 
Inclusion criteria: 
Residing in Calif 
Exclusion criteria: 
NR 
Sampling plan: 
Stratified random sample of adults and 
all 12 to 17 yr old adolescents 
Sample size: 
1990: 3,912 
1992: 883 
1993: 2,814 
Definition of smoking: 
Cigarettes 
• Current users: respondents who 
smoked a cigarette within last 30 
days 
Smokeless tobacco 
• Current users: reported use of 
smokeless tobacco within last 30 
days 
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Evidence Table 8. Effect of smokeless tobacco product marketing and use on population harm from tobacco 
use (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
NA 
Intervention:  
NA 
Method of assessment: 
Telephone survey 
 
Statistical analysis:  
Multivariate logistic 
regression 
Data verification: 
NR 
Dependent variables: 
• Current use and 
susceptibility to use ST 
• Current cigarette use 
• Exposure to other ST 
users 
• Exposure to ST 
advertisements 
• Rebelliousness 
• Participation in team 
sports 
• Depression 
• Peer Use of drugs or 
alcohol 
• Peer norms 
Baseline data: 
NA 
Ever experimented w/ ST:  
1990: 15.2% (95% CI, 13.7-16.7) 
1992: 12.3% (95% CI, 9.8 - 14.8) 
1993: 13.8% (95% CI, 12.3-15.3) 
Current use of ST (%) 1993: 
• 12 to 13 yrs:  
OR = 0.3 (95% CI, 0.1 -0.05) 
• 14 to 15 yrs:  
OR = 2.6 (95% CI, 1.0 - 4.2) 
• 16 to 17 yrs:  
OR = 6.6 (95% CI, 4.1 - 9.1) 
Susceptibility to use ST (%) in 
1993: 
• 12 to 13 yrs:  
OR = 16.8 (95% CI, 13.7 - 19.9) 
• 14 to 15 yrs:  
OR = 17.3 (95% CI, 14.8 - 19.8) 
• 16-17 yrs:  
OR = 18.8 (95% CI, 14.6 - 23.0) 
Exposure to SLT advertising (%) in 
1993: 
• 12 to 13 yrs:  
OR = 21.0 (95% CI, 17.4 - 24.6) 
• 14 to 15 yrs:  
OR = 34.3 (95% CI, 30.3 - 38.3) 
• 16 to 17 yrs:  
OR = 43.8 (95% CI, 38.3 - 48.8) 
Recall of ST advertisements in 
1993:  
AOR 7.5 (95% CI, 3.1 – 18.1),  
(P < 0.001)  
Susceptibility to use of ST in 1993:  
OR = 1.6 (95% CI, 1.2 – 2.0), 
(P<.001) 
Cigarette smokers risk of being ST 
users in 1993:  
OR = 3.3 (95% CI, 1.9 -5.7), 
(P<.001) 
 
Quality rating: 
Fair 
Comments: 
Cross sectional study 
design; only reported 
analysis on 1993 
data and youth 
subjects; no clear 
explanation of final 
sample size 
Adequate 
randomization: 
Yes 
Attrition rate: 
NR 
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Evidence Table 8. Effect of smokeless tobacco product marketing and use on population harm from tobacco 
use (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Tomar; 2003 
Geographic area: 
US 
Funding agency: 
NR 
Study setting: 
Population-based 
 
Study objective: 
To assess 4-yr initiation rates of ST use and 
cigarette smoking in relation to each other 
and examine switching b/w products 
Population: 
• Adolescents, ages 11 to 19 
• Young adults 
• Men  
Study design: 
• Cross-sectional 
• Nationally-representative, cross-sectional 
telephone and mail survey 
Inclusion criteria: 
• 11 to 19 yrs of age at baseline 
• Reside in households interviewed for 
National Health Interview Survey 
• Male 
Exclusion criteria: 
NR 
Sampling plan: 
1989 TAPS-I and its 1993 followup 
TAPS-II: TAPS-I sampling frame 
consisted of all teenagers aged 12–18 
yrs on November 1, 1989, who resided 
in households interviewed for the NHIS 
during last two quarters of 1988 and first 
two quarters of 1989 
Sample size: 
Total: 3,996 
Definition of smoking: 
Cigarettes 
• Current smoker: reported smoking at 
least 100 cigarettes in their lifetime 
and smoked at least 1 cigarette in 30 
days preceding interview 
• Former smoker: smoked at least 100 
cigarettes in their lifetime, but smoked 
no cigarettes in last 30 days 
preceding interview 
• Never smokers: had not smoked 100 
cigarettes in their lifetime 
Smokeless tobacco groups: 
• never user of ST 
• used ST, but never regularly 
• used ST regularly but not currently 
• current, regular user of ST 
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Evidence Table 8. Effect of smokeless tobacco product marketing and use on population harm from tobacco 
use (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures Quality Comments 
Intervention methods: 
NA 
Intervention:  
NA 
Method of assessment: 
• Computer-assisted 
telephone interviews 
• Traditional telephone 
interviews 
• Mailed surveys (TAPS-I 
1989 data and TAPS-II 
1993 data) 
 
Statistical analysis:  
• Estimates of prevalence 
and initiation rates 
included 95% CI 
• Multiple logistic 
regression modeling 
used to adjust for age 
and race/ethnicity 
• OR estimate interpreted 
as significantly different 
from reference group, at 
95% level of confidence, 
if its 95% CI, excluded 
1.0 
• All analyses of TAPS 
data conducted using 
sampling weights 
developed by National 
Center for Health 
Statistics 
Data verification: 
NR 
Dependent variables: 
• ST use 
• Cigarette use 
Baseline data: 
Prevalence of tobacco use 
at baseline (males only):  
• current smoker: 9% 
• former smoker: 1.6% 
• regular ST user at 
sometime: 6.1% 
• current regular ST user: 
2.7% 
 
 
At 4 yr followup:  
• current smokers: 21.2%  
• regular users of ST at sometime: 
11.9%  
• current regular users: 5.7% 
After adjusting for age and race, 
males who had been regular users 
of ST were more than 3 times as 
likely as never users of ST to 
become smokers,  
OR = 3.45 (95% CI, = 1.84 -6.47) 
Current smokers not different from 
never smokers in rate of initiating 
current regular ST use  
OR = 1.45 (95% CI, = .5-4.22)  
NS 
Among males who were regular ST 
users but were not smokers at 
baseline:  
• continued to exclusively use ST 
at followup: 44.8% 
• had switched to smoking at 
followup: 25.5% 
• continued to use ST while also 
smoking at followup: 14.3% 
• no longer using tobacco: 15.2% 
Of smokers at baseline who were 
not ST users: 
• switched to ST exclusively: 8% 
• continued to smoke but also use 
ST: 3.6% 
• quit using tobacco: 16.9% 
 
Quality rating: 
Fair 
Comments: 
• Self report without 
any biochemical 
verification; 
participants lost at 
followup may have 
been more difficult 
to capture because 
they were more 
likely to progress to 
current smoking or 
regular use of ST 
• Definition of ST 
use relied on 
respondents’ self 
characterization of 
regular use 
Adequate 
randomization: 
NR 
Attrition rate: 
NR 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors 
Study Characteristics Study design Sample Design and Definition 
Author: 
Brown et al., 2001 
Geographic area: 
US 
Funding agency: 
National Institute on Drug 
Abuse; American Cancer 
Society 
Study setting: 
Population-based 
Research objective: 
To assess the efficacy of a standard, 
cognitive–behavioral smoking cessation 
treatment vs standard cessation treatment 
combined with CBT for depression in 
smokers with a positive history of MDD 
Population:  
• Smokers with a positive history of MDD 
Study type: 
RCT 
Inclusion criteria: 
• Ages of 18 and 70 years 
• Smoked for at least 1 year 
• Currently smoking at least 10 cigarettes 
per day 
• Had a history of MDD according to the 
DSM-III 
Exclusion criteria: 
• DSM–III–R diagnosis of current MDD, 
dysthymia, or other Axis I disorder 
• DSM–III–R diagnosis of psychoactive 
substance abuse or dependence within 
the past 6 months (other than nicotine) 
• Current use of psychotropic medication 
• Current weekly psychotherapy 
• Use of other tobacco products 
• Intent to use pharmacological aid to 
cessation 
Sampling plan:  
• Potential participants screened by 
telephone prior to an intake interview 
to confirm eligibility 
• Eligible participants required to 
provide a $75 deposit, refunded 
incrementally on completion of follow-
up procedures 
• 358 invited to study center for 
diagnostic interview to confirm 
eligibility; 100 did not show up  
• 258 participants completed informed 
consent and participated in the 
interview; 5 withdrew prior to being 
assigned to a treatment condition; 74 
did not meet inclusion–exclusion 
criteria  
Sample size: 
G1: 86 
C1: 93 
Definition of smoking:  
• Smoked at least 10 cigarettes a day 
for at least 1 year  
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data Outcome Measures Quality Comments 
Intervention methods:  
• Group counseling 
• Tailored cognitive 
behavioral therapy 
Intervention:  
G1: Eight 2-hr sessions over 
6 weeks standard 
comprehensive CBT for 
smoking cessation, plus 
cognitive behavioral coping 
for depression 
C1: Eight 2-hr sessions over 
6 weeks; comprehensive, 
standard CBT for smoking 
cessation  
Method of assessment: 
Assessment battery 
administered at 
pretreatment; questionnaires 
administered at each 
session during treatment; 
follow-up phone interviews 
occurred at 1, 6, and 12 
months posttreatment, and 
self-reported abstinence was 
verified biochemically 
Baseline data: 
Groups were similar 
Statistical analysis: 
• Chi-square analyses 
• Repeated measures 
analyses for categorical 
outcomes using 
generalized estimating 
equation 
Data verification: 
• Self report  
• CO and saliva cotinine 
Dependent variables:  
• Demographic 
characteristics (age, 
gender, marital status, 
and years of education) 
• Nicotine dependence 
severity (FTND score, 
number of years 
smoking, average daily 
smoking rate, and saliva 
cotinine) 
• Depression severity and 
chronicity 
No statistical difference between 
groups were found for 7 day point 
prevalence abstinence rates at 1, 6  
and 12 months for C1 = 30.1%, 
24.7%, 24.7%, respectively; G1 = 
39.5%, 24.4%, 32.5%.  
In the final step of the GEE 
analysis a significant interaction 
was found between treatment and 
heavy smoking (P = 0.02), and 
between treatment and recurrent 
depression (P = 0.02) 
 
 
Quality rating: 
Fair 
Adequate 
randomization: 
NR 
Attrition rate:  
• 5% at 1 month 
• 8.9% at 6 months 
• 7.8% at 1 year 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Brown et al., 2003 
Geographic area: 
US 
Funding agency: 
None listed 
Study setting: 
Psychiatric hospital 
 
Study objective: 
To test hypothesis that among adolescent 
smokers hospitalized for psychiatric and/or 
substance use disorders, MIwould lead to 
more and longer quit attempts, reduced 
smoking, and more abstinence from 
smoking over 12 mo followup 
Population: 
• Adolescents 
• Aged 13 to 17 from Providence, RI 
Study type: 
RCT w/ systematic cohort randomization 
Inclusion criteria: 
• Hospitalized for psychiatric and/or 
substance use disorder 
• Age 13 to 17 
• Smoked at least 1 cigarette/wk for 4 wks 
prior to hospitalization 
• Access to phone 
Exclusion criteria: 
• DSM-IV criteria for psychotic disorder 
• Recent violent behavior 
• Recent participation in another study 
• Uncertain guardianship status 
• Language incompatibility 
• Sibling in study 
• Significant cognitive impairment 
• Residing too far away to complete 
followups 
• Patient or parent refusal 
Sampling plan: 
Consecutive sample of eligible 13 to 17 
yr olds hospitalized for psychiatric 
and/or substance use disorder but not 
psychotic 
Sample size: 
G1: 116 
G2: 75 
Definition of smoking: 
Cigarettes 
• Number of cigarettes smoked per day
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Results Quality Comments 
Intervention methods: 
• Self-help 
• Individual counseling by health 
professional 
• Telephone counseling 
• Pharmaceuticals 
Intervention:  
G1: Two in-person 45-minute MI 
sessions during hospitalization or 
on outpatient basis; self-help 
pamphlet and manual; offer of up 
to two 8-wk courses of free 
transdermal NPtherapy if eligible; 
up to 6 postdischarge phone 
counseling sessions; up to 4 brief 
parent intervention phone 
counseling sessions. 
G2: 5-10 minute in-person advice 
to quit smoking; self-help 
pamphlet; offered one course of 
transdermal NPtxt if eligible 
C1: NA 
Method of assessment: 
Pre and postintervention 
assessment of various outcomes 
at 1, 3, 6, 9, and 12 mo follow ups 
Smoking: 
• Self-report and biochemical 
verification for those claiming 
abstinence 
Nicotine Dependence:  
• Fagerstrom tolerance 
questionnaire  
• Psychopathology dz:  
C-DISC  
• Intent to change: Self-report to 
single item 
• Self-efficacy: SCQ 
 
Statistical analysis:  
Hierarchical Linear Modeling 
GEE 
Linear and Logistic 
Regression 
Data verification: 
Self-report plus biochemical 
verification (saliva cotinine) for 
those claiming tobacco use 
abstinence 
Dependent variables: 
• Point prevalence abstinence
• Quit attempts 
• Changes in smoking rate 
• Longest quit attempt 
Baseline data: 
• Female: 62.3 
• Mean age: 15.4 
 
Race/ethnicity 
• White: 94.8 
• HispaniC1: 1.6 
• African American: 0  
• Other Race: 3.6 
 
Other 
• Mean age at first cigarette: 
10.85 
• Smoked on avg: 91.19% of 
previous 3 mos 
• Mean: 14.48 cigarettes on 
smoking days 
• Daily smokers: 63.9  
• Mean Fagerstrom tolerance 
score: 4.9 
• Met DSM-IV criteria for 
nicotine dependence: 68.6 
• Mean length inpatient stay: 
9.11 days 
• Used NRT during hospital 
stay: 26% 
Mean of anxiety 
disorders: 
G1: 1.1 
G2: 1.3 
P = NS 
Odds for quit attempts 
AOR 1.99 (95% CI, 1.08, 
3.71) 
Longest quit attempt, days:  
G1: 48.2 
G2: 60.9 
P > 0.05 
NS 
Point prevalence 
abstinence at 1, 6 and 12 
mos:  
P > 0.30, NS 
Smoking rate: (b = 0.05, 
SE = 0.16, P = 0.74, NS) 
Higher discharge scores 
on situational confidence 
questionnaire associated 
w/ significantly less 
smoking during followup (b 
= -0.02, SE = 0.007, P = 
0.007) 
 
Quality rating: 
Fair 
Comments: 
• High refusal rate 
• Due to slow 
participant flow, 
recruitment ended 
before all cohorts 
completed, 
resulting in 
imbalance of 
participants across 
conditions 
• Inconsistent txt 
implementation 
Adequate 
randomization: 
Yes 
Attrition rate: 
20 (9%) 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Hitsman et al., 1999 
Geographic area: 
US 
Funding agency: 
VA Merit Review award by 
NIDA, and Eli Lilly and 
Company 
Study setting: 
Population-based 
 
Study objective: 
To identify individual differences that predict 
cessation when fluoxetine is combined w/ 
CBT 
Population: 
• Adults 
Study type: 
RCT w/ simple randomization  
Inclusion criteria: 
Participants are: 
• 18 to 65 yrs of age 
• have smoked daily for at least one yr 
• exhibit a baseline expired CO level of 
greater than 8 ppm 
• agree to declare a quit date within 2 wks 
after second study visit (Source: Borrelli, 
et al. 1997) 
Exclusion criteria: 
• Clinically significant depression HDRS 
score greater than 14 
• Pregnancy 
• Hypertension 
• Use of psychotropic medication or current 
psychiatric illness 
• Alcohol or drug abuse in past yr 
• Current use of nicotine replacement 
• Unstable medical condition or major 
health event in past 6 months 
• Use of ST, pipes or cigars 
• Recent experience of a major life event 
(e.g., divorce or major job change) 
• Suicidal ideation 
• History of bipolar disorder (Source: 
Borrelli, et al. 1997) 
Sampling plan: 
Specific randomization scheme NR. 
Sample size: 
Total: 253 
Definition of smoking: 
Cigarettes 
• Reported smoking 
• Expired CO greater than 8 ppm 
• Saliva continine value greater than 10 
ng/ml 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Outcome Measures 
Quality 
Comments 
Intervention methods: 
• Individual counseling by 
health professional 
• Pharmaceuticals 
Intervention:  
G1: Nine, 1-hr individual 
CBT sessions + fluoxetine 
30 mg for a total of 10 wks  
• Participants required to 
set a quit date within 2 
wks after drug txt began 
• Participants quit 
smoking at 3rd CBT 
session 
• Medication stopped at 
9th CBT session, at 
which time 6-month 
followup period began 
• CBT not explained 
• Patients w/ fluoxetine 
level less than or equal 
to 150 ng/ml considered 
compliant 
G2: Same as G1:, except 
fluoxetine dose of 60 mg 
and fluoxetine blood level 
less than or equal to 
300ng/ml considered 
compliant 
C1: Same as G1, except 
given placebo 
Method of assessment: 
Self report of smoking, 
expired CO, and saliva 
continine 
Also used depresion scale, 
nicotine dependence, 
weight restraint scale, and 
self-efficacy questionnaire 
 
Statistical analysis:  
Constructed predictive 
models using logistic 
regression w/ 
hierarchical approach to 
variable selection. 
Models evaluated w/ 
parallel analyses using 
stepwise selection 
procedure 
Data verification: 
Expired CO and saliva 
continine 
Dependent variables: 
Depression, nicotine 
dependence, weight 
concerns, self-efficacy 
about quitting smoking 
Baseline data: 
No significant difference 
b/w txt groups in 
baseline characteristics: 
age, gender, education, 
smoking history, baseline 
level of nicotine 
dependence, depression, 
weight concern, and self-
efficacy 
At 1 wk postcessation: higher 
levels of depression predicted 
failure to achieve abstinence (ITT 
analysis); higher levels of 
nicotine dependence and 
depression associated w/ 
decreasing likelihood of 
abstinence (analysis of txt-
compliant patients) and likelihood 
of abstinence for participants on 
fluoxetine tended to be higher 
than for those on placebo (P = 
0.06); At 1 month postcessation: 
higher levels of weight concern 
predicted lower abstinence (Χ2 
4.8, P = 0.78); patients on 
fluoxetine had positive 
association b/w degree of 
depression and likelihood of 
abstinence (highest quartile 
HRSD = 3, OR = 2, 95% CI, 
0.85-4.70); At 3 months 
postcessation: patients treated w/ 
fluoxetine had positive 
association b/w HRSD scores 
and abstinence likelihood 
(highest quartile HRSD = 3, OR = 
1.44, 95% CI, 0.53-3.91) 
Smoking characteristics 
predicting txt compliance were 
nicotine intake at baseline, saliva 
cotinine (Χ2 = 11.4, P < 0.001), 
and expired CO ( Χ2 = 5.3, P < 
0.05) 
 
Quality rating: 
Fair 
Comments: 
• Authors didn't 
report numbers 
of participants 
per arm of study, 
baseline 
demographic 
characteristics of 
those groups, 
nor 6 month 
followup results 
• Inclusion/ 
exclusion criteria 
are described in 
companion 
article, Borrelli, 
et al. 1997 
Adequate 
randomization: 
NR 
Attrition rate: 
NR 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Joseph, 1993 
Geographic area: 
US 
Funding agency: 
NR 
Study setting: 
Hospital 
 
Study objective: 
To evaluate effect of smoke-free policies in 
in-patient alcohol txt wards and effect of 
these policies on long-term txt outcomes 
Population: 
• Adults 
Study type: 
Prospective cohort study 
Inclusion criteria: 
NR 
Exclusion criteria: 
Excluded patients admitted b/w May and 
July, 1988, because they would have 
overlapped w/ the implementation of smoke-
free policy 
Sampling plan: 
• Enrolled consecutive patients  
• Admitted to an inpatient substance 
abuse txt program prior to 
implementation of a smoke-free 
policy and those patients admitted 
after smoke-free policy was 
implemented 
Sample size: 
G1: 407 
G2: 299 
Definition of smoking: 
NR 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Results Quality Comments 
Intervention methods: 
• Group counseling 
• Classroom instruction 
Intervention:  
G1: Patients not given 
specific information about 
smoking or cessation; 
smoking on the ward only 
permitted in 2 designated 
rooms and not allowed 
during group sessions 
G2: Patients required upon 
admission to acknowledge 
the smoke-free policy and 
sign a contract agreeing to 
abstain from nicotine during 
their stay; smoking cessation 
program designed for 
substance abusers delivered 
(didactic lectures on 
pharmacology of nicotine, 
films, and discussion group); 
Clonidine patches available 
but not studied in a 
systematic fashion 
Method of assessment: 
A one-pg, standardized, self-
administered questionnaires 
given upon admission to 
hospital and third wk of 
hospitalization to assess 
smoking status and 
motivation to quit  
 
Structured telephone 
interviews at 1 yr 
posthospitalization (pre 
policy group interviewed at 
16.2 mos and post policy 
group at 10.7 mos) 
conducted to assess use of 
substances other than 
nicotine 
 
Improvement in chemical 
dependency defined as less 
or no use of substance 
abuse they were treated for 
at hospital 
 
Statistical analysis:  
NR 
Data verification: 
NR 
Dependent variables: 
Tobacco-use status; 
motivation to quit; use of 
substances other than 
nicotine 
Baseline data: 
Demographic data from 
both groups similar at 
baseline 
Proportion of patients that want to 
quit smoking while in hospital at 
three-wk followup:  
G1: 24% 
G2: = 61% 
P = < 0.001 
Proportion of patients that has 
abstained from smoking for > 1 wk:  
G1: 9% 
G2: 41% 
P = < 0.001 
Proportion of patients that cut down 
smoking while in hospital:  
G1: 46%  
G2: 93% 
P = < 0.001 
Quit smoking as reported at 1 yr 
followup interview:  
G1: 3% 
G2: 8% 
P < 0.05 quit smoking 
No significant difference found in 1-
yr followup for non-nicotine 
substance use b/w groups 
 
Quality rating: 
Fair 
Comments: 
• Statistical methods 
NR 
• No biochemical 
verification 
• High attrition 
Adequate 
randomization: 
NR 
Attrition rate: 
Attrition at 1-yr 
followup:  
G1: 61.7%  
G2: 45.5% 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Study Characteristics Study design Sample Design and Definition 
Author:  
Joseph, Willenbring et al., 
2004 
Geographic area:  
US 
Funding agency:  
National Institute on Alcohol 
Abuse and Alcoholism; 
Health Services Research 
and Development Center for 
Chronic Disease Outcomes 
Research, Veterans Affairs 
Study setting: 
Residential treatment 
program 
 
Research objective:  
To compare the effects of smoking 
treatment and intensive treatment for alcohol 
dependence, delivered concurrently, with 
treatment delayed by 6 months on smoking 
outcomes and alcohol use 
Population:  
Adult men and women ages 21-75 
Study type:  
RCT Stratified random sampling  
Inclusion criteria: 
• Met criteria for alcohol dependence or 
abuse according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th 
ed. and who smoked more than 5 
cigarettes per day for more than 1 year 
• Completed first week of alcoholism 
treatment 
Exclusion criteria: 
• No interest in stopping smoking 
• Diagnosis of dementia or schizophrenia 
• Inability to comply with the protocol due to 
severe psychiatric symptoms or cognitive 
deficits 
• Refusal to provide the name of a contact 
or source of collateral information 
• Unwillingness to attend visits as planned 
in the protocol 
Sampling plan: 
• Treatment assignment accomplished 
by stratifying by substance use 
disorder treatment site and blocking 
within site in groups of 10. Computer 
generated random sequence was 
concealed from study personnel 
• Initial screening included questions 
about interest in participating in a 
research study, stage of change and 
potential concerns about participating. 
(Screen A) 
• Patients passing Screen A invited to 
do Screen B, a computerized self-
administered Quick Diagnostic 
Interview Schedule to confirm that 
they met criteria for alcohol 
dependence.  
• 1,943 adults assessed for eligibility 
• 499 adults agreed to participate 
Sample size:  
G1: 251 
G2: 248 
Definition of smoking:  
Any smoking within past 7 days 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data Outcome Measures Quality Comments 
Intervention methods:  
Behavioral counseling and 
pharmacological treatment 
Intervention:  
G1 (concurrent treatment): 
Individual counseling (1-hour 
face-to-face session) and up 
to 3 follow-up sessions 
conducted in person or by 
telephone 
Participants in the action 
stage of change received a 
free prescription for NRT, 
unless they declined or had 
a medical contraindication  
Medication algorithm 
recommended nicotine 
patches (21 mg for 6 weeks, 
14 mg for 2 weeks and 7 mg 
for 2 weeks). A combination 
of patches and nicotine gum 
was offered to participants 
who smoked more than 20 
cigarettes per day. 
Method of assessment: 
• Data collected at 
treatment site, research 
study office or by 
telephone at 6, 12 and 18 
months after study 
enrollment 
• Brief smoking outcome 
data were also collected 
at 3 and 9 months 
Baseline data: 
No baseline group 
differences 
Statistical analysis:  
• Simple likelihood ratio 
chi-square tests 
compared rates of 
tobacco and alcohol 
abstinence  
• Logistic regression 
analyses modeled the 
odds of smoking 
abstinence and 
prolonged alcohol 
abstinence as a function 
of intervention group 
and baseline measures 
that might affect 
smoking and alcohol 
treatment outcomes 
Data verification: 
Self-report abstinence  
Smoking validated by 
expired carbon monoxide; 
alcohol by breath alcohol 
concentration. 
Dependent variables:  
• Smoking: 7 day point 
prevalence 
• Smoking abstinence at 
3, 6 and 12 months 
• Prolonged (6-mo.) 
smoking abstinence at 
18 months 
• Number of quit and 
relapse episodes  
• Participation in 
treatment 
• Alcohol: 6-months 
duration of alcohol  
• 1-months duration of 
alcohol abstinence and 
number of drinking days 
in the past 6 months 
• Relapse to alcohol 
 
Smoking Cessation Outcomes  
Intention-to-Treat Analysis 
7 day point prevalent smoking 
abstinence rates at 3 months were 
15.5% in the concurrent treatment 
group and 4.4% in the delayed 
group (P < 0.0001); at 6 months, 
10.5% vs. 5.2% ( P = 0.02) (note 
that at 3 and 6 months the delayed 
treatment group had not received 
intervention). At 9,12 and 18 
months there were no significant 
differences between treatment 
groups.  
Alcohol Abstinence Outcomes 
At 6- 12- and 18-month visits, point 
prevalent alcohol abstinence was 
lower in the concurrent treatment 
group than in the delayed 
treatment group (P = 0.004,  
P = 0.11, and P = .001, 
respectively) 
 
Quality rating: 
Good 
Comments:  
• Very low 
participation rate in 
expired carbon 
monoxide testing, 
34% at 12 months 
and 25% at 18 
months 
• 6.6% failed to 
support self-
reported 
abstinence rates 
Adequate 
randomization: 
Yes 
Attrition rate:  
18% at 6 months 
20% at 18 months 
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Evidence Table 9. Tobacco cessation interventions for persons w/ co-occurring morbidities and risk 
behaviors (continued) 
Study Characteristics Study Design Sample Design and Definitions 
Author: 
Murray et al., 1995 
Geographic area: 
US 
Canada 
Funding agency: 
Division of Lung Diseases 
of the NHLBI 
Study setting: 
Practice/provider settings 
 
Study objective: 
Explore relationship b/w alcohol 
consumption and smoking cessation 
Population: 
• Adults 
• Describe: aged 35 to 60 
Study type: 
RCT w/ simple randomization  
Multi-center clinical trial 
Inclusion criteria: 
• Smokers 
• Age 35 to 60 w/ evidence of early stage 
COPD 
Exclusion criteria: 
• Serious health condition that is likely to 
affect lung function 
• Use of regular medications that might 
interfere w/ study results 
• Consumption of more than 25 alcohol 
drinks per wk or 8 drinks in one occasion 
once a mo or any consumption of alcohol 
in past yr for recovering alcoholics 
Sampling plan: 
NR 
Sample size: 
G1: 2,649 
C1: 1,327 
Definition of smoking: 
Cigarettes 
Defined as smoking at any clinic visit 
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behaviors (continued) 
Intervention Details 
Statistical Analysis and 
Baseline Data  Results Quality Comments 
Intervention methods: 
• Group counseling 
• Pharmaceuticals 
Intervention:  
G1: Bronchodilator inhaler or 
placebo inhaler and multi-
component counseling and 
nicotine gum; counseling 
intervention included a multi-
component approach w/ 
standard cognitive-
behavioral strategies such as 
stimulus control, avoidance, 
role playing, assertiveness 
training, reinforcement, and 
relaxation techniques 
• Following counseling 
program, regular 
maintenance program 
scheduled on at least a 
monthly basis 
• Maintenance programs 
included weight 
management and exercise 
• In addition an extended 
group intervention 
program offered to 
participants who relapsed 
and want to try and quit 
again; NRT available free 
of charge to study 
participants but not 
tracked systematically in 
relationship to quit rates 
C1: Usual care 
Method of assessment: 
• Baseline interviews using 
self-reported alcohol and 
tobacco use 
• Intervention group (only), 
contacted monthly for 1st 
yr then w/ clinic visits 
every 4 mos w/ alcohol 
used assessed at 12 mos 
 
Statistical analysis:  
Polychotomous ordinal 
logistic regression 
Data verification: 
Self-report on CO in 
expired air 
Dependent variables: 
• Current alcohol use 
• History of alcoholism 
• History and current use 
of tobacco 
• Family smoking 
• Attitudes towards 
smoking and stopping 
smoking 
• Physical dependence on 
nicotine (Fagerstrom) 
Baseline data: 
Similar w/ an exception, 
less female alcoholics in C 
than in txt group (2.8% 
vs5.8%) 
Outcome measures: 
No significant relationship b/w 
amount of alcohol consumed at 
baseline and smoking status after 1 
yr for G1.  
In G2, women baseline drinkers 
more likely not to be smoking after 
1 yr:  
G1:14% 
G2: 6.3% 
P = NR 
Currently drinking at end of 
intervention:  
G1: 
Smokers: 5.24 drinks/wk 
Nonsmokers: 4.46 drinks/wk  
(t = 1.94, 1,440df, P = 0.05) 
Within smoking cessation 
intervention (G1), those who drank 
eight or more drinks per occasion 
(binge drinkers) more likely to be 
current smokers (i.e., lower 
cessation rate) after 1 yr (men 
binge = 44.8%, no binge = 51%, P 
< 0.05) and (women binge = 
27.3%, no binge = 41.8%,  
P < 0.01) 
Within intervention group, binge 
drinkers smoked more cigarettes 
per day than those without a history 
of binge drinking (Men binge = 
12.5, no binge = 10.3, P < 0.05) 
and (women binge = 14.3, no binge 
= 10.7,  
P < 0.01) 
When volume of drinking and 
drinking of eight or more drinks per 
occasion were compared in 
polychotomous ordinal logistic 
regressions, only binge drinking for 
men predicted failure at smoking 
cessation (Chi sq = 4.11, 1 d.f.  
P < 0.05, OR = 0.76) 
 
Quality rating: 
Poor 
Comments: 
• Changed exclusion 
criteria after 
recruiting 1/3 of 
participants 
• Post randomization 
of subjects 
(excluded 
recovering 
alcoholics) 
• No systematic 
control of NRT use
• No information on 
attrition 
• Within txt group 
analysis 
Adequate 
randomization: 
Yes 
Attrition rate: 
NR 
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Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Ebbert et al., 
2004 
Geographic area 
United Kingdom 
Funding source 
No source of 
support supplied 
Time period 
covered 
Databases 
searched 
systematically 
through March 
2004 
 
Inclusion criteria 
Randomized trials of behavioral or 
pharmacologicial interventions to help 
users of ST to quit, w/ a followup of at 
least 6 months 
Population 
Users of any tobacco product that is 
placed in mouth and not burned, 
including moist snuff, chewing tobacco 
and betel quid 
Characteristics of studies 
(Interventions) 
Interventions studies could be 
pharmacologicial (NRT or bupropion) or 
behavioral, either directed at individual 
ST users or a groups of users 
Method of review 
• One author examined all titles 
generated from search and obtained 
abstracts 
• Abstracts considerd by two authors for 
full text review 
• Differences of opinion resolved by 
consensus 
Study design 
Cochrane Systematic Review and meta 
analysis. 
Studies included in meta-analysis 
• Eight behavioral trials 
• Separate meta analyses performed on 
4 studies that randomized individuals 
and on 4 studies that gave oral exams 
and feedback to ST users 
 
Aim of review 
To assess effects of 
behavioral and 
pharmacotherapeutic 
interventions to treat ST 
use 
Main results 
No evidence of ST 
abstinence for trials using 
bupropion, NRT, or 
nicotine gum 
 
Three trials showed 
significant effects using 
behavioral interventions 
 
A subgroup of behavioral 
studies that randomized 
individuals showed a 
pooled significant effect 
(OR 1.43, 95% CI, 1.06 
to 1.93); OR higher in 
trials that included an oral 
exam and feedback (OR 
2.41, 95% CI, 1.79 to 
3.24) 
 
Quality rating 
Good 
Adverse events 
Yes 
All reported adverse 
events associated w/ 
NRT such as skin 
reactions, nausea, 
headache and 
gastro-intestinal 
distress 
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Author, year Study Characteristics 
Main Results/ 
Aim of Review Quality Rating 
Author, year 
El-Guebaly et al., 
2002 
Geographic area 
Canada 
Funding source 
NR 
Time period 
covered 
Reveiwed the 
following databases 
between 1991 
through 2001: 
Medline, CINAHL, 
PsycINFO, Best 
evidence, 
Healthstar, 
Cochrane 
Database of 
Systematic 
Reviews, Legal 
Trac, Bioethicsline, 
Philosopher’s 
Index, and 
Dissertation 
abstracts 
 
Inclusion criteria 
Studies that presented data on samples of 
people with diagnoses of specific mental 
illness or addictive disorders , with not 
restrictions as to methodology. Broader 
studies reporting symptomatic sub groups 
in their analysis were excluded 
Population 
People with diagnoses of specific mental 
illness or addictive disorders 
Characteristics of studies 
(interventions) 
Smoking cessation interventions targeted 
at people with diagnoses of specific 
mental illness or addictive disorders 
Method of review 
NR 
Study design 
Qualitative narrative synthesis 
What studies are included in meta-
analysis 
NA 
 
Main results 
Twenty-four studies, 8 
included schizophrenia, 8 
included depression, and 8 
included persons with 
addictive disorders 
Interventins used a 
combination of medication, 
educational and cognitive-
behavioral approaches  
Post-treatment quit rates 
for Schizphrenia ranged 
from 35% to 56%, and a 6 
months quit rate of 12% 
Postreatment quit rates for 
depression ranged from 
31% to 72%, and 12 
months quit rates 11.8% to 
46% 
Postreatment quit rates for 
addictive disorders ranged 
from 7% to 60%, and 12 
months quit rates 13% to 
27% 
Aim of review 
To assess the impact of 
smoking cessation 
approaches on individuals 
with mental illness or 
addictive disorders 
Quality rating 
Fair 
Comments 
NR 
Adverse events 
NA 
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Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Lancaster et al., 
2005 
Geographic area 
United Kingdom 
Funding source 
Internal: 
Department of 
Primary Health 
Care, University 
of Oxford UK 
External: NHS 
Research and 
Development 
Programme UK 
Time period 
covered 
Databases 
searched 
systematically 
through April 
2005 
 
Inclusion criteria 
Randomized trials of smoking cessation 
w/ followup of at least six months, where 
at least one arm tested a self-help 
intervention 
Self help defined as a structured 
program of smokers trying to quit without 
intensive contact w/ a therapist 
Population 
Any smoker except pregnant smokers 
and adolescent smokers. 
Characteristics of studies 
(Interventions) 
• Self-help interventions used by 
individual to assist a quit attempt not 
aided by health professionals, 
counsellors and group support 
• Included written materials, audio, 
videotape or computer programs 
Method of review 
• Two authors extracted data 
• Trials categorized according to 
amount of face to face contact 
provided to both txt and comparison 
intervention, and according to whether 
txt group received any written 
materials 
Study design 
Cochrane Systematic Review and meta 
analysis performed where appropriate 
Studies included in meta-analysis 
NR 
 
Aim of review 
To detemine 
effectiveness of different 
forms of self-help 
materials, compared w/ 
no txt and w/ other 
minimal contact 
strategies; effectiveness 
of adjuncts to self-help, 
such as computer 
generated feedback, 
telephone hotlines, and 
pharmacotherapies 
Main results 
Self-help vs no 
intervention: OR favored 
self-help intevention, 
although C1 narrowly 
excluded 1 (N = 13,773; 
OR 1.24, 95% CI, 1.07 - 
1.45) 
• Two trials excluded 
due to significant 
heterogeneity 
• Where controls 
received an alterative 
form of written 
materials -- no 
evidence of an effect 
(N = 4,807; OR .87, 
95% CI, .68 to 1.12);  
• Failed to find evidence 
of an increased quit 
rate by adding self-help 
to advice or NRT 
• Based on 3 studies 
self-help tailored 
materials were better 
than no intervention (N 
= 7,790 OR 1.38, 95% 
CI, 1.15 - 1.66) 
 
Quality rating 
Good 
Adverse events 
No 
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Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Lancaster et al., 
2005 
Geographic area 
United Kingdom 
Funding source 
Internal: Oxford 
University of 
Primary Health 
Care UK; 
External: NHS 
Research and 
Development 
Programme UK 
Time period 
covered 
Databases 
systematically 
searched though 
Dec 2004 
 
Inclusion criteria 
Randomized and quasi-randomized 
trials w/ a least one txt are consisting of 
face to face individual counseling from a 
health care worker not involved in 
routine clinical care and outcome of 
smoking cessation at least 6 months 
after intervention 
Population 
Any smoker except children, 
adolescents, and pregnant women. 
Characteristics of studies 
(Interventions) 
• Face to face encounter b/w a smoking 
patient and a counsellor trained in 
assisting smoking cessation 
• Excludes studies of counseling 
delivered by doctors or nurses 
involved in regular clinical care 
• Also excluded multiple risk factor 
interventions 
Method of review 
• Two authors extracted data 
• Studies summarized  
• Results reported as odds ratios 
• Meta analysis used when appropriate 
Study design 
Cochrane Systematic Review w/ meta 
analysis of pooled studies 
Studies included in meta-analysis 
NR 
 
Aim of review 
To determine effects of 
individual counseling 
Main results 
• Studies comparing 
counseling w/ minimal 
contact controls 
reported counseling 
significantly increases 
likelihood of cessation 
compared to less 
intense support (OR 
1.56 95% CI, 1.32-
1.84) 
• No evidence of benefit 
from more intensive 
compared to brief 
counseling (OR .98, 
95% CI, .61-1.56);  
• Cessation rates higher 
in trials that used NRT, 
and patients w/ 
coronary artery 
disease 
• No significant 
differences occured 
b/w the comparison of 
counseling approaches 
 
Quality rating 
Good 
Adverse events 
No 
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Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Lancaster et al., 
2004 
Geographic area 
United Kingdom 
Funding source 
NHS Research 
and Development 
Programme UK 
Time period 
covered 
Reviewed the 
following 
databases b/w 
1972 and 2003. 
Tobacco 
Addiction Group 
Register, Medline, 
Embase, Psyclit 
and the Cochrane 
Central Register 
of Controlled 
Trials, 
handsearching of 
specialist 
journals, and 
conference 
proceedings 
 
Inclusion criteria 
• Randomized trials of smoking 
cessation advice from a medical 
practitioner in which abstinence was 
assessed at least 6 months following 
advice. 
• For inclusion in meta analysis: 1) had 
to have at least 2 txt groups, and 2) 
allocation to groups must use formal 
randomization 
Population 
• Participants were smokers recruited in 
any setting 
• Pregnant smokers excluded 
Characteristics of studies 
(Interventions) 
Studies included physician advice to 
stop smoking vs no advice or comparing 
different levels of physician advice to 
stop smoking 
Method of review 
• Data extracted from published reports 
by 2 people independently 
• Disagreeements resolved by referral 
to a third party 
• Quality assessment performed on all 
studies 
Study design 
Cochrane systematic reivew and meta 
analysis 
Studies included in meta-analysis 
Seventeen trials of brief advice vs no 
advice were pooled 
 
Aim of review 
To assess effectiveness 
of advice from physicians 
in promoting smoking 
cessation; to compare 
minimal interventions by 
physicians w/ more 
intensive interventions; to 
assess effectiveness of 
various aids to advice in 
prom 
Main results 
Small satistically 
significant increase in 
odds of quiting (OR 1.74, 
95% CI,1.48 to 2.05); 
Intense advice vs no 
advice and minimal 
advice showed a small 
but significant advantage 
to more intense advice 
 
A subset of 10 trials of 
smoker NOT selected as 
having smoking related 
disease showed a 
marginal significant 
impact for more intensive 
interventions (OR 1.24, 
95% CI, 1.02 to 1.50);  
 
Studies that included 
followup visits had a 
higher success rate vs no 
advice than those studies 
that didn't have followup 
visits (OR 2.55, 95% CI, 
2.04 to 3.19) 
 
Lack of evidence as to 
effectiveness of aids 
used in addition to 
providing advice and 
motivational counseling 
vs brief advice did not 
increase cessation rates 
 
Quality rating 
Good 
Adverse events 
NA 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Lancaster et al., 
2000 
Geographic area 
United Kingdom 
Funding source 
Internal: 
Department of 
Primary Health 
Care, University 
of Oxford UK;  
External: NHS 
Anglia and Oxford 
Region Research 
and Development 
Programme UK; 
NHS Research 
and Dvelopment 
National Cancer 
Programme UK 
Time period 
covered 
Database 
searched 
systematically 
through May 2000 
 
Inclusion criteria 
• Randomized trials in which the 
intervention was training of health 
care professionals in smoking 
cessation 
• Only used trials w/ outcomes from 
patient smoking rates at least 6 
months after intervention 
Population 
Health care practitioner or health care 
practice 
Characteristics of studies 
(Interventions) 
• Health care professionals trained in 
methods to promote smoking 
cessation among their patients 
• Allocated health care professionals 
into at least 2 groups by a formal 
method of randomization 
• Studies that compared trained 
professionals to C and studies that 
examined effectiveness of adding 
prompts and reminders to training 
Method of review 
• Two reviewers independently 
extracted data from published articles. 
Disagreement resolved by referral to 
another person 
Study design 
Cochrane Systematic Review using a 
narrative approach to synthesising data 
Studies included in meta-analysis 
NR 
 
Aim of review 
To assess effectiveness 
of training health care 
professionals to deliver 
smoking cessation 
interventions to their 
patients, and to assess 
additional effects of 
prompts and reminders to 
the health professional to 
intervene 
Main results 
• 10 studies met criteria  
• Trained professionals 
about 1.5 to 2.5 times 
more likely to counsel 
patients about smoking 
• One study found a 
significant effect of 
training on sustained 
abstinence at one yr 
(8.8% trained group vs 
6.1% and 4.4% in 
comparison groups P < 
0.001) 
• Prompts increase 
frequency of health 
professions performing 
intervention but only 1 
out of 3 studies 
reported significant 
abstinence rates 
 
Quality rating 
Good 
Adverse events 
No 
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Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Lumley et al., 
2004 
Geographic area 
United Kingdom 
Funding source 
NHS Central R & 
D Programme, 
Dept. of Health 
1995-1996 UK; 
Victorian Health 
Promotion 
Foundation 
Australia; Dept. of 
Health, funding 
for EPI Center, 
London University 
UK; Public Health 
Branch Victoria 
Dept. of Human 
Services 
Australia; La 
Trobe University 
Time period 
covered 
Databases 
searched 
systematically 
though July 2003 
 
Inclusion criteria 
Randomized and quasi-randomized 
trials of smoking cessation programs 
implemented during pregnancy in 
settings such as hopitals, and 
community clinics 
Population 
Healthy pregnant women, women 
seeking a pre pregnancy consultation, 
and health professionals. 
Characteristics of studies 
(Interventions) 
Interventions include programs providing 
information on risks of smoking to fetus 
and infant, benefits of quitting, 
recommendations to quit, setting quit 
date, feedback about fetus and harmful 
levels of cotinine or CO, teaching 
cognitive behavior strategies, advice 
tailored to stages of change model, 
rewards/incentives, social support or 
peer support, and NRT 
Method of review 
• Two reviewers independently 
extracted data from published reports  
• Quality review of methodology 
assessed 
• Heterogeneity tested In all pooled 
analyses 
Study design 
Cochrane Systematic Review and meta 
analysis 
Studies included in meta-analysis 
NR 
 
Aim of review 
To assess effects of 
smoking cessation 
programs implemented 
during pregnancy on 
health of fetus, infant, 
mother, and family 
Main results 
• 48 trials revealed a 
significant reduction in 
smoking in late 
pregnancy for 
aintervention groups 
(RR.09, 95% CI, .93 - 
.95) this is an absolute 
difference of 6 out of 
100 women continuing 
smoking 
• With biochemically 
validated studies, 
absolute difference 
was same (RR.94, 
95% CI, .92 - .95) 
• Smoking cessation 
interventions 
signifcantly reduced 
low birth weight, 
preterm birth, and 
increase birth weight 
by 33 g (RR .81, 95% 
CI, .70 - .94), (RR .84, 
95% CI, .72 - .98), and 
(95% CI, 11g - 55g) 
• Intervention strategy 
(reward + social 
support) showed 
significantly greater 
smoking reduction (RR 
.77, 95% CI, .72 - .82) 
• Stages of change and 
relapse showed no 
significant reduction in 
smoking 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Author, year Study Characteristics 
Main Results/ 
Aim of Review Quality Rating 
Author, year 
Melvin et al., 2003 
Geographic area 
United States 
Funding source 
The Robert Wood 
Johnson 
Foundation 
Time period 
covered 
Databases 
systematically 
search from 
January 1994 
through March 31 
2002. 
Inclusion criteria:  
Randomized, comparison-controlled 
intervention trials for pregnant smokers at 
the individual level 
Population 
Pregnant smokers  
Characteristics of studies 
(interventions) 
• Brief counseling approach  for pregnant 
smokers 
• Improving disclosure of smoking status 
• Spontaneous quitting and eminence of 
cessation 
• Postpartum relapse prevention 
• Adjuncts to brief counseling 
• Exposure to second hand smoke 
around time of pregnancy 
• Disclosure of second hand smoke 
around time of pregnancy 
• Increasing compliance with best 
practice 
Method of review 
Pre-screened published articles for 
relevance, two reviewers assessed 
studies independently for inclusion, data 
extracted by 1 reviewer and checked by a 
second, and used narrative synthese 
Study design 
Systematic review of literature 
What studies are included in meta-
analysis 
NA 
 
Aim of review 
To review the 
recommendations made in 
2000 regarding treatment 
for pregnant and parenting 
Main results 
The 5 A’s approach is still 
the best treatment for light 
and moderate smokers 
Clinicians offering care to 
postpartum women and 
parents should asses 
smoking status and second 
hand smoke exposure 
For parents willing to quit, 
the use of 
pharmacotherapy should 
be used to help 
To assess compliance of 
practice guidelines with 
best practice guide 
evaluation of effectiveness, 
assessment of financial 
incentives, and 
identification of methods is 
needed 
Additional research is 
recommended on ways to 
improve disclosure, safety 
and efficacy of 
pharmacotherapy, use of 
biomarker feedback or 
incentives, partner 
involvement, and 
interventions to reduce 
second hand smoke 
 
 
Quality rating 
Good 
Adverse events 
NR 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Moher et al., 2005 
Geographic area 
United Kingdom 
Funding source 
Internal: 
Department of 
Primary Health 
Care, Oxford 
University, 
External: NHS 
Research and 
Development 
Program UK 
Time period 
covered 
Databases 
searched 
systematically 
through October 
2004. 
 
Inclusion criteria 
Interventions categorized into two 
groups: 1)Interventions aimed at 
individual to promote smoking cessation 
in the workplace setting (included 
randomized control trials) 2) 
Interventions aimed at workplace as a 
whole (included controlled trials w/ 
baseline and post interventionoutcomes 
and interrrupted times series studies) 
Population 
Adults, over 18 yrs of age, in 
employment, who smoked. 
Characteristics of studies 
(Interventions) 
• Smoking cessation programs aimed at 
individual in workplace including 
individual and group counseling, self 
help materials, advice from physicians 
and NRT 
• Interventions aimed at workforce 
population to assess a comprehensive 
approach to workers health, including 
smoking cessation 
Method of review 
• Prescreened published articles for 
relevance 
• Two reviewers assessed studies 
independently for inclusion 
• Data extracted by 1 reviewer and 
checked by a second 
• Because of considerable 
heterogeneity studies were combined 
using qualitative narrative synthesis 
Study design 
Cochrane Systematic Review 
Studies included in meta-analysis 
NR 
 
Aim of review 
To assess extent to 
which different kinds of 
workplace smoking 
programs help smokers 
to reduce or stop 
cigarette consumption. 
Main results 
• Group and individual 
counseling (particularly 
by a physician), and 
NRT significantly 
increased cessation 
rates vs no txt or 
minimal intervention 
controls 
• Self-help interventions 
less effective 
• Tobacco bans aimed at 
workplace as a whole 
decreased cigarette 
consumption at work 
but no evidence that 
total consumption 
decreased 
• Quit rates not 
increased by adding 
social or environmental 
support to workplace 
programs Competitions 
and incentives 
increased attempts to 
quit but less evidence 
for actual quitting 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Prochaska et al., 
2004 
Geographic area 
US 
Funding source 
Calif Tobacco-
Related Disease 
Research 
Program, and 
National Institute 
on Drug Abuse 
Time period 
covered 
January 1966 
through 
September 2003 
 
Inclusion criteria 
Randomized controlled designs of 
evaluations of a smoking cessation 
intervention where study participants 
were in addiction txt or recovery 
 
Studies used quantitative assessment 
Population 
Adults aged 18 yrs and older. 
Characteristics of studies 
(Interventions) 
• Psychosocial smoking cessation 
interventions provided in all but 1 
study and included the following: brief 
advice, educational information, skill 
based, behavioral, cognitive 
behavioral, motivational, or staged 
based interventions 
• Eleven studies provided NRT, one 
evaluated bupropion, and another 
fluoxetine 
Method of review 
• Two reviewers independently 
conducted article abstraction 
• One reviewer blinded to study author, 
institution, artile title, journal, and yr of 
publication 
• Qualilty assessment used a 3 pt scale 
• Discrepancies settled though 
discussion or consulting a third 
reviewer 
Study design 
• Abstinence ratios used to measure 
effect for smoking and substance use 
• Meta Analysis performed using 2X2 
tables for txt and Cs 
• To reduce bias .5 was added to every 
cell in the table containing a zero 
• Abstinence rates expressed as 
relative risk w/ 95% CI; RR > 1.0 
indicated favoring of intervention for 
increased abstinence 
Studies included in meta-analysis 
• 19 studies  
• 12 conducted w/ 1,410 participants in 
addiction txt and 7 studies w/ 638 
participants in recovery 
 
Aim of review 
To examine outcomes of 
smoking cessastion 
interventions evaluated 
w/ individual in current 
addictions txt or recovery 
Main results 
• Abstinence rates for 
addictions txt were 
12% vs 3% in 
intervention and Cs 
• Abstinence rates for 
recovery were 38% vs 
22% in intervention 
and Cs 
• Summary RR for 
addiction txt 2.03 (95% 
CI, 1.21 - 3.39; 
heterogeneity, P = 
0.519) indicated a 
significant increase in 
likelihood of abstinence 
in intervention group 
• Summary RR for 
recovery 1.77 (95%CI, 
1.37-2.30; 
heterogeneity, P = 
0.878) indicated a 
significant increase in 
likelihood of abstinence 
in intervention group 
• ANOVA comparing 
addiction and recovery 
intervention effects 
were NS 
• Long term follow up no 
significant differences 
in smoking outcomes 
by condition 
• Significant increase of 
drug and alcohol 
abstinence occurred in 
intervention groups RR 
= 1.25 (95% CI, 1.07 – 
1.46, heterogeneity, P 
= 0.496) 
• NRT studies revealed 
stronger effects and 
more recently 
published 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Author, year Study Characteristics 
Main Results/ 
Aim of Review Quality Rating 
Author, year 
Rigotti et al., 2002 
Geographic area 
United Kingdom 
Funding source 
NHS Research and 
Development 
Programme UK 
and Department of 
Primary Health 
Care, Oxford 
University,UK 
Time period 
covered 
Databases 
systematically 
searched through 
March 2002 
 
Inclusion criteria:  
• Randomized and quasi-randomized 
trials of behavioral, pharmacological or 
multicomponent interventions to help 
patients to stop smoking conducted with 
hospitalized patients 
• Trials of secondary prevention or 
cardiac rehabilitation that did not recruit 
on the basis of smoking history and 
trials in patients hospitalized for 
psychiatric disorders or substance 
abuse (including inpatient tobacco 
addiction programs) were excluded. 
Population 
Patients who were hospitalized, or about 
to be hospitalized and who were currently 
smoking or had recently quit.   
Characteristics of studies 
(interventions) 
Any intervention to  increase motivation to 
quit, to assist a quit attempt or to help 
recent quitters avoid relapse.  
Interventions during the hospital stay were 
categorized according to whether they 
included follow-up after discharge and by 
level of intensity leading to four categories 
of intervention intensity: 
• Single contact in hospital lasting ≤ 15 
minutes, no follow-up support 
• One of more contacts in hospital lasting 
in total > 15 minutes, no follow-up 
support 
• Any hospital contact plus follow-up ≤ 1 
month 
• Any hospital contact plus follow-up ≥ 1 
month 
Method of review 
Pre-screened published articles for 
relevance, three reviewers assessed 
studies independently for inclusion, data 
extracted by 1 reviewer and checked by a 
second, and used statistical methods for 
pooling described by Peto’s group (Yusuf 
1985) 
Study design 
Cochrane Systematic Review 
What studies are included in meta-
analysis 
17 trials conducted in the US, the UK, 
Canada and Spain between 1990 and 
2002  
 
Aim of review 
To determine the 
effectiveness of 
interventions for smoking 
cessation in hospitalized 
patients. 
Main results 
Intensive intervention 
(inpatient contact plus 
follow-up for at least 1 
month) was associated 
with a significantly higher 
quit rate compared to 
control (Peto Odds Ratio = 
1.82 (95% CI, 1.49-2.22, 
six trials). Inteventions with 
less than a month of follow-
up did not show evidence 
of significant benefit (Peto 
Odds Ratio 1.99, (95%CI, 
0.91-1.31, seven trials). 
There was no evidence to 
judge the effect of very 
brief (<20 minutes) 
interventions delivered only 
during rhe hospital stay. 
Longer inteventions 
delivered only during the 
hospital stay were not 
significantly associated 
with a higher quit rate 
(Peto Odds Ratio 1.07 
(95% CI, 0.79-1.44, three 
trials). Although the 
interventions increased quit 
rates irrespective of 
whether nicotine 
replacement therapy (NRT) 
was used, the results for 
NRT were compatible with 
other data indicating that it 
increases quit rates. There 
was no strong evidence 
that clincial diagnosis 
affected the likelihood of 
quitting. 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Secker-Walker et 
al., 2002 
Geographic area 
United Kingdom 
Funding source 
No source of 
support supplied 
Time period 
covered 
Databases 
searched 
systematically 
through August, 
2001 
 
Inclusion criteria 
Controlled trials of community 
interventions for reducing smoking 
prevalence in adult smokers where 
primary outcome measure was smoking 
behavior 
Population 
Adults, 18 yrs and older 
Characteristics of studies 
(Interventions) 
Coordinated, multidimensional programs 
aimed at changing adult smoking 
behavior involving several segments of 
the community and conducted in a 
defined geographical area such as a 
town, city, county, or administrative 
district 
Method of review 
• Prescreened published articles for 
relevance 
• Two reviewers assessed studies 
independently for inclusion 
• Data extracted by 1 reviewer and 
checked by a second 
• Studies combined using qualitative 
narrative synthesis 
Study design 
Cochrane Systematic Review 
Studies included in meta-analysis 
NR 
 
Aim of review 
To assess effectiveness 
of community 
interventions for reducing 
prevalence of smoking 
Main results 
• Changes in smoking 
prevalence measured 
using cross sectional 
data in 27 studies 
• Net decline ranged 
from -1.0% to 3.0%/yr; 
for women -.2% to 
3.5%/yr; for men -.4% 
to 1.6%/yr 
• Two rigorous studies 
found significant 
results:1) change in 
smoking prevalence 
among light/moderate 
smokers, 2) greater 
quit rates among men 
but community level 
changes not found 
• Projects that address 
smoking alone scarcely 
more effective than 
general health 
prevention projects 
• Longer project, 
projects using 
formative research, 
and projects w/ higher 
levels of participation 
and awareness were 
more effective 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Sinclair et al., 
2005 
Geographic area 
United Kingdom 
Funding source 
University of 
Aberdeen UK 
Time period 
covered 
Databases 
systematically 
searched through 
March 2003. 
 
Inclusion criteria 
Randomized trials which compared 
interventions by community pharmacy 
personnel to promote smoking cessation 
amongst their clients who were smokers 
compared to usual pharmacy support or 
any less intensive program 
Population 
Community pharmacy clients who are 
smokers and wish to stop. 
Characteristics of studies 
(Interventions) 
Any intervention by community 
pharmacy personnel to promote smoking 
cessation amongst their clients 
Pharmaceutical trials which compared 
only NRT w/ a control in the community 
pharmacy setting did not fall within 
scope of this review 
Method of review 
• Studies generated by search strategy 
reviewed by two authors, according to 
inclusion criteria 
• Data extracted by one author and 
checked by a second 
Study design 
Cochrane Systematic Review 
Studies included in meta-analysis 
NR 
 
Aim of review 
To assess effectiveness 
of interventions by 
community pharmacy 
personnel to assist clients 
to stop smoking 
Main results 
• Two trials met the 
criteria w/ a total of 976 
smokers 
• Both studies involved 
training using stages of 
change model, and 
compared a support 
program of counseling 
and record keeping w/ 
a C who recieved 
normal services 
• Significant result for 
study 1 showed 
cotinine-validated 
continuous abstinence 
at 12 months of 14.3% 
in intervention group 
and 2.7% in C 
• Study 2 did not show a 
statistically significant 
effect at any followup, 
but there was a 
consistent trend toward 
benefits fro intervention 
• Using a random effects 
model to pool results 
showed no evidence of 
significant benefits 
 
Quality rating 
Good 
Adverse events 
NA 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Sowden et al., 
2003 
Geographic area 
United Kingdom 
Funding source 
NHS Center for 
Reviews and 
Dissemination, 
UK 
Time period 
covered 
Databases 
searched 
systematically 
through 
September 2002 
 
Inclusion criteria 
Randomized and non RCTs that 
assessed effectiveness of multi-
component community (geographical or 
school district) interventions to prevent 
uptake of smoking in young people 
Population 
Young people aged less than 25 yrs 
Characteristics of studies 
(Interventions) 
Interventions targeted at entire or parts 
of entire communities or lage ares w/ 
intention of influencing smoking 
behaviors of young people 
Method of review 
• Prescreened published articles for 
relevance 
• Two reviewers assessed studies 
independently for inclusion 
• Data extracted by 1 reviewer and 
checked by a second, 
• Studies combined using qulitative 
narrative synthesis 
Study design 
Cochrane Systematic Review 
Studies included in meta-analysis 
NR 
 
Aim of review 
To determine 
effectiveness of 
community interventions 
in preventing initation of 
smoking in young people. 
Main results 
• Community 
interventions vs no 
intervention controls 
reported lower smoking 
prevalence; 
• Community 
interventions vs 
school-based only 
intervention found a 
significant smoking 
prevalence in one 
study 
• Community 
interventions vs 
community w/ school-
based component 
found no differences in 
smoking cessation 
rates 
• Community 
intervention w/ media 
component vs media 
alone found 
significantly lower rate 
of increased smoking 
in community and 
media intervention 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Sowden et al., 
1998 
Geographic area 
United Kingdom 
Funding source 
Internal: NHS 
Centre for 
Reviews and 
Dissemination 
UK; External: 
NHS Research 
and Development 
National Cancer 
Programme, 
England UK 
Time period 
covered 
Databases 
searched 
systematically 
through June 
1998 
 
Inclusion criteria 
Studies that evaluated effectiveness of 
mass media campaigns influencing 
smoking behaviors in young people 
using the following designs: 1) RCT w/ 
unit of analysis as school, community or 
geographic area, 2) controlled trial w/o 
randomization, 3) time series 
Population 
Young people aged less than 25 yrs. 
Characteristics of studies 
(Interventions) 
• Mass media interventions using 
communication channels such as TV, 
radio, newspapers, bill boards, 
posters, leaflets or booklets intended 
to prevent uptake of smoking in young 
people 
• Also mass media campaigns 
combined w/ school-based programs 
designed to influence smoking 
behaviors were included 
Method of review 
• Stage 1: Reports of evaluations 
prescreened for relevance by at least 
one reviewer 
• Stage 2: Relevant studies assessed 
independently by 2 reviewers 
• Stage 3: Data extracted from included 
studies by one reviewer and checked 
by a second reviewer 
• Stage 4: Studies combined using 
qualitative narrative synthesis 
Study design 
• Cochrane Systematic Review 
• Studies combined using qualitative 
narrative synthesis 
Studies included in meta-analysis 
NR 
 
Aim of review 
To determine 
effectiveness of mass 
media campaigns in 
preventing uptake of 
smoking in young people. 
Main results 
• Two of these six 
control trial design 
interventions found to 
be associated w/ 
reductions in smoking 
behavior 
• A media campaign 
aimed at girls found 
4% lower smoking 
rates for girls in the 
media county (8.6% vs 
12.4%, P < 0.01); OR 
of being a smoker in 
intervention county 
compared w/ being a 
smoker in control was 
.74 (95% CI, .64 to .86) 
after adjusting for 
baseline and gender 
• A media campaign 
combined w/ a school-
based program vs 
school based program 
alone found a lower 
risk for weekly smoking 
at 2 yr in communities 
w/ combined 
intervention (OR .62, 
95% CI, .49 to .78) 
• Both studies had 
effective campaigns w/ 
solid theoretical basis, 
used formative 
research in designing 
messages, and 
message broadcasts 
were intense over a 
extensive period of 
time 
• Problems w/ other 
studies: allocation of 
communities, areas 
and schools, unit of 
analysis, differences in 
baseline measure, and 
high attrition 
 
Quality rating 
Good 
Adverse events 
NA 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Stead et al., 2005 
Geographic area 
United Kingdom 
Funding source 
Internal: 
Department of 
Primary Helath 
Care, Oxford 
University UK, 
External: NHS 
Research and 
Development 
National Cancer 
Programme UK 
Time period 
covered 
Database 
searched 
sytematically 
through February 
2005 
 
Inclusion criteria 
Randomized trials w/ a minimum of two 
group meetings and followup at least 6 
months 
Population 
Smokers of either gender irrespective of 
initial level of nicotine dependency, 
except for pregnant smokers. 
Characteristics of studies 
(Interventions) 
Studies where smokers met for 
scheduled meetings and received some 
form of behavioral therapy delivered 
over at least 2 sessions 
Method of review 
• Studies idenified and reviewed 
independently by 2 authors and 
disagreements referred to a third party 
• If 2 group methods were compared w/ 
another method the groups were 
combined and compared w/ the non 
group method 
Study design 
Cochrane Systematic Review and meta 
analysis performed if appropriate 
Studies included in meta-analysis 
NR 
 
Aim of review 
To determine effects of 
smoking cessation 
programs delivered in a 
group format compared 
to self-help materials, no 
intervention, individual 
counseling, advice from 
Physician, and NRT 
Main results 
• Group therapy 
significantly increased 
cessation vs self-help 
using same or different 
content (N = 4395, OR 
2.04, 95% CI, 1.60 - 
2.60) 
• Higher quit rates 
comparing group to no 
intervention N = 815, 
OR 2.17, 95% CI, 1.37 
- 3.45); No significant 
difference comparing 
group w/ individual 
therapy and only 
limited evidence that 
group produces extra 
benefits when 
combined w/ physician 
advice and NRT 
 
Quality rating 
Good 
Adverse events 
No 
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Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Stead, 2003 
Geographic area 
United Kingdom 
Funding source 
NHS Research 
and Development 
Programme UK 
Time period 
covered 
Databases 
searched 
systematically 
through 
September 2002 
 
Inclusion criteria 
Randomized or quasi-RCTs in which 
proactive or reactive telephone 
counseling to assist smoking cessation 
was offered to smokers or recent quitters 
Population 
Smokers or recent quitters 
Characteristics of studies 
(Interventions) 
• Proactive or reactive telephone 
counseling to assist smoking 
cessation to any population 
• Also studies that combined telephone 
counseling w/ self-help materials 
Method of review 
Relevant studies identified by one 
person and checked for inclusion or 
exclusion by a second person 
Data extracted by one author and 
checked by a second 
Study design 
Cochrane Systematic Review and if no 
signficant heterogeneity studies pooled 
for a meta analysis 
Studies included in meta-analysis 
NR 
 
Aim of review 
To evaluate effect of 
proactive and reactive 
telephone support to help 
smokers quit 
Main results 
• Procative phone 
counseling + minimal 
intervention vs minimal 
intervention only: 
indicted a significant 
benefit from addition of 
phone counseling 
when minimal 
intervention used 
standard self-help 
material (OR 1.56, 
95% CI, 1.38 - 1.77) 
• Proactive phone 
counseling increasec 
quit rates from 4.1% to 
7.5% when compared 
to self-help or reactive 
counseling; Adding 
telephone counseling 
to face to face 
interventions failed to 
significantly increase 
OR (OR 1.08, 95% CI, 
.87- 1.33) 
• Adding proactive 
counseling to NRT did 
not signficantly 
increasequit rates; 
proactive counseling 
compared to group 
counseling showed no 
differences 
• Access to a hotline or 
reactive phone 
counseling showed a 
significant benefit in 
one out of 3 trials 
 
Quality rating 
Good 
Adverse events 
No 
 
C-209 
Evidence Table 10. Systematic and meta-analysis reviews (continued) 
Study 
Demographics Study Characteristics 
Aim of Review 
Main Results Quality Rating 
Author, yr 
Thomas et al., 
2002 
Geographic area 
United Kingdom 
Funding source 
No source of 
support supplied 
Time period 
covered 
Databases 
systematically 
searched through 
January 2002 
 
Inclusion criteria 
Studies where individual students, 
classes, schools, or school districts were 
randomised to intervention or Cs and 
followed for at least 6 months 
Population 
Children (aged 5 to 12) or adolescents 
(aged 13 to 18) in school settings 
Characteristics of studies 
(Interventions) 
Classroom programs or curricula, 
including those associated w/ family or 
community interventions, intended to 
deter use of tobacco 
Method of review 
• Prescreened published articles for 
relevance 
• Two reviewers assessed studies 
independently for inclusion 
• Data extracted by 1 reviewer and 
checked by a second 
• Because of considerable 
heterogeneity the studies were 
combined using qualitative narrative 
synthesis 
Study design 
Cochrane Systematic Reveiw 
Studies included in meta-analysis 
NR 
 
Aim of review 
To review all RCTs of 
behavioural interventions 
in schools to prevent 
children and adolescents 
starting smoking 
Main results 
• Information curriculum 
interventions less 
effective or showed no 
difference compared to 
other models of 
delivery 
• SLT (most widely used 
theory) had 8 studies 
w/ positive effects and 
7 w/o positive effects 
and HSPP study had 
no effect  
• SLT lacks evidences 
about effectiveness 
• Limited evidence that 
combining social 
influence models w/ 
other components 
improves effectiveness 
 
Quality rating 
Good 
Adverse events 
No 
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